,Article,Date,Symbol,Time,Title,Url
0,"  Patrick Reed made up for some wayward driving with a sizzling putting display in dazzling sunshine to charge into a one-shot lead in Thursday's opening round of the $5.7 million Humana Challenge at La Quinta, California.The 23-year-old American took advantage of ideal scoring conditions in the California desert as he fired a flawless nine-under-par 63 on the Arnold Palmer Private course at PGA West, one of three venues hosting the pro-am event.Reed piled up nine birdies and totaled only 27 putts to finish a picture-perfect day with barely a breath of wind one stroke in front of fellow Americans Ryan Palmer, Justin Hicks, Daniel Summerhays and 2007 champion Charley Hoffman.""Even though I didn't hit many fairways, I kept it in play and that's the main thing around this golf course,"" Texan Reed told Golf Channel after taking control of the PGA Tour event.""And then whenever I was on the green, it was one of those days when everything I read was the right line, I hit the line every time and I got hot with the putter. ""When any guy out here gets hot with the putter, they're going to be able to shoot a low number,"" said Reed, who won his maiden PGA Tour title at last year's Wyndham Championship where he beat rookie sensation Jordan Spieth in a playoff.Reed's wife Justine is expecting the couple's first child, a baby girl, in May and has handed over her usual caddying duties for her husband to her brother, Kessler Karain.Palmer also started out on the Palmer layout on Thursday, Hicks and Daniel Summerhays played on the Nicklaus Private at PGA West and Hoffman launched his title bid at La Quinta Country Club. ""It was a little interesting,"" said three-time PGA Tour winner Palmer, who recorded two bogeys in his first six holes before stunningly ending his round with six successive birdies.""I guess you could say I slept walked the first six holes. I hit some good shots, just couldn't get a putt to go in. ""After bogeying six, I hit a great nine-iron on seven to about three feet which kind of jump-started my round. And then on 14, I just exploded. I hit it close pretty much every hole. That was a fun start.""American world number six Zach Johnson, who clinched his 11th PGA Tour victory at the Hyundai Tournament of Champions in Hawaii 10 days ago, and Scotland's Russell Knox were among seven players who opened with 65s.Brandt Snedeker, the 2012 FedExCup champion, carded a 72 in his first PGA Tour start of the year while fellow American Brian Gay, who won last year's Humana Challenge in a three-way playoff, launched his title defense with a 69 at La Quinta.(Reporting by Mark Lamport-Stokes in Los Angeles; Editing by Frank Pingue)",2014-01-17,HUM,"Thu Jan 16, 2014 | 7:43pm EST",American Reed sizzles in California desert,http://www.reuters.com//article/us-golf-pga-idUSBREA0G01K20140117?type=companyNews
1,"  American Patrick Reed once again flourished in near-perfect scoring conditions as he stretched his lead to two shots in Friday's second round of the $5.7 million Humana Challenge at La Quinta, California.One stroke ahead overnight after opening with a nine-under-par 63 on the Arnold Palmer Private course at PGA West, the red-hot Reed followed up with another sizzling 63, this time at La Quinta Country Club.The 23-year-old piled up eight birdies, an eagle at the par-five fifth and a lone bogey in dazzling desert sunshine with barely a hint of wind to post an 18-under total of 126 in the pro-am event being played at three venues.American journeyman Brendon Todd birdied his final hole for a flawless 63 on the Palmer Private layout, ending the day a stroke in front of compatriot Ryan Palmer, who carded a 65 at La Quinta.Fellow American Charley Hoffman, the 2007 champion, was a further shot back at 14 under after returning a 66 on the Nicklaus Private course.Reed, who made up for some wayward driving in Thursday's opening round with a sizzling putting display, tightened his hold on the tournament after producing much better form off the tee on Friday.""To start off the day hitting a perfect drive on the first and second holes ... gave me a little bit of extra confidence in that club,"" the Texan told reporters. ""So I was able to attack and be more aggressive off the tees. ""Whenever you start with hitting a soft sand wedge to four feet on the first and tap in for birdie ... you just carry that momentum straight through.""PLAYOFF BREAKTHROUGH Reed is bidding for his second PGA Tour title, having clinched his first at last year's Wyndham Championship where he beat rookie sensation Jordan Spieth in a playoff. ""What I'm doing so far is working - 63, 63 - so we're just going to stick to that game plan, stick to our notes and hopefully close it out,"" said Reed.""My putter is really working. I hit a lot of good putts today, missed a couple, but at the same time I made some. As long as I keep doing that, come Sunday, we'll see.""Todd, still seeking his maiden PGA Tour title after playing his rookie season on the U.S. circuit in 2009, said Reed's sizzling scoring had spurred him on to stay in touch with the lead. ""It just kind of kept me motivated coming in to make as many birdies as I could, distance myself from the pack and get near Patrick,"" Todd told Golf Channel""I just have to keep doing what I am doing. I've got a good team around me. Just keep working on the same things and gain some more experience out here.""Keegan Bradley aced the par-three third on the Nicklaus Private course with a seven-iron from 177 yards, his ball pitching on the front portion of the green before curling from right to left and then disappearing into the cup.Bradley, who clinched his maiden major title at the 2011 PGA Championship, ended up shooting a 66 to sit a distant nine strokes off the pace heading into Saturday's third round.American world number six Zach Johnson, who won the Hyundai Tournament of Champions in Hawaii 11 days ago, carded a 68 on the Nicklaus Private course to finish at 11 under.(Reporting by Mark Lamport-Stokes in Los Angeles; Editing by Gene Cherry)",2014-01-18,HUM,"Fri Jan 17, 2014 | 7:29pm EST",Red-hot Reed moves two ahead at La Quinta,http://www.reuters.com//article/us-golf-pga-idUSBREA0H00E20140118?type=companyNews
2,"  American Patrick Reed survived a few anxious moments and poor swings midway through the final round to seal his second PGA Tour victory by two shots at the $5.7 million Humana Challenge on Sunday in La Quinta, California.A commanding seven strokes ahead overnight, Reed mixed four bogeys with three birdies in a roller-coaster stretch of eight holes from the fifth but held steady after that to close with a one-under-par 71 on the Palmer Private course at PGA West.""I wasn't pleased with the round today but I got it done,"" the burly 23-year-old told Golf Channel after completing a wire-to-wire victory with a 28-under total of 260, finishing two ahead of fellow American Ryan Palmer (63).""The first three days were kind of grind and go, play as low as you can,"" said Reed, who became the first player on the PGA Tour to post scores no worse than 63 in each of the first three rounds.""But Sundays are always a little harder, as everyone knows, and also the flags are a little tougher. I just tried to stick to the game plan, tried to post a decent number.""World number six Zach Johnson, who clinched his 11th PGA Tour title at the Hyundai Tournament of Champions in Hawaii earlier this month, sensationally birdied the last five holes for a best-of-the-week 10-under 62.Johnson's flawless round left him in a tie for third at 25-under with fellow American Justin Leonard (65), and he will now take a four-week break before returning to the PGA Tour for the February 19-23 WGC-Accenture Match Play Championship in Arizona.Little-known American Brendon Todd applied early pressure on playing partner Reed with four birdies in the first six holes but then lost momentum as he closed with a 69 to share sixth place at 23 under with 2010 champion Bill Haas (67). Most eyes on Sunday, however, were focused firmly on Reed in his bid to become only the second wire-to-wire winner at the pro-am event, compatriot Rik Massengale having achieved the feat in 1977 when the tournament was played over 90 holes.COMMANDING LEAD His commanding overnight lead at an event known for its low scoring in the California desert was cut to six after James Driscoll birdied the first two holes, before Reed recorded a two-putt birdie at the par-five second to get to 28 under. Todd then piled on pressure with birdies at the second, third and fourth - the last of them a perfectly judged 14-foot putt - to trim Reed's advantage to five.Though Todd faltered with a bogey at the par-three fifth where his tee shot ended up in water, Reed also dropped a stroke there after chipping to nine feet and missing the par putt.Both Todd and Reed birdied the par-five sixth after reaching the green in two before Reed's lead was cut to four when he bogeyed the seventh, after finding rough off the tee.If Reed felt any pressure, he was a picture of ice-cool calm playing the par-four eighth where he struck a superb approach to four feet and sank the birdie putt, then parred the ninth to reach the turn five ahead of the chasing pack. However, he bogeyed the 10th after finding a fairway bunker off the tee and soon after was just three strokes in front when Leonard knocked in a four-foot birdie putt at the par-five 11th.Reed rebounded with a birdie of his own at the 11th after reaching the green in two and two-putting before apparently succumbing to nerves with an ugly bogey at the par-three 12th, where he chunked his second shot from a greenside bunker.Johnson's sizzling five-birdie finish briefly trimmed Reed's lead to just two but the burly American immediately rebounded with a birdie at the par-three 15th, pumping his right fist in delight after draining an 18-foot putt.Reed surprisingly missed a birdie attempt from only six feet at the par-three 17th but rock-solid pars on the last three holes earned him his second PGA Tour victory, having claimed his maiden title at last year's Wyndham Championship.He also became the event's second youngest winner after Jack Nicklaus, who triumphed in 1963 aged 23 years and 13 days.(Reporting by Mark Lamport-Stokes in Los Angeles; Editing by Gene Cherry/Peter Rutherford)",2014-01-20,HUM,"Sun Jan 19, 2014 | 9:22pm EST",Reed triumphs by two shots at La Quinta,http://www.reuters.com//article/us-golf-pga-idUSBREA0J02620140120?type=companyNews
3,"  Patrick Reed has long strived to prove he belongs among the game's elite and he took a big step in that direction after ending a record-breaking week with a two-shot victory at the Humana Challenge in La Quinta, California.Not only did the burly American become the first player ever on the PGA Tour to post scores no worse than 63 in each of the first three rounds but he earned a seal of approval from former U.S. president Bill Clinton after securing the win.Midway through Reed's post-victory news conference, he took a phone call from Clinton, a keen amateur golfer whose own charitable foundation officially linked up with the Humana Challenge in 2012.""He was congratulating me, not only on a great win, but also told me to get myself back in that zone more often,"" a smiling Reed told reporters when asked what the former U.S. president had said to him.""He said it was a lot of fun to watch and ... how cool and calm and collected I was all week. And that's key out here. You have to be. To hear that not only from others, but also hear it from the president, that's special.""Reed, who clinched his maiden PGA Tour victory at last year's Wyndham Championship where he beat rookie sensation Jordan Spieth in a playoff, felt had proved himself among his peers with the high quality of his golf at La Quinta. ""I always play to try to prove to everybody that I belong out here, not only out here on the PGA Tour, but also with the best players in the world,"" Reed said after following his three opening nine-under-par 63s with a closing 71.""What I did this week with rattling off 63 three days in a row, and then being able to coast in with a victory, definitely shows that ... 63 three days in a row has never been done before.""WIGGLE ROOM  Though Reed had his commanding overnight lead of seven shots trimmed to just two during Sunday's final round, he always felt he had enough wiggle room to hold on for victory.""I started towards the end playing for par, just because I knew pars weren't going to hurt me,"" he said after mixing five birdies with four bogeys to post a 28-under total of 260.""I had a five-shot lead or four-shot lead going into the back nine, so I knew someone was going to have to do something spectacular to catch me. ""To come out and not have my full game and to have that much of a cushion to be able to just coast in, that's a good feeling. So I just coasted in, tried to make some pars.""Reed safely parred the last three holes, surprisingly missing a birdie attempt from six feet at the par-three 17th, before he was embraced by his wife Justine on the edge of the 18th green.Justine is expecting the couple's first child, a baby girl, in May and has handed over her usual caddying duties for her husband to her brother, Kessler Karain, for the past two PGA Tour events.""I can't wait to be a dad and have a little girl running around at the golf course and whenever I come home have her run up, hanging out with dad,"" said a beaming Reed, who earned $1.026 million for his second PGA Tour victory.(Reporting by Mark Lamport-Stokes in Los Angeles; Editing by Gene Cherry)",2014-01-20,HUM,"Sun Jan 19, 2014 | 9:22pm EST",Triumphant Reed earns seal of approval from Clinton,http://www.reuters.com//article/us-golf-pga-reed-idUSBREA0J04220140120?type=companyNews
4,"   By Caroline Humer  Humana Inc said on Wednesday that it received 202,000 applications for Obamacare health insurance plans, many of them from young people, but still gave a wide forecast for 2014 profit as it waits to see the demographics of future customers.The U.S. health insurer made the disclosure as it reported a fourth-quarter loss due to a $243 million charge to set aside financial reserves for a group of long-term care policies that it no longer sells.President Barack Obama's national healthcare reform law, often called Obamacare, set up state-based insurance exchanges to let individuals buy policies with income-based subsidies.Enrollment in exchange products has been hampered by technology problems both with HealthCare.gov, the online marketplace for 36 states, and in some of the other 14 states that run their own sites.In November, Obama asked insurers to allow old policies to be extended under political pressure to keep a promise he had made that people who liked their plan, could keep their plan. On Monday, the Congressional Budget Office lowered its estimate for total exchange enrollment to 6 million, citing these extensions. The government has said about 3 million people have signed up so far.Humana, which previously cut its outlook for sign-ups by at least half because of the technology failures, said it saw that more customers than usual were extending their old health plans.Because of the light enrollment, Humana said it expects that it will not get the proportion of healthy and sick customers that it had expected.Still, Chief Executive Officer Bruce Broussard said that its first look at enrollees so far shows that they are ""scaling a bit more to the younger side.""Young people, typically defined as adults under age 35, have fewer medical problems and are less expensive to insure, making them an important element to ensure the long-term viability of the exchanges.""This could potentially mitigate some of the adverse impact associated with the risk pool deterioration from our higher membership in non-ACA compliant plans,"" Broussard said, in reference to plans that do not meet the criteria of the Affordable Care Act, also known as Obamacare. Humana also said that costs of these patients interacting with its customer service centers have been higher than it anticipated.WAITING ON PRIVATE MEDICARE RATES Broussard also painted an uncertain outlook for its private Medicare Advantage business, which accounts for two-thirds of its revenue. The government is expected to announce 2015 reimbursement rates for private Medicare on February 21 that he said could cut funding by 6 percent to 7 percent.Humana shares fell 1.3 percent to $96.25 while shares of competitors Aetna Inc, UnitedHealth Group Inc, WellPoint Inc and Cigna gained. Aetna and Cigna also report this week.""It all falls back to Medicare Advantage reimbursement rates and what is going to end up being the ultimate enrollment demographics for the exchanges. It looks pretty reasonable to me for the most part, but there is still a lot of uncertainty,"" said Vishnu Lekraj, an analyst at Morningstar. Humana's number of exchange applications - 202,000 by January 31 - compares with the 400,000 people that competitor WellPoint Inc said it had signed up on the exchanges when it announced results last month. Both are in 14 states.For 2014, Humana said it expected its total individual membership, which includes plans sold to people outside the exchanges, to be flat to up 100,000.Besides health plans, Humana also provides dental, vision and other supplemental health and financial products. Most of its revenue comes from the sale of private Medicare plans.Humana said that it still expected to spend 50 cents to 90 cents per share on investment and startup expenses for new state-based Medicaid contracts and the state-based insurance exchanges this year, affirming details it gave in January.The company also backed its 2014 earnings outlook, also presented in January, of $7.25 to $7.75 per share, compared with $7.73 in 2013. LOSS REFLECTS POLICYHOLDER COSTS Humana reported a fourth-quarter loss of $30 million, or 19 cents per share, compared with year-earlier earnings of $192 million, or $1.19 per share.Excluding the 99-cent-per-share expense, the company would have posted a profit of 80 cents per share. On that basis, analysts were expecting earnings of 94 cents, according to Thomson Reuters I/B/E/S.Revenue rose to $10.19 billion from $9.56 billion as the company's individual and Medicare businesses signed up more people.The company spent 85.8 percent of its policy premiums on benefits, up from 83.7 percent a year earlier, due primarily to the $243 million set aside to strengthen reserves in that closed block of long-term care policies that it took on in 2007 with the acquisition of KMG America.Humana said it had adjusted the reserves to reflect policyholder longevity, increased in-home healthcare use and lower interest rates.Humana said it is considering strategic alternatives for that business.During the quarter, Humana said costs increased in its retail segment because of spending on the exchanges and Medicaid contracts as well as some higher marketing expenses for new Medicare products.(Reporting by Caroline Humer; Editing by Lisa Von Ahn and Jan Paschal)",2014-02-05,HUM,"Wed Feb 5, 2014 | 1:37pm EST",Humana says young people signing up for Obamacare,http://www.reuters.com//article/us-humana-results-idUSBREA140MJ20140205?type=companyNews
5,"  Feb 5 Humana Inc :  * CEO Bruce Broussard says during conference call that company evaluating strategic alternatives for its closed long-term care insurance business  * CEO says seeing higher retention of individuals in non-Obamacare health plansdue to extensions of old plans  * CEO says believes risk pool will deteriorate as old policies are renewed  * CEO says receiving more applications from young people, possibly because of payment subsidies from government  * CEO says 82 percent of new members from Obamacare receiving government subsidies  * CEO says more young people are signing up for Obamacare plans, likely because of these subsidies",2014-02-05,HUM,"Wed Feb 5, 2014 | 9:22am EST",BRIEF-Humana CEO says extension of old policies affects Obamacare sign-ups,http://www.reuters.com//article/humana-results-idUSWEN00CGI20140205?type=companyNews
6,"  Feb 5 U.S. health insurer Humana Inc  said on Wednesday that it had received 202,000 applications through Jan. 31 for 2014 Obamacare health insurance plans in the 14 states where it offers them.Humana made the disclosure as it reported a fourth-quarter loss due to a $243 million charge to set aside financial reserves for a group of long-term care policies that it no longer sells.President Barack Obama's national healthcare reform law, often called Obamacare, set up state-based insurance exchanges to allow individuals to buy policies with income-based subsidies.Enrollment in exchange products has been hampered by technology problems both with HealthCare.gov, the online marketplace for 36 states, and in some of the other 14 states that run their own sites.In addition, the U.S. government's decision to allow some old policies to be extended has cut into demand. On Monday, the Congressional Budget Office lowered its estimate for total exchange enrollment to 6 million. The government has said about 3 million people have signed up so far.Humana's application rate compares with the 400,000 people that competitor WellPoint Inc said it had signed up on the exchanges when it announced results last month. That company is also in 14 states. For 2014, Humana said it expected its total individual membership, which also includes plans sold to people outside the exchanges, to be flat to up 100,000.Besides health plans, Humana also provides dental, vision and other supplemental health and financial products.   Most of its revenue comes from the sale of private Medicare plans.Humana said that it still expected to spend 50 cents to 90 cents per share on investment and startup expenses for new state-based Medicaid contracts and the state-based insurance exchanges this year, affirming details it gave in January. The company also backed its 2014 earnings outlook, also presented in January, of $7.25 to $7.75 per share, compared with $7.73 in 2013.LOSS REFLECTS POLICYHOLDER COSTS Humana reported a fourth-quarter loss of $30 million, or 19 cents per share, compared with year-earlier earnings of $192 million, or $1.19 per share. Excluding the 99-cent-per-share expense, the company would have posted a profit of 80 cents per share. On that basis, analysts were expecting earnings of 94 cents, according to Thomson Reuters I/B/E/S.Revenue rose to $10.19 billion from $9.56 billion as the company's individual and Medicare businesses signed up more people.The company spent 85.8 percent of its policy premiums on benefits, up from 83.7 percent a year earlier, due primarily to the $243 million set aside to strengthen reserves in that closed block of long-term care policies that it took on in 2007 with the acquisition of KMG America.Humana said it had adjusted the reserves to reflect policyholder longevity, increased in-home healthcare use and lower interest rates.During the quarter, Humana said, costs increased in its retail segment because of spending on the exchanges and Medicaid contracts as well as some higher marketing expenses for new Medicare products.",2014-02-05,HUM,"Wed Feb 5, 2014 | 7:57am EST","UPDATE 2-Humana says 202,000 Obamacare exchange members signed up",http://www.reuters.com//article/humana-results-idUSL2N0LA0DT20140205?type=companyNews
7,"  Feb 5 U.S. health insurer Humana Inc on Wednesday reported a fourth-quarter loss as it took a 99-cent-per-share charge to set aside financial reserves for a group of long-term care insurance policies that it no longer sells.Besides health plans, Humana also provides dental, vision and other supplemental health and financial products.   Most of its revenue comes from the sale of private Medicare plans.  Humana said it had a loss of 19 cents per share, compared with earnings of $1.19 a year earlier. ",2014-02-05,HUM,"Wed Feb 5, 2014 | 6:13am EST",Humana reports fourth-quarter loss due to charge,http://www.reuters.com//article/humana-results-idUSL2N0LA0DB20140205?type=companyNews
8,"  NEW YORK Feb 19 A flurry of bearish bets placed Wednesday in the options for some health insurers caught the eye of several analysts, who said it appears that someone is banking on a sizeable drop in their stocks by the end of the week, which is also when 2015 Medicare payment rates are expected from the government.The most aggressive activity occurred in options on UnitedHealth Group Inc's shares, with a spate of purchases of puts that would benefit from a drop in the stock.According to options analytics firm TradeAlert, a trader bought 2,053 contracts of February puts at a strike price of $71, which is about 3.5 percent lower than the stock's current price of $73.55. These contracts will expire on Friday, and it has been more than two months since the stock has seen that large a move lower over a two-day period.The February $72 puts also saw heavy activity, according to TradeAlert. Volume was brisker than normal.""Given that other trades are usually 200-300 contracts (in the stock), this purchase, which was made so close to expiration, definitely seems to be some sort of speculative move if there is news coming out,"" said Randy Frederick, managing director at Charles Schwab in Austin, Texas. Options activity in Humana Inc also perked up, with one of the most active contracts being some weekly February $94 puts that expire Feb. 28, as well as some monthly Feb $92.35 puts that expire on Friday. Both strike prices are substantially below the stock's $101.98 closing price on Wednesday.The activity comes ahead of a key government announcement due as early as this week about next year's expected Medicare reimbursement rates, a key revenue source for both UnitedHealth and Humana. It has jolted these stocks before. Just about one year ago, the stocks took a pounding when Medicare Advantage plan payment rates were forecast to be cut under a preliminary proposal from the Centers for Medicare and Medicaid Services. Humana's shares plunged 6.4 percent in one day, while UnitedHealth's stock shed 3.7 percent over two days.The stocks rebounded sharply just over a month later when the final payment rates did not reflect as large a cut as originally proposed. Meanwhile, readings of implied volatility, a key component of options prices, have been rising for both stocks ahead of the expected announcement.The 30-day at-the-money implied call and put volatilities for United National Health were at around 23 on Wednesday, the highest level since before the company's third-quarter earnings announcement in October, according to Thomson Reuters data. The level was also higher than ahead of last year's Medicare rate announcement.In Humana, the 30-day implied volatility  options as well, up to nearly 40 percent from a day ago and at the highest level in nearly a year.As implied volatility rises, options premiums, or prices, typically follow suit, reflecting the elevated risk to the seller in the event of an outsized move in the stock.",2014-02-20,HUM,"Wed Feb 19, 2014 | 7:20pm EST",Bearish bets seen on U.S. insurers ahead of Medicare rate announcement,http://www.reuters.com//article/medicare-insurers-options-idUSL2N0LO24F20140220?type=companyNews
9,"  * S&P 500 hits intraday record; Nasdaq climbs to 14-year high* Insurance stocks rise after Humana comments* Men's Wearhouse raises offer for Jos. A. Bank* Dow up 0.6 pct; S&P 500 up 0.6 pct; Nasdaq up 0.7 pctBy Caroline ValetkevitchNEW YORK, Feb 24 U.S. stocks rose on Monday and the S&P 500 hit a record intraday high, helped by gains in health insurers' shares and optimism about merger activity.The Nasdaq reached a 14-year high, though all three indexes closed off their highs for the session. The S&P 500 finished less than a point away from its record closing high of 1,848.38.Humana Inc and UnitedHealth Group ranked among the S&P 500's biggest percentage gainers, with Humana's stock jumping 10.6 percent to $113.69 after it said the government's proposed cuts to the private Medicare program appeared to be less than it had forecast. UnitedHealth shares rose 3 percent to $76.01.Aetna Inc rose 2 percent to close at $71.80 after giving a 2014 earnings outlook. Weak economic data has largely been blamed on harsh winter weather, which has kept investors hopeful that the economy's recovery remains intact. The latest data showed the Chicago Fed National Activity index fell to -0.39 in January from 0.16 in December while financial data firm Markit's preliminary February reading on the services sector fell to 52.7 from 56.7.""There's still a lot of hope right now (that) the slightly weaker (economic) numbers we've been seeing are weather- related,"" said Bryant Evans, portfolio manager at Cozad Asset Management in Champaign, Illinois.The Dow Jones industrial average rose 103.84 points or 0.64 percent, to close at 16,207.14. The S&P 500  gained 11.36 points or 0.62 percent, to end at 1,847.61, after rising to an intraday record of 1,858.71.The Nasdaq Composite added 29.558 points or 0.69 percent, to finish at 4,292.968. The S&P 500 broke above resistance at 1,841, which propelled further gains, said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.The Dow Jones Transportation Average, whose components include package-shipping companies like FedEx  and United Parcel Service, rose 0.4 percent.In the deal arena, chipmaker RF Micro Devices Inc  agreed to buy TriQuint Semiconductor Inc for about $1.6 billion. Men's Wearhouse Inc raised its cash tender offer for rival men's clothing retailer Jos. A. Bank Clothiers Inc  to $63.50 per share from $57.50.Shares of RF Micro shot up 21 percent to $7.03 while TriQuint's stock surged 26.1 percent to $11.64. Men's Wearhouse shares jumped 7.5 percent to $48.51 while Jos. A. Bank's stock soared 9.1 percent to close at $60.04.Helping lift the Nasdaq, shares of eBay rose 3.1 percent to $56.30 as billionaire investor Carl Icahn called again for the spinoff of eBay's fast-growing PayPal payments business.Adding some support was news that Ukrainian President Viktor Yanukovich was ousted. While that leaves a potential power vacuum and an ailing economy, it calmed some worries.Many traders are looking ahead to Thursday, when Federal Reserve Chair Janet Yellen will speak to the Senate Banking Committee in her semi-annual testimony about monetary policy.Yellen's comments will be scoured for insight into the extent to which bad weather has affected economic activity, as well as for confirmation that the Fed will not make any changes to its schedule for trimming stimulus.After the bell, shares of Tenet Healthcare declined 3.8 percent to $46.50 following the release of its results.About 7.1 billion shares changed hands on U.S. exchanges, just above the 7 billion average so far this month, according to data from BATS Global Markets.Advancers beat decliners on the New York Stock Exchange by a ratio of about 1.6 to 1 and on the Nasdaq by about 1.8 to 1.",2014-02-24,HUM,"Mon Feb 24, 2014 | 5:32pm EST",US STOCKS-S&P 500 ends less than 1 point below record closing high,http://www.reuters.com//article/markets-usa-stocks-idUSL1N0LT24G20140224?type=companyNews
10,"  * S&P 500 hits intraday record; Nasdaq climbs to 14-year high* Insurance stocks rise after Humana comments* Men's Wearhouse raises offer for Jos. A. Bank* Dow up 0.6 pct; S&P 500 up 0.6 pct; Nasdaq up 0.7 pctBy Caroline ValetkevitchNEW YORK, Feb 24 U.S. stocks rose on Monday and the S&P 500 hit a record intraday high, helped by gains in health insurers' shares and optimism about merger activity.The Nasdaq reached a 14-year high, though all three indexes closed off their highs for the day, with the S&P 500 finishing less than a point away from its record closing high of 1,848.38.Humana Inc and UnitedHealth Group ranked among the S&P 500's biggest percentage gainers, with Humana's stock jumping 10.6 percent to $113.69 after it said the government's proposed cuts to the private Medicare program appeared to be less than it had forecast. UnitedHealth shares rose 3 percent to $76.01. Aetna Inc rose 2 percent to close at $71.80 after giving a 2014 earnings outlook.Weak recent economic data has largely been blamed on harsh winter weather, which has kept investors hopeful that the pickup in the economy remains intact. The latest data showed the Chicago Fed National Activity index fell to -0.39 in January from 0.16 in December while financial data firm Markit's preliminary February reading on the services sector fell to 52.7 from 56.7.""There's still a lot of hope right now (that) the slightly weaker (economic) numbers we've been seeing are weather- related,"" said Bryant Evans, portfolio manager at Cozad Asset Management, in Champaign, Illinois.The Dow Jones industrial average rose 103.84 points or 0.64 percent, to close at 16,207.14. The S&P 500  gained 11.36 points or 0.62 percent, to end at 1,847.61, after rising to an intraday record of 1,858.71. The Nasdaq Composite added 29.558 points or 0.69 percent, to finish at 4,292.968.The S&P 500 broke above resistance at 1,841, which propelled further gains, said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.In the deal arena, RF Micro Devices Inc agreed to buy TriQuint Semiconductor Inc for about $1.6 billion, while Men's Wearhouse Inc raised its cash tender offer for rival men's clothing retailer Jos. A. Bank Clothiers Inc  to $63.50 per share from $57.50. Shares of RF Micro shot up 21 percent to $7.03 while TriQuint's stock surged 26.1 percent to $11.64.Men's Wearhouse shares jumped 7.5 percent to $48.51 while Jos. A. Bank's stock soared 9.1 percent to close at $60.04.Adding some support was news that Ukrainian President Viktor Yanukovich was ousted. While that leaves a potential power vacuum and an ailing economy, it calmed some worries.Many traders are looking ahead to Thursday, when Federal Reserve Chair Janet Yellen will speak to the Senate Banking Committee in her semi-annual testimony about monetary policy.Yellen's comments will be scoured for insight into the extent to which bad weather has affected economic activity, as well as for confirmation that the Fed will not make any changes to its schedule for trimming stimulus.About 6.8 billion shares changed hands on U.S. exchanges, below the 7 billion average so far this month, according to data from BATS Global Markets.Advancers beat decliners on the New York Stock Exchange by a ratio of about 1.6 to 1 and on the Nasdaq by about 1.8 to 1.",2014-02-24,HUM,"Mon Feb 24, 2014 | 4:47pm EST",US STOCKS-S&P 500 ends just shy of record close; insurers climb,http://www.reuters.com//article/markets-usa-stocks-idUSL1N0LT21E20140224?type=companyNews
11,"  * S&P 500 hits record, Nasdaq at 14-year high* Insurance stocks rise after Humana comments* Men's Wearhouse raises offer for Jos. A. Bank* Indexes up: Dow 1.1 pct, S&P 1.1 pct, Nasdaq 1.1 pctBy Caroline ValetkevitchNEW YORK, Feb 24 U.S. stocks jumped on Monday, with the S&P 500 climbing above key resistance to a record high, as optimism over merger activity helped Wall Street erase this year's early weakness.Gains were broad, with nine of the 10 S&P 500 sectors up on the day and a number of bellwethers, including Caterpillar Inc  and Merck & Co, hitting 52-week highs. Among merger and acquisition news, RF Micro Devices Inc  agreed to buy TriQuint Semiconductor Inc for about $1.6 billion, while Men's Wearhouse Inc raised its cash tender offer for rival men's clothing retailer Jos. A. Bank Clothiers Inc to $63.50 per share from $57.50.With the day's gains, the S&P 500 turned positive for the year while the Nasdaq hit a 14-year high. More than two-thirds of companies traded on the New York Stock Exchange rose on the day, while 63 percent of Nasdaq-listed companies gained.The S&P 500 broke above 1,841, which seemed to propel further gains.""That, probably from a technical perspective, provided some enthusiasm for stocks,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia. Also boosting stocks was news that Ukrainian President Viktor Yanukovich was ousted. While that leaves a potential power vacuum and an ailing economy, it calmed some worries.""The macroeconomic risk of some kind of encounter in the Ukraine seemed to dissipate with the removal of the president and some calm being restored,"" Luschini said.The Dow Jones industrial average rose 179.91 points, or 1.12 percent, to 16,283.21, the S&P 500 gained 19.54 points, or 1.06 percent, to 1,855.79 and the Nasdaq Composite  added 45.092 points, or 1.06 percent, to 4,308.502. Shares of RF climbed 20 percent to $6.96 while TriQuint gained 25.8 percent to $11.61. Men's Wearhouse rose 9 percent to $49.16 while Jos. A. Bank was up 8.2 percent at $59.58.Humana Inc and UnitedHealth Group were both among the S&P's biggest percentage gainers, with Humana up 8.2 percent to $111.24 after it said the government's proposed cuts to the private Medicare program appeared to be less than it had forecast. UnitedHealth rose 3 percent to $75.99.Aetna Inc rose 2.4 percent to $72.14 after giving a 2014 earnings outlook.Despite the day's gains, many investors were concerned that markets were becoming overvalued as recent economic data failed to meet expectations, though the weak data has largely been blamed on harsh winter weather rather than worsening fundamentals.Many traders are looking ahead to Thursday, when Federal Reserve Chair Janet Yellen will speak to the Senate Banking Committee in a semi-annual testimony about monetary policy.Yellen's comments will be scoured for insight into the extent to which bad weather has impacted economic activity, as well as for confirmation that the Fed will not make any changes to its schedule for trimming stimulus.",2014-02-24,HUM,"Mon Feb 24, 2014 | 2:43pm EST","US STOCKS-S&P 500 rises to record, Nasdaq climbs to 14-year high",http://www.reuters.com//article/markets-usa-stocks-idUSL1N0LT1PG20140224?type=companyNews
12,"  * Shares of U.S. health insurers rise, Humana up 9 pct* Funding decline of 3.5 - 4 pct vs expectations of 7 pct -Humana* Insurers expected to lobby for fewer cuts in final rule   (Adds details on other insurers, analyst comments, stock prices)By Caroline HumerFeb 24 U.S. health insurers including Humana Inc  said on Monday that the government's proposed cuts to privately run Medicare programs appear to represent a funding decline of around 4 percent, less than the possible cuts of 7 percent or deeper that analysts had been expecting.Shares of most insurers rose on Monday, with Humana leading the pack, up 9.2 percent at $112.29 on the New York Stock Exchange in early afternoon. Shares of UnitedHealth Group Inc  were up 2.8 percent at $75.91 and Aetna Inc was up 2.6 percent at $72.24. The U.S. Department of Health and Human Services late on Friday released its proposal for 2015 Medicare Advantage funding. The 148-page document includes details that the companies use to calculate the government funding for the program and to set next year's premiums.Analysts and some companies said on Friday their first look indicated that the cuts would be worse than the 7 percent expected by the industry, and would require deeper reductions in benefits for the program's elderly beneficiaries. Shares of insurers fell in after-hours trading on Friday.Republican lawmakers said the proposed funding was too low and would hurt the elderly and disabled, adding to the party's criticism of President Barack Obama's healthcare reform law. The Patient Protection and Affordable Care Act requires some cuts in Medicare funding and also introduces new taxes and fees. More than 15 million of nearly 50 million Americans eligible for Medicare are enrolled in Medicare Advantage plans, which are managed by private insurers.Insurer shares were higher on Monday as the view changed to a ""less-worse"" outcome, according to CRT Capital's Sheryl Skolnick. Insurers will likely lobby for less of a cut, but even if they fail to get it, she said, ""it's not the disaster people thought it could be.""Humana said in a regulatory filing on Monday that its analysis showed the proposed funding included cuts of about 3.5 percent to 4 percent. It had told investors earlier this month that it was anticipating a cut of 6 percent to 7 percent. The company said the funding calculation includes a positive effect of 3.25 percent from an increasing number of younger, healthier baby boomers in the mix of Medicare recipients.Humana also said that its analysis excluded risk assessments that it planned to protest and which could potentially result in additional significant funding declines. The government is expected to release final Medicare payment rates on April 7.An executive at another Medicare Advantage provider said on Monday that his company was also interpreting the proposal as a cut of about 4 percent. When the document was released on Friday, the company initially viewed the cut as 8 to 10 percent, but after further analysis over the weekend it found that the proposal actually included an unexpected increase in payments related to the baby boom population. The executive requested anonymity because he was not authorized to discuss the matter.A spokeswoman for Aetna said her company was still evaluating the rate notice, but that it believed any cuts on top of last year's 6 percent would disrupt the Medicare Advantage program and be harmful to seniors.One analyst, Ana Gupte of Leerink Research, said she believes the proposal represents a proposed cut of up to 7 percent but that industry lobbying will reduce the cut to 3.5 to 4 percent in the final rule.   (Reporting by Caroline Humer in New York; editing by Bernadette Baum and Matthew Lewis)",2014-02-24,HUM,"Mon Feb 24, 2014 | 12:44pm EST",UPDATE 1-U.S. insurers say proposed Medicare cuts less than feared,http://www.reuters.com//article/humana-medicare-idUSL1N0LT14C20140224?type=companyNews
13,"  * S&P 500 hits record, Nasdaq at 14-year high* Insurance stocks rise after Humana comments* Men's Wearhouse raises offer for Jos. A. Bank* Indexes up: Dow 1.1 pct, S&P 1.2 pct, Nasdaq 1.1 pctBy Ryan VlastelicaNEW YORK, Feb 24 U.S. stocks jumped 1 percent on Monday, with the S&P 500 climbing to an all-time high as optimism over merger activity helped Wall Street erase this year's early weakness.Gains were broad, with nine of the 10 S&P 500 sectors up on the day and a number of bellwethers, including Caterpillar Inc  and Merck & Co, hitting 52-week highs.With the day's gains, the S&P 500 turned positive for the year while the Nasdaq hit a 14-year high. More than two-thirds of companies traded on the New York Stock Exchange rose on the day, while 63 percent of Nasdaq-listed companies gained. ""People are recognizing that while some economic data has been muted, there is still a lot of value in the market based on corporate cash positions and multiples. From a perspective of overall fundamentals, things look pretty good, especially relative to other asset classes,"" said Matthew Keator, partner in the Keator Group, a wealth management firm in Lenox, Massachusetts.RF Micro Devices Inc agreed to buy TriQuint Semiconductor Inc for about $1.6 billion, while Men's Wearhouse Inc raised its cash tender offer for rival men's clothing retailer Jos. A. Bank Clothiers Inc to $63.50 per share from $57.50.Shares of RF climbed 16 percent to $6.77 while TriQuint gained 22 percent to $11.25. Men's Wearhouse rose 7.2 percent to $48.38 while Jos. A. Bank was up 8.4 percent at $59.65.Humana Inc and UnitedHealth Group were both among the S&P's biggest percentage gainers, with Humana up 8.2 percent to $111.24 after it said the government's proposed cuts to the private Medicare program appeared to be less than it had forecast. UnitedHealth rose 3 percent to $75.99. Aetna Inc rose 2.4 percent to $72.14 after giving a 2014 earnings outlook.The Dow Jones industrial average was up 181.61 points, or 1.13 percent, at 16,284.91. The Standard & Poor's 500 Index was up 21.09 points, or 1.15 percent, at 1,857.34. The Nasdaq Composite Index was up 45.62 points, or 1.07 percent, at 4,309.03.Despite the day's gains, many investors were concerned that markets were becoming over-valued as recent economic data failed to meet expectations, though the weak data has largely been blamed on harsh winter weather rather than worsening fundamentals. ""Seeing merger activity is a good sign for a continued growth market, but we've started to taper back our domestic holdings in favor of international markets which seem cheaper given the S&P's (price-to-earnings ratio),"" said Paul Radeke, vice president at the Minneapolis-based KDV Wealth Management, which has about $660 million in assets under management.Overseas markets remained in focus after Ukrainian President Viktor Yanukovich was ousted following deadly street protests, leaving a potential power vacuum and an ailing economy. Ukraine's finance ministry said the economy required $35 billion in foreign aid over the next two years, with the first tranche needed within two weeks.While most U.S. companies have limited direct exposure to Ukraine, investors worry that the instability in the region could spread throughout emerging markets.In the latest U.S. data, the Chicago Fed National Activity index fell to -0.39 in January from 0.16 in December while financial data firm Markit's preliminary February read on the services sector fell to 52.7 from 56.7.Pfizer Inc shares rose 1.7 percent to $31.98 after the company said that its drug Prevenar 13 prevented community-acquired pneumonia in individuals age 65 and older in a study.Many traders are looking ahead to Thursday, when Federal Reserve Chair Janet Yellen will speak to the Senate Banking Committee in her semi-annual testimony about monetary policy.Yellen's comments will be scoured for insight into the extent to which bad weather has impacted economic activity, as well as for confirmation that the Fed will not make any changes to its schedule for trimming stimulus.",2014-02-24,HUM,"Mon Feb 24, 2014 | 12:09pm EST","US STOCKS-S&P 500 at record in broad rally, Nasdaq at 14-year high",http://www.reuters.com//article/markets-usa-stocks-idUSL1N0LT1B020140224?type=companyNews
14,"  * S&P 500 hits record on merger, acquisition activity* Insurance stocks rise after Humana comments* Men's Wearhouse raises offer for Jos. A. Bank* Indexes up: Dow 0.8 pct, S&P 0.7 pct, Nasdaq 0.8 pctBy Ryan VlastelicaNEW YORK, Feb 24 U.S. stocks rose on Monday, advancing in a broad rally as merger activity boosted the S&P 500 to an all-time high.Despite the day's gains, many investors were concerned that markets were getting overvalued with recent data failing to meet expectations, though the latter has largely been blamed on harsh winter weather rather than worsening fundamentals.RF Micro Devices Inc agreed to buy TriQuint Semiconductor Inc for about $1.6 billion, while Men's Wearhouse Inc raised its cash tender offer for rival men's clothing retailer Jos. A. Bank Clothiers Inc JOSB.O to $63.50 per share from $57.50. Shares of RF climbed 15.5 percent to $6.70 while TriQuint gained 20 percent to $11.04. Men's Wearhouse rose 7.7 percent to $48.57 while Jos. A. Bank was up 8.8 percent at $59.89.""Seeing merger activity is a good sign for a continued growth market, but we've started to taper back our domestic holdings in favor of international markets which seem cheaper given the S&P's (price-to-earnings ratio),"" said Paul Radeke, vice president at the Minneapolis-based KDV Wealth Management, which has about $660 million in assets under management.Monday's deals followed Facebook's massive acquisition of messaging company WhatsApp last week.Humana Inc and UnitedHealth Group were both among the S&P's biggest percentage gainers, with Humana up 5.5 percent to $109.24 after it said the government's proposed cuts to the private Medicare program appeared less than it had forecast. UnitedHealth rose 3.1 percent to $76.09. Aetna Inc rose 1.6 percent to $71.52 after giving a 2014 earnings outlook.The Dow Jones industrial average was up 126.53 points, or 0.79 percent, at 16,229.83. The Standard & Poor's 500 Index was up 13.68 points, or 0.74 percent, at 1,849.93. The Nasdaq Composite Index was up 31.93 points, or 0.75 percent, at 4,295.34.Nine of the S&P's 10 sectors rose on the day, with energy shares up 1.7 percent following positive comments from KLR Group on Noble Energy, which jumped 4.3 percent to $69.74. More than two-thirds of companies traded on the New York Stock Exchange rose on the day, while 63 percent of Nasdaq-listed companies gained. Overseas markets remained in focus after Ukrainian President Viktor Yanukovich was ousted following deadly street protests, leaving a potential power vacuum and an ailing economy. Ukraine's finance ministry said the economy required $35 billion in foreign aid over the next two years, with the first tranche needed within two weeks.While most U.S. companies have limited direct exposure to Ukraine, investors worry that the instability in the region could spread throughout emerging markets.In the latest U.S. data, the National Activity index fell to -0.39 in January from 0.16 in December while financial data firm Markit's preliminary February read on the services sector fell from 56.7 to 52.7.Pfizer Inc shares rose 1.4 percent to $31.91 after the company said that its drug Prevenar 13 prevented community-acquired pneumonia in individuals age 65 and older in a study.Verizon Communications Inc dipped 1.2 percent to $46.70 after the company gave a 2014 revenue outlook.Many traders are looking ahead to Thursday, when Federal Reserve Chair Janet Yellen will speak to the Senate Banking Committee in her semi-annual testimony about monetary policy.Yellen's comments will be scoured for insight into the extent to which bad weather has impacted economic activity, as well as for confirmation that the Fed will not make any changes to its schedule for trimming stimulus.",2014-02-24,HUM,"Mon Feb 24, 2014 | 10:39am EST",US STOCKS-S&P 500 hits record in broad market rally,http://www.reuters.com//article/markets-usa-stocks-idUSL1N0LT13L20140224?type=companyNews
15,"  Feb 24 Humana Inc said on Monday that the government's proposed cuts to the private Medicare program appear to represent a funding decline of about 3.5 percent to 4 percent, less than the 6 percent to 7 percent it had expected.Shares in Humana rose 7.6 percent in morning trading.The U.S. Department of Health and Human Services on Friday released its proposal for 2015 Medicare Advantage funding. The proposal includes many factors that are used to determine funding, which can vary by plan. Analysts said then the cuts appeared worse than the 7 percent decline that they had been expecting at most. Humana, which manages Medicare Advantage plans for the government, said in a regulatory filing on Monday that its analysis excluded risk assessments that it planned to protest and which could potentially result in additional significant funding declines. Insurers have 45 days from the time of the announcement to voice their concerns and a final version of the rule will be published on April 7.Shares in UnitedHealth Group Inc rose 3.3 percent to $76.23.",2014-02-24,HUM,"Mon Feb 24, 2014 | 10:17am EST",Humana says proposed Medicare cuts appear less than it forecast,http://www.reuters.com//article/humana-medicare-idUSL1N0LT11E20140224?type=companyNews
16,"   By Caroline Humer  U.S. health insurers including Humana Inc said on Monday that the government's proposed cuts to privately run Medicare programs appear to represent a funding decline of around 4 percent, less than the possible cuts of 7 percent or deeper that analysts had been expecting.Shares of most insurers rose on Monday, with Humana leading the pack, up 9.2 percent at $112.29 on the New York Stock Exchange in early afternoon. Shares of UnitedHealth Group Inc were up 2.8 percent at $75.91 and Aetna Inc was up 2.6 percent at $72.24.The U.S. Department of Health and Human Services late on Friday released its proposal for 2015 Medicare Advantage funding. The 148-page document includes details that the companies use to calculate the government funding for the program and to set next year's premiums.Analysts and some companies said on Friday their first look indicated that the cuts would be worse than the 7 percent expected by the industry, and would require deeper reductions in benefits for the program's elderly beneficiaries. Shares of insurers fell in after-hours trading on Friday.Republican lawmakers said the proposed funding was too low and would hurt the elderly and disabled, adding to the party's criticism of President Barack Obama's healthcare reform law. The Patient Protection and Affordable Care Act requires some cuts in Medicare funding and also introduces new taxes and fees. More than 15 million of nearly 50 million Americans eligible for Medicare are enrolled in Medicare Advantage plans, which are managed by private insurers.Insurer shares were higher on Monday as the view changed to a ""less-worse"" outcome, according to CRT Capital's Sheryl Skolnick. Insurers will likely lobby for less of a cut, but even if they fail to get it, she said, ""it's not the disaster people thought it could be."" Humana said in a regulatory filing on Monday that its analysis showed the proposed funding included cuts of about 3.5 percent to 4 percent. It had told investors earlier this month that it was anticipating a cut of 6 percent to 7 percent.The company said the funding calculation includes a positive effect of 3.25 percent from an increasing number of younger, healthier baby boomers in the mix of Medicare recipients.Humana also said that its analysis excluded risk assessments that it planned to protest and which could potentially result in additional significant funding declines. The government is expected to release final Medicare payment rates on April 7. An executive at another Medicare Advantage provider said on Monday that his company was also interpreting the proposal as a cut of about 4 percent. When the document was released on Friday, the company initially viewed the cut as 8 to 10 percent, but after further analysis over the weekend it found that the proposal actually included an unexpected increase in payments related to the baby boom population. The executive requested anonymity because he was not authorized to discuss the matter.A spokeswoman for Aetna said her company was still evaluating the rate notice, but that it believed any cuts on top of last year's 6 percent would disrupt the Medicare Advantage program and be harmful to seniors.One analyst, Ana Gupte of Leerink Partners, said she believes the proposal represents a proposed cut of up to 7 percent but that industry lobbying will reduce the cut to 3.5 to 4 percent in the final rule.(Reporting by Caroline Humer in New York; Editing by Bernadette Baum and Matthew Lewis)",2014-02-25,HUM,"Tue Feb 25, 2014 | 12:46pm EST",U.S. insurers say proposed Medicare cuts less than feared,http://www.reuters.com//article/us-humana-medicare-idUSBREA1O1FS20140225?type=companyNews
17,"  (Corrects firm's name to Leerink Partners, from Leerink Research, in final paragraph)* Shares of U.S. health insurers rise, Humana up 9 pct* Funding decline of 3.5 - 4 pct vs expectations of 7 pct -Humana* Insurers expected to lobby for fewer cuts in final ruleBy Caroline HumerFeb 24 U.S. health insurers including Humana Inc  said on Monday that the government's proposed cuts to privately run Medicare programs appear to represent a funding decline of around 4 percent, less than the possible cuts of 7 percent or deeper that analysts had been expecting.Shares of most insurers rose on Monday, with Humana leading the pack, up 9.2 percent at $112.29 on the New York Stock Exchange in early afternoon. Shares of UnitedHealth Group Inc  were up 2.8 percent at $75.91 and Aetna Inc was up 2.6 percent at $72.24. The U.S. Department of Health and Human Services late on Friday released its proposal for 2015 Medicare Advantage funding. The 148-page document includes details that the companies use to calculate the government funding for the program and to set next year's premiums.Analysts and some companies said on Friday their first look indicated that the cuts would be worse than the 7 percent expected by the industry, and would require deeper reductions in benefits for the program's elderly beneficiaries. Shares of insurers fell in after-hours trading on Friday.Republican lawmakers said the proposed funding was too low and would hurt the elderly and disabled, adding to the party's criticism of President Barack Obama's healthcare reform law. The Patient Protection and Affordable Care Act requires some cuts in Medicare funding and also introduces new taxes and fees. More than 15 million of nearly 50 million Americans eligible for Medicare are enrolled in Medicare Advantage plans, which are managed by private insurers.Insurer shares were higher on Monday as the view changed to a ""less-worse"" outcome, according to CRT Capital's Sheryl Skolnick. Insurers will likely lobby for less of a cut, but even if they fail to get it, she said, ""it's not the disaster people thought it could be.""Humana said in a regulatory filing on Monday that its analysis showed the proposed funding included cuts of about 3.5 percent to 4 percent. It had told investors earlier this month that it was anticipating a cut of 6 percent to 7 percent. The company said the funding calculation includes a positive effect of 3.25 percent from an increasing number of younger, healthier baby boomers in the mix of Medicare recipients.Humana also said that its analysis excluded risk assessments that it planned to protest and which could potentially result in additional significant funding declines. The government is expected to release final Medicare payment rates on April 7.An executive at another Medicare Advantage provider said on Monday that his company was also interpreting the proposal as a cut of about 4 percent. When the document was released on Friday, the company initially viewed the cut as 8 to 10 percent, but after further analysis over the weekend it found that the proposal actually included an unexpected increase in payments related to the baby boom population. The executive requested anonymity because he was not authorized to discuss the matter.A spokeswoman for Aetna said her company was still evaluating the rate notice, but that it believed any cuts on top of last year's 6 percent would disrupt the Medicare Advantage program and be harmful to seniors.One analyst, Ana Gupte of Leerink Partners, said she believes the proposal represents a proposed cut of up to 7 percent but that industry lobbying will reduce the cut to 3.5 to 4 percent in the final rule.   (Reporting by Caroline Humer in New York; Editing by Bernadette Baum and Matthew Lewis)",2014-02-25,HUM,"Tue Feb 25, 2014 | 12:39pm EST",CORRECTED-UPDATE 1-U.S. insurers say proposed Medicare cuts less than feared,http://www.reuters.com//article/humana-medicare-idUSL1N0LT14C20140225?type=companyNews
18,"   By Caroline Humer | NEW YORK, March 11  NEW YORK, March 11 U.S. health insurers are struggling to set prices for their Obamacare plans in 2015 and decide which regions to return to before the deadlines for submitting those plans to regulators.Some insurers already expect to lose money this year following the rocky launch of President Barack Obama's Affordable Care Act, which aims to provide coverage to millions of uninsured Americans with the help of government subsidies. The rollout was marred by technical errors that held up early enrollment, last-minute regulatory changes and steady political opposition from Republicans.For 2015, insurers must describe their health plans and proposed rates to state and federal regulators starting in April and May. But before they do, some of the most important factors that go into those decisions may not be known, from the size of the doctor and hospital networks that the federal government will approve to final 2014 enrollment figures and the relative health of their new plan holders.Without that data, said Jon Urbanek, senior vice president of commercial markets at Florida's market-leading Blue Cross Blue Shield, ""I can't tell you exactly yet that we've decided about counties and products and all those pieces, but we feel like participating in the marketplaces is very consistent with our mission.""Cigna Corp Chief Executive Officer David Cordani said the nation's fifth-largest insurer was still undecided on which if any new markets it might enter, although ""that decision needs to be made in short order,"" he said in an interview.The result, industry executives and experts say, is that some of the larger insurers may pull out of individual markets where they already know they can't make money. Otherwise they will try to hold steady until 2016, when the number of people on Obamacare plans is expected to surge as high as 22 million.Some smaller insurers offering health plans in 2014 may back out altogether if they can't afford to ride out the program's early troubles.""There will be some sort of a shakeout,"" said Tim Jost, a health law expert and professor at Washington and Lee University in Virginia. Small health plans and cooperatives that priced their health coverage too high and got few customers are among the most vulnerable, he said. ""On the other hand, (the national insurers) have been watching the markets, and if 2014 turns out to look better than expected, they may jump in,"" Jost said.John Morrison, who founded The National Alliance of State Health CO-OPs, a trade group, was more optimistic about the small insurers. He said the coops have low overhead and are required to keep enough capital on hand to last them into at least the second or third year of the exchanges. They will all be open, he believes, and enrolling new customers in 2015.PRICE, POLICY SURPRISES  A handful of large insurers have won most of the customers so far among more than 100 active on the Obamacare marketplaces in the 50 states. By their own estimates, WellPoint, Aetna Inc, Humana Inc, and Health Net  together pulled in about 970,000 enrollment applications by the end of January out of about 3 million nationwide at that time.But large insurers including Cigna and Aetna said they do not expect to make money this year on the new Obamacare exchanges.In January, Aetna Chief Executive Officer Mark Bertolini suggested that the company's participation in 2015 could depend on whether the administration would allow it to raise rates enough to cover expenses.""Are (rate increases) going to be double-digit, and are we going to get beat up because of the double digit, or are we going to just have to pull out of the program? Those questions can't be answered until we see the population we have today,"" he said in an interview with cable news channel CNBC. Health Net said it is breaking even on its exchange customers after hitting targets in Southern California, its largest market. As of early February it had signed up 168,000 people in California and Arizona.""I feel like we're all in and we are happy we are,"" Health Net Inc CEO Jay Gellert told investors in January.Insurers are also bracing for more late policy changes that could disrupt the Obamacare business model. Just last week the administration said it would allow insurers to extend by two more years health policies that were supposed to end in 2014 because they don't comply with the healthcare law.""We expect consumers will continue to have a robust number of plan choices available to them for the 2015 open enrollment season as insurance companies compete for the business of millions of Americans seeking coverage with the assistance of tax credits,"" said Aaron Albright, a spokesman for the Centers for Medicare and Medicaid Services, which oversees the Obamacare marketplaces.Actuaries, who help insurers calculate what rates to charge, note that the government's most recent guidance to the industry, in the form of a 300-page report released last week, raised new questions on how to predict the Obamacare market in 2015.For instance, the government said it is still considering what percentage of health insurance premiums paid to insurers must be used to cover medical expenses rather than administrative costs, a decision that could directly impact industry profits.""Even when something is a final rule it has not meant that it is not subject to further change,"" said Hans Leida, an actuary at Milliman, referring to the government's regulation of Obamacare. ""There is still great uncertainty to come.""",2014-03-11,HUM,"Tue Mar 11, 2014 | 5:31pm EDT",Insurers wary of Obamacare unknowns as they plan for 2015,http://www.reuters.com//article/usa-healthcare-insurers-idUSL1N0M31BY20140311?type=companyNews
19,"  LONDON The founder of Britain's Sports Direct (SPD.L) has bought an 11 percent stake in House of Fraser, a source close to the deal said, only days after China's Sanpower Group agreed to buy a 89 percent in the British department store.Mike Ashley, who holds 62 percent of sport goods retailer Sports Direct, the firm he founded in 1982, has long been linked to attempts to acquire Britain's House of Fraser and finally bought the stake this week from Scottish tycoon Tom Hunter, the source said.British media said the deal was worth 50 million pounds.It was unclear however whether Ashley, who also owns English Premier League soccer club Newcastle United, had bought the stake personally or done so via Sports Direct, but media reports said it was likely to be the latter. On Friday a source said China's Sanpower Group SPGCL.UL had agreed to buy an 89 percent stake in the 160-year-old House of Fraser in a deal valuing the department store at over 450 million pounds ($746 million), including debt. House of Fraser trades from 61 stores in Britain and Ireland and has annual sales of about 1.2 billion pounds.Sports Direct, which has over 600 sports stores in Europe, including 400 in the UK, grew rapidly during the economic downturn on demand for its value offers, supported by a mixture of acquisitions, expanding online sales and the demise of rivals like JJB Sports. Sports Direct and House of Fraser declined to comment.(Reporting by Neil Maidment; Writing by Silvia Antonioli; editing by David Evans)",2014-04-06,HUM,"Sun Apr 6, 2014 | 7:03am EDT",Sports Direct founder buys stake in House of Fraser,http://www.reuters.com//article/us-house-of-fraser-sports-direct-idUSBREA3506G20140406?type=companyNews
20,"  LONDON, April 6 The founder of Britain's Sports Direct has bought an 11 percent stake in House of Fraser, a source close to the deal said, only days after China's Sanpower Group agreed to buy a 89 percent in the British department store.Mike Ashley, who holds 62 percent of sport goods retailer Sports Direct, the firm he founded in 1982, has long been linked to attempts to acquire Britain's House of Fraser and finally bought the stake this week from Scottish tycoon Tom Hunter, the source said.British media said the deal was worth 50 million pounds. It was unclear however whether Ashley, who also owns English Premier League soccer club Newcastle United, had bought the stake personally or done so via Sports Direct, but media reports said it was likely to be the latter.On Friday a source said China's Sanpower Group  had agreed to buy an 89 percent stake in the 160-year-old House of Fraser in a deal valuing the department store at over 450 million pounds ($746 million), including debt. House of Fraser trades from 61 stores in Britain and Ireland and has annual sales of about 1.2 billion pounds. Sports Direct, which has over 600 sports stores in Europe, including 400 in the UK, grew rapidly during the economic downturn on demand for its value offers, supported by a mixture of acquisitions, expanding online sales and the demise of rivals like JJB Sports.Sports Direct and House of Fraser declined to comment.   (Reporting by Neil Maidment; Writing by Silvia Antonioli; editing by David Evans)",2014-04-06,HUM,"Sun Apr 6, 2014 | 6:58am EDT",Sports Direct founder buys stake in House of Fraser,http://www.reuters.com//article/house-of-fraser-sports-direct-idUSL6N0MY0C720140406?type=companyNews
21,"   By Caroline Humer  Managed care company Humana Inc said on Wednesday it expects revenue to grow this year as it adds hundreds of thousands of new customers to its Obamacare plans, despite government funding cuts to its largest business, Medicare Advantage for seniors. Humana stood by its forecast for a decline in profit this year, however, saying that it was still not sure about the health costs of the new individual customers or how much it will charge for premium prices in 2015 and 2016. The company said it expects government payments this year of $575 million to $775 million in 2014 to offset its outsized risk on the new clients who signed up under President Barack Obama's healthcare law. Many of them were previously uninsured.Humana is seeking to raise Obamacare premium rates by single to double-digit percentages for 2015, in part to offset declining risk payments next year. Humana is ""just beginning"" to work with state and federal regulators on how the individual exchange business will transition off these payments, which mostly end after 2016.Obama's healthcare reform law, which is vehemently opposed by Republicans, is being scrutinized to determine if its costs will be sustainable. The plans, which are sold both on and off exchanges created by the government, come with income-based subsidies and must meet new benefits standards set by the government.     Humana said it has received 700,000 applications for individual healthcare plans for 2014, putting it on track to be one of the largest players on the exchanges. Humana said it has studied the pharmacy claims of its early enrollees and that their health appears in line with previous expectations. Humana said it rolled back its view on the health of its customers three months ago after the government decided to allow the extension of some plans that don't comply with the new law, known as the Affordable Care Act, altering the make-up of the pool of customers.This forecast comes in contrast to rival WellPoint Inc, which reported similar sized exchange enrollment last week but said it is making money off its new customers and does not expect to receive any payments from the government.""There's a lot of uncertainty,"" said Morningstar Research analyst Vishnu Lekraj. ""We haven't seen a whole quarter or two of claims activity from the exchanges. We don't know what's going to happen there."" Humana shares were up 1.9 percent at $111.86 in Wednesday morning trading. UnitedHealth Group Inc, WellPoint, Aetna Inc and Cigna Corp. were all trading slightly higher.Humana said it will add 435,000 people this year to Medicare Advantage plans. At the end of the first quarter, it had about 2.8 million people in these plans, which are offered to seniors.Humana had warned earlier this year that government funding cuts would negatively effect its Medicare Advantage business. On Wednesday it estimated a 2 percent cut to funding for 2015 based on the government payment rates, a smaller amount than its previous view of 3 percent. The company stuck by its outlook for earnings of $7.25 to $7.75 per share, which it said has factored in higher-than-expected costs for new Hepatitis C treatments of about 40 cents to 50 cents per share. It spent $20 million on these drugs in Medicare programs during the first quarter, offseting some lower medical services use.The company reported net profit of $368 million, or $2.35 per share, down from $473 million, or $2.95 per share a year earlier. The year-earlier figure included a 41 cent-per-share benefit from settling contract claims.The company's earnings beat analyst expectations of $1.94 per share, according to ThomsonReuters I/B/E/S. (Reporting by Caroline Humer; Editing by W Simon and Sofina Mirza-Reid)",2014-05-07,HUM,"Wed May 7, 2014 | 12:52pm EDT",Humana sees 2014 membership growth as Obamacare sales surge,http://www.reuters.com//article/us-humana-results-idUSKBN0DN0NS20140507?type=companyNews
22,"   By Caroline Humer  Managed care company Humana Inc (HUM.N) said on Wednesday it expects revenue to grow this year as it adds hundreds of thousands of new customers to its Obamacare plans, despite government funding cuts to its largest business, Medicare Advantage for seniors.Humana stood by its forecast for a decline in profit this year, however, saying that it was still not sure about the health costs of the new individual customers or how much it will charge for premium prices in 2015 and 2016.The company said it expects government payments this year of $575 million to $775 million in 2014 to offset its outsized risk on the new clients who signed up under President Barack Obama's healthcare law. Many of them were previously uninsured.Humana is seeking to raise Obamacare premium rates by single to double-digit percentages for 2015, in part to offset declining risk payments next year. Humana is ""just beginning"" to work with state and federal regulators on how the individual exchange business will transition off these payments, which mostly end after 2016.Obama's healthcare reform law, which is vehemently opposed by Republicans, is being scrutinized to determine if its costs will be sustainable. The plans, which are sold both on and off exchanges created by the government, come with income-based subsidies and must meet new benefits standards set by the government. Humana said it has received 700,000 applications for individual healthcare plans for 2014, putting it on track to be one of the largest players on the exchanges.Humana said it has studied the pharmacy claims of its early enrollees and that their health appears in line with previous expectations. Humana said it rolled back its view on the health of its customers three months ago after the government decided to allow the extension of some plans that don't comply with the new law, known as the Affordable Care Act, altering the make-up of the pool of customers.This forecast comes in contrast to rival WellPoint Inc WLP.N, which reported similar sized exchange enrollment last week but said it is making money off its new customers and does not expect to receive any payments from the government. ""There's a lot of uncertainty,"" said Morningstar Research analyst Vishnu Lekraj. ""We haven't seen a whole quarter or two of claims activity from the exchanges. We don't know what's going to happen there.""Humana shares were up 1.9 percent at $111.86 in Wednesday morning trading. UnitedHealth Group Inc (UNH.N), WellPoint, Aetna Inc (AET.N) and Cigna Corp (CI.N). were all trading slightly higher.Humana said it will add 435,000 people this year to Medicare Advantage plans. At the end of the first quarter, it had about 2.8 million people in these plans, which are offered to seniors. Humana had warned earlier this year that government funding cuts would negatively effect its Medicare Advantage business. On Wednesday it estimated a 2 percent cut to funding for 2015 based on the government payment rates, a smaller amount than its previous view of 3 percent.The company stuck by its outlook for earnings of $7.25 to $7.75 per share, which it said has factored in higher-than-expected costs for new Hepatitis C treatments of about 40 cents to 50 cents per share. It spent $20 million on these drugs in Medicare programs during the first quarter, offseting some lower medical services use.The company reported net profit of $368 million, or $2.35 per share, down from $473 million, or $2.95 per share a year earlier. The year-earlier figure included a 41 cent-per-share benefit from settling contract claims.The company's earnings beat analyst expectations of $1.94 per share, according to ThomsonReuters I/B/E/S.(Reporting by Caroline Humer; Editing by W Simon and Sofina Mirza-Reid)",2014-05-07,HUM,"Wed May 7, 2014 | 12:50pm EDT",Humana sees 2014 membership growth as Obamacare sales surge,http://www.reuters.com//article/us-humana-results-idUSBREA460BA20140507?type=companyNews
23,"  (Adds more details on exchanges)By Caroline HumerMay 7 Managed care company Humana Inc  said on Wednesday it expects revenue to grow this year as it adds hundreds of thousands of new customers to its Obamacare plans, despite government funding cuts to its largest business, Medicare Advantage for seniors.Humana stood by its forecast for a decline in profit this year, however, saying that it was still not sure about the health costs of the new individual customers or how much it will charge for premium prices in 2015 and 2016.The company said it expects government payments this year of $575 million to $775 million in 2014 to offset its outsized risk on the new clients who signed up under President Barack Obama's healthcare law. Many of them were previously uninsured.Humana is seeking to raise Obamacare premium rates by single to double-digit percentages for 2015, in part to offset declining risk payments next year. Humana is ""just beginning"" to work with state and federal regulators on how the individual exchange business will transition off these payments, which mostly end after 2016. Obama's healthcare reform law, which is vehemently opposed by Republicans, is being scrutinized to determine if its costs will be sustainable. The plans, which are sold both on and off exchanges created by the government, come with income-based subsidies and must meet new benefits standards set by the government.Humana said it has received 700,000 applications for individual healthcare plans for 2014, putting it on track to be one of the largest players on the exchanges.Humana said it has studied the pharmacy claims of its early enrollees and that their health appears in line with previous expectations. Humana said it rolled back its view on the health of its customers three months ago after the government decided to allow the extension of some plans that don't comply with the new law, known as the Affordable Care Act, altering the make-up of the pool of customers. This forecast comes in contrast to rival WellPoint Inc , which reported similar sized exchange enrollment last week but said it is making money off its new customers and does not expect to receive any payments from the government.""There's a lot of uncertainty,"" said Morningstar Research analyst Vishnu Lekraj. ""We haven't seen a whole quarter or two of claims activity from the exchanges. We don't know what's going to happen there.""Humana shares were up 1.9 percent at $111.86 in Wednesday morning trading. UnitedHealth Group Inc, WellPoint, Aetna Inc and Cigna Corp. were all trading slightly higher. Humana said it will add 435,000 people this year to Medicare Advantage plans. At the end of the first quarter, it had about 2.8 million people in these plans, which are offered to seniors.Humana had warned earlier this year that government funding cuts would negatively effect its Medicare Advantage business. On Wednesday it estimated a 2 percent cut to funding for 2015 based on the government payment rates, a smaller amount than its previous view of 3 percent.The company stuck by its outlook for earnings of $7.25 to $7.75 per share, which it said has factored in higher-than-expected costs for new Hepatitis C treatments of about 40 cents to 50 cents per share. It spent $20 million on these drugs in Medicare programs during the first quarter, offseting some lower medical services use.The company reported net profit of $368 million, or $2.35 per share, down from $473 million, or $2.95 per share a year earlier. The year-earlier figure included a 41 cent-per-share benefit from settling contract claims.The company's earnings beat analyst expectations of $1.94 per share, according to ThomsonReuters I/B/E/S.   (Reporting by Caroline Humer; Editing by W Simon and Sofina Mirza-Reid)",2014-05-07,HUM,"Wed May 7, 2014 | 12:50pm EDT",UPDATE 3-Humana sees 2014 membership growth as Obamacare sales surge,http://www.reuters.com//article/humana-results-idUSL2N0NT0DK20140507?type=companyNews
24,"  Managed care company Humana Inc. said on Wednesday it expects a percentage rise in the single-digits to the double-digits in the premium rates for 2015 individual health plans that comply with the national healthcare reform law.Humana executives said during a conference call that those rate increases are partly due to the extension of some existing individual healthcare policies that are believed to have diverted some healthier people from the pool of new policy holders. They also reflect a scheduled decline in 2015 risk-related payments to insurers who sell plans on the exchanges, Humana executives said.    (Reporting by Caroline Humer; Editing by Alden Bentley)",2014-05-07,HUM,"Wed May 7, 2014 | 9:52am EDT",Humana says expects 2015 exchange rate increases,http://www.reuters.com//article/us-humana-results-rates-idUSKBN0DN0ZM20140507?type=companyNews
25,"  May 7 Managed care company Humana Inc.  said on Wednesday it expects a percentage rise in the single-digits to the double-digits in the premium rates for 2015 individual health plans that comply with the national healthcare reform law.Humana executives said during a conference call that those rate increases are partly due to the extension of some existing individual healthcare policies that are believed to have diverted some healthier people from the pool of new policy holders. They also reflect a scheduled decline in 2015 risk-related payments to insurers who sell plans on the exchanges, Humana executives said.  (Reporting by Caroline Humer; Editing by Alden Bentley)",2014-05-07,HUM,"Wed May 7, 2014 | 9:45am EDT",Humana says expects 2015 exchange rate increases,http://www.reuters.com//article/humana-results-rates-idUSL2N0NT0SV20140507?type=companyNews
26,  May 7 Humana Inc Chief Executive Officer Bruce Broussard said on Wednesday the managed health care company spent $20 million on Hepatitis C drugs for Medicare Advantage and Medicare Part D customers during the first quarter. Broussard said during a conference call with investors that the company has factored higher drug costs into its 2014 earnings outlook and is watching closely to see if there is another increase in use after the release of the next new drug later this year.   (Reporting by Caroline Humer; Editing by Jeffrey Benkoe)  ,2014-05-07,HUM,"Wed May 7, 2014 | 9:18am EDT",Humana CEO says spent $20 million on Hepatitis C drugs,http://www.reuters.com//article/humana-results-ceo-idUSL2N0NT0QM20140507?type=companyNews
27,"  May 7 Humana Inc said on Wednesday that first-quarter profit fell as it spent more on marketing and investments related to new products, such as certain Medicare Advantage and Obamacare exchange plans, as well as healthcare reform taxes and fees.The company reported net profit of $368 million, or $2.35 per share, down from $473 million, or $2.95 per share a year earlier. The year-earlier figure included a 41 cent-per-share benefit from settling contract claims.  Humana kept its 2014 outlook unchanged at $7.25 to $7.75 per share, which it said accounted for such factors as better performance across its businesses but higher-than-expected drug costs for the treatment of Hepatitis C.   (Reporting by Caroline Humer Editing by W Simon) ",2014-05-07,HUM,"Wed May 7, 2014 | 6:22am EDT",Humana reports lower profit due to marketing costs,http://www.reuters.com//article/humana-results-idUSL2N0NS0Z820140507?type=companyNews
28,"   By Susan Kelly | June 2  June 2 Managed care company Humana Inc  has filed a lawsuit against Medtronic Inc accusing the medical device maker of falsely representing its Infuse bone growth-stimulation product as safe and effective in spinal fusion surgeries.The suit, filed on Friday in federal court in Tennessee, alleges that Medtronic paid for academic literature that fraudulently portrayed the product as safe and effective for uses not approved by the U.S. Food and Drug Administration.Humana said it paid for the use of Infuse, a bioengineered bone protein, when less expensive and more medically sound alternative procedures were available.It said Medtronic engaged in a ""sophisticated and deeply deceptive marketing strategy"" to expand the market for Infuse, paying and encouraging spine surgeons to use the product by overstating its benefits while minimizing serious risks. Medtronic, in a separate statement, said the product's label has reflected its risks from the time of FDA approval in 2002.""Medtronic strongly believes that the safety profile reported to the FDA and detailed in product labeling support the continued safe use of Infuse Bone Graft for approved indications,"" the company said.Medtronic also said it ""vigorously disagrees with any suggestion that the company improperly influenced peer-reviewed published manuscripts."" Physicians are compensated for intellectual property rights and for legitimate and documented consulting services provided to the company, Medtronic said.Independent reviews of the product initiated by Medtronic last year determined that Infuse works as well as traditional bone grafts taken from patients, but may not be as safe. The reviews were prompted by questions raised by spine experts and U.S. lawmakers about the safety of the product, which contains a genetically engineered protein known recombinant human bone morphogenetic protein 2 to promote bone growth.Infuse was once hailed as a major advance in spinal fusion surgery, offering an alternative to painful bone harvesting from other parts of the body to perform a bone graft.But in 2011, Infuse became the subject of investigations by the U.S. Senate and Department of Justice over off-label use of the product and omissions of safety problems from its clinical trial data.The product also drew intense public scrutiny after the influential Spine Journal ran an entire issue criticizing it in June 2011, charging that surgeons who were paid tens of millions of dollars by Medtronic failed to report serious complications such as male sterility, increased risk of cancer, infections, pain and bone dissolution.   (Reporting by Susan Kelly in Chicago; Editing by Eric Walsh)",2014-06-02,HUM,"Mon Jun 2, 2014 | 3:48pm EDT",Humana sues Medtronic over Infuse bone growth product,http://www.reuters.com//article/medtronic-humana-lawsuit-idUSL1N0OJ1OE20140602?type=companyNews
29,"  U.S. health insurer Humana Inc reported a lower profit owing to higher costs on Wednesday, as mounting concerns about increased medical spending drove health insurance industry shares lower for a second straight day.Humana said its higher costs were related to medical spending by new enrollees in the exchanges created under President Barack Obama's healthcare reform law, investments for those exchanges and costly new hepatitis C drug treatments.Humana shares fell 6.5 percent to $119.26, while WellPoint Inc, which also announced earnings on Wednesday, declined 1.9 percent to $110.45. Aetna Inc, which reported higher medical costs on Tuesday, fell 3.8 percent, UnitedHealth Group Inc declined 2.7 percent and Cigna, which reports on Thursday, fell 1.9 percent.Investor concerns about rising costs coincide with a rise in the rate of people with health insurance. The Obamacare exchanges signed up 8 million people for their first year in 2014, while enrollment in the government's Medicaid program for the poor has swelled by 7 million. Hospitals including HCA Holdings Inc have reported increased use of their services. ""Moving forward, the economy should increase utilization of services and plan costs should go up accordingly. That's just natural when the economy starts to pick up and people use healthcare benefits a little bit more liberally,"" Morningstar Research analyst Vishnu Lekraj said. U.S. economic growth rebounded in the second quarter, the Commerce Department said on Wednesday.  Humana's second-quarter net income fell to $344 million, or $2.19 per share, from $420 million, or $2.63 a share, a year earlier. That was in line with analysts' estimates.Most of Humana's revenue is from Medicare Advantage and Medicare Part D, the privately run medical and drug plans under the government health program for older people and the disabled. But revenue from Obamacare and other individual plans became a larger portion of its business, rising to $852 million from $241 million a year earlier.    Total revenue rose 18 percent to $12.2 billion. Both Medicare Advantage and Medicare Part D added new customers. The company's individual customer base increased 122 percent to more than 1.1 million members. Humana's medical benefit expense ratio, or the percentage of premiums spent on medical services, fell to 83.1 percent from 83.4 percent. Those ratios were higher in its retail and employer group, partly due to the cost of a new drug for hepatitis C from Gilead Sciences Inc, Humana said. Humana said it is losing money on its new Obamacare exchange customers but expects to break even in that market during 2015. Higher use of medical services by these consumers should taper off as it has in other businesses, Humana said.Humana predicted 2014 earnings per share of $7.25 to $7.75, lower than a Wall Street consensus of $7.84.      (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2014-07-30,HUM,"Wed Jul 30, 2014 | 1:34pm EDT",Humana shares fall as U.S. health insurer cost worries grow,http://www.reuters.com//article/us-humana-results-idUSKBN0FZ0YB20140730?type=companyNews
30,"  Humana Inc Chief Financial Officer Brian Kane said on Wednesday that customers who signed up later in the year for new individual health plans created under President Barack Obama's national healthcare reform law were healthier and younger.The plans went on sale on Jan. 1 and enrollment continued into April. Humana still expects to receive risk-related payments from the government of $575 million to $775 million in 2014 for reinsurance. Going forward, it said the pool of exchange customers will balance out in coming years and help offset the phase-out of most government risk payments.   (Reporting by Caroline Humer; Editing by Jeffrey Benkoe)",2014-07-30,HUM,"Wed Jul 30, 2014 | 10:11am EDT","Humana CFO says later Obamacare customers were younger, healthier",http://www.reuters.com//article/us-humana-results-cfo-idUSKBN0FZ1LT20140730?type=companyNews
31,"  July 30 Humana Inc Chief Financial Officer Brian Kane said on Wednesday that customers who signed up later in the year for new individual health plans created under President Barack Obama's national healthcare reform law were healthier and younger.The plans went on sale on Jan. 1 and enrollment continued into April. Humana still expects to receive risk-related payments from the government of $575 million to $775 million in 2014 for reinsurance.  Going forward, it said the pool of exchange customers will balance out in coming years and help offset the phase-out of most government risk payments.   (Reporting by Caroline Humer; Editing by Jeffrey Benkoe) ",2014-07-30,HUM,"Wed Jul 30, 2014 | 10:09am EDT","Humana CFO says later Obamacare customers were younger, healthier",http://www.reuters.com//article/humana-results-cfo-idUSL2N0Q517920140730?type=companyNews
32,"  (Adds revenue, membership growth)July 30 U.S. health insurer Humana Inc  said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments.Humana said membership growth and a lower share count due to stock buybacks had helped offset some of the new costs. The company said net income fell to $344 million, or $2.19 per share, from $420 million, or $2.63 a share, a year earlier. That was in line with analysts' estimates.Most of Humana's revenue is from Medicare Advantage and Medicare Part D, the privately run medical and drug plans under the government health program for older people and the disabled. Humana said revenue rose 18 percent to $12.2 billion. Both Medicare Advantage and Medicare Part D added new customers, and the company's individual customer base increased 122 percent to more than 1.1 million members. The company's medical benefit expense ratio, or the percentage of premiums spent on medical services, fell to 83.1 percent from 83.4 percent.Higher ratios in the retail and employer group, due in part to the expense of a new breakthrough drug for hepatitis C from Gilead Sciences Inc, were offset overall by exiting the Puerto Rico Medicaid business, Humana said.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2014-07-30,HUM,"Wed Jul 30, 2014 | 6:54am EDT","UPDATE 1-Humana says profit fell on health reform, drug costs",http://www.reuters.com//article/humana-results-idUSL2N0Q50IN20140730?type=companyNews
33,"  July 30 U.S. health insurer Humana Inc  said on Wednesday that second-quarter profit fell due to investments in the insurance exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments.Humana said membership growth and share buybacks had helped offset some of the new costs.  The company said net income fell to $344 million, or $2.19 per share, from $420 million, or $2.63 a share, a year earlier. That was in line with analysts' estimates.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn) ",2014-07-30,HUM,"Wed Jul 30, 2014 | 6:29am EDT","Humana says quarterly profit fell on health reform, drug costs",http://www.reuters.com//article/humana-results-idUSL2N0Q50IA20140730?type=companyNews
34,"  (The following statement was released by the rating agency) CHICAGO, August 14 (Fitch) Fitch Ratings has affirmed the 'BBB' ratings assigned  to Humana Inc.'s (HUM) senior unsecured notes and the 'A' Insurer Financial  Strength (IFS) ratings assigned to various Humana insurance company  subsidiaries. The Rating Outlooks are Stable.  HUM's 'A' IFS ratings reflect financial metrics and performance that in recent  years have generally been supportive of 'AA' category IFS ratings and the impact  of the companies' concentrations in the Medicare market in the U.S., the  characteristics of which Fitch views as supportive of IFS ratings in the 'A' to  'BBB' rating categories.         KEY RATING DRIVERS Industry Profile and Operating Environment: Fitch believes that the U.S.  Government's ability to set reimbursement rates and influence conditions in the  Medicare Advantage market makes it difficult for health insurers with Medicare  Advantage membership concentrations, such as HUM to generate sustained  EBITDA-based margins and capital stability required to support IFS ratings  higher than 'A'. Fitch views on-going federal government fiscal pressures and  heightened demands on Medicare tied to the aging U.S. population, as factors  that effectively limit the ratings levels of health insurers with membership  concentrations in Medicare Advantage. Favorably from a ratings perspective,  Fitch believes that these same fiscal and demographic pressures contribute to  consistent demand for Medicare Advantage products.  Market Position and Size/Scale: Fitch views HUM as maintaining 'medium' sized  market position and size/scale characteristics. Under Fitch's health insurance  rating guidelines, such characteristics are consistent with 'A' category IFS  ratings. HUM maintains a leading market share in the Medicare Advantage market  and the company's membership is well diversified throughout the country.  Additionally, HUM has built integrated delivery capabilities, primarily through  acquisitions, in geographic regions where the company maintains significant  membership. Fitch believes that HUM maintains large membership and revenue bases  that the help the company generate significant amounts of EBITDA and capital and  benefit from economies of scale.  Financial Performance and Earnings: Fitch believes that HUM's financial  performance and earnings over the next 12-24 months will remain supportive of  the company's ratings. Fitch's view is that HUM's market position, size and  scale characteristics and benefits derived from aspects of the company's  integrated care delivery capabilities will help offset margin pressure from  consistent reductions in Medicare funding rates, the Affordable Care Act's (ACA)  imposition of an 85% minimum benefit ratio on Medicare Advantage products, and  various ACA-related fees.  In recent years HUM's financial performance has been strong relative to Fitch's  'A' category guidelines. In the first half of 2014 HUM generated $24 billion of  revenues and $1.6 billion of EBITDA. The company's 1H'14 ratios of  EBITDA-to-revenues and annualized net return on average capital were 6.7X and  11.8% respectively and from 2011-2013 these ratios averaged 6.4% and 12.9%.  Capitalization and Financial Leverage: Fitch views HUM's targeted capitalization  and financial leverage metrics to be consistent with those expected at the 'A'  IFS rating category, while the company's reported metrics for the past several  years have been more consistent with those expected at the 'AA' rating category.  At June 30, 2014 HUM's ratio of debt-to-annualized EBITDA was 0.8X and its  financial leverage ratio was 21%. From 2011-2013 these ratios averaged 0.9x and  21% respectively. The company targets a debt-to-capital ratio of 25%-30% and  Fitch believes that debt-funded acquisitions and share repurchases are potential  ways in which HUM may manage its debt-to-capital ratio toward its target.    Debt Service Capabilities and Financial Flexibility: HUM's debt service  capabilities and financial flexibility have historically been consistent with  Fitch's 'AA' rating category guidelines.   The company's operating EBITDA-based  interest coverage ratio through 1H'14 was 23.0X and from 2011- 2013 averaged  21.2x. HUM has access to an untapped $1 billion credit facility that expires in  2018. At June 30, 2014, the company maintained $11.1 billion of cash and  high-quality and liquid investment securities that exceeded the value of its  medical benefit and future policy benefit reserves by $4 billion.    RATING SENSITIVITIES Key rating triggers that could lead to an upgrade of HUM's ratings are:  --Over the longer term, an improved outlook for Medicare Advantage funding;  --Reduced near-term uncertainty surrounding the impact on HUM's margins of the  Affordable Care Act's (ACA) minimum medical benefit ratio and industry-wide fees  designed to fund portions of the ACA;        --A reduction in HUM's targeted debt-to-capital ratio to 20% and increase in the  company's organization-wide NAIC RBC to 350%;  --Financial metrics, especially interest coverage and EBITDA/revenue margin  ratios that approximate current levels.    Key rating triggers that could lead to a downgrade of the ratings are:  --Over the longer-term, a deterioration in the outlook for Medicare Advantage  funding;  --EBITDA-based interest coverage and EBITDA/revenue ratios below 7x and 5%,  respectively; --Debt-to-annualized (prior four quarters) EBITDA ratios above 1.5x;  --HUM increasing its targeted or reported financial leverage ratio above 30% or  reducing its organization-wide NAIC RBC ratio target below 200%; --Acquisitions that Fitch views as aggressively financed or containing an  excessive amount of integration risk.   Fitch has affirmed the following ratings:  Humana, Inc.  --Long-term Issuer Default Rating (IDR) at 'BBB+' with a Stable Outlook; --$500 million of 6.45% senior unsecured notes due June 1, 2016 at 'BBB'; --$500 million of 7.2% senior unsecured notes due June 15, 2018 at 'BBB';  --$300 million of 6.3% senior unsecured notes due Aug. 1, 2018 at 'BBB';  --$600 million of 3.15% senior unsecured notes due Dec. 1, 2022 at 'BBB'; --$250 million of 8.15% senior unsecured notes due June 15, 2038 affirmed at  'BBB'; --$400 million of 4.625% senior unsecured notes due Dec. 1, 2042 at 'BBB'. The following companies' Insurer Financial Strength (IFS) ratings are affirmed  at 'A' with a Stable Outlook:   Humana Insurance Company Humana Medical Plan, Inc.  Humana Health Plan, Inc.  Humana Health Benefit Plan of Louisiana  Careplus Health Plans, Inc.  Contact: Primary Analyst Mark Rouck, CPA, CFA   Senior Director  +1-312-368-2085 Fitch Ratings, Inc. 70 W. Madison Street Chicago IL 60602 Secondary Analyst Greg Dickerson   Director  +1-212-908-0220  Committee Chairperson Martha M. Butler, CFA  Senior Director  +1-312-368-3191 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com' Applicable Criteria and Related Research:  --'Insurance Rating Methodology', November 2013; --'Health Insurance and Managed Care (U.S.) Sector Credit Factors, December  2013. Applicable Criteria and Related Research:  Insurance Rating Methodology  here Health Insurance and Managed Care (U.S.) here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-08-14,HUM,"Thu Aug 14, 2014 | 3:54pm EDT",Fitch Affirms Humana's Sr. Notes at 'BBB' & IFS Ratings at 'A'; Outlook Stable,http://www.reuters.com//article/fitch-affirms-humanas-sr-notes-at-bbb-if-idUSFit72473920140814?type=companyNews
35,"  (The following statement was released by the rating agency) CHICAGO, September 16 (Fitch) Fitch Ratings has assigned a 'BBB(EXP)' rating to  Humana Inc.'s (HUM) planned issuance of senior notes of various maturities. The  ratings are equivalent to Fitch's ratings on HUM's currently outstanding senior  notes.  Fitch anticipates HUM using proceeds from the planned issue to redeem $500  million of 6.45% senior notes due June 1, 2016 or for general corporate  purposes, which Fitch believes may include share repurchases. On Sept. 16, HUM  announced that its board had approved a new $2 billion share repurchase plan.  Prior to today, Fitch's most recent rating action on HUM was on Aug. 14, 2014  when it affirmed the 'BBB' ratings on the company's senior notes and the 'A'  Insurer Financial Strength ratings on certain HUM subsidiaries.    KEY RATING DRIVERS Fitch expects the planned issuance and planned use of proceeds, to increase  HUM's financial leverage ratio to 25-30% from 21% at June 30, 2014. Under this  scenario HUM's ratio of debt-to-annualized EBITDA is likely to be 1.3x-1.5x  compared with 0.8x at June 30, 2014. Fitch considers these post-planned issue  financial leverage metrics consistent with those expected at HUM's current  ratings levels.       Fitch projects HUM's operating-EBITDA-based interest coverage ratio at  approximately 15x a decline from 2013's 17.6x but strongly supportive of HUM's  ratings. In recent years HUM's financial performance has been strong relative to  Fitch's 'A' category guidelines. In the first half of 2014 HUM generated $24  billion of revenues and $1.6 billion of EBITDA. The company's 1H'14 ratios of  EBITDA-to-revenues and annualized net return on average capital were 6.7X and  11.8% respectively and from 2011-2013 these ratios averaged 6.4% and 12.9%.  In addition to the financial metrics cited above, other key factors impacting  HUM's ratings are Fitch's views on the credit-quality of the Medicare market and  HUM's position within the Medicare market. Fitch believes that it will be  difficult for HUM to generate sustained EBITDA-based margins and capital  stability required to support IFS ratings higher than 'A' and senior debt  ratings higher than 'BBB' due to the U.S. Government's ability to set  reimbursement rates and influence conditions in the Medicare market. Fitch views HUM as maintaining 'medium' sized market position and size/scale  characteristics. Under Fitch's health insurance rating guidelines, these are  consistent with 'A' category IFS ratings. HUM maintains a leading market share  in the Medicare Advantage market. Additionally, HUM has built integrated  delivery capabilities in geographic regions where the company maintains  significant membership. Fitch believes that HUM maintains large membership and  revenue bases that the help the company generate significant amounts of EBITDA  and capital and benefit from economies of scale.  RATING SENSITIVITIES Key rating triggers that could lead to an upgrade of HUM's ratings are:  --Over the longer term, an improved outlook for Medicare Advantage funding;  --Reduced near-term uncertainty surrounding the impact on HUM's margins of the  Affordable Care Act's (ACA) minimum medical benefit ratio and industry-wide fees  designed to fund portions of the ACA;        --A reduction in HUM's targeted debt-to-capital ratio to 20% and increase in the  company's organization-wide NAIC RBC to 350%;  --Financial metrics, especially interest coverage and EBITDA/revenue margin  ratios that approximate current levels.   Key rating triggers that could lead to a downgrade of the ratings are:  --Over the longer-term, a deterioration in the outlook for Medicare Advantage  funding;  --EBITDA-based interest coverage and EBITDA/revenue ratios below 7x and 5%,  respectively; --Debt-to-annualized (prior four quarters) EBITDA ratios above 1.5x;  --HUM increasing its targeted or reported financial leverage ratio above 30% or  reducing its organization-wide NAIC RBC ratio target below 200%; --Acquisitions that Fitch views as aggressively financed or containing an  excessive amount of integration risk.  Contact: Primary Analyst Mark Rouck, CPA, CFA   Senior Director  +1-312-368-2085 Fitch Ratings, Inc. 70 W. Madison Street Chicago IL 60602 Secondary Analyst Greg Dickerson   Director  +1-212-908-0220  Committee Chairperson Martha M. Butler, CFA  Senior Director  +1-312-368-3191 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com' Applicable Criteria and Related Research:  --'Insurance Rating Methodology', September 2014; --'Health Insurance and Managed Care (U.S.) Sector Credit Factors', August 2014. Applicable Criteria and Related Research:  Insurance Rating Methodology here Health Insurance and Managed Care (U.S.) (Sector Credit Factors) here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-09-16,HUM,"Tue Sep 16, 2014 | 10:10am EDT",Fitch Rates Humana's Planned Issuance 'BBB(EXP)',http://www.reuters.com//article/fitch-rates-humanas-planned-issuance-bbb-idUSFit75658020140916?type=companyNews
36,"   By Caroline Humer | BOSTON  BOSTON New competition between health insurers offering so-called Obamacare plans in 2015 is having an impact on the pricing of such coverage, based on a first look at proposed insurance premiums, the head of Humana Inc said on Wednesday.The state insurance exchanges offering coverage under the Affordable Care Act. President Barack Obama's landmark healthcare law will begin enrolling customers for 2015 benefits in mid-November. Now in its second year, Obamacare is attracting health insurers to offer plans in more states after over 8 million people enrolled for coverage in 2014.The country's largest insurer, UnitedHealth Group Inc, sold Obamacare plans in only a few states in 2014. But for 2015, it will sell plans in about two dozen states. Aetna Inc, Cigna Corp, WellPoint Inc and Humana have said they would stick to most of their markets.""United is coming in. There is more competition coming into the marketplace. It's going to make us all a little bit more competitive,"" Humana Chief Executive Officer Bruce Broussard said in an interview.He said that larger insurers are pricing their premiums within a narrower range of about 10 percent in many markets. That strategy contrasts with 2014, when Obamacare plan pricing showed much greater variation. Humana will sell plans in 15 states for 2015 and has asked for premium rate increases of 3 percent to the 20 percent range, depending on the market. Last year, large insurers were hesitant to enter the new marketplace, concerned by conservatives' political opposition as well as federal regulations that required that the plans be available to any individual regardless of age or health status.When the exchanges first launched in October 2013, technology failures crippled the federal enrollment website, Healthcare.gov, and many websites run by individual states. But as the government fixed those problems, enrollment came in ahead of forecast. Now many insurers expect their Obamacare business to have profit margins of 2 percent to 3 percent within a few years, based on government forecasts for the market to grow to 13 million people in 2015 and 25 million by 2017.Broussard said insurers may grapple with customer churn as consumers seek better prices as well as more technology problems as existing customers try to re-enroll either in the same plan or in a new plan for 2015. Humana, which has about 700,000 members enrolled in Obamacare plans, has a large business providing medical benefits and prescription drug plans under the Medicare program for the elderly, and sees a risk posed by pricey new drugs expected to reach the U.S. market in the next few years.Insurers are already calling for a change in how new drugs are priced after paying more than they expected for Gilead Sciences Inc's new $84,000 Hepatitis C treatment. New personalized treatments for cancer and an experimental class of cholesterol fighting drugs are seen inflating those costs further.""We've had a great trend over the last couple of years in healthcare cost staying flat or decreasing,"" Broussard said. ""If these drugs come out at the price they are, I think you are going to see a reversal of that."" (Reporting by Caroline Humer; editing by Michele Gershberg and G Crosse)",2014-09-17,HUM,"Wed Sep 17, 2014 | 5:48pm EDT",Humana CEO: New competition curbs Obamacare plan prices,http://www.reuters.com//article/us-usa-healthcare-humana-idUSKBN0HC2F920140917?type=companyNews
37,"  (The following statement was released by the rating agency) CHICAGO, September 22 (Fitch) Fitch Ratings has published a new report detailing  key credit metrics of nine-publicly-traded U.S. health insurance and managed  care companies that are either rated or followed by Fitch: Aetna, Inc., Centene  Corp., Cigna Corp., Health Net Inc., Humana, Inc., Molina Health Care Inc.  UnitedHealth Group, Incorporated, WellCare Health Plans, Inc. and WellPoint,  Inc.  The report is meant to be used as a desktop guide, providing financial data and  rankings, key credit strengths and concerns, and current ratings levels and  rating sensitivities. Fitch views the key credit metrics of these nine publicly traded health insurers  as improving in the first half of 2014 compared to the prior year period. Strong  revenue growth driven by the Affordable Care Act's (ACA) exchanges and Medicaid  expansion, continuing popularity of Medicare Advantage products and  acquisition-related growth generated increases in EBITDA that more than offset  declining margins. Interest coverage ratios improved, and leverage ratios  declined modestly. The first section of the report includes company rankings based on revenue  growth, EBITDA margin and returns on capital as well as capitalization measures  such as debt-to-EBITDA and financial leverage. The second section of the report  provides a more detailed discussion of the nine individual companies including  credit strengths and concerns, ratings and rating triggers (where applicable),  and detailed information about each company's capital structure. The report 'U.S. Health Insurance: Credit Metrics Update' is available on the  Fitch web site at 'www.fitchratings.com'.  Contact:  Mark Rouck, CPA, CFA  Senior Director +1-312-368-2085 Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602  Doug Pawlowski, CFA  Senior Director +1-312-368-2054  Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'. Applicable Criteria and Related Research: U.S. Health Insurance: Credit Metrics  Update here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-09-22,HUM,"Mon Sep 22, 2014 | 2:30pm EDT",Fitch Releases U.S. Health Insurance Credit Metrics Update,http://www.reuters.com//article/fitch-releases-us-health-insurance-credi-idUSFit75128020140922?type=companyNews
38,"  (The following statement was released by the rating agency) NEW YORK, September 29 (Fitch) Fitch Ratings has assigned a 'B/RR1' rating to  the new $350 million secured FILO term loan and a 'CCC+/RR3' to the $1,025  million secured B-4 term loan that is being launched at Toys 'R' Us - Delaware,  Inc.(Toys-Delaware) this week.  The new term loans will be used to repay the  $646 million B-1 term loan and $350 million of the 7.375% senior secured term  loans, both due Sept. 1, 2016.  The company will also refinance up to $380  million of the $580 million of B-2 and B-3 term loans. Toys-Delaware will seek  amendments to the term loan and asset-backed loan (ABL) credit agreements to  complete these transactions.    Effective this refinancing, Fitch has downgraded the remaining $200 million B-2  and B-3 term loans to 'CCC/RR4' from 'CCC+/RR3'. Fitch has also downgraded the  $450 million 10.375% senior unsecured notes due August 2017 and $400 million  7.375% senior unsecured notes due October 2018 at Toys 'R' Us, Inc. (Toys,  HoldCo) to 'CC/RR6' from 'CCC-/RR5', given the structural enhancements provided  to the new loans discussed under the 'Recovery Analysis and Considerations'  section. The transaction will address all of Toys-Delaware's 2016 maturities and a  portion of 2018 maturities. This will push Toy's next maturities to 2017 when  $1.175 billion of debt comes due. Fitch has affirmed the Issuer Default Ratings (IDRs) on Toys and its various  domestic subsidiaries at 'CCC'. A full list of rating actions follows at the end  of this press release. KEY RATING DRIVERS Fitch's ratings on Toys reflects the company's weak top-line and EBITDA trends  and weakening liquidity position given Fitch's expectation of negative free cash  flow (FCF). Toys' adjusted EBITDA declined materially to $521 million in 2013  from the average $1 billion range posted in the last few years. Fitch expects  EBITDA to remain depressed at $475 million to $550 million over the next three  years, relative to approximately $800 million required annually to cover cash  interest expense, capex and modest taxes.  While Toys reported positive comparable store sales (comps) growth in the first  half of 2014, Fitch expects Toys' comps will remain flat to modestly negative  over the intermediate term given the weakness in its major categories such as  juvenile (approximately 30% of Toys' total sales) and sustained weakness in the  entertainment category (11% of total sales) due to low birth rates and ongoing  secular pressure on the category.  The company faces intensified pricing competition from both discount and online  retailers. Despite Toys' multichannel strategy and series of product and service  initiatives, Fitch believes it will be expensive and difficult for Toys to  compete on pricing and retain its market share without sacrificing margins.  Fitch estimates that Toys would need to grow sales by 1.5% to 2% and have flat  to modestly improved gross margin to generate annual EBITDA in the $725 million  range to cover annual cash interest expense of $415 million to $420 million  post-refinancing, capex of $250 million and modest cash taxes. However,  achieving this level is likely challenging without significantly lowering its  cost structure and controlling inventory levels.  Fitch expects 2014 EBITDA to be in the $475 million-$500 million range, assuming  flat comps and flat-to-modest lower gross margin for the second half of the  year. Assuming similar trends for 2015/2016, Fitch expects EBITDA to remain at  these levels or modestly better with some modest SG&A reduction given that Toys  will need to make further investments in sharpening its prices, growing its  online business and improving store presentation and service. Fitch expects leverage (adjusted debt/EBITDAR) to be mid-9x and FCF to be  negative $300 million, excluding significant working capital swings in 2014 and  2015. Availability under the ABL revolver during peak working capital season is  expected to be around $700 million in 2014 and $400 million to $450 million in  2015. This indicates adequate liquidity over the next 24 months but concerns  remain around declining liquidity and significant debt maturities in 2017  ($1.175 billion) and 2018 ($600 million).  RECOVERY ANALYSIS AND CONSIDERATIONS For issuers with IDRs at 'B+' and below, Fitch performs a recovery analysis for  each class of obligations of the issuer. Issue ratings are derived from the IDR  and the relevant Recovery Rating and notching based on the expected recoveries  in a distressed scenario of each of the company's debt issues and loans. Toys'  debt is at three types of entities: operating companies (OpCo); property  companies (PropCo); and HoldCo, with a summary structure highlighted below: Toys 'R' Us, Inc. (HoldCo) (I) Toys 'R' Us-Delaware, Inc. (Toys-Delaware) is a subsidiary of HoldCo. (a) Toys 'R' Us Canada (Toys-Canada) is a subsidiary of Toys-Delaware. (b) Toys 'R' Us Property Co. II, LLC (PropCo II) is a subsidiary of  Toys-Delaware. (II) Toys 'R' Us Property Co. I, LLC (PropCo I) is a subsidiary of HoldCo. OpCo Debt Fitch takes the higher of liquidation value or enterprise value (based on  5.0x-5.5x multiple applied to the stressed EBITDA) at the OpCo levels -  Toys-Delaware and Toys-Canada.  The 5.0x-5.5x is consistent with the low end of  the 10-year valuation for the public retail space and Fitch's average distressed  multiple across the retail portfolio. The stressed liquidation or enterprise  value (EV) is adjusted for 10% administrative claims.  Toys-Canada Toys has a $1.85 billion ABL revolver with Toys Delaware as the lead borrower,  and this contains a $200 million sub-facility in favor of Canadian borrowers.  Any assets of the Canadian borrower and its subsidiaries secure only the  Canadian liabilities under the ABL facility. The $200 million sub-facility is  more than adequately covered by the EV calculated based on stressed EBITDA at  the Canadian subsidiary. Therefore, the fully recovered sub-facility is  reflected in the recovery of the consolidated $1.85 billion revolver discussed  below.  The residual value of approximately $200 million is applied toward certain debt  at Toys-Delaware.  Toys-Delaware At the Delaware level, the recovery on the various debt tranches is based on  the: (1)liquidation value of the domestic assets at the Toys-Delaware level  estimated at $1.75 billion; (2) estimated value for Toys' trademarks and IP  assets (which are held at Geoffrey, LLC (IPCo) as a wholly owned subsidiary of  Toys-Delaware; (3) equity residual from Toys-Canada; and (4) the benefit to the  new B-4 term loan from an unsecured guarantee from the indirect parent of PropCo  I.  The $1.85 billion revolver is secured by a first lien on inventory and  receivables of Toys-Delaware. In allocating an appropriate recovery, Fitch has  considered the liquidation value of domestic inventory and receivables assumed  at seasonal peak (at the end of the third quarter), and has applied advance  rates of 75% and 80%, respectively. Fitch assumes $1.3 billion or approximately  70% of the facility commitment is drawn under the revolver. The facility is  fully recovered and is therefore rated 'B/RR1'.  The new financing at Toys-Delaware will consist of a new $350 million FILO term  loan and $1,025 million B-4 term loan. The new term loans will be used to repay  the $646 million B-1 term loan and $350 million of the 7.375% senior secured  term loans, both due Sept. 1, 2016.  The company will also refinance up to $380  million of the $580 million of B-2 and B-3 term loans. The FILO term loan will be secured by the same collateral as the existing $1.85  billion ABL facility and will rank second in repayment priority relative to the  ABL.  The proposed FILO Tranche will be governed by the residual borrowing base  within the ABL facility and will benefit from a lien against 50% of the  estimated value of real estate at Toys-Canada.  Fitch has assigned a 'B/RR1'  rating to the FILO term loan based on outstanding recovery prospects (91%-100%)  as it benefits from the excess liquidation value of domestic inventory and A/R  and the recovery on the Canadian real estate.  The new B-4 term loan will benefit from the same credit support as the existing  B-2 and B-3 term loans which includes a first lien on all present and future IP,  trademarks, copyrights, patents, websites and other intangible assets and a  second lien on the ABL collateral.  It will also benefit from an unsecured  guaranty by the indirect parent of PropCo I and will be secured by a first  priority pledge on two-thirds of the Canadian subsidiary stock.  After pro-rating the ascribed value of the IP assets (estimated at $400  million), the residual equity in Toys-Canada (of which half was applied to the  FILO term loan) and applying the benefit from the guaranty by the indirect  parent of PropCo I, the new loans are expected to have good recovery prospects  (51% to 70%), and are therefore assigned a rating of 'CCC+/RR3'. The $200 million in remaining B-2 and B-3 term loans have been downgraded to  'CCC/RR4' as they are expected to have average recovery prospects (31% to 50%)  mainly from their prorated claim against the IP assets.  The $22 million 8.75% debentures due Sept. 1, 2021, have poor recovery prospects  (0% to 10%) and are therefore rated 'CC/RR6'.  PropCo Debt At the PropCo levels - Toys 'R' Us Property Co. I, LLC; Toys 'R' Us Property Co.  II, LLC; and other international PropCos - LTM net operating income (NOI) is  stressed at 20%.  PropCo I and PropCo II are set up as bankruptcy-remote entities with a 20-year  master lease through 2029 covering all the properties, which requires  Toys-Delaware to pay all costs and expenses related to leasing these properties  from these two entities. The ratings on the PropCo debt reflect a distressed  capitalization rate of 12% applied to the stressed NOI of the properties to  determine a going-concern valuation. The stressed rates reflect downtime and  capital costs that would need to be incurred to re-tenant the space. Applying these assumptions to the $725 million 8.50% senior secured notes at  PropCo II and the $985 million senior unsecured term loan at PropCo I results in  recovery in excess of 90%. Therefore, these facilities are rated 'B/RR1'. The PropCo II notes are secured by 125 properties. The PropCo I unsecured term  loan facility benefits from a negative pledge on all PropCo I real estate assets  (343 properties). Fitch typically limits the Recovery Rating on unsecured debt  at 'RR2' or two notches above the IDR level (under its criteria 'Recovery  Ratings and Notching Criteria for Non-financial Corporate Issuers' dated Nov.  20, 2013). However, in the few instances where the recovery waterfall suggests  an 'RR1' rating and such a Recovery Rating is supported by the structural and  legal characteristics of the debt, unsecured debt may qualify for an 'RR1'  rating. In addition, the rating also benefits from the structural consideration  that Toys 'R' Us has limited capacity to secure debt using real estate given  that there is a limitation on principal property of domestic subsidiaries at 10%  of consolidated net tangible assets under the $400 million of 7.375% notes due  2018 issued by HoldCo. As described above, the residual value of $300 million after fully recovering  the $985 million term loan at PropCo I is applied towards the Delaware B-4 term  loan via an unsecured guaranty by the indirect parent of PropCo I.   Toys 'R' Us, Inc. - HoldCo Debt The $450 million 10.375% unsecured notes due Aug. 15, 2017, and the $400 million  7.375% unsecured notes due Oct. 15, 2018 will no longer benefit from the  residual value at PropCo I, as there is no residual value ascribed from  Toys-Delaware or other operating subsidiaries. Therefore the HoldCo debt and the  $577 million senior notes due to Toys-Delaware that are considered pari passu  with the publicly traded HoldCo notes have poor recovery prospects (0% to 10%)  and have been downgraded to 'CC/RR6' from 'CCC-/RR5'.  RATING SENSITIVITIES A negative rating action could result if comps trends in the U.S. and  international businesses revert to mid-single-digit declines and/or gross  margins decline by similar rates to 2013 without any offset from cost  reductions. This would indicate more severe market share losses and lead to  tighter liquidity than Fitch's current expectation over the next 18-24 months. A positive rating action could result if there is sustainable improvement in  Toys' store and online traffic, indicating improved market share positioning,  and meaningful cost restructuring. Toys would need to drive EBITDA improvement  to a level where it can meet its obligations of interest expense, capex and  taxes and fund any working capital swings, and manage refinancing of upcoming  debt maturities on a timely basis.  Fitch has taken the following rating action on Toys and its various  subsidiaries:  Toys 'R' Us, Inc.  --IDR affirmed at 'CCC'; --Senior unsecured notes downgraded to 'CC/RR6' from 'CCC-/RR5'. Toys 'R' Us - Delaware, Inc.  --IDR affirmed at 'CCC'; --Secured revolver affirmed at 'B/RR1'; --Secured FILO term loan assigned 'B/RR1'; --Secured B-4 term loan assigned 'CCC+/RR3'; --Secured B-2 and B-3 term loans downgraded to 'CCC/RR4' from 'CCC+/RR3'; --Senior unsecured notes affirmed at 'CC/RR6'. Toys 'R' Us Property Co. II, LLC  --IDR affirmed at 'CCC'; --Senior secured notes affirmed at 'B/RR1'. Toys 'R' Us Property Co. I, LLC  --IDR affirmed at 'CCC'; --Senior unsecured term Loan facility affirmed at 'B/RR1'. Contact:  Primary Analyst Monica Aggarwal, CFA Senior Director +1-212-908-0282  Fitch Ratings, Inc. 33 Whitehall Street  New York, NY 10004  Secondary Analyst Phil Zahn, CFA Senior Director +1-312-606-2336  Committee Chairperson Sharon Bonelli Managing Director +1-212-908-0581  Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research:  --'Corporate Rating Methodology' (May 28, 2014); --'Recovery Ratings and Notching Criteria for Nonfinancial Corporate Issuers'  (Nov. 20, 2013); --'Recovery Rating and Notching Criteria for Equity REITs' (Nov. 19, 2013). Applicable Criteria and Related Research:  Recovery Rating and Notching Criteria for Equity REITs  Effective May 12, 2011  to May 3, 2012 here Recovery Ratings and Notching Criteria for Non-Financial Corporate Issuers here Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-09-29,HUM,"Mon Sep 29, 2014 | 5:36pm EDT",Fitch Assigns Ratings to Toys' New Term Loans; Affirms IDR at 'CCC',http://www.reuters.com//article/fitch-assigns-ratings-to-toys-new-term-l-idUSFit77214020140929?type=companyNews
39,"  Humana Inc, which manages private Medicare and individual Obamacare insurance plans, said on Monday it has integrated its consumer health application with Apple Inc's HealthKit.The move, the first announced by a major insurer, enables Humana customers to more easily manage fitness data and other personal health goals, the company said in a statement.Humana's wellness program, called HumanaVitality, rewards members for hitting these goals, which include being more active, eating better or losing weight, with items such as movie tickets and fitness equipment. Apple's HealthKit gathers data such as blood pressure and weight from various applications, enabling it to be viewed by consumers and doctors in one place. Its ease of use is expected to increase the data sharing between doctors and patients.  Apple delayed the launch of HealthKit earlier this month when it pulled back its iOS 8 operating system for iPhones and iPads. HealthKit and the new Humana application, which has about 3.8 million eligible members, launched on Friday.  (Reporting by Caroline Humer. Editing by Andre Grenon)",2014-09-29,HUM,"Mon Sep 29, 2014 | 12:46pm EDT",Humana to integrate its health application with Apple's HealthKit,http://www.reuters.com//article/us-humana-apple-idUSKCN0HO1RU20140929?type=companyNews
40,"  Sept 29 Humana Inc, which manages private Medicare and individual Obamacare insurance plans, said on Monday it has integrated its consumer health application with Apple Inc's HealthKit.The move, the first announced by a major insurer, enables Humana customers to more easily manage fitness data and other personal health goals, the company said in a statement. Humana's wellness program, called HumanaVitality, rewards members for hitting these goals, which include being more active, eating better or losing weight, with items such as movie tickets and fitness equipment. Apple's HealthKit gathers data such as blood pressure and weight from various applications, enabling it to be viewed by consumers and doctors in one place. Its ease of use is expected to increase the data sharing between doctors and patients. Apple delayed the launch of HealthKit earlier this month when it pulled back its iOS 8 operating system for iPhones and iPads. HealthKit and the new Humana application, which has about 3.8 million eligible members, launched on Friday.    (Reporting by Caroline Humer. Editing by Andre Grenon)",2014-09-29,HUM,"Mon Sep 29, 2014 | 12:36pm EDT",Humana to integrate its health application with Apple's HealthKit,http://www.reuters.com//article/humana-apple-idUSL2N0RU11520140929?type=companyNews
41,"   By Soyoung Kim, Olivia Oran and Greg Roumeliotis  Health insurer Humana Inc (HUM.N) is exploring a sale of its urgent care subsidiary Concentra in a deal that could value it at around $1 billion, according to three people familiar with the matter.The effort to sell Concentra comes less than four years after the unit was acquired. It indicates that Humana, one of the largest providers of Medicare plans for the elderly in the United States, has faced challenges in trying to run healthcare centers itself in order to better manage medical costs.Humana has hired investment bank Goldman Sachs Group Inc (GS.N) to advise on the sale process, the people said on Wednesday, declining to be named because the matter is not public. Humana, based in Louisville, Kentucky, could not be reached for comment. Goldman Sachs declined to comment. Humana shares were down 1.5 percent at $131.3 in afternoon trading in New York. Concentra provides occupational medicine, urgent care, physical therapy and wellness services from more than 300 medical centers in 38 states, and also operates more than 245 workplace medical facilities, according to its website.Humana, which has a market capitalization of more than $20 billion, acquired Concentra for $790 million in 2010 from private equity firm Welsh, Carson, Anderson & Stowe, which had taken it private in 1999 for $1.1 billion. Last year, Humana sold Concentra's toxicology and clinical laboratory business to Quest Diagnostics Inc (DGX.N) for an undisclosed amount. ""What we are trying to do with that Concentra asset is to shift its focus more towards primary care as opposed to workers' compensation and occupational medicine,"" Humana's chief operating officer, James Murray, told analysts on the company's second-quarter earnings call in July. ""(Concentra's) base business is performing well, but again, it's a small component of our overall results as a company,"" Murray said. Humana's chief executive, Bruce Broussard, told investors last month that the company was reviewing strategic alternatives for its pharmacy benefit management business. (Reporting by Soyoung Kim in Seoul and Olivia Oran and Greg Roumeliotis in New York; Editing by Meredith Mazzilli)",2014-10-22,HUM,"Wed Oct 22, 2014 | 2:11pm EDT",Humana looks to sell urgent care subsidiary Concentra: sources,http://www.reuters.com//article/us-concentra-m-a-idUSKCN0IB28O20141022?type=companyNews
42,"  (Adds Humana share price, background, bylines)By Soyoung Kim, Olivia Oran and Greg RoumeliotisOct 22 Health insurer Humana Inc is exploring a sale of its urgent care subsidiary Concentra in a deal that could value it at around $1 billion, according to three people familiar with the matter.The effort to sell Concentra comes less than four years after the unit was acquired. It indicates that Humana, one of the largest providers of Medicare plans for the elderly in the United States, has faced challenges in trying to run healthcare centers itself in order to better manage medical costs.Humana has hired investment bank Goldman Sachs Group Inc  to advise on the sale process, the people said on Wednesday, declining to be named because the matter is not public. Humana, based in Louisville, Kentucky, could not be reached for comment. Goldman Sachs declined to comment. Humana shares were down 1.5 percent at $131.3 in afternoon trading in New York.Concentra provides occupational medicine, urgent care, physical therapy and wellness services from more than 300 medical centers in 38 states, and also operates more than 245 workplace medical facilities, according to its website. Humana, which has a market capitalization of more than $20 billion, acquired Concentra for $790 million in 2010 from private equity firm Welsh, Carson, Anderson & Stowe, which had taken it private in 1999 for $1.1 billion.Last year, Humana sold Concentra's toxicology and clinical laboratory business to Quest Diagnostics Inc for an undisclosed amount. ""What we are trying to do with that Concentra asset is to shift its focus more towards primary care as opposed to workers' compensation and occupational medicine,"" Humana's chief operating officer, James Murray, told analysts on the company's second-quarter earnings call in July.""(Concentra's) base business is performing well, but again, it's a small component of our overall results as a company,"" Murray said.Humana's chief executive, Bruce Broussard, told investors last month that the company was reviewing strategic alternatives for its pharmacy benefit management business.   (Reporting by Soyoung Kim in Seoul and Olivia Oran and Greg Roumeliotis in New York; Editing by Meredith Mazzilli)",2014-10-22,HUM,"Wed Oct 22, 2014 | 2:07pm EDT",UPDATE 1-Humana looks to sell urgent care subsidiary Concentra -sources,http://www.reuters.com//article/concentra-ma-idUSL2N0SH26H20141022?type=companyNews
43,"  Oct 22 Health insurer Humana Inc is exploring a sale of its urgent care subsidiary Concentra in a deal that could value it at around $1 billion, according to three people familiar with the matter, less than four years after acquiring it.The move indicates that Humana, one of the largest providers of Medicare plans for the elderly in the United States, has faced challenges with its attempts to run healthcare centers itself in order to better manage medical costs.  Louisville, Kentucky-based Humana has hired investment bank Goldman Sachs Group Inc to advise on the sale process, the people said on Wednesday, declining to be named because the matter is not public. Humana and Goldman Sachs declined to comment.    (Reporting by Soyoung Kim in Seoul and Olivia Oran and Greg Roumeliotis in New York; Editing by Meredith Mazzilli) ",2014-10-22,HUM,"Wed Oct 22, 2014 | 1:48pm EDT",Humana looks to sell urgent care subsidiary Concentra- sources,http://www.reuters.com//article/concentra-ma-idUSL2N0SH25A20141022?type=companyNews
44,"  U.S. health insurer Humana Inc (HUM.N) reported a lower-than- expected fourth-quarter profit as it spent more on new hepatitis C treatments and flu season expenses increased, but it said those and other costs are behind it and predicted a better 2015.Humana shares, which were off slightly before a company conference call began, rose 1.9 percent to $151.39 in mid-morning New York Stock Exchange trading.Humana, which has a large Medicare Advantage business, said that so far in 2015 enrollment in individual plans sold on the public exchanges is within expectations and in line with premium pricing, an improvement from 2014.""I think they convinced everyone they are very comfortable about the pricing and health risk they are seeing on the public exchanges,"" Leerink Partners analyst Ana Gupte said on a conference call. The company also said its 2015 financial outlook had not factored in a recently negotiated discount on pricey hepatitis C treatments from Gilead Inc (GILD.O). On Tuesday, Gilead said it had negotiated payer contracts with discounts of more than 40 percent, higher than some investors had been estimating. Hepatitis C costs as well as investments in new programs weighed on 2014 profits, Humana executives said during a conference call with investors.In addition, costs related to the flu cut into profits in the fourth quarter but flu cases have since fallen from their peak and medical costs are more normal, its Chief Financial Officer Brian Kane said. The medical benefit ratio in the company's retail unit, its largest, increased to 83.3 percent in the fourth quarter from 82.7 percent a year earlier.The ratio is the amount an insurer spends on medical claims compared with its income from premiums. Humana's net income rose to $145 million, or 94 cents per share, in the quarter ended Dec. 31 compared with a loss of $30 million, or 19 cents per share, a year earlier, when it set aside funds for long-term care policies that it no longer sells. Excluding items, the company earned $1.09 per share, below average analysts' estimate of $1.16 per share, according to Thomson Reuters I/B/E/S. Revenue rose 21 percent to $12.33 billion, below the average estimate of $12.40 billion. It expects 2015 earnings of $8.87 per share and revenue of $54.5 billion to $55 billion.The company reiterated its forecast of a 13 percent rise in Medicare Advantage membership for 2015. (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Don Sebastian and James Dalgleish)",2015-02-04,HUM,"Wed Feb 4, 2015 | 10:48am EST",Humana profit misses but shares rise on 2015 outlook,http://www.reuters.com//article/us-humana-results-idUSKBN0L814E20150204?type=companyNews
45,"  (Adds outlook, analyst comment, shares)Feb 4 U.S. health insurer Humana Inc  reported a lower-than- expected fourth-quarter profit as it spent more on new hepatitis C treatments and flu season expenses increased, but it said those and other costs are behind it and predicted a better 2015.Humana shares, which were off slightly before a company conference call began, rose 1.9 percent to $151.39 in mid-morning New York Stock Exchange trading.Humana, which has a large Medicare Advantage business, said that so far in 2015 enrollment in individual plans sold on the public exchanges is within expectations and in line with premium pricing, an improvement from 2014.""I think they convinced everyone they are very comfortable about the pricing and health risk they are seeing on the public exchanges,"" Leerink Partners analyst Ana Gupte said on a conference call. The company also said its 2015 financial outlook had not factored in a recently negotiated discount on pricey hepatitis C treatments from Gilead Inc. On Tuesday, Gilead said it had negotiated payer contracts with discounts of more than 40 percent, higher than some investors had been estimating. Hepatitis C costs as well as investments in new programs weighed on 2014 profits, Humana executives said during a conference call with investors.In addition, costs related to the flu cut into profits in the fourth quarter but flu cases have since fallen from their peak and medical costs are more normal, its Chief Financial Officer Brian Kane said.The medical benefit ratio in the company's retail unit, its largest, increased to 83.3 percent in the fourth quarter from 82.7 percent a year earlier. (bit.ly/16mgDwY) The ratio is the amount an insurer spends on medical claims compared with its income from premiums.Humana's net income rose to $145 million, or 94 cents per share, in the quarter ended Dec. 31 compared with a loss of $30 million, or 19 cents per share, a year earlier, when it set aside funds for long-term care policies that it no longer sells. Excluding items, the company earned $1.09 per share, below average analysts' estimate of $1.16 per share, according to Thomson Reuters I/B/E/S.Revenue rose 21 percent to $12.33 billion, below the average estimate of $12.40 billion.It expects 2015 earnings of $8.87 per share and revenue of $54.5 billion to $55 billion.The company reiterated its forecast of a 13 percent rise in Medicare Advantage membership for 2015.       (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Don Sebastian and James Dalgleish)",2015-02-04,HUM,"Wed Feb 4, 2015 | 10:45am EST",UPDATE 2-Humana profit misses but shares rise on 2015 outlook,http://www.reuters.com//article/humana-results-idUSL4N0VE4V420150204?type=companyNews
46,"  Feb  4U.S. health insurer Humana Inc  posted a pretax profit for the fourth quarter, compared with a loss a year earlier, reflecting a rise in individual Medicare Advantage memberships.The company reported pretax income of $287 million, or 94 cents per share, compared with a loss of $49 million, or 19 cents per share, a year earlier when it set aside funds for long-term care policies that it no longer sells.  The company reiterated its forecast of a 13 percent rise in Medicare Advantage membership for 2015.   (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Don Sebastian) ",2015-02-04,HUM,"Wed Feb 4, 2015 | 6:18am EST",Health insurer Humana reports pretax profit,http://www.reuters.com//article/humana-results-idUSL4N0VD5ZB20150204?type=companyNews
47,"  (Adds Colbun, Nexen Energy, Griffin Real Estate, Zinjin, Amer Sports, Sterigenics; updates Tenet, Ivanhoe Mines, Humana))March 23 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** China National Chemical Corp (ChemChina) is to buy Pirelli, the world's fifth-largest tyre maker, in a 7.1 billion euro ($7.7 billion) deal that will place one of the symbols of Italy's manufacturing industry in Chinese hands.** Royal Bank of Scotland is to sell up to $3.3 billion more shares in its U.S. bank Citizens to cut its stake to less than half and accelerate its retreat to its home UK market.** Private equity firm Warburg Pincus LLC has agreed to acquire a majority stake in Sterigenics International LLC in a deal that values the U.S. provider of contract sterilization services at more than $2 billion, including debt, a source familiar with the transaction said.** Austrian anti-trust authorities have approved Deutsche Wohnen's offer to buy Austrian real estate peer Conwert for 1.2 billion euros ($1.31 billion), according to a document from competition watchdog BWB seen by Reuters.** Optimal Payments Plc said it would buy Sentinel Topco Ltd and its units, known as Skrill Group, for an enterprise value of about 1.1 billion euros ($1.19 billion) to expand its online payment and digital wallet services.** Ireland's transport minister on Monday said talks with British Airways owner IAG on a bid for Aer Lingus  were ""workmanlike and constructive"" and that he expected the cabinet to decide whether to back the bid within weeks.International Consolidated Airlines Group (IAG) made a 1.36 billion euro ($1.5 billion) bid for Aer Lingus in January and the Irish carrier's board recommended the offer to shareholders.** Health insurer Humana Inc said on Monday that it would sell its Concentra urgent care and physical therapy services unit for about $1 billion to private equity firm Welsh, Carson, Anderson & Stowe and Select Medical Holdings Corp .** Tenet Healthcare Corp said it would become the largest U.S. provider of outpatient surgery services through a joint venture with United Surgical Partners International and expects to fully own the company within five years.** Chinese e-commerce company Alibaba Group is investing in the funds of Jerusalem Venture Partners (JVP), one of Israel's leading venture capital groups. The Calcalist financial newspaper said on its website the investment amounted to tens of millions of dollars. ** Australia's Village Roadshow Ltd, operator of the country's biggest cinema chain and several theme parks, said it will form a $500 million joint venture with China's CITIC Ltd  to invest in theme parks on the mainland.** Poland's state-run post Poczta Polska said it was interested in buying 25-percent stake in Bank Pocztowy from the country's biggest bank PKO BP to gain full control over the smaller lender, the post's chief executive said on Monday.** Nordex is not opposed to potential takeover attempts, Chief Executive Juergen Zeschky told reporters on Monday, adding the group would be open to being bought up if it makes sense from a strategic and operational point of view.** Hotel Shilla Co Ltd said it would buy a 44 percent stake in U.S. in-flight duty free retailer DFASS for $105 million, the latest push abroad by a South Korean duty free store operator amid intensifying competition at home.** Austrian property group Immofinanz AG plans to offer 18.50 euros ($20) per share for a stake of up to 29 percent in CA Immobilien, turning the tables on its rival, which is seeking to increase its stake in Immofinanz.** Nippon Steel & Sumitomo Metal Corp, Japan's top steelmaker, has signed a contract with Idemitsu Kosan Co Ltd  to buy a 10 percent stake in its Boggabri coal mine in Australia. The value of the deal was not disclosed. ** Dairy Crest Group Plc said the sale of its dairy operations was being referred back to the UK Competition and Markets Authority (CMA) by the European Commission for review. Britain's largest dairy food company said the deal to sell the operations to Mller UK & Ireland Group remained on track.** Spanish and Belgian gas transmission companies Enagas  and Fluxys said they had agreed to buy Swedish operator Swedegas. While the companies did not give details about the full value of the deal, they said that each company would invest 100 million euros ($108.1 million) of their own capital, with the rest of the transaction price covered with debt.** Taiwan's Cathay Financial Holding Co Ltd will take over two loss-making local life insurance companies, a government regulator said Monday. The government will pay T$30.3 billion ($963.77 million) to Cathay for the takeover of Singfor Life Insurance Co and Global Life Insurance Co, an official with the Taiwan Insurance Guaranty Fund told Reuters.** Dubai's Arabtec plans to sell four of its five Saudi Arabian units, the builder's annual results show despite also stating that one of its main aims this year is to expand its activities in the kingdom.** Finnish sporting goods group Amer Sports will buy U.S. baseball brand Louisville Slugger for $70 million to step up growth at its ball sports unit, it said on Monday. ** BDO Unibank Inc, Philippines' largest lender, said it is not bidding for industrial conglomerate San Miguel Corp's controlling stake in mid-sized lender Bank of Commerce.** U.S. private equity firm Bain Capital LLC plans to acquire Japan Wind Development Co Ltd through a tender offer in a deal worth up to 9.7 billion yen ($81 million), the Nikkei business daily reported on Monday.** China's Zijin Mining Group  is set to buy a 9.9 percent stake in Ivanhoe Mines Ltd for about C$105 million ($83 million) and is in ""detailed"" talks on jointly developing Ivanhoe's copper project in central Africa, the two companies said on Monday.** Qatar Investment Authority and Swiss travel retailer Dufry are teaming up to bid for Italian travel retailer World Duty Free (WDF), which belongs to the Benetton family, two sources familiar with the matter told Reuters on Monday.** Canadian miner Noront Resources Ltd said on Monday that it would buy Cliffs Natural Resources Inc's  chromite assets in the northern Ontario Ring of Fire district for $20 million, financed by a loan from Franco-Nevada Corp .** Chinese automaker BAIC Motor Corp Ltd plans to deepen its partnership with Daimler AG by taking a 35 percent stake in the German firm's Mercedes-Benz Leasing Co, they said in a joint statement on Sunday.** Spain's Santander said it had presented a non-binding offer for Portugal's Novo Banco, the successor to rescued Banco Espirito Santo (BES), in the second phase of a sale process that has attracted 14 other potential bidders.** Luxembourg's Griffin Real Estate and U.S. investment fund Pimco plan to raise their stake in Polish business space developer Echo Investment to 66 percent, they said on Monday.** Nexen Energy, a wholly owned subsidiary of China's CNOOC Ltd, is closing its crude oil trading division following a round of job cuts announced last week, four market sources said on Monday.** Chilean energy firm Colbun said it is considering bidding for the controlling stake in electricity generator Isagen that the Colombian government is putting up for sale.($1 = 0.92 euros)  ($1 = T$31.44)  ($1 = 120.01 yen)   (Compiled by Rohit T.K. and Yashaswini Swamynathan in Bengaluru)",2015-03-23,HUM,"Mon Mar 23, 2015 | 4:02pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0WP46P20150323?type=companyNews
48,"  NEW YORK Health insurer Humana Inc (HUM.N) said on Monday that it would sell its Concentra urgent care and physical therapy services unit for about $1 billion to private equity firm Welsh, Carson, Anderson & Stowe and Select Medical Holdings Corp (SEM.N).Humana, which focuses on providing Medicare Advantage plans to older people, has been reviewing its assets for possible sales, and Wall Street analysts had surmised that Concentra was one of them. Humana said it would use the net proceeds to fund its existing $2 billion share buyback program and other corporate spending.Humana purchased Concentra in 2010 for $790 million, before current Chief Executive Officer Bruce Broussard took the helm in 2013. In 2010, Concentra had sales of $800 million and was seen as a way to diversify revenue and expand strategically. Humana sold some of its assets in the interim.Broussard said in a press release that Concentra ""did not ultimately align with Humanas strategy as well as we had originally anticipated"" but that the company would continue to invest in other primary care assets. Those assets fit better with Humana's care delivery strategies than Concentra's focus on occupational injuries, Humana said.Humana also said it would continue to review other business lines for possible sale. ""The Concentra asset was not as good a fit or synergistic with Humana's core Medicare Advantage business,"" Leerink Partners analyst Ana Gupte said in a research note. She noted it was the first sale under Humana Chief Financial Officer Brian Kane, formerly of Goldman Sachs' investment bank.Shares of Humana were down 0.5 percent at $181.90 in morning trading, while Select Medical rose 3.3 percent to $15.11. Humana expects the sale to the joint venture run by Welsh Carson and Select Medical Holdings to close in the second quarter. Welsh Carson took Select Medical, which runs long term acute care hospitals and rehabilitation facilities, private in 2004 and then conducted an initial public offering of it in 2009. According to Thomson Reuters data, Welsh Carson no longer held a stake in the company as of Dec. 31, 2014.Humana reiterated its 2015 earnings forecast of $8.50 to $9 per share. It said the sale would reduce profit slightly this year, excluding any one-time gain. Humana was advised by Goldman Sachs & Co (GS.N) and Fried, Frank, Harris, Shriver & Jacobson LLP was legal advisor. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2015-03-23,HUM,"Mon Mar 23, 2015 | 1:30pm EDT",Humana to sell Concentra medical center unit for $1 billion,http://www.reuters.com//article/us-humana-welshcarson-m-a-idUSKBN0MJ1GF20150323?type=companyNews
49,"  (Adds comments from Humana, details on Concentra, names of advisers)NEW YORK, March 23 Health insurer Humana Inc  said on Monday that it would sell its Concentra urgent care and physical therapy services unit for about $1 billion to private equity firm Welsh, Carson, Anderson & Stowe and Select Medical Holdings Corp.Humana, which focuses on providing Medicare Advantage plans to older people, has been reviewing its assets for possible sales, and Wall Street analysts had surmised that Concentra was one of them. Humana said it would use the net proceeds to fund its existing $2 billion share buyback program and other corporate spending.Humana purchased Concentra in 2010 for $790 million, before current Chief Executive Officer Bruce Broussard took the helm in 2013. In 2010, Concentra had sales of $800 million and was seen as a way to diversify revenue and expand strategically. Humana sold some of its assets in the interim. Broussard said in a press release that Concentra ""did not ultimately align with Humana's strategy as well as we had originally anticipated"" but that the company would continue to invest in other primary care assets. Those assets fit better with Humana's care delivery strategies than Concentra's focus on occupational injuries, Humana said.Humana also said it would continue to review other business lines for possible sale. ""The Concentra asset was not as good a fit or synergistic with Humana's core Medicare Advantage business,"" Leerink Partners analyst Ana Gupte said in a research note. She noted it was the first sale under Humana Chief Financial Officer Brian Kane, formerly of Goldman Sachs' investment bank.Shares of Humana were down 0.5 percent at $181.90 in morning trading, while Select Medical rose 3.3 percent to $15.11. Humana expects the sale to the joint venture run by Welsh Carson and Select Medical Holdings to close in the second quarter. Welsh Carson took Select Medical, which runs long term acute care hospitals and rehabilitation facilities, private in 2004 and then conducted an initial public offering of it in 2009. According to Thomson Reuters data, Welsh Carson no longer held a stake in the company as of Dec. 31, 2014.Humana reiterated its 2015 earnings forecast of $8.50 to $9 per share. It said the sale would reduce profit slightly this year, excluding any one-time gain.Humana was advised by Goldman Sachs & Co and Fried, Frank, Harris, Shriver & Jacobson LLP was legal advisor.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn and Andrew Hay)",2015-03-23,HUM,"Mon Mar 23, 2015 | 1:30pm EDT",UPDATE 2-Humana to sell Concentra medical center unit for $1 billion,http://www.reuters.com//article/humana-welshcarson-ma-idUSL2N0WP0OL20150323?type=companyNews
50,"  NEW YORK, March 23 Health insurer Humana Inc  said on Monday that it would sell its Concentra urgent care and physical therapy services unit for about $1 billion to private equity firm Welsh, Carson, Anderson & Stowe and Select Medical Holdings Corp.Humana, which focuses on providing Medicare Advantage plans to older people, has been reviewing its assets. It purchased Concentra in 2010, before current Chief Executive Officer Bruce Broussard took the helm.  The sale to the joint venture run by Welsh Carson and Select Medical Holdings is expected to closed in the second quarter.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn) ",2015-03-23,HUM,"Mon Mar 23, 2015 | 9:17am EDT",Humana to sell Concentra for $1 billion,http://www.reuters.com//article/humana-welshcarson-ma-idUSL2N0WP0NZ20150323?type=companyNews
51,"   By Caroline Humer | NEW YORK  NEW YORK Humana Inc, one of the largest U.S. providers of Medicare Advantage healthcare plans for older people, said on Tuesday that it believes a previously disclosed government query for information is part of a wider review involving many healthcare companies.Humana first said the U.S. Department of Justice had asked it to volunteer information about risk adjustment matters on Feb. 18.""Humana believes that this request for information is in connection with a wider review of Medicare risk adjustment generally that includes a number of Medicare Advantage plans, providers and vendors,"" the company said in a regulatory filing on Tuesday. The disclosure came the morning after DaVita Healthcare Partners Inc said in a regulatory filing that its JSA Medical Group unit had received a subpoena from the U.S. Department of Health and Human Services' Office of Inspector General. JSA provides medical services through clinics and pharmacies.DaVita said it had been advised by a Justice Department lawyer that the subpoena related to a civil investigation of Humana and its service providers' risk adjustment practices and data including patient diagnoses. DaVita said the time period involved was from 2008 through 2013 and that the subpoena related in particular to two Florida physicians that had previously contracted with it.The government makes risk adjustment payments to Humana and other companies that provide Medicare Advantage when they have patients who are sicker than average. ""As matter of policy, the department generally neither confirms nor denies the existence of an investigation,"" Justice Department spokeswoman Nicole Navas said.Susquehanna analyst Chris Rigg said in a research note that the Humana disclosure fit with the DaVita request and a notice to insurers from a Health and Human Services division earlier this year about its review of the use of patient in-home risk assessments by insurers.Humana shares were up 0.4 percent at $182.77 in morning trading. DaVita was down 0.6 percent at $82.32.   (Additional reporting by Lindsay Dunsmuir in Washington D.C.)",2015-03-24,HUM,"Tue Mar 24, 2015 | 11:35am EDT",Humana says previously disclosed DOJ query involves other companies,http://www.reuters.com//article/humana-investigation-idUSL2N0WQ15Z20150324?type=companyNews
52,"  NEW YORK Humana Inc, one of the largest U.S. providers of Medicare Advantage healthcare plans for older people, said on Tuesday that it believes a previously disclosed government query for information is part of a wider review involving many healthcare companies.Humana first said the U.S. Department of Justice had asked it to volunteer information about risk adjustment matters on Feb. 18.""Humana believes that this request for information is in connection with a wider review of Medicare risk adjustment generally that includes a number of Medicare Advantage plans, providers and vendors,"" the company said in a regulatory filing on Tuesday.The disclosure came the morning after DaVita Healthcare Partners Inc said in a regulatory filing that its JSA Medical Group unit had received a subpoena from the U.S. Department of Health and Human Services' Office of Inspector General. JSA provides medical services through clinics and pharmacies.DaVita said it had been advised by a Justice Department lawyer that the subpoena related to a civil investigation of Humana and its service providers' risk adjustment practices and data including patient diagnoses. DaVita said the time period involved was from 2008 through 2013 and that the subpoena related in particular to two Florida physicians that had previously contracted with it.The government makes risk adjustment payments to Humana and other companies that provide Medicare Advantage when they have patients who are sicker than average.  As matter of policy, the department generally neither confirms nor denies the existence of an investigation, Justice Department spokeswoman Nicole Navas said.Susquehanna analyst Chris Rigg said in a research note that the Humana disclosure fit with the DaVita request and a notice to insurers from a Health and Human Services division earlier this year about its review of the use of patient in-home risk assessments by insurers. Humana shares were up 0.4 percent at $182.77 in morning trading. DaVita was down 0.6 percent at $82.32. (Reporting by Caroline Humer; Additional reporting by Lindsay Dunsmuir in Washington D.C.; Editing by Lisa Von Ahn)",2015-03-24,HUM,"Tue Mar 24, 2015 | 11:30am EDT",Humana says previously disclosed DOJ query involves other companies,http://www.reuters.com//article/us-humana-investigation-idUSKBN0MK1LY20150324?type=companyNews
53,"  (Adds DaVita, DOJ response)NEW YORK, March 24 Humana Inc, one of the largest U.S. providers of Medicare Advantage healthcare plans for older people, said on Tuesday that it believes a previously disclosed government query for information is part of a wider review involving many healthcare companies.Humana first said the U.S. Department of Justice had asked it to volunteer information about risk adjustment matters on Feb. 18.""Humana believes that this request for information is in connection with a wider review of Medicare risk adjustment generally that includes a number of Medicare Advantage plans, providers and vendors,"" the company said in a regulatory filing on Tuesday. The disclosure came the morning after DaVita Healthcare Partners Inc said in a regulatory filing that its JSA Medical Group unit had received a subpoena from the U.S. Department of Health and Human Services' Office of Inspector General. JSA provides medical services through clinics and pharmacies.DaVita said it had been advised by a Justice Department lawyer that the subpoena related to a civil investigation of Humana and its service providers' risk adjustment practices and data including patient diagnoses. DaVita said the time period involved was from 2008 through 2013 and that the subpoena related in particular to two Florida physicians that had previously contracted with it.The government makes risk adjustment payments to Humana and other companies that provide Medicare Advantage when they have patients who are sicker than average. ""As matter of policy, the department generally neither confirms nor denies the existence of an investigation,"" Justice Department spokeswoman Nicole Navas said.Susquehanna analyst Chris Rigg said in a research note that the Humana disclosure fit with the DaVita request and a notice to insurers from a Health and Human Services division earlier this year about its review of the use of patient in-home risk assessments by insurers.Humana shares were up 0.4 percent at $182.77 in morning trading. DaVita was down 0.6 percent at $82.32.   (Reporting by Caroline Humer; Additional reporting by Lindsay Dunsmuir in Washington D.C.; Editing by Lisa Von Ahn)",2015-03-24,HUM,"Tue Mar 24, 2015 | 11:25am EDT",UPDATE 1-Humana says previously disclosed DOJ query involves other companies,http://www.reuters.com//article/humana-investigation-idUSL2N0WQ0ZR20150324?type=companyNews
54,"   By Caroline Humer | NEW YORK, March 30  NEW YORK, March 30 UnitedHealth Group Inc's  planned takeover of No. 4 U.S. pharmacy benefits provider Catamaran Corp will give the companies added heft in price talks with drug companies, serving as a catalyst for deals allowing other insurers to bulk up.The $12.8 billion deal comes at a time when Wall Street has been parsing the possibilities that top insurers like Aetna Inc  with Cigna Corp could pair up. Smaller companies like Health Net Inc, Molina Healthcare Inc or WellCare Health Plans Inc are also increasingly seen as takeover targets.""There has been chatter about large-scale M&A coming out of some recent investor conferences,"" Mizuho Securities senior healthcare analyst Sheryl Skolnick said. ""I don't know if $12.8 billion qualifies as large scale M&A in the space, but now you have the answer. Yes, there will be transactions.""Express Scripts Holdings Corp, the largest pharmacy benefit manager and the only stand-alone PBM, may be pressed to do a deal with a distribution company or pharmacy if margins become too tight, analysts said on Monday.The link-up could force a tie-up between Express Scripts and Walgreens Boots Alliance, for instance, which has pharmacy and drug distribution operations but no pharmacy management business, Evercore ISI analyst Michael Cherny said in a research report.That could put it at a disadvantage to CVS Health, the No. 2 pharmacy benefit manager which also owns one of the nation's largest pharmacy chains. Meanwhile, Envision RX, a small pharmacy benefit manager, recently announced plans to be bought by national drug store chain Rite Aid. Healthcare companies are able to use scale to negotiate better prices. Late last year, for instance, Express Scripts was able to negotiate a steep discount for an important hepatitis C drug from AbbVie Inc, and has said it will use its size to extract discounts for cancer drugs and cholesterol drugs in the future.A spokesman for Express Scripts, whose shares were up 3.7 percent to $85.39 in mid-afternoon trading, declined to comment on the Catamaran deal but said its business model was differentiated and in demand.IMPACTING INSURERS The shifting competitive landscape could mean more changes for Humana Inc, which manages pharmacy benefits for Medicare, Skolnick said. Humana had been reviewing the possible sale of that business, but ultimately decided to keep it. The purchase will make Humana the fourth largest pharmacy benefit manager, and it could make sense for Humana to invest in that business, grow the commercial pharmacy business and add more covered customers, she said.Other insurers will be reviewing where they stand now against UnitedHealth. Anthem, Aetna and Cigna have inked deals in recent years where they turned to Express Scripts, CVS and Catamaran respectively to manage their pharmacy benefits and get better prices, Leerink Partners analyst Ana Gupte explained.""In some ways the deal could catalyze more consolidation,"" Gupte said, adding that insurers would face pressure to bulk up. ""Clearly scale is an advantage more than ever in this business,"" Gupte said. (Reporting by Caroline Humer; Editing by Christian Plumb)",2015-03-30,HUM,"Mon Mar 30, 2015 | 3:22pm EDT",UnitedHealth-Catamaran deal sets up healthcare M&A chessboard,http://www.reuters.com//article/catamaran-ma-unitedheal-grp-idUSL2N0WW1IL20150330?type=companyNews
55,"  NEW YORK, April 7 Humana Inc, a health insurer that manages Medicare Advantage health plans for the elderly and disabled, said on Tuesday that it believes the government's final plan payment rates represent a 0.8 percent increase in funding to it.The government on Monday evening said it would raise payment rates in 2016 to private insurers for the Medicare Advantage plans that they manage by 1.25 percent on average. It had previously planned a 0.95 percent cut.  Humana said that it will see less of an increase than the average because of changes in how the government compensates insurers for sicker-than-average patients, which was part of the same government announcement.    (Reporting by Caroline Humer; Editing by Meredith Mazzilli) ",2015-04-07,HUM,"Tue Apr 7, 2015 | 9:18am EDT",Humana expects Medicare Advantage payments to create funding increase,http://www.reuters.com//article/humana-medicare-idUSL2N0X40OI20150407?type=companyNews
56,"  * Humana declines as hospital admissions pick-up* UnitedHealth is the biggest drag on the Dow* Higher oil prices weigh on airline stocks* First-qtr GDP growth lower-than-expected* Indexes down: Dow 0.7 pct, S&P 0.6 pct, Nasdaq 0.9 pct   (Updates to early afternoon, changes comment)By Tanya AgrawalApril 29 U.S. stocks fell sharply in early afternoon trading on Wednesday, led by health insurers after Humana reported an unexpected pick-up in hospital admissions in March and April.Nine out of the 10 major S&P 500 sectors were down, with the health index's 1.2 percent fall being the steepest. Humana shares fell 7 percent to $168.28, making them the second biggest loser on the S&P 500. The insurer's statement also hit shares of rivals Aetna, Anthem and UnitedHealth, whose 4.5 percent fall to $112.33 made it the biggest drag on the Dow.As harsh weather put off shoppers and energy companies cut spending, U.S. economic growth braked more sharply than expected in the first quarter, data showed, reinforcing expectations for a gradual pace of interest rate rises by the Federal Reserve.Investors were also awaiting the Fed's statement, expected at 1400 p.m. EDT (1800 GMT), for clues on when rates are likely to be increased. ""People are speculating that we are in a low patch after growing well over the last year and the pace and momentum going in to the second quarter doesn't seem to be as strong as people expected,"" said Omar Aguilar, chief investment officer at Charles Schwab Management in San Francisco.At 13:18 EDT (1718 GMT) the Dow Jones industrial average  was down 118.75 points, or 0.66 percent, at 17,991.39, the S&P 500 was down 13.61 points, or 0.64 percent, at 2,101.15 and the Nasdaq Composite was down 43.21 points, or 0.85 percent, at 5,012.22.Higher oil prices also pushed down airline stocks, with United Continental falling 5 pct to $58.45, American Airlines declining 5.7 percent to $48.30, Delta  slipping 3.7 percent at $44.51 and Southwest Airlines Co  dropping 4 percent to $40.24.Earnings released on Wednesday painted a mixed picture. ""Corporate America is very, very busy trying to create earnings that justify the current pricing of the market,"" said Dave Heidel, regional investment manager at U.S. Bank Wealth Management in Minneapolis, which oversees $128 billion.Heidel said the consequence of companies cutting costs to boost earnings reflects in the poor GDP numbers, which were partly due to low corporate spending.Twitter dived 6.5 percent to $39.50, a day after the company cut its full-year forecast due to weak demand for its new direct response advertising.MasterCard rose as much as 3.7 percent to a record of $93.59 after reporting a better-than-expected profit. The results also pushed up Visa 0.8 percent to $67.30.Lumber Liquidators slumped as much as 21 percent to a three-year low of $26.54 after the hardwood flooring retailer said the Department of Justice is seeking criminal charges related to certain imports.Declining issues outnumbered advancing ones on the NYSE by 2,106 to 859, for a 2.45-to-1 ratio on the downside; on the Nasdaq, 1,826 issues fell and 839 advanced for a 2.18-to-1 ratio favoring decliners.   (Additional reporting by Caroline Valetkevitch and Sinead Carew; Editing by Savio D'Souza)",2015-04-29,HUM,"Wed Apr 29, 2015 | 1:33pm EDT",US STOCKS-Wall St falls as health insurers weigh; Fed meeting eyed,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XQ5BU20150429?type=companyNews
57,"   By Caroline Humer  U.S. health insurer Humana Inc (HUM.N) said on Wednesday there was an unexpected pick-up in the rate of hospital admissions late in March and in April, sparking a sell-off in its own and other insurers' shares.The comments came during a conference call to discuss the company's first-quarter profit, which missed Wall Street expectations. Shares in Humana, which specializes in Medicare health insurance and drug plans for the elderly and disabled, fell more than 6 percent to $168.66 and brought down larger competitors, including UnitedHealth Group Inc, Aetna Inc and Anthem Inc.Investors are keeping a close watch on insurers and hospitals for signs that medical use and costs are rising more rapidly than expected, which can hurt insurer profits and help hospitals.Humana Chief Financial Officer Brian Kane said hospital inpatient admissions were on the rise, the first such cautionary comments from an insurer this quarter.""During the last weeks of the quarter and into April, we are seeing an elevated level of authorizations for hospital admissions, which, although still declining, are slightly higher than we had anticipated,"" Kane said.He said a lower per-admission cost was encouraging, but that the company would be watching admissions closely.UnitedHealth shares fell 3.7 percent to $113.19, Aetna was down 2.5 percent to $107.65 and Anthem - which also reported earnings on Wednesday - fell 2.5 percent to $150.38.Sheryl Skolnick, healthcare analyst at Mizuho Securities, said insurer shares were already under pressure and that the comments seemed to be speeding the decline.  Humana also gave a more dour forecast than its competitors for its individual insurance business, which has grown with the creation of the public exchanges under the national healthcare reform law. In particular, Humana said more Georgia residents needed care than it had anticipated.Georgia accounts for about half of Humana's individual business, based on state insurance data, Goldman Sachs analyst Matthew Borsch said in a research note. Excluding tax benefits from the sale of Concerta Inc, Humana earned $2.47 per share, below the average analyst estimate of $2.56 per share, according to Thomson Reuters I/B/E/S. CLAIMS COSTS RISE The company said the medical benefit ratio (MBR) for the first quarter ended March 31 increased by 80 basis points to 83.1 percent. The measure represents the percentage of premiums paid out in medical claims.Revenue increased 18.1 percent to $13.8 billion, beating the average analyst estimate of $13.51 billion. (Reporting by Caroline Humer in New York aAmrutha Penumudi in Bengaluru; Editing by Savio D'Souza, Saumyadeb Chakrabarty and Gunna Dickson)",2015-04-29,HUM,"Wed Apr 29, 2015 | 12:14pm EDT",Humana says hospital admissions up as sector shares fall,http://www.reuters.com//article/us-humana-results-idUSKBN0NK18C20150429?type=companyNews
58,"  (Adds sector share declines, analyst)By Caroline HumerApril 29 U.S. health insurer Humana Inc  said on Wednesday there was an unexpected pick-up in the rate of hospital admissions late in March and in April, sparking a sell-off in its own and other insurers' shares.The comments came during a conference call to discuss the company's first-quarter profit, which missed Wall Street expectations.Shares in Humana, which specializes in Medicare health insurance and drug plans for the elderly and disabled, fell more than 6 percent to $168.66 and brought down larger competitors, including UnitedHealth Group Inc, Aetna Inc and Anthem Inc.Investors are keeping a close watch on insurers and hospitals for signs that medical use and costs are rising more rapidly than expected, which can hurt insurer profits and help hospitals.Humana Chief Financial Officer Brian Kane said hospital inpatient admissions were on the rise, the first such cautionary comments from an insurer this quarter. ""During the last weeks of the quarter and into April, we are seeing an elevated level of authorizations for hospital admissions, which, although still declining, are slightly higher than we had anticipated,"" Kane said.He said a lower per-admission cost was encouraging, but that the company would be watching admissions closely.UnitedHealth shares fell 3.7 percent to $113.19, Aetna was down 2.5 percent to $107.65 and Anthem - which also reported earnings on Wednesday - fell 2.5 percent to $150.38. Sheryl Skolnick, healthcare analyst at Mizuho Securities, said insurer shares were already under pressure and that the comments seemed to be speeding the decline.Humana also gave a more dour forecast than its competitors for its individual insurance business, which has grown with the creation of the public exchanges under the national healthcare reform law. In particular, Humana said more Georgia residents needed care than it had anticipated.Georgia accounts for about half of Humana's individual business, based on state insurance data, Goldman Sachs analyst Matthew Borsch said in a research note. Excluding tax benefits from the sale of Concerta Inc, Humana earned $2.47 per share, below the average analyst estimate of $2.56 per share, according to Thomson Reuters I/B/E/S.CLAIMS COSTS RISE The company said the medical benefit ratio (MBR) for the first quarter ended March 31 increased by 80 basis points to 83.1 percent. The measure represents the percentage of premiums paid out in medical claims.Revenue increased 18.1 percent to $13.8 billion, beating the average analyst estimate of $13.51 billion.   (Reporting by Caroline Humer in New York aAmrutha Penumudi in Bengaluru; Editing by Savio D'Souza, Saumyadeb Chakrabarty and Gunna Dickson)",2015-04-29,HUM,"Wed Apr 29, 2015 | 12:13pm EDT",UPDATE 3-Humana says hospital admissions up as sector shares fall,http://www.reuters.com//article/humana-results-idUSL4N0XQ3IE20150429?type=companyNews
59,"  NEW YORK, April 29 Humana Inc Chief Financial Officer Brian Kane said on Wednesday that the insurer had seen a ""slight uptick"" in hospital admissions for Medicare Advantage members during the last few weeks of the first quarter and in April.Kane said on a conference call with investors that the cost per-admission was on the decline. Humana CEO Bruce Broussard said that might indicate that the admissions were related to an extension of the influenza season and is not a new trend.  Investors are closely watching medical services use for signs that it is picking up, which could cause insurers to spend more money on medical claims.   (Reporting by Caroline Humer) ",2015-04-29,HUM,"Wed Apr 29, 2015 | 9:39am EDT",Humana CFO says Medicare hospitalizations higher than foreseen,http://www.reuters.com//article/humana-results-cfo-idUSL1N0XQ1A820150429?type=companyNews
60,"  April 29 U.S. health insurer Humana Inc  reported a rise in quarterly profit as it added more members to its individual Medicare Advantage business.The company's profit rose to $2.82 per share, including a 35 cents tax benefit, in the first quarter from $2.35 per share a year earlier.  Humana, which manages large Medicare Advantage health plans for the elderly and disabled, also increased its quarterly dividend.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza) ",2015-04-29,HUM,"Wed Apr 29, 2015 | 6:13am EDT",Health insurer Humana's profit rises,http://www.reuters.com//article/humana-results-idUSL4N0XO61220150429?type=companyNews
61,"  (Adds comments on medical use, share movement)April 30 Cigna Corp said on Thursday that medical services use did not change among customers in its Medicare Advantage health plans for elderly people and the disabled, a contrast to comments from competitor Humana Inc.Shares of Cigna and most other insurers rose.Cigna, which reported a better-than-expected first-quarter profit on Thursday, was questioned by analysts during a conference call about whether the rate of hospitalizations or other medical uses had changed.""We really didn't see any significant change in (Medicare Advantage) utilization in the quarter,"" Chief Financial Officer Thomas McCarthy said.Humana said on Wednesday that hospitalizations rose in March and April, sparking investor concerns about increased costs for insurers. The comments drove down shares of the five largest publicly traded companies. Cigna said higher claims costs during the quarter were related to new drug plan customers whose prescriptions are often higher in the first three months.HIGHER PROFIT BEATS FORECAST  Cigna's quarter was helped by an increase in premiums and fees in the health insurer's commercial business, which added more members.Premiums and fees in Cigna's largest division, which includes its commercial and government insurance businesses, rose 12 percent to $6.73 billion in the first quarter. The number of customers increased 4 percent to 14.7 million. Cigna raised its full-year forecast for adjusted income from operations to $8.15-$8.50 per share from $8.00-$8.40.It reported first-quarter adjusted income from operations of $1.96 per share, well above the average analyst estimate of $1.84 per share, according to Thomson Reuters I/B/E/S.Shareholders' net income increased to $533 million, or $2.04 per share, from $528 million, or $1.92 per share, a year earlier.Revenue rose 11.4 percent to $9.47 billion, above the $9.28 billion analysts expected.Cigna stock rose 0.1 percent to $126.79. Shares in Aetna Inc , Anthem Inc and Cigna were all higher in Thursday trading.        (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Simon Jennings, Joyjeet Das and Jeffrey Benkoe)",2015-04-30,HUM,"Thu Apr 30, 2015 | 10:28am EDT","UPDATE 2-Cigna sees no change in medical use in 1st qtr, unlike Humana",http://www.reuters.com//article/cigna-results-idUSL4N0XR5F820150430?type=companyNews
62,"   By Greg Roumeliotis and Olivia Oran  Humana Inc (HUM.N) is considering selling itself after receiving multiple expressions of takeover interest, a person familiar with the matter said on Friday, highlighting the widening consolidation in the U.S. health insurance industry.Humana is working with investment bank Goldman Sachs Group Inc (GS.N) on the potential sale, the person said, asking not to be identified because the matter is confidential. The Wall Street Journal first reported on the sale process and said competitors Aetna Inc (AET.N) and Cigna Corp (CI.N) are among those that have held preliminary merger discussions with Humana.Humana, whose shares closed 20 percent higher on the news, could not be reached for comment. Goldman Sachs, Cigna and Aetna declined to comment.Humana has missed analyst expectations for financial results several times in the past year, and its business of providing individual insurance on the Obamacare exchanges has struggled.   Some of the company's shareholders had privately called on the company in recent months to explore a sale, people familiar with the matter said this week. They asked not to be identified because those discussions were confidential. Being part of a bigger company could help Humana's flagship Medicare Advantage health insurance and individual insurance businesses if it negotiates better contracts with doctors and creates more competitively structured networks of providers, said Leerink Partners analyst Ana Gupte. Its sale may trigger consolidation that shrinks the number of large publicly traded health insurers from five down to three, she said, explaining ""It's a huge push for scale.""  Executives from Aetna and Anthem Inc (ANTM.N) have said in recent weeks they are interested in doing large deals. Analysts said on Friday that Anthem may also look at Humana. The government has pressured health insurers to cut costs with the new Obamacare exchange plans and in Medicare while employers have also gotten tough on spending for medical procedures and drugs. Humana's top shareholders include Glenview Capital Management, which in 2013 pushed for change at hospital operator Health Management Associates Inc.The Justice Department, which reviews insurance mergers, will scrutinize any possible deal city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the Justice Department now at Washington law firm Doyle, Barlow and Mazard PLLC.""Humana is going to be selling itself to another mega player and the antitrust division has shown itself to be interested in scrutinizing mega mergers. The deal could be met with some resistance,"" said Barlow. (Additional reporting by Diane Bartz in Washington, D.C. and Caroline Humer in New York; editing by Richard Chang)",2015-05-29,HUM,"Fri May 29, 2015 | 5:41pm EDT",Health insurer Humana explores sale:  source,http://www.reuters.com//article/us-humana-m-a-idUSKBN0OE29E20150529?type=companyNews
63,"  (Adds analyst comment and strategic rationale)By Greg Roumeliotis and Olivia OranMay 29 Humana Inc is considering selling itself after receiving multiple expressions of takeover interest, a person familiar with the matter said on Friday, highlighting the widening consolidation in the U.S. health insurance industry.Humana is working with investment bank Goldman Sachs Group Inc on the potential sale, the person said, asking not to be identified because the matter is confidential.The Wall Street Journal first reported on the sale process and said competitors Aetna Inc and Cigna Corp are among those that have held preliminary merger discussions with Humana.Humana, whose shares closed 20 percent higher on the news, could not be reached for comment. Goldman Sachs, Cigna and Aetna declined to comment. Humana has missed analyst expectations for financial results several times in the past year, and its business of providing individual insurance on the Obamacare exchanges has struggled.Some of the company's shareholders had privately called on the company in recent months to explore a sale, people familiar with the matter said this week. They asked not to be identified because those discussions were confidential. Being part of a bigger company could help Humana's flagship Medicare Advantage health insurance and individual insurance businesses if it negotiates better contracts with doctors and creates more competitively structured networks of providers, said Leerink Partners analyst Ana Gupte.Its sale may trigger consolidation that shrinks the number of large publicly traded health insurers from five down to three, she said, explaining ""It's a huge push for scale.""Executives from Aetna and Anthem Inc have said in recent weeks they are interested in doing large deals. Analysts said on Friday that Anthem may also look at Humana. The government has pressured health insurers to cut costs with the new Obamacare exchange plans and in Medicare while employers have also gotten tough on spending for medical procedures and drugs.Humana's top shareholders include Glenview Capital Management, which in 2013 pushed for change at hospital operator Health Management Associates Inc.The Justice Department, which reviews insurance mergers, will scrutinize any possible deal city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the Justice Department now at Washington law firm Doyle, Barlow and Mazard PLLC.""Humana is going to be selling itself to another mega player and the antitrust division has shown itself to be interested in scrutinizing mega mergers. The deal could be met with some resistance,"" said Barlow.   (Additional reporting by Diane Bartz in Washington, D.C. and Caroline Humer in New York; editing by Richard Chang)",2015-05-29,HUM,"Fri May 29, 2015 | 5:34pm EDT",UPDATE 3-Health insurer Humana explores sale - source,http://www.reuters.com//article/humana-ma-idUSL3N0YK5D020150529?type=companyNews
64,"  * GDP revised to show economy contracted in Q1* Consumer sentiment, PMI fall in May* Humana hits record on takeover interest* Altera rises on report of Intel interest* Indexes down: Dow 0.6 pct, S&P 0.6 pct, Nasdaq 0.6 pct   (Updates to close)By Caroline ValetkevitchMay 29 U.S. stocks closed lower on Friday as data showed the economy contracted in the first quarter but indexes still posted gains for the month.Transportation shares also weighed on the market, extending recent losses. The Dow Jones transportation average fell 0.8 percent, putting it just shy of correction territory, almost 10 percent below its 2014 high. Data showed the U.S. economy contracted at a 0.7 percent annual rate in the quarter, a sharp turnaround from the earlier estimate of growth of 0.2 percent.Weak reports on factory activity in the Midwest and consumer sentiment for May suggested that the growth pace was modest early in the second quarter.""We had some weak numbers, but it's the end of the month for the trading of May, which can sometimes cause a selloff. It's also Friday and Greece worries are still in the marketplace,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York. U.S. Treasury Secretary Jack Lew repeated warnings on Friday not to minimize the global stability risk of Greece sliding out of the euro zone.The Dow Jones industrial average fell 115.44 points, or 0.64 percent, to 18,010.68, the S&P 500 lost 13.4 points, or 0.63 percent, to 2,107.39 and the Nasdaq Composite  dropped 27.95 points, or 0.55 percent, to 5,070.03.For the month, the Dow was up 1 percent, the S&P 500 was up 1.1 percent and the Nasdaq gained 2.6 percent.For the week, stocks posted losses, however. The Dow was down 1.2 percent, the S&P 500 fell 0.9 percent and the Nasdaq lost 0.4 percent. Weighing on the market Friday, shares of Bristol-Myers Squibb tumbled 6.6 percent, its biggest daily drop since 2012, following a company presentation at a cancer meeting.  The stock had gained 8.5 percent this month before the presentation.Humana jumped 20.3 percent to a record high after a source said it is considering selling itself.Intel was up 1.3 percent to $34.46. People familiar with the matter said it has resumed talks to buy programmable-chip maker Altera Corp and is close to a $16 billion deal. Altera rose 4 percent to $48.85.Declining issues outnumbered advancing ones on the NYSE by 2,097 to 945, for a 2.22-to-1 ratio on the downside; on the Nasdaq, 1,723 issues fell and 1,039 advanced for a 1.66-to-1 ratio favoring decliners.The S&P 500 posted 16 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 77 new highs and 36 new lows.About 7 billion shares changed hands on U.S. exchanges, above the 6.1 billion daily average for May, according to BATS Global Markets.    (Additional reporting by Sweta Singh in Bengaluru; Editing by Savio D'Souza and Nick Zieminski)",2015-05-29,HUM,"Fri May 29, 2015 | 4:50pm EDT",US STOCKS-Wall St ends down after weak economic data but gains in May,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0YK2KH20150529?type=companyNews
65,"  (Adds Humana, TCV, HSBC, Eni, Steris, Mediobanca, PZU, Bank Asya and Doverie United)May 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:** Intel Corp has resumed talks to buy programmable-chip maker Altera Corp and is close to a $16 billion deal, people familiar with the matter said on Friday, paving way for the third mega semiconductor-chip deal this year.** Humana Inc is considering selling itself after receiving multiple expressions of takeover interest, a person familiar with the matter said, highlighting the potential for further consolidation in the U.S. health insurance industry.** French cancer drug maker Cellectis is in potential sale talks with a few suitors, including U.S.-based Pfizer Inc, the Financial Times reported, citing people familiar with the matter.** The chairman of Fiat Chrysler   confirmed that CEO Sergio Marchionne had sent an email to General Motors about a possible tie-up, adding that discussions had taken place with other players as well.** Technology Crossover Ventures (TCV) is exploring a sale of its minority stake in Merkle Inc, in a deal that could value the fast-growing marketing technology company at more than $1 billion, according to people familiar with the matter.** NG Group NV, BNP Paribas and Bahrain-based Arab Banking Corp (ABC) have submitted bids to buy HSBC's Turkish business, a source familiar with the process said.** Bank of China Ltd's Hong Kong-listed unit has shortlisted at least four bidders, including New China Life Insurance Co, for the sale of Nanyang Commercial Bank valued at about $6.8 billion, people familiar with the matter said on Friday.** Talks between Eni and suitors including Chinese state utility Huadian for a stake of around 15 percent in the Italian oil major's prized Mozambique gas field are dragging on due to differences over price, industry and banking sources said. ** The U.S. Federal Trade Commission, which enforces antitrust law, filed a lawsuit on Friday aimed at stopping the $1.9 billion merger of Steris Corp and Synergy Health SYR.L, the agency said.** Italian investment bank Mediobanca will sell its 1.6 percent stake in domestic phone operator Telecom Italia  on the market by the end of June, a source close to the matter said.** Central Europe's biggest insurance company PZU  has been chosen as preferred buyer for a key stake in mid-tier Polish lender Alior Bank, two sources familiar with the matter said.** Turkish authorities said on Friday they had decided to take over Bank Asya, the Islamic lender caught up in a feud between President Tayyip Erdogan and U.S.-based Muslim cleric Fethullah Gulen. ** Bulgaria's Doverie United Holding has signed a preliminary deal to acquire Tokuda Bank through its Industrial Holding Doverie unit for an undisclosed sum, the company said in a statement.** Investment group Penta, Belgian bank KBC's CSOB unit and an undisclosed third investor from Slovakia are interested in buying Sberbank's Slovak unit, daily newspaper SME reported on Friday.** U.S. data center company Equinix Inc said on Friday it had agreed to buy British peer Telecity Group  in a deal worth 2.35 billion pounds ($3.6 billion) which ends Telecity's pursuit of smaller Dutch firm Interxion Holding NV .** Thai billionaire Charoen Sirivadhanabhakdi is considering buying cognac maker Louis Royer, people familiar with the matter said, potentially locking horns with a Philippine tycoon for the French firm amid a forecast rebound in Asian demand for luxury spirits. ** Some of the biggest investors in Vodafone say they are open to a European tie-up with Liberty Global , as the British company is now in a stronger position to negotiate a deal with John Malone's cable group.** Daum Kakao Corp, operator of KakaoTalk, said it would acquire Path, a social networking service with 10 million monthly active users as well as messaging app Path Talk to strengthen its presence in Indonesia. Daum Kakao declined to disclose how much it is paying for the deal.** Taiwan's CTBC Financial Holding Co Ltd will buy 100 percent of CITIC Bank International (China) Ltd for T$11.67 billion ($380 million), CTBC officials said at a press briefing on Tuesday.** Sterilization services provider Synergy Health Plc  and U.S. medical tech company Steris Corp said they would contest the U.S. Federal Trade Commission's attempt to block Steris's acquisition of the British company.** ING Groep NV, Qatar National Bank and the Bahrain-based Arab Banking Corp are among the potential bidders for HSBC's Turkish business, sources familiar with the process said on Friday.** French oil major Total sees no reason currently to sell its Hutchinson rubber unit and the group will explain in due time what its plans are for the business, its chief executive said on Friday.** The European Bank of Reconstruction and Development (EBRD) said on Friday it was in talks with Borsa Istanbul about acquiring a 10 percent stake in the stock exchange ahead of its planned public offering in 2016.** A $1.2 billion share sale by Fosun International Ltd  this month was likely only the start of a love affair with equity deals, bankers say, as the Chinese conglomerate seeks to cut reliance on debt to fund its huge acquisition ambitions.** French media group Vivendi said on Friday it would book a 4.2 billion euro ($4.6 billion) pretax gain from the sale of Brazilian telecommunications company GVT, which would help it pay interim dividends.   ($1 = 30.71 Taiwan dollars)  ($1 = 0.65 pounds)  ($1 = 0.91 euros)   (Compiled by Neha Dimri and Anya George Tharakan in Bengaluru)",2015-05-29,HUM,"Fri May 29, 2015 | 4:07pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0YK3O920150529?type=companyNews
66,"  * GDP revised to show economy contracted in Q1* Consumer sentiment, PMI fall in May* Humana hits record on takeover interest, insurers gain* Altera hits 15-year high on report on Intel interest* Indexes down: Dow 0.36 pct, S&P 0.24 pct, Nasdaq 0.11 pct   (Updates prices)By Sweta SinghMay 29 U.S. stocks were lower in early afternoon trading on Friday, weighed by data that showed the economy contracted in the first quarter and as weak data for May added to concerns about the strength of a recovery.The economy contracted at a 0.7 percent annual rate in the quarter, a sharp turnaround from an earlier estimate of growth of 0.2 percent.Weak data on factory activity in the Midwest and consumer sentiment for May, suggested that the growth pace was modest early in the second quarter. That mirrored other recent soft data on retail sales and industrial production. The economy appears poised for its worst first-half performance since 2011.""The data is telling us that the economy is improving but it is not super strong,"" said Kim Forrest, a senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.The pace of the recovery will add to investor's concerns about the timing of an increase in interest rates by the Federal Reserve.""Today's market action says the rate increase is going to happen in September,"" Forrest added. Adam Sarhan, chief executive of Sarhan Capital in New York, however, ruled out the threat of an imminent interest rate increase, which should be supportive of stocks.""There is no need for the Fed to raise rates now. The economy simply is not strong enough and that's what today's data tells us,"" Sarhan said.The GDP report also showed that corporate profits declined 8.7 percent in the first quarter, the largest drop in a year.Conflicting reports on Greece's ability to strike a deal with its euro zone partners also weighed on global markets. At 13:44 p.m. ET (1744 GMT) the Dow Jones industrial average  was down 64.96 points, or 0.36 percent, at 18,061.16, the S&P 500 was down 5.09 points, or 0.24 percent, at 2,115.7 and the Nasdaq Composite was down 5.80 points, or 0.11 percent, at 5,092.17.Eight of the 10 S&P 500 sectors were down. The biggest drop was the industrial sector's 0.71 percent, with United Rental's 6.5 percent fall to $88.85 leading the losers after Bank of America Merrill Lynch downgraded the stock.Humana jumped as much as 18 percent to hit a record of $210.65 after the Wall Street Journal reported that the health insurer had received takeover interest. Other health insurers also rose.Intel was up 1.4 percent to $34.49 after the New York Post reported that it was close to buying Altera  for about $15 billion. Altera rose as much as 6.1 percent to a more than 15-year high of $50.10.ITT Educational Services more than doubled to $4.85 after the for-profit education provider reported higher-than-expected annual results.Decliners outnumbered advancers on the NYSE by 1,924 to 1,033, for a 1.86-to-1 ratio on the downside. On the Nasdaq, 1,449 issues fell and 1,200 advanced for a 1.21-to-1 ratio favoring decliners.The S&P 500 index showed 14 new 52-week highs and seven new lows, while the Nasdaq recorded 64 new highs and 26 new lows.   (Additional reporting by Sayantani Ghosh in Bengaluru; Editing by Savio D'Souza)",2015-05-29,HUM,"Fri May 29, 2015 | 1:57pm EDT",US STOCKS-Wall St slips on weak economic data,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0YK59A20150529?type=companyNews
67,"  May 29 Health insurer Humana Inc is considering selling itself and it has received indications of takeover interest, the Wall Street Journal reported, citing sources familiar with the matter.Aetna Inc and Cigna Corp are among the possible bidders for Humana, the Journal reported. Humana is working with Goldman Sachs on a potential sale, the Journal said. (on.wsj.com/1cnEfE6)  Humana, Aetna and Cigna could not be immediately reached for comment.                    (Reporting by Ankur Banerjee in Bengaluru; Editing by Kirti Pandey)",2015-05-29,HUM,"Fri May 29, 2015 | 1:32pm EDT",Health insurer Humana considering selling itself - WSJ,http://www.reuters.com//article/humana-ma-idUSL3N0YK5C920150529?type=companyNews
68,"  ZAGREB, June 11 The Croatian government said on Thursday it would invite banks to advise on the sale of a stake of up to 60 percent in indebted state-owned motorway management company HAC which it hoped would raise around 1.5 billion euros ($1.7 billion).""We have told the privatisation agency CERP to start preparations for choosing an adviser for HAC's IPO,"" Transport Minister Sinisa Hajdas Doncic told a cabinet session.""HAC will secure the needed funds and the government will choose the adviser,"" he added.The public road company's overall debt amounts to some 4.3 billion euros. Besides the 1.5 billion euros that could be raised, most of the remaining debt would be refinanced in deals with international financial institutions, according to a government document. Hajdas Doncic did not provide a time frame for completing the IPO. The Social Democrat-led government faces a parliamentary election due in late 2015 or January 2016.In March the government abandoned a tender to lease the operation of its motorways to foreign companies in the face of strong opposition from local trade unions and civic groups. They protested that the lease plan amounted to selling off the family silver and called for a referendum on the issue. Before cancelling the tender, the government had received several non-binding bids for running the motorways. It did not name the bidders but local media said the three most likely bidders were a Goldman Sachs-led consortium including local pension funds, Austria's Strabag and Australia's Macquarie.Croatia, which depends heavily on tourism income, took out loans over the previous 15 years to complete a motorway network of more than 1,000 km (620 miles) to improve access to its Adriatic coast.But the motorway management has not been able to raise enough from tolls to repay the debt, while Croatia's public debt is already nearing 90 percent of gross domestic product. ($1 = 0.8883 euros)   (Reporting by Igor Ilic; Editing by Zoran Radosavljevic and Keith Weir)",2015-06-11,HUM,"Thu Jun 11, 2015 | 6:07am EDT",Croatia seeks adviser for IPO of state motorway company,http://www.reuters.com//article/croatia-ipo-highways-idUSL5N0YX1IC20150611?type=companyNews
69,"  WASHINGTON Health insurer Aetna Inc (AET.N) has made a takeover proposal to rival Humana Inc (HUM.N), the Wall Street Journal reported on Saturday. It gave no details.        (Reporting by Mohammad Zargham Editing by W Simon) ",2015-06-20,HUM,"Sat Jun 20, 2015 | 5:00pm EDT",Aetna Inc makes takeover proposal to Humana Inc - WSJ,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKBN0P00SX20150620?type=companyNews
70,"  WASHINGTON, June 20 Health insurer Aetna Inc  has made a takeover proposal to rival Humana Inc , the Wall Street Journal reported on Saturday. It gave no details.        (Reporting by Mohammad Zargham Editing by W Simon)   ",2015-06-20,HUM,"Sat Jun 20, 2015 | 4:54pm EDT",Aetna Inc makes takeover proposal to Humana Inc -WSJ,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0Z60JG20150620?type=companyNews
71,"  U.S. health insurer Aetna Inc (AET.N) is close to buying rival Humana Inc (HUM.N) and a deal could be signed as early as this weekend, Bloomberg reported, citing people familiar with the matter.Humana has also received an offer from Cigna Corp (CI.N), but Humana's board prefers the offer from Aetna, Bloomberg reported. Aetna and Humana were in talks, a source familiar with the matter told Reuters on Thursday, adding that there was no certainty Aetna would prevail. Cigna is also in the running, a second source confirmed to Reuters.Aetna made a formal cash-and-stock bid this week to buy Humana, Bloomberg said.Humana, which had a market value of $27.59 billion as of Thursday's close, was not immediately available for comment.  Aetna and Cigna declined to comment.Reuters has previously reported that Humana is in takeover talks with Aetna and Cigna.Bloomberg said discussions between Humana and Aetna intensified in the past few days after it emerged over the weekend that rivals Anthem Inc (ANTM.N) and Cigna had held merger talks of their own. Anthem said on Saturday it had offered $47 billion in cash and stock for smaller rival Cigna, who rebuffed the offer the next day.The intensifying talks come as insurers seek scale to trim administrative costs and negotiate lower prices with doctors, moves they say will make plans more affordable. Aetna's shares jumped 4.3 percent to a record $133.05 after the report, while Humana's shares were up 6.5 percent at $196.21 in afternoon trading.Cigna shares rose 2.7 percent to a record high of $170.20, before giving up some gains to trade up 1 pct at $167.51. (Reporting by Rosmi Shaji in Bengaluru and Olivia Oran and Gregory Roumeliotis in New York; Editing by Maju Samuel and Savio D'Souza)",2015-06-25,HUM,"Thu Jun 25, 2015 | 5:55pm EDT",Aetna close to buying Humana: Bloomberg,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKBN0P52G920150625?type=companyNews
72,"  (Adds Aetna comments)June 25 U.S. health insurer Aetna Inc is close to buying rival Humana Inc and a deal could be signed as early as this weekend, Bloomberg reported, citing people familiar with the matter.Humana has also received an offer from Cigna Corp, but Humana's board prefers the offer from Aetna, Bloomberg reported. (bloom.bg/1Cwt3fL)Aetna and Humana were in talks, a source familiar with the matter told Reuters on Thursday, adding that there was no certainty Aetna would prevail. Cigna is also in the running, a second source confirmed to Reuters.Aetna made a formal cash-and-stock bid this week to buy Humana, Bloomberg said. Humana, which had a market value of $27.59 billion as of Thursday's close, was not immediately available for comment.Aetna and Cigna declined to comment. Reuters has previously reported that Humana is in takeover talks with Aetna and Cigna.Bloomberg said discussions between Humana and Aetna intensified in the past few days after it emerged over the weekend that rivals Anthem Inc and Cigna had held merger talks of their own. Anthem said on Saturday it had offered $47 billion in cash and stock for smaller rival Cigna, who rebuffed the offer the next day.The intensifying talks come as insurers seek scale to trim administrative costs and negotiate lower prices with doctors, moves they say will make plans more affordable.Aetna's shares jumped 4.3 percent to a record $133.05 after the report, while Humana's shares were up 6.5 percent at $196.21 in afternoon trading.Cigna shares rose 2.7 percent to a record high of $170.20, before giving up some gains to trade up 1 pct at $167.51.   (Reporting by Rosmi Shaji in Bengaluru and Olivia Oran and Gregory Roumeliotis in New York; Editing by Maju Samuel and Savio D'Souza)",2015-06-25,HUM,"Thu Jun 25, 2015 | 5:54pm EDT",UPDATE 2-Aetna close to buying Humana - Bloomberg,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZB58Q20150625?type=companyNews
73,"  (Corrects spelling of Bloomberg in headline)June 25 Health insurer Aetna Inc is close to buying rival Humana Inc, and a deal could be signed as early as this weekend, Bloomberg reported. Aetna made a formal bid this week to buy Humana in the form of cash and stock, Bloomberg reported, citing people familiar with the matter. (bloom.bg/1Cwt3fL) Humana has also received an offer from Cigna Corp, but the Humana board prefers the offer from Aetna, Bloomberg said. Humana and Aetna were not immediately available for comment.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)",2015-06-25,HUM,"Thu Jun 25, 2015 | 2:15pm EDT",REFILE-Aetna close to buying Humana - Bloomberg,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZB58820150625?type=companyNews
74,"  July 2 U.S. health insurer Cigna Corp has had its first meetings with competitor Anthem Inc after it rebuffed Anthem's $47 billion merger proposal last month, a person familiar with the matter said on Thursday.It was not immediately clear if the new talks, which were held in the last few days, would lead to the companies reaching a deal. The talks come as both Cigna and rival Aetna Inc  consider the possible acquisition of smaller player Humana Inc , people familiar with the matter have said previously.The source on the Cigna-Anthem talks asked not to be identified because the discussions are confidential. Cigna and Anthem declined to comment. CNBC first reported on the latest talks between the two companies.A combined Cigna and Anthem would have 53 million customers in commercial, government, consumer and other kinds of health insurance plans. Big U.S. health insurers are seeking acquisitions to boost membership in government-paid healthcare plans and employer-based insurance. The bigger the insurer, the more power it has negotiating prices and improving its doctor networks. Earlier on Thursday, U.S. health insurer Centene Corp  said it would buy smaller rival Health Net Inc  for $6.3 billion, underscoring the healthcare industry's rush to bulk up to negotiate more advantageous prices with suppliers and hospitals, and attract new customers.In rejecting Anthem's offer, Cigna previously cited Anthem's ""lack of growth strategies,"" complications related to its membership of Blue Cross Blue Shield Association and a ""massive"" data breach it suffered in February. Cigna's board is also concerned by Anthem's ""insistence"" that one person - Joseph Swedish, Anthem's president and chief executive officer - assume four roles of the combined company: chairman, CEO, president and head of integration.Anthem has said it believes investors support its refusal to guarantee that the CEO role of the combined company would go to Cigna CEO David Cordani.    (Reporting by Greg Roumeliotis in New York; Editing by Peter Galloway)",2015-07-02,HUM,"Thu Jul 2, 2015 | 11:52am EDT","Anthem, Cigna in new round of talks -source",http://www.reuters.com//article/cigna-ma-anthem-idUSL1N0ZI1CQ20150702?type=companyNews
75,"  July 2 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.* The shutdown of Greece's banking system is crippling businesses and making it hard for people to pay their bills. The freezing of Greece's banking system is the most dramatic moment of the country's five-year debt crisis - and perhaps its most pivotal. Since Monday, Greeks can get only 60 euros a day at cash machines and can't transfer money abroad. (on.ft.com/1C0Frto)* Puerto Rico's economic problems stem in some part from how the U.S. commonwealth has to operate under the same minimum-wage rules as the more prosperous 50 states. (on.wsj.com/1IuDyGC) * President Barack Obama formally announced that the United States is renewing diplomatic relations with Cuba and called on Congress to lift the long-standing embargo, setting in motion what is likely to be a longer and more uncertain battle on Capitol Hill to dismantle laws keeping the trade and travel bans in place. (on.wsj.com/1Nx3eBP) * The Justice Department is investigating whether U.S. airlines colluded on expansion plans, amid concerns from consumer advocates and politicians that the industry is trying to control capacity to keep airfares high. The four largest U.S. airlines - American Airlines Group, United Continental Holdings, Delta Air Lines, and Southwest Airlines - confirmed that they are part of the probe and said they are cooperating. (on.wsj.com/1R5NE6B) * Sealed Air Corp, the original seller of Bubble Wrap since 1960, is rolling out a revamped version of its signature product. Dubbed iBubble Wrap, the new packaging is sold in flat plastic sheets that the shipper fills with air using a custom-made pump. The inflated bubbles look much like traditional Bubble Wrap, with one key difference: They don't burst when pressure is applied. (on.wsj.com/1f38DG9)* The U.S. government's release of new data on health-insurer payments under the Affordable Care Act is roiling the industry, including potentially affecting the timing of any deal for Humana Inc, as suitors pore over the detailed information disclosed late Tuesday. (on.wsj.com/1UaSBde)     (Compiled by Supriya Kurane in Bengaluru)",2015-07-02,HUM,"Thu Jul 2, 2015 | 12:28am EDT",PRESS DIGEST - Wall Street Journal - July 2,http://www.reuters.com//article/press-digest-wsj-idUSL3N0ZI1TS20150702?type=companyNews
76,"  (Adds no comment from Cigna, regulators involved in deal, paragraphs 2, 8)By Luciana LopezNEW YORK, July 3 Aetna Inc's $37 billion deal to buy smaller health insurer Humana Inc will face rigorous scrutiny from U.S. regulators, which antitrust experts said could also make other large-scale mergers in the sector more difficult.The Aetna-Humana tie-up would be the largest such deal among health insurers. Friday's announcement starts the clock on an examination by regulators of whether consumers will be hurt by diminished competition. Competition regulators include the Department of Justice and various state-level agencies.The deal follows weeks of intense discussions about potential combinations among the five biggest U.S. health insurers: Aetna, Humana, Cigna Corp, Anthem Inc  and UnitedHealth Group.Insurers want more leverage in a healthcare system that has seen major consolidation among hospitals and doctor practices, as well as mergers between medical device makers and other suppliers. The cost of new drugs has soared, and President Barack Obama's healthcare law has made it harder for insurers to pass on higher costs to customers.Last month, Anthem offered to buy Cigna for $47 billion. The combined company would have surpassed UnitedHealth to become the single largest U.S. health insurer.Cigna, which had also considered purchasing Humana, has so far rejected the buyout approach. Some industry watchers expect a potential buyout of Cigna to be revived after Aetna's deal.Industry sources said Cigna and Anthem may have just a few months to sign a deal if they want it to be considered by antitrust authorities along with the Aetna-Humana deal. Cigna declined to comment about the Aetna-Humana deal. Anthem said it had nothing to say about other potential mergers.Regulators ""should be exceedingly skeptical of this deal"" between Aetna and Humana, said Diana Moss, president of the American Antritrust Institute. ""Depending on who merges and the change to the market structure, that affects the concerns about the competition.""Aetna said it is ready to address regulatory concerns.""Obviously this is something that we expect will get a thorough and careful review,"" Shawn Guertin, Aetna's chief financial officer, said in an interview. ""We've spent a lot of time looking at this at a fairly detailed level, and we certainly think that's a manageable situation."" Guertin conceded that a combined company could have some overlap, but declined to name possible divestitures that regulators might seek.""We're in the same business at the highest level, and so there certainly is an overlap in that regard,"" he said.""It's really about local markets,"" Guertin said. RECENT DEALS SCUTTLED Antitrust experts said a regulatory review of Aetna and Humana could also factor in whether there is another major deal in the industry.Regulators are expected to scrutinize how competition in local markets will be affected for each line of insurance: Medicare for the elderly, Medicaid for the poor, individual insurance, commercial insurance for small and large business and the large employer business.Regulators have recently scuttled deals in other industries that would have created mega players. In April, Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc because of antitrust worries.This month, the U.S. Justice Department sued to stop Sweden's Electrolux AB from buying General Electric Co's appliance business.""Agencies are becoming increasingly skeptical about whether you can remedy anti-competitive mergers by having some kind of divestiture,"" said David Balto, formerly the policy director of the Bureau of Competition of the Federal Trade Commission.Mergers might give insurers more punch to negotiate lower prices with pharmaceutical companies, Balto said. But he called that a ""Faustian bargain.""""Maybe they have more buying power, but then they're going to have more selling power.""   (Additional reporting by Caroline Humer and Gregory Roumeliotis; Editing by David Gregorio)",2015-07-03,HUM,"Fri Jul 3, 2015 | 4:46pm EDT",UPDATE 1-Aetna's Humana deal to bring scrutiny on other insurer tie-ups -experts,http://www.reuters.com//article/healthcare-ma-regulator-idUSL1N0ZJ10J20150703?type=companyNews
77,"   By Luciana Lopez | NEW YORK  NEW YORK Aetna Inc's (AET.N) $37 billion deal to buy smaller health insurer Humana Inc (HUM.N) will face rigorous scrutiny from U.S. regulators, which antitrust experts said could also make other large-scale mergers in the sector more difficult. The Aetna-Humana tie-up would be the largest such deal among health insurers. Friday's announcement starts the clock on an examination by regulators of whether consumers will be hurt by diminished competition.The deal follows weeks of intense discussions about potential combinations among the five biggest U.S. health insurers: Aetna, Humana, Cigna Corp (CI.N), Anthem Inc (ANTM.N) and UnitedHealth Group (UNH.N).  Insurers want more leverage in a healthcare system that has seen major consolidation among hospitals and doctor practices, as well as mergers between medical device makers and other suppliers. The cost of new drugs has soared, and President Barack Obama's healthcare law has made it harder for insurers to pass on higher costs to customers. Last month, Anthem offered to buy Cigna for $47 billion. The combined company would have surpassed UnitedHealth to become the single largest U.S. health insurer.Cigna, which had also considered purchasing Humana, has so far rejected the buyout approach. Some industry watchers expect a potential buyout of Cigna to be revived after Aetna's deal. Industry sources said Cigna and Anthem may have just a few months to sign a deal if they want it to be considered by antitrust authorities along with the Aetna-Humana deal.Cigna did not respond to a request for comment about the Aetna-Humana deal. Anthem said it had nothing to say about other potential mergers.  Regulators ""should be exceedingly skeptical of this deal"" between Aetna and Humana, said Diana Moss, president of the American Antritrust Institute. ""Depending on who merges and the change to the market structure, that affects the concerns about the competition."" Aetna said it is ready to address regulatory concerns.""Obviously this is something that we expect will get a thorough and careful review,"" Shawn Guertin, Aetna's chief financial officer, said in an interview. ""We've spent a lot of time looking at this at a fairly detailed level, and we certainly think that's a manageable situation. Guertin conceded that a combined company could have some overlap, but declined to name possible divestitures that regulators might seek.""We're in the same business at the highest level, and so there certainly is an overlap in that regard,"" he said. ""It's really about local markets,"" Guertin said.RECENT DEALS SCUTTLED  Antitrust experts said a regulatory review of Aetna and Humana could also factor in whether there is another major deal in the industry.  Regulators are expected to scrutinize how competition in local markets will be affected for each line of insurance: Medicare for the elderly, Medicaid for the poor, individual insurance, commercial insurance for small and large business and the large employer business.Regulators have recently scuttled deals in other industries that would have created mega players. In April, Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc because of antitrust worries. This month, the U.S. Justice Department sued to stop Sweden's Electrolux AB from buying General Electric Co's appliance business. ""Agencies are becoming increasingly skeptical about whether you can remedy anti-competitive mergers by having some kind of divestiture,"" said David Balto, formerly the policy director of the Bureau of Competition of the Federal Trade Commission. Mergers might give insurers more punch to negotiate lower prices with pharmaceutical companies, Balto said. But he called that a ""Faustian bargain."" ""Maybe they have more buying power, but then they're going to have more selling power."" (Additional reporting by Caroline Humer and Gregory Roumeliotis; Editing by David Gregorio)",2015-07-03,HUM,"Fri Jul 3, 2015 | 4:28pm EDT",Aetnas Humana deal to bring scrutiny on other insurer tie-ups,http://www.reuters.com//article/us-healthcare-m-a-regulator-idUSKCN0PD28X20150703?type=companyNews
78,"   By Luciana Lopez | NEW YORK, July 3  NEW YORK, July 3 Aetna Inc's $37 billion deal to buy smaller health insurer Humana Inc will face rigorous scrutiny from U.S. regulators, which antitrust experts said could also make other large-scale mergers in the sector more difficult.The Aetna-Humana tie-up would be the largest such deal among health insurers. Friday's announcement starts the clock on an examination by regulators of whether consumers will be hurt by diminished competition.The deal follows weeks of intense discussions about potential combinations among the five biggest U.S. health insurers: Aetna, Humana, Cigna Corp, Anthem Inc  and UnitedHealth Group.Insurers want more leverage in a healthcare system that has seen major consolidation among hospitals and doctor practices, as well as mergers between medical device makers and other suppliers. The cost of new drugs has soared, and President Barack Obama's healthcare law has made it harder for insurers to pass on higher costs to customers.Last month, Anthem offered to buy Cigna for $47 billion. The combined company would have surpassed UnitedHealth to become the single largest U.S. health insurer.Cigna, which had also considered purchasing Humana, has so far rejected the buyout approach. Some industry watchers expect a potential buyout of Cigna to be revived after Aetna's deal.Industry sources said Cigna and Anthem may have just a few months to sign a deal if they want it to be considered by antitrust authorities along with the Aetna-Humana deal.Cigna did not respond to a request for comment about the Aetna-Humana deal. Anthem said it had nothing to say about other potential mergers. Regulators ""should be exceedingly skeptical of this deal"" between Aetna and Humana, said Diana Moss, president of the American Antritrust Institute. ""Depending on who merges and the change to the market structure, that affects the concerns about the competition.""Aetna said it is ready to address regulatory concerns.""Obviously this is something that we expect will get a thorough and careful review,"" Shawn Guertin, Aetna's chief financial officer, said in an interview. ""We've spent a lot of time looking at this at a fairly detailed level, and we certainly think that's a manageable situation.""Guertin conceded that a combined company could have some overlap, but declined to name possible divestitures that regulators might seek. ""We're in the same business at the highest level, and so there certainly is an overlap in that regard,"" he said.""It's really about local markets,"" Guertin said.RECENT DEALS SCUTTLED  Antitrust experts said a regulatory review of Aetna and Humana could also factor in whether there is another major deal in the industry.Regulators are expected to scrutinize how competition in local markets will be affected for each line of insurance: Medicare for the elderly, Medicaid for the poor, individual insurance, commercial insurance for small and large business and the large employer business.Regulators have recently scuttled deals in other industries that would have created mega players. In April, Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc because of antitrust worries.This month, the U.S. Justice Department sued to stop Sweden's Electrolux AB from buying General Electric Co's appliance business.""Agencies are becoming increasingly skeptical about whether you can remedy anti-competitive mergers by having some kind of divestiture,"" said David Balto, formerly the policy director of the Bureau of Competition of the Federal Trade Commission.Mergers might give insurers more punch to negotiate lower prices with pharmaceutical companies, Balto said. But he called that a ""Faustian bargain.""""Maybe they have more buying power, but then they're going to have more selling power.""   (Additional reporting by Caroline Humer and Gregory Roumeliotis; Editing by David Gregorio)",2015-07-03,HUM,"Fri Jul 3, 2015 | 4:13pm EDT",Aetna's Humana deal to bring scrutiny on other insurer tie-ups -experts,http://www.reuters.com//article/healthcare-ma-regulator-idUSL1N0ZJ0U520150703?type=companyNews
79,"   By Greg Roumeliotis  Health insurer Aetna Inc (AET.N) on Friday said it would buy smaller rival Humana Inc (HUM.N) for about $37 billion in cash and stock, in the largest ever deal in the insurance industry.The combination will push Aetna close to Anthem Inc's (ANTM.N) No.2 insurer spot by membership, and would nearly triple Aetna's Medicare Advantage business.The deal will face antitrust scrutiny but if it goes through it would dwarf the previous largest insurance deal announced just this week, where Swiss property and casualty giant ACE Ltd (ACE.N) announced it was buying Chubb Corp (CB.N) for $28 billion. It would also dwarf Anthem Inc's purchase of WellPoint in 2004 for $16.6 billion.Analysts have said that M&A activity in the healthcare sector had been waiting for last week's Supreme Court ruling on Obamacare, which upheld key subsidies that underpin the reform and thus gave more certainty to healthcare insurers.The bigger the insurer, the more power it has negotiating prices and improving its doctor networks.Anthem has offered to buy Cigna Corp (CI.N) to create the largest insurer in the country, toppling UnitedHealth Group Inc (UNH.N).Media reports have also said UnitedHealth could be eyeing Cigna and Aetna. On Thursday, Centene Corp (CNC.N) said it would buy smaller rival Health Net Inc HNT.N for $6.3 billion.ANTITRUST ISSUES Antitrust authorities, who were aggressive in their review of the failed deal between Comcast (CMCSA.O) and Time Warner Cable TWC.N, are expected to scrutinize how the combination of insurers will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business. Aetna and Humana are in nine of the same states in Medicare Advantage. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.    Wall Street analysts and some antitrust experts have said  they expect the combination will be approved, although regulators may ask for some divestitures. Others have said it is unclear that this group of regulators will stick to the usual review playbook for such a large deal and may add other restrictions. The Justice Department, which reviews insurance mergers, will scrutinize deals city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the department who is now at Washington law firm Doyle, Barlow and Mazard PLLC.Aetna said the combined company is projected to have over 33 million medical members, based on memberships as of March 31. Operating revenue is expected to be about $115 billion this year, with approximately 56 percent from government-sponsored programs including Medicare and Medicaid.Last week, the U.S. Supreme Court upheld subsidies for individuals under President Barack Obama's signature healthcare law, keeping a large chunk of patients intact under the Medicare and Medicaid programs.Insurers have said subsidies are key to bringing in new customers and the ruling has removed uncertainty for insurers looking for acquisitions. It could also spur more deal making in the health insurance sector, which has already seen a blitz of merger activity this year. U.S. Senate Majority Leader Mitch McConnell, of Kentucky, praised Humana's presence in his home state but also noted the role of the healthcare law in the merger.""This morning's announcement, as I predicted during the debate five years ago, is the inevitable result of Obamacares push toward consolidation as doctors, hospitals, and insurers merge in response to an ever-growing government,"" the Republican said in a statement.The deal includes a $1 billion break-up fee payable by Aetna to Humana, should the deal fail because of antitrust concerns, an Aetna spokeswoman confirmed. The fee was first reported by the Wall Street Journal. CASH AND SHARES Hartford, Conn.-based Aetna said it would pay Humana shareholders $125 in cash and 0.8375 Aetna shares for each share held. The offer of about $230 per share is a 23 percent premium to Humana's closing price on Thursday.Following the deal, Aetna shareholders would own about 74 percent of the combined company with Humana shareholders owning the rest. Aetna Chief Executive Mark Bertolini will serve as chairman and CEO of the combined company. The deal is expected to close in the second half of 2016 and add to operating earnings per share from 2017.Humana's sale has been anticipated since May when it was first reported that Cigna Corp (CI.N) and Aetna were interested, and multiple sources confirmed to Reuters that the company was entertaining offers. Humana, based in Louisville, Kentucky, has been under pressure for more than a year from investors, which include activist fund Glenview Capital Management, to produce higher returns.   Last year Humana hired a CFO from investment bank Goldman Sachs and went through a strategic review that included asset sales. But it missed several quarters of earnings targets and struggled with profits in its individual business, disappointing Wall Street.Aetna said it has received commitments from Citi and UBS Investment Bank to finance the deal.Citi and Lazard are financial advisers for Aetna and Davis Polk & Wardwell LLP is its legal adviser. Goldman Sachs is the financial adviser to Humana, while Fried, Frank, Harris, Shriver & Jacobson LLP is its legal adviser. (Additional reporting by Rama Venkat Raman in Bengaluru and Caroline Humer in New York; Editing by Ken Wills and Andrea Ricci)",2015-07-03,HUM,"Fri Jul 3, 2015 | 12:32pm EDT",Aetna to buy Humana for $37 billion in largest insurance deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0PD04720150703?type=companyNews
80,"  (Adds break-up fee)By Greg RoumeliotisJuly 3 Health insurer Aetna Inc on Friday said it would buy smaller rival Humana Inc for about $37 billion in cash and stock, in the largest ever deal in the insurance industry.The combination will push Aetna close to Anthem Inc's  No.2 insurer spot by membership, and would nearly triple Aetna's Medicare Advantage business.The deal will face antitrust scrutiny but if it goes through it would dwarf the previous largest insurance deal announced just this week, where Swiss property and casualty giant ACE Ltd  announced it was buying Chubb Corp for $28 billion. It would also dwarf Anthem Inc's purchase of WellPoint in 2004 for $16.6 billion.Analysts have said that M&A activity in the healthcare sector had been waiting for last week's Supreme Court ruling on Obamacare, which upheld key subsidies that underpin the reform and thus gave more certainty to healthcare insurers.The bigger the insurer, the more power it has negotiating prices and improving its doctor networks.Anthem has offered to buy Cigna Corp to create the largest insurer in the country, toppling UnitedHealth Group Inc .Media reports have also said UnitedHealth could be eyeing Cigna and Aetna. On Thursday, Centene Corp said it would buy smaller rival Health Net Inc for $6.3 billion.ANTITRUST ISSUES  Antitrust authorities, who were aggressive in their review of the failed deal between Comcast and Time Warner Cable, are expected to scrutinize how the combination of insurers will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Aetna and Humana are in nine of the same states in Medicare Advantage. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Wall Street analysts and some antitrust experts have said  they expect the combination will be approved, although regulators may ask for some divestitures.Others have said it is unclear that this group of regulators will stick to the usual review playbook for such a large deal and may add other restrictions.The Justice Department, which reviews insurance mergers, will scrutinize deals city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the department who is now at Washington law firm Doyle, Barlow and Mazard PLLC.Aetna said the combined company is projected to have over 33 million medical members, based on memberships as of March 31. Operating revenue is expected to be about $115 billion this year, with approximately 56 percent from government-sponsored programs including Medicare and Medicaid. Last week, the U.S. Supreme Court upheld subsidies for individuals under President Barack Obama's signature healthcare law, keeping a large chunk of patients intact under the Medicare and Medicaid programs.Insurers have said subsidies are key to bringing in new customers and the ruling has removed uncertainty for insurers looking for acquisitions. It could also spur more deal making in the health insurance sector, which has already seen a blitz of merger activity this year.U.S. Senate Majority Leader Mitch McConnell, of Kentucky, praised Humana's presence in his home state but also noted the role of the healthcare law in the merger.""This morning's announcement, as I predicted during the debate five years ago, is the inevitable result of Obamacare's push toward consolidation as doctors, hospitals, and insurers merge in response to an ever-growing government,"" the Republican said in a statement.The deal includes a $1 billion break-up fee payable by Aetna to Humana, should the deal fail because of antitrust concerns, an Aetna spokeswoman confirmed. The fee was first reported by the Wall Street Journal. CASH AND SHARES Hartford, Conn.-based Aetna said it would pay Humana shareholders $125 in cash and 0.8375 Aetna shares for each share held. The offer of about $230 per share is a 23 percent premium to Humana's closing price on Thursday.Following the deal, Aetna shareholders would own about 74 percent of the combined company with Humana shareholders owning the rest. Aetna Chief Executive Mark Bertolini will serve as chairman and CEO of the combined company.The deal is expected to close in the second half of 2016 and add to operating earnings per share from 2017.Humana's sale has been anticipated since May when it was first reported that Cigna Corp and Aetna were interested, and multiple sources confirmed to Reuters that the company was entertaining offers.Humana, based in Louisville, Kentucky, has been under pressure for more than a year from investors, which include activist fund Glenview Capital Management, to produce higher returns.Last year Humana hired a CFO from investment bank Goldman Sachs and went through a strategic review that included asset sales. But it missed several quarters of earnings targets and struggled with profits in its individual business, disappointing Wall Street.Aetna said it has received commitments from Citi and UBS Investment Bank to finance the deal.Citi and Lazard are financial advisers for Aetna and Davis Polk & Wardwell LLP is its legal adviser. Goldman Sachs is the financial adviser to Humana, while Fried, Frank, Harris, Shriver & Jacobson LLP is its legal adviser.   (Additional reporting by Rama Venkat Raman in Bengaluru and Caroline Humer in New York; Editing by Ken Wills and Andrea Ricci)",2015-07-03,HUM,"Fri Jul 3, 2015 | 12:28pm EDT",UPDATE 7-Aetna to buy Humana for $37 bln in largest insurance deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZJ07920150703?type=companyNews
81,"  July 3 Health insurer Aetna Inc said it will buy Humana Inc for about $37 billion, or about $230 per share, in a cash-and-stock deal.Humana shareholders will receive $125 in cash and 0.8375 Aetna shares for each share held, an about 23 percent premium to the stock's closing price on Thursday.  Following the deal, Aetna's shareholders would own about 74 percent of the combined company.   (Reporting by Rama Venkat Raman in Bangalore; Editing by Gopakumar Warrier) ",2015-07-03,HUM,"Fri Jul 3, 2015 | 2:33am EDT",Aetna to buy Humana for $37 bln in cash and stock,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZJ2D320150703?type=companyNews
82,"  (Fixes Humana's location to Louisville, not Lexington, in 7th paragraph)By Greg RoumeliotisJuly 2 U.S health insurer Aetna Inc is nearing an agreement to buy rival Humana Inc for about $34 billion in a cash and stock deal, people familiar with the matter told Reuters on Thursday.One person said Aetna's offer would value Humana at about $230 per share and that a deal could be announced as early as Friday.The offer, if it goes through, would make it the largest deal in the insurance industry, dwarfing Anthem Inc's  acquisition of WellPoint in 2004 for $16.6 billion.A $230 per share offer would be at a premium of nearly 23 percent to Humana's close on the New York Stock Exchange on Thursday.Representatives from Humana and Aetna declined to comment. Humana's sale has been anticipated since May when it was first reported that Cigna Corp and Aetna were interested, and multiple sources confirmed to Reuters that the company was entertaining offers.Humana, based in Louisville, Kentucky, has been under pressure for more than a year from investors, who include activist fund Glenview Capital Management, to produce higher returns.Last year Humana hired a CFO from investment bank Goldman Sachs and went through a strategic review that included asset sales. But it missed several quarters of earnings targets and struggled with profits in its individual business, disappointing Wall Street. A deal would push Hartford, Conn.-based Aetna close to Anthem's No. 2 insurer spot by membership, and would nearly triple Aetna's Medicare Advantage business.The company's Medicare Advantage business offers government paid insurance for older people and the disabled to about 4.6 million customers. ANTITRUST ISSUES Antitrust authorities, who were aggressive in their review of the failed deal between Comcast and Time Warner Cable, are expected to scrutinize how the combination of insurers will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Aetna and Humana are in nine of the same states in Medicare Advantage. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Wall Street analysts and some antitrust experts have said  they expect the combination will be approved, although regulators may ask for some divestitures. Others have said it is unclear that this group of regulators will stick to the usual review playbook for such a large deal and may add other restrictions.The Justice Department, which reviews insurance mergers, will scrutinize any possible deal city-by-city to see if the combination would have a monopoly in any metropolitan area, said Andre Barlow, a veteran of the Justice Department who is now at Washington law firm Doyle, Barlow and Mazard PLLC.   (Reporting by Rosmi Shaji and Aurindom Mukherjee and Rama Venkat Raman in Bengaluru; Editing by Ken Wills)",2015-07-03,HUM,"Fri Jul 3, 2015 | 1:30am EDT",CORRECTED-UPDATE 4-Aetna nears deal to buy Humana for about $34 bln -sources,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZJ01T20150703?type=companyNews
83,"  July 2 U.S health insurer Aetna Inc is nearing an agreement to buy rival Humana Inc in a cash and stock deal, two people familiar with the matter told Reuters on Thursday.One source said Aetna's offer would value Humana at about $230 per share and could be announced as early as Friday. Earlier, Bloomberg reported the expected deal was valued at about $34 billion, citing unnamed sources. (bloom.bg/1GShqBy)  The $230 per share offer is at a premium of nearly 23 percent to Humana's close on the New York Stock Exchange on Thursday.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Ken Wills) ",2015-07-03,HUM,"Thu Jul 2, 2015 | 9:30pm EDT",Aetna nears deal to buy Humana at $230 a share -sources,http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZJ0GA20150703?type=companyNews
84,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc's chief executive said Monday he was confident any antitrust review of the health insurer's proposed purchase of smaller rival Humana Inc  would allow the deal to close in the second half of 2016.Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana's business in the largest-ever U.S. health insurance deal. The two sides announced the $37 billion transaction on Friday. Hospital and state officials said they would take a hard look at whether the deal would diminish competition for consumers.""We took a conservative view of what we would need to divest,"" Bertolini said during an investor conference call.Aetna has not discussed the deal directly with the U.S. Department of Justice, but has consulted with regulatory experts, Bertolini told cable channel CNBC.""We believe that given the legal advice we have...that this is a very manageable transaction,"" he said.The bigger the insurer, the more power it has negotiating prices with hospitals and other providers, as well as improving its doctor networks. Aetna and Humana are in nine of the same states in one of their key businesses - Medicare Advantage plans for the elderly. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Regulators would also look for the impact on competition in each local market for the companies' Medicaid plans for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Attorneys general in several U.S. states said on Monday they would be ready to review the proposed deal. ""Our office is aware of these mergers, and we will be looking to determine whether or not there's any significant impact on Massachusetts,"" said Chloe Gotsis, a spokeswoman for the state AG's office.Healthcare providers are concerned that further consolidation will decrease competition in the insurance industry, said Alicia Mitchell, spokeswoman for the American Hospital Association.""Any potential deal of this magnitude needs rigorous scrutiny. That's why the AHA will call upon the DOJ and Congress to exercise a significant level of scrutiny,"" Mitchell said in an emailed statement. Health insurers have been in a race to consolidate, saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs.No. 2 health insurer Anthem Inc has offered to buy No. 5 Cigna Corp. The two companies have revived discussions in light of the Humana-Aetna deal, though it is not clear whether they can agree on terms including price and governance issues, sources familiar with the matter have told Reuters.If an Anthem-Cigna deal is announced within the next two to three months, regulators could look at the impact of both mergers at the same time, Bertolini said.""It really depends on whether or not any other deals are announced,"" he told investors. ""Currently we anticipate that our transaction will be viewed alone at this point in time, but they could be bundled together at some point.""Aetna shares fell 6.4 percent to $117.43 on Monday as investors took stock of the regulatory and financial risks of the deal. Humana also lowered its 2015 financial forecasts, citing higher than expected expenses in its Medicare business.Humana shares closed up 0.8 percent at $188.96, well below the value of Aetna's proposed cash and stock offer of $223, based on the most recent share prices.    (Additional reporting by Greg Roumeliotis, Susan Kelly and Karen Freifeld)",2015-07-06,HUM,"Mon Jul 6, 2015 | 6:40pm EDT",Aetna CEO addresses antitrust concerns over Humana deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZM18G20150706?type=companyNews
85,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc's (AET.N) chief executive said Monday he was confident any antitrust review of the health insurer's proposed purchase of smaller rival Humana Inc (HUM.N) would allow the deal to close in the second half of 2016.Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana's business in the largest-ever U.S. health insurance deal. The two sides announced the $37 billion transaction on Friday. Hospital and state officials said they would take a hard look at whether the deal would diminish competition for consumers.""We took a conservative view of what we would need to divest,"" Bertolini said during an investor conference call.Aetna has not discussed the deal directly with the U.S. Department of Justice, but has consulted with regulatory experts, Bertolini told cable channel CNBC.""We believe that given the legal advice we have...that this is a very manageable transaction,"" he said.The bigger the insurer, the more power it has negotiating prices with hospitals and other providers, as well as improving its doctor networks. Aetna and Humana are in nine of the same states in one of their key businesses - Medicare Advantage plans for the elderly. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.  Regulators would also look for the impact on competition in each local market for the companies' Medicaid plans for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Attorneys general in several U.S. states said on Monday they would be ready to review the proposed deal. ""Our office is aware of these mergers, and we will be looking to determine whether or not there's any significant impact on Massachusetts,"" said Chloe Gotsis, a spokeswoman for the state AG's office.  Healthcare providers are concerned that further consolidation will decrease competition in the insurance industry, said Alicia Mitchell, spokeswoman for the American Hospital Association.""Any potential deal of this magnitude needs rigorous scrutiny. That's why the AHA will call upon the DOJ and Congress to exercise a significant level of scrutiny, Mitchell said in an emailed statement.Health insurers have been in a race to consolidate, saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs. No. 2 health insurer Anthem Inc (ANTM.N) has offered to buy No. 5 Cigna Corp (CI.N). The two companies have revived discussions in light of the Humana-Aetna deal, though it is not clear whether they can agree on terms including price and governance issues, sources familiar with the matter have told Reuters. If an Anthem-Cigna deal is announced within the next two to three months, regulators could look at the impact of both mergers at the same time, Bertolini said.""It really depends on whether or not any other deals are announced,"" he told investors. ""Currently we anticipate that our transaction will be viewed alone at this point in time, but they could be bundled together at some point.""    Aetna shares fell 6.4 percent to $117.43 on Monday as investors took stock of the regulatory and financial risks of the deal. Humana also lowered its 2015 financial forecasts, citing higher than expected expenses in its Medicare business.Humana shares closed up 0.8 percent at $188.96, well below the value of Aetna's proposed cash and stock offer of $223, based on the most recent share prices.  (Reporting by Caroline Humer in New York; Additional reporting by Greg Roumeliotis, Susan Kelly and Karen Freifeld; Editing by Bernadette Baum and Christian Plumb)",2015-07-06,HUM,"Mon Jul 6, 2015 | 6:32pm EDT",Aetna CEO addresses antitrust concerns over Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0PG1EO20150706?type=companyNews
86,"  (Adds comments from Massachusetts attorney general, American Hospital Association)By Caroline HumerNEW YORK, July 6 Aetna Inc's chief executive said Monday he was confident any antitrust review of the health insurer's proposed purchase of smaller rival Humana Inc would allow the deal to close in the second half of 2016.Mark Bertolini said Aetna had already prepared for possible divestitures to address overlaps with Humana's business in the largest-ever U.S. health insurance deal. The two sides announced the $37 billion transaction on Friday. Hospital and state officials said they would take a hard look at whether the deal would diminish competition for consumers.""We took a conservative view of what we would need to divest,"" Bertolini said during an investor conference call.Aetna has not discussed the deal directly with the U.S. Department of Justice, but has consulted with regulatory experts, Bertolini told cable channel CNBC.""We believe that given the legal advice we have...that this is a very manageable transaction,"" he said. The bigger the insurer, the more power it has negotiating prices with hospitals and other providers, as well as improving its doctor networks.Aetna and Humana are in nine of the same states in one of their key businesses - Medicare Advantage plans for the elderly. Combined, they would have market share of 88 percent in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri.Regulators would also look for the impact on competition in each local market for the companies' Medicaid plans for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business.Attorneys general in several U.S. states said on Monday they would be ready to review the proposed deal. ""Our office is aware of these mergers, and we will be looking to determine whether or not there's any significant impact on Massachusetts,"" said Chloe Gotsis, a spokeswoman for the state AG's office.Healthcare providers are concerned that further consolidation will decrease competition in the insurance industry, said Alicia Mitchell, spokeswoman for the American Hospital Association.""Any potential deal of this magnitude needs rigorous scrutiny. That's why the AHA will call upon the DOJ and Congress to exercise a significant level of scrutiny,"" Mitchell said in an emailed statement. Health insurers have been in a race to consolidate, saying that being larger would help them negotiate better prices with doctors and hospitals as well as cut administrative costs.No. 2 health insurer Anthem Inc has offered to buy No. 5 Cigna Corp. The two companies have revived discussions in light of the Humana-Aetna deal, though it is not clear whether they can agree on terms including price and governance issues, sources familiar with the matter have told Reuters.If an Anthem-Cigna deal is announced within the next two to three months, regulators could look at the impact of both mergers at the same time, Bertolini said.""It really depends on whether or not any other deals are announced,"" he told investors. ""Currently we anticipate that our transaction will be viewed alone at this point in time, but they could be bundled together at some point.""Aetna shares fell 6.4 percent to $117.43 on Monday as investors took stock of the regulatory and financial risks of the deal. Humana also lowered its 2015 financial forecasts, citing higher than expected expenses in its Medicare business.Humana shares closed up 0.8 percent at $188.96, well below the value of Aetna's proposed cash and stock offer of $223, based on the most recent share prices.    (Reporting by Caroline Humer in New York; Additional reporting by Greg Roumeliotis, Susan Kelly and Karen Freifeld; Editing by Bernadette Baum and Christian Plumb)",2015-07-06,HUM,"Mon Jul 6, 2015 | 6:31pm EDT",UPDATE 3-Aetna CEO addresses antitrust concerns over Humana deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N0ZM1GU20150706?type=companyNews
87,"   By Caroline Humer | NEW YORK  NEW YORK Humana Inc, fresh from announcing an agreement to be purchased by larger rival Aetna Inc, prompted new investor concerns about the $33 billion deal on Monday by lowering its 2015 financial forecasts.The transaction announced on Friday is already expected to face a tough review by U.S. antitrust regulators, particularly if another major deal among health insurers emerges.Humana, which has posted disappointing results for several quarters in a row, said on Monday that members of its Medicare Advantage plans for the elderly were using hospital services at a higher rate than the company expected.That increase could cut into already tight profit margins, if Humana ends up paying more for medical claims than they anticipated when setting monthly insurance rates. Humana CEO Bruce Broussard said on a conference call with investors that inpatient hospital admissions have not performed in line with what the company had forecast. That contributed to its decision to slash expected 2015 operating profits by more than 8 percent. The company said it had taken the higher Medicare Advantage hospital use into account when it priced premiums for 2016.""If you take the 8 percent downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive,"" said Joel Emery, a portfolio manager at Tareo Capital Management in New York. The degree to which Humana will boost Aetna's earnings in 2017 and 2018 is less than what some investors had hoped for, he said.Aetna's offer of $125 in cash and 0.8375 Aetna shares for each Humana share valued Humana at $230 per share. On Monday, Aetna fell 6 percent to $117, bringing down the offer price to $223 per share. Reflecting growing doubts about the deal, Humana shares traded well below the proposed offer price, closing at $188.96.""Aetna shareholders have to approve the deal, and with such a large premium, there is some outside chance that shareholders will not approve it,"" said Standard & Poor's equity analyst Jeffrey Loo. Humana's negative comments provided a silver lining to hospital operators, who stand to benefit if patient admissions rise and they are reimbursed for more of their services, said Les Funtledyer, portfolio manager at ESquared asset management. He owns shares of HCA Holdings and Universal Health Services.Consolidation among health insurers is also spurring investors to seek out cheaper stocks in the healthcare sector, such as hospitals, said Jessica Bemer, portfolio manager for Snow Capital Management in Sewickley, Pennsylvania.""If there are fewer insurers for healthcare investors to own, that means they have to get their healthcare exposure elsewhere,"" Bemer said.Shares of Community Health Systems, Tenet Healthcare  and HCA bucked the overall market's decline and gained 0.7 percent, 0.5 percent and 1.8 percent on Monday. Bemer holds Community Health shares.   (Additional reporting by Susan Kelly in Chicago)",2015-07-06,HUM,"Mon Jul 6, 2015 | 6:27pm EDT","Humana cuts outlook, raising new concerns about Aetna deal",http://www.reuters.com//article/humana-ma-aetna-investors-idUSL1N0ZM2HT20150706?type=companyNews
88,"   By Caroline Humer | NEW YORK  NEW YORK Humana Inc, fresh from announcing an agreement to be purchased by larger rival Aetna Inc, prompted new investor concerns about the $33 billion deal on Monday by lowering its 2015 financial forecasts. The transaction announced on Friday is already expected to face a tough review by U.S. antitrust regulators, particularly if another major deal among health insurers emerges. Humana, which has posted disappointing results for several quarters in a row, said on Monday that members of its Medicare Advantage plans for the elderly were using hospital services at a higher rate than the company expected. That increase could cut into already tight profit margins, if Humana ends up paying more for medical claims than they anticipated when setting monthly insurance rates.Humana CEO Bruce Broussard said on a conference call with investors that inpatient hospital admissions have not performed in line with what the company had forecast. That contributed to its decision to slash expected 2015 operating profits by more than 8 percent. The company said it had taken the higher Medicare Advantage hospital use into account when it priced premiums for 2016. ""If you take the 8 percent downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive,"" said Joel Emery, a portfolio manager at Tareo Capital Management in New York. The degree to which Humana will boost Aetna's earnings in 2017 and 2018 is less than what some investors had hoped for, he said.Aetna's offer of $125 in cash and 0.8375 Aetna shares for each Humana share valued Humana at $230 per share. On Monday, Aetna fell 6 percent to $117, bringing down the offer price to $223 per share.Reflecting growing doubts about the deal, Humana shares traded well below the proposed offer price, closing at $188.96. ""Aetna shareholders have to approve the deal, and with such a large premium, there is some outside chance that shareholders will not approve it,"" said Standard & Poor's equity analyst Jeffrey Loo.Humana's negative comments provided a silver lining to hospital operators, who stand to benefit if patient admissions rise and they are reimbursed for more of their services, said Les Funtledyer, portfolio manager at ESquared asset management. He owns shares of HCA Holdings and Universal Health Services.  Consolidation among health insurers is also spurring investors to seek out cheaper stocks in the healthcare sector, such as hospitals, said Jessica Bemer, portfolio manager for Snow Capital Management in Sewickley, Pennsylvania. ""If there are fewer insurers for healthcare investors to own, that means they have to get their healthcare exposure elsewhere,"" Bemer said.Shares of Community Health Systems, Tenet Healthcare and HCA bucked the overall market's decline and gained 0.7 percent, 0.5 percent and 1.8 percent on Monday. Bemer holds Community Health shares. (Additional reporting by Susan Kelly in Chicago; Editing by Christian Plumb)",2015-07-06,HUM,"Mon Jul 6, 2015 | 6:26pm EDT","Humana cuts outlook, raising new concerns about Aetna deal",http://www.reuters.com//article/us-humana-m-a-aetna-investors-idUSKCN0PG2HI20150706?type=companyNews
89,"   By Caroline Humer | NEW YORK, July 6  NEW YORK, July 6 Humana Inc, fresh from announcing an agreement to be purchased by larger rival Aetna Inc, prompted new investor concerns about the $33 billion deal on Monday by lowering its 2015 financial forecasts.The transaction announced on Friday is already expected to face a tough review by U.S. antitrust regulators, particularly if another major deal among health insurers emerges.Humana, which has posted disappointing results for several quarters in a row, said on Monday that members of its Medicare Advantage plans for the elderly were using hospital services at a higher rate than the company expected.That increase could cut into already tight profit margins, if Humana ends up paying more for medical claims than they anticipated when setting monthly insurance rates. Humana CEO Bruce Broussard said on a conference call with investors that inpatient hospital admissions have not performed in line with what the company had forecast. That contributed to its decision to slash expected 2015 operating profits by more than 8 percent. The company said it had taken the higher Medicare Advantage hospital use into account when it priced premiums for 2016.""If you take the 8 percent downgrade of their earnings and roll that through, that makes what Aetna paid pretty expensive,"" said Joel Emery, a portfolio manager at Tareo Capital Management in New York. The degree to which Humana will boost Aetna's earnings in 2017 and 2018 is less than what some investors had hoped for, he said.Aetna's offer of $125 in cash and 0.8375 Aetna shares for each Humana share valued Humana at $230 per share. On Monday, Aetna fell 6 percent to $117, bringing down the offer price to $223 per share. Reflecting growing doubts about the deal, Humana shares traded well below the proposed offer price, closing at $188.96.""Aetna shareholders have to approve the deal, and with such a large premium, there is some outside chance that shareholders will not approve it,"" said Standard & Poor's equity analyst Jeffrey Loo. Humana's negative comments provided a silver lining to hospital operators, who stand to benefit if patient admissions rise and they are reimbursed for more of their services, said Les Funtledyer, portfolio manager at ESquared asset management. He owns shares of HCA Holdings and Universal Health Services.Consolidation among health insurers is also spurring investors to seek out cheaper stocks in the healthcare sector, such as hospitals, said Jessica Bemer, portfolio manager for Snow Capital Management in Sewickley, Pennsylvania.""If there are fewer insurers for healthcare investors to own, that means they have to get their healthcare exposure elsewhere,"" Bemer said.Shares of Community Health Systems, Tenet Healthcare  and HCA bucked the overall market's decline and gained 0.7 percent, 0.5 percent and 1.8 percent on Monday. Bemer holds Community Health shares.   (Additional reporting by Susan Kelly in Chicago; Editing by Christian Plumb)",2015-07-06,HUM,"Mon Jul 6, 2015 | 6:20pm EDT","Humana cuts outlook, raising new concerns about Aetna deal",http://www.reuters.com//article/humana-ma-aetna-investors-idUSL1N0ZM1P120150706?type=companyNews
90,"  * Tsipras to present aid proposal at euro zone meet Tuesday* Aetna falls after Humana deal* U.S. crude futures settle down near 8 pct for the session* Indexes down: Dow 0.3 pct, S&P 0.4 pct, Nasdaq 0.3 pct   (Updates prices, changes comment, byline)By Rodrigo CamposJuly 6 U.S. stocks fell in a volatile Monday session as Greeks resoundingly backed their government in rejecting the austerity terms of a bailout and China implemented emergency measures to stop a selloff in Shanghai's market.Greek Prime Minister Alexis Tsipras promised German Chancellor Angela Merkel that Greece would bring a proposal for a cash-for-reforms deal to an emergency summit of euro zone leaders on Tuesday, a Greek official said. It was unclear how much it would differ from other proposals rejected in the past.Equity futures tumbled at the open late on Sunday after Greeks voted 'No' to the terms imposed by its creditors. However the S&P 500 didn't fall more than 1 percent throughout the Monday session and even turned positive in morning trading.Though Greece is causing a lot of uncertainty, a deal should get done to keep them in the Euro Zone, according to Karyn Cavanaugh, market strategist at Voya Investment Management in New York. ""Greece can't pay their bills, there's no middle ground there and other countries are going to have to foot the bill and they are angry,"" she said.But more than billions in debt are in play as ""Greece is the southern gateway to Europe. The strategic value is not being quantified.""The Dow Jones industrial average fell 46.53 points, or 0.26 percent, to 17,683.58, the S&P 500 lost 8.02 points, or 0.39 percent, to 2,068.76 and the Nasdaq Composite  dropped 17.27 points, or 0.34 percent, to 4,991.94.Weighing further on investor sentiment, Chinese brokerages and fund managers vowed to buy massive amounts of stocks as Beijing unleashed an unprecedented series of support measures to stem a decline of nearly 30 percent in the main Shanghai index over the past three weeks. ""People see 'emergency measures' and they think 'that can't be good',"" said Voya's Cavanaugh.The Shanghai index rose 2.4 percent overnight but a measure of Chinese stocks traded in the United States  fell the most in 19 months, pointing to caution from investors outside of China about the effectiveness of the government's measures.Energy stocks led the decline on Wall Street after U.S. crude futures prices settled almost 8 percent lower on concern over growth in China and the Greek uncertainty.The S&P 500 energy index fell 1.3 percent, marking its fourth decline of more than 1 percent in the past seven sessions. Health insurer Aetna fell 6.4 percent to $117.43 after it said it would buy smaller rival Humana for about $37 billion. Humana closed up 0.8 percent to $188.96.The deal is seen facing antitrust scrutiny, which could make other large-scale mergers in the sector more difficult. Anthem , Cigna, Centene and Health Net, which are all in takeover talks, ended lower.Declining issues outnumbered advancing ones on the NYSE by 1,946 to 1,132, for a 1.72-to-1 ratio on the downside; on the Nasdaq, 1,600 issues fell and 1,181 advanced for a 1.35-to-1 ratio favoring decliners.The benchmark S&P 500 index posted 5 new 52-week highs and 32 new lows; the Nasdaq Composite recorded 44 new highs and 130 new lows.About 6.6 billion shares traded on all U.S. platforms, according to BATS exchange data, below the average of 7.6 billion in the past five sessions.(Reporting by Rodrigo Campos; Editing by Andrew Hay)",2015-07-06,HUM,"Mon Jul 6, 2015 | 4:27pm EDT","US STOCKS-Energy leads Wall St lower with eyes on Greece, China",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0ZM24620150706?type=companyNews
91,"  (Adds Teva, Unicredit, Rosneft, Black Swan Energy, Saint-Gobain, Siemens, PKP, Aston Martin; updates Aetna, Royal Bank of Scotland, Stemcor)July 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** Health insurer Aetna Inc said on Friday it would buy smaller rival Humana Inc for about $37 billion in cash and stock, in the largest ever deal in the insurance industry.Aetna's chief executive said on Monday that he was confident an antitrust review of the health insurer's proposed purchase of smaller rival Humana would allow the deal to close in the second half of 2016, seeking to allay investor concerns.** Teva Pharmaceutical Industries Ltd is preparing to raise its bid for rival drugmaker Mylan NV by as much as $2 billion to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter.** The Chinese central bank has bought a 2 percent stake in lenders UniCredit and Monte dei Paschi di Siena , adding to a string of investments in large Italian companies, a regulatory filing showed on Monday.** Russia's top oil producer Rosneft said on Monday that Brazilian regulator had cleared a purchase of 55 percent stake in oil and gas project in the Solimoes Basin from PetroRio, allowing the Kremlin-controlled company to gain full control over it.** Britain is planning to sell half its stake in Royal Bank of Scotland, worth 16 billion pounds ($25 billion), within two years of a possible first sale in September, sources with knowledge of government thinking told Reuters.** Black Swan Energy Ltd, a privately held exploration and production company, said on Monday it completed its planned C$200 million ($158 million) acquisition of Carmel Bay Exploration, boosting its land position in the highly sought after Montney region in British Columbia.** A 2.2 billion euro ($2.43 billion) loan and bond financing backing the buyout of Saint-Gobain's glass bottle unit Verallia remains on hold after Greece rejected a compromise with international creditors, bankers said on Monday.** Siemens could still be interested in buying power generation assets from French rival Alstom on the same terms it offered a year ago if General Electric's  deal to buy them falls through, a senior management source said.** State-controlled oil producer Petroleo Brasileiro SA  could sell a stake in Brazil's Braskem SA and build provisions against tax debts nearing 40 billion reais ($12.7 billion) to reduce costs and make finances sustainable, Valor Economico newspaper said.** Canada's Potash Corp of Saskatchewan said it was confident of addressing concerns raised by K+S over its 7.9 billion euro ($8.7 billion) takeover proposal for the German potash miner, giving K+S's stock a boost.** Polish state-run railway group PKP said on Monday it invited global private equity fund CVC to exclusive talks on the takeover of its utility arm PKP Energetyka.** Russian broadcaster CTC Media said it had received a $200 million offer for 75 percent of its operating assets in Russia and Kazakhstan from UTH Russia, part-owned by billionaire Alisher Usmanov. ** Family-owned German car parts maker Eberspaecher is exploring a partnership with an overseas peer or a partial sale as it seeks to expand internationally, several sources familiar with the matter said.** Abu Dhabi Islamic Bank, which recently failed in its bid for Citigroup's Egypt retail business, is targeting acquisitions in 2016 in Asia, the Middle East, and North Africa, its chief executive said.** Kuwait's Al Ahli Bank received approval from the Gulf state's central bank to buy Piraeus Bank's  Egyptian unit, it said on Monday.** German asset manager Union Investment has bought most of the remaining assets of Austria's Volksbanken as the part-nationalized group winds down after failing European bank stress tests.** U.S. cigarette giant Philip Morris International Inc  plans to sell a stake worth at least $1 billion in Indonesian unit PT HM Sampoerna Tbk to comply with free-float rules, two people familiar with the matter said on Monday.** China Molybdenum Luoyang Co is poised to make an offer for an overseas mining project costing up to $2.15 billion, the latest push by a Chinese enterprise to acquire resource assets beyond its borders. ** U.S. media group Scripps Networks Interactive has offered to pay a total of 3.2 billion zlotys ($843.64 million) to buy the shares in Polish broadcaster TVN it does not already own to take full control over the company and delist it.** Elliott Associates has bought shares in Samsung Fire & Marine Insurance Co Ltd, a spokeswoman for the South Korean firm said, potentially strengthening the U.S. hedge fund's hand in its bid to block an $8 billion proposed merger of another two Samsung Group companies.** Australian childcare operator Affinity Education  on Monday urged shareholders not to accept a $121 million takeover offer from larger rival G8 Education Ltd, saying it would refer the all-share bid to regulators after what it called ""opportunistic"" off-market purchases of Affinity stock by G8.** Berlin is wooing private investors including Macquarie  and JP Morgan to take a stake in its much-delayed new international airport, German newspaper Bild wrote on Sunday.** Mercedes F1 non-executive chairman Niki Lauda has dismissed a report suggesting Formula One rival Red Bull could switch from Renault to Mercedes engines with Aston Martin branding.** Aston Martin has had plenty of approaches from Formula One teams wanting to bring the brand back to the sport but the chances of a deal are improbable at best, Chief Executive Andy Palmer told Reuters on Monday.** Formula One's commercial rights holders CVC Capital Partners are under no pressure to sell their controlling stake in the sport and want to keep it, co-chairman Donald Mackenzie told Reuters. ** German utility RWE is considering a restructuring that could see units such as RWE Generation and RWE Innogy being merged or swallowed up by the parent group as it battles an industry-wide crisis, a German newspaper reported on Saturday.** Consolidation continues to be necessary in the auto industry but there is nothing new to report on Fiat Chrysler's   desire for a tie-up with General Motors , FCA CEO Sergio Marchionne said on Friday.** South African gaming and hotel group Tsogo Sun Holdings  has scrapped plans to buy a minority stake in two casinos owned by Sun International, the companies said.** Copenhagen-based private equity firm Polaris said it had made a binding offer to acquire all outstanding shares in Danish ferry company Mols-Linien and planned to delist the company from the stock exchange.** Creditors of insolvent German wind park operator Prokon have voted to try to revive the company themselves, rejecting a takeover bid from utility EnBW, the administrator said on Thursday.** The entertainment arm of Chinese property conglomerate Dalian Wanda Group said on Friday it would lead an almost 6 billion yuan ($967 million) investment into one of China's biggest travel websites, its first foray into online tourism.** Dutch lender ING Group is set to win the auction to buy HSBC Holdings Plc's Turkish business, people familiar with the matter said on Thursday.** Dollar Tree Inc was given the go-ahead to buy Family Dollar Stores Inc by the U.S. Federal Trade Commission on condition that they sell 330 Family Dollar stores, putting to rest a year-long merger saga.** Sycamore Partners is preparing an offer for Belk Inc that could value the U.S. department store chain at between $3 billion and $3.5 billion, including debt, and become the buyout firm's largest deal, people familiar with the matter said on Thursday.** Debt-laden steel trader Stemcor, one of Britain's largest private companies, has agreed a deal with U.S. distressed investment fund Apollo and with its other creditors which ""secures its future,"" it said on Monday.** India's Reliance Industries Ltd plans to sell a 3.1 percent stake, worth $32 million at the current market price, in unit Network18 Media & Investments Ltd to comply with rules mandating public ownership in listed firms.** The European Bank for Reconstruction and Development said it was considering taking a significant minority stake in the loss-making Ukrainian unit of Raiffeisen Bank International (RBI).($1 = 3.79 zlotys)  ($1 = 0.90 euros)  ($1 = 6.20 Chinese yuan renminbi)  ($1 = 0.64 pounds)  ($1 = 3.15 Brazilian reais)   (Compiled by Anya George Tharakan, Natalie Grover and Lehar Maan in Bengaluru)",2015-07-06,HUM,"Mon Jul 6, 2015 | 4:00pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0ZM4EZ20150706?type=companyNews
92,"  * IMF says will help Greece if asked, ECB holds call* Tsipras to present aid proposal at euro zone meet Tuesday* Aetna falls after Humana deal, other insurers lower* Energy index leads losses as oil prices fall* Indexes down: Dow 0.2 pct, S&P 0.29 pct, Nasdaq 0.3 pct   (Updates to early afternoon)By Tanya AgrawalJuly 6 U.S. stocks were lower in early afternoon trading, but were well off their lows earlier on Monday as investors remained optimistic that a deal could be reached to prevent Greece's exit from the euro zone.Greeks rejected the conditions of a rescue package from creditors on Sunday and the country's finance minister resigned on Monday, removing a major obstacle to any deal. Prime Minister Alexis Tsipras agreed to present an aid proposal at an emergency euro zone meeting on Tuesday. Stock markets globally fell, but analysts said the declines were less than expected due to expectations that the European Central Bank would act to limit any damage.U.S. stocks opened more than half a percent lower, but pared some of those losses, even turning positive briefly, after the International Monetary Fund said it is ready to assist Greece if asked.""The referendum doesn't really change anything with the negotiations,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.""I think after the initial knee jerk reaction, the majority opinion is that there is still a possibility of some sort of a deal that keeps Greece in the euro zone."" Greece's immediate fate is in the hands of the ECB, which began a conference call late afternoon to decide how long to go on keeping Greek banks afloat. Several people familiar with ECB policy said it would probably reject a Greek request to raise a cap on emergency liquidity assistance.U.S. economic growth prospects got a boost after data from the Institute for Supply Management showed the pace of growth in the U.S. services ticked higher in June after dropping in May. The Federal Reserve has said it will raise rates only when it sees a sustained economic recovery.At 13:03 p.m. ET the Dow Jones industrial average was down 35.47 points, or 0.2 percent, at 17,694.64. The S&P 500  was lower by 6.01 points, or 0.29 percent, at 2,070.77. The Nasdaq Composite was down 14.89 points, or 0.3 percent, at 4,994.32. All the 10 major S&P 500 sectors were lower. The energy index led the declines with a 0.73 percent fall as oil prices slumped more than 6 percent after the Greek referendum and on a strengthening dollar.Chevron's shares dropped as much as 1.5 percent to $94.48, its lowest since November 2011.Health insurer Aetna fell 7.3 percent to $116.40 after it said it would buy smaller rival Humana for about $37 billion. Humana rose 2 percent to $191.38.The deal is sure to face rigorous antitrust scrutiny, which could also make other large-scale mergers in the sector more difficult. Anthem, Cigna, Centene and Health Net, which are all in takeover talks, were lower.Weight Watchers soared 17.6 percent to $4.81 after the New York Post reported an activist hedge fund was in talks with potential partners to buy the company. The hedge fund and a partner ""would like to offer perhaps double"" Thursday's closing price, the report said.Declining issues outnumbered advancing ones on the NYSE by 1,932 to 1,057. On the Nasdaq, 1,664 issues fell and 1,041 advanced.The S&P 500 index showed four new 52-week highs and 27 new lows, while the Nasdaq recorded 32 new highs and 113 new lows.   (Editing by Savio D'Souza)",2015-07-06,HUM,"Mon Jul 6, 2015 | 1:40pm EDT",US STOCKS-Wall St off session lows as Greece aid deal optimism grows,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0ZM4ZL20150706?type=companyNews
93,"  (Corrects to add dropped word ""is"" in first paragraph)* IMF says will help Greece if asked to* ECB's governing council to hold call this afternoon* Aetna falls after Humana deal, other insurers lower* Energy index leads losses as oil prices fall* Indexes down: Dow 0.22 pct, S&P 0.21 pct, Nasdaq 0.14 pctBy Tanya AgrawalJuly 6 U.S. stocks erased most of their earlier losses, even turning positive briefly, on Monday after the International Monetary Fund said it is ready to assist Greece if asked.Greeks rejected the conditions of a rescue package from creditors on Sunday, but investors remained optimistic that a deal could be reached to prevent the country's exit from the euro zone. Stock markets globally fell, but analysts said the declines were less than expected due to expectations that the European Central Bank would act to limit any damage.""The referendum doesn't really change anything with the negotiations,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.""I think after the initial knee jerk reaction, the majority opinion is that there is still a possibility of some sort of a deal that keeps Greece in the euro zone.""The ECB's governing council is due to hold a conference call on Monday afternoon to discuss the provisions of emergency funding to Greece's banks. A new deal is needed for Greece to meet a July 20 deadline to repay $3.9 billion of bonds to the ECB. Greece's finance minister quit after the vote and Prime Minister Alexis Tsipras said his government was ready to return immediately to negotiations with creditors.U.S. stocks opened more than half a percent lower, but by 11:39 a.m. ET they had pared most of their losses and even briefly turned positive after the IMF offered a helping hand.The Dow Jones industrial average was down 46.73 points, or 0.26 percent, at 17,683.38. The S&P 500 was lower 5.71 points, or 0.27 percent, at 2,071.07. The Nasdaq Composite was down 15.25 points, or 0.3 percent, at 4,993.97.Nine of the 10 major S&P 500 sectors were lower. The energy index led the declines with a 0.85 percent fall as oil prices fell more than 3 percent after the Greek referendum and on a strengthening dollar. Chevron fell as much as 1.5 percent to $94.68, its lowest since November 2011. U.S. economic growth prospects got a boost after Institute for Supply Management data showed the pace of growth in the U.S. services ticked higher in June after dropping in May.The Federal Reserve has said it will raise rates only when it sees a sustained economic recovery.Health insurer Humana's shares rose 3.6 percent to $194.50 after bigger rival Aetna said on Friday it would buy the company for about $37 billion. Aetna fell 4.9 percent at $119.20.The deal follows weeks of intense discussions about potential combinations among health insurers, but rigorous scrutiny from U.S. regulators could also make mergers more difficult. Anthem and Cigna, which are in takeover talks, declined more than 1 percent.Weight Watchers soared 16.4 percent to $4.76 after the New York Post reported an activist hedge fund was in talks with potential partners to buy the company. The hedge fund and a partner ""would like to offer perhaps double"" Thursday's closing price, the report said.Declining issues outnumbered advancers on the NYSE by 1,912 to 1,038. On the Nasdaq, 1,680 issues fell and 976 advanced.The S&P 500 index showed five new 52-week highs and 28 new lows, while the Nasdaq recorded 23 new highs and 106 new lows.   (Editing by Savio D'Souza)",2015-07-06,HUM,"Mon Jul 6, 2015 | 11:54am EDT",REFILE-US STOCKS-Wall St pares losses after IMF says ready to help Greece,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0ZM4SC20150706?type=companyNews
94,"  Health insurer Humana Inc and buyer Aetna Inc set fees to be paid in the event of a failure of the largest deal in the health insurance industry. Aetna, which said last week it would buy Humana for about $37 billion in cash and stock, has to pay a termination fee of $1.69 billion, Humana said in a regulatory filing on Tuesday (1.usa.gov/1JSxWVr)Humana would pay the larger rival $1.31 billion if the deal is terminated. The deal faces antitrust issues as the authorities scrutinize how the combination will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business. (reut.rs/1LLQn1n) Wall Street analysts and some antitrust experts have said that they expect the combination to be approved, although regulators may insist on some divestitures. Aetna's chief executive said on Monday that he was confident about an antitrust approval for the deal to close by June 30, 2016. The company had already prepared for possible divestitures to address overlaps with Humana's business, he added.  Aetna is also required to pay Humana $1 billion if the deal is not closed by June 30, 2016, according to Tuesday's filing.  (Reporting by Rosmi Shaji in Bengaluru)",2015-07-07,HUM,"Tue Jul 7, 2015 | 6:43pm EDT","Humana, Aetna set termination fees for deal",http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0PH2JG20150707?type=companyNews
95,"  July 7 Health insurer Humana Inc and buyer Aetna Inc set fees to be paid in the event of a failure of the largest deal in the health insurance industry.Aetna, which said last week it would buy Humana for about $37 billion in cash and stock, has to pay a termination fee of $1.69 billion, Humana said in a regulatory filing on Tuesday (1.usa.gov/1JSxWVr)Humana would pay the larger rival $1.31 billion if the deal is terminated. The deal faces antitrust issues as the authorities scrutinize how the combination will affect competition for each line of insurance: Medicare, Medicaid for the poor, individual insurance, commercial insurance for small and large businesses and the large employer business. (reut.rs/1LLQn1n) Wall Street analysts and some antitrust experts have said that they expect the combination to be approved, although regulators may insist on some divestitures. Aetna's chief executive said on Monday that he was confident about an antitrust approval for the deal to close by June 30, 2016. The company had already prepared for possible divestitures to address overlaps with Humana's business, he added.Aetna is also required to pay Humana $1 billion if the deal is not closed by June 30, 2016, according to Tuesday's filing.   (Reporting by Rosmi Shaji in Bengaluru)",2015-07-07,HUM,"Tue Jul 7, 2015 | 6:36pm EDT","Humana, Aetna set termination fees for deal",http://www.reuters.com//article/humana-ma-aetna-idUSL3N0ZN5NL20150707?type=companyNews
96,"   By Leela Parker Deo and Karen Schwartz | NEW YORK  NEW YORK U.S. health insurer Aetna Inc (AET.N) is lining up a $16.2 billion bridge loan to fund its acquisition of smaller rival Humana Inc (HUM.N), which is the first multibillion M&A loan of the second half of 2015 and the second-largest acquisition bridge loan so far this year, according to Thomson Reuters LPC data.Aetna said on July 3 that it would buy Humana for $37 billion in cash and stock in the insurance industrys largest-ever acquisition.The deal will boost third quarter investment grade loan issuance and support expectations that a surplus of corporate cash is contributing to a growing pipeline of M&A transactions.Investment grade M&A-related lending totaled $63 billion in the first half of the year. 2015 totals could reach $200 billion based on the pipeline of financings building in the second half of the year, according to a lender survey by Thomson Reuters LPC.The merger is the latest transaction amid ongoing consolidation in the health insurance sector and was announced just before global markets were roiled by the decisive July 5 referendum in Greece which rejected additional harsh austerity measures and Chinas attempts to stabilize its ailing stock market.These macroeconomic developments and slumping oil and iron ore prices have the potential to disrupt the syndicated loan market, but dislocation is more likely to be felt by non-investment grade companies rather than high-grade issuers, one analyst said.Highly rated companies are in a relatively strong position to attract financing because of their credit profiles, he noted, and tend to benefit from any flight to quality in a risk-off environment. I wont say its not going to be somewhat choppy. The marketplace always tends to be somewhat choppier when you have these big geopolitical issues popping up. Its just one of several things theyre going to need to navigate over the next six months, the analyst said.HEALTHY BRIDGE Citigroup and UBS are providing the 364-day senior unsecured bridge facility, according to regulatory filings. The bridge loan is expected to be taken out with permanent financing that could include a mix of term debt, bonds and commercial paper, sources said. Citigroup and UBS are currently syndicating a $3.2 billion, three-year term loan, the sources added. If the merger clears antitrust scrutiny, it will dwarf the previous largest ever insurance deal announced in early July, when Swiss property and casualty giant ACE Ltd (ACE.N) said it was buying Chubb Corp (CB.N) for $28 billion, Reuters reported.In the past two weeks, Anthem also has offered to buy Cigna Corp to create the largest insurer in the country, toppling UnitedHealth Group Inc, according to Reuters, as U.S. insurers grapple with the issue of providing universal coverage, which is a key policy of Barak Obamas presidency.Were through this tunnel of managing through at least the initial implementation phase of the ACA [Affordable Care Act], said the analyst. Companies are now thinking more strongly about how they want to position in the next 3-5 years, and I think M&A will increasingly be a part of that thought process. The acquisition gives Aetna a strong leg up in government-sponsored managed Medicare, a growth market in the health insurance sector, the analyst added. This will vault them into a leadership position, assuming the deal goes through.The bridge loan pricing is tied to a ratings grid, ranging from 75bp-125bp over Libor.Pricing opens at 100bp over Libor based on Aetnas senior unsecured debt ratings of Baa1/A/A- and the loan pays a 10bp commitment fee. Pricing includes 25bp margin step-ups at 90, 180 and 270 days, respectively, after closing. The loan also pays duration fees, a periodic fee on the outstanding balance of the bridge loan, of 50bp, 75bp and 100bp, according to the same schedule.The deal, which is expected to close in the second half of 2016, is also being financed through $3.4 billion of available cash, and $16 billion of new shares. Humanas existing debt of $3.8 billion will be assumed.Aetna expects to maintain a solid investment grade rating and access to short-term debt markets. The company also expects to deleverage rapidly thanks to strong cash flow. (Editing By Tessa Walsh and Jon Methven)",2015-07-09,HUM,"Thu Jul 9, 2015 | 3:33pm EDT",Aetna's $16.2 billion bridge loan is second-biggest this year,http://www.reuters.com//article/us-aetna-bridge-idUSKCN0PJ2KI20150709?type=companyNews
97,"   By Leela Parker Deo and Karen Schwartz | NEW YORK, July 9  NEW YORK, July 9 U.S. health insurer Aetna Inc  is lining up a $16.2 billion bridge loan to fund its acquisition of smaller rival Humana Inc, which is the first multibillion M&A loan of the second half of 2015 and the second-largest acquisition bridge loan so far this year, according to Thomson Reuters LPC data.Aetna said on July 3 that it would buy Humana for $37 billion in cash and stock in the insurance industry's largest-ever acquisition.The deal will boost third quarter investment grade loan issuance and support expectations that a surplus of corporate cash is contributing to a growing pipeline of M&A transactions.Investment grade M&A-related lending totaled $63 billion in the first half of the year. 2015 totals could reach $200 billion based on the pipeline of financings building in the second half of the year, according to a lender survey by Thomson Reuters LPC.The merger is the latest transaction amid ongoing consolidation in the health insurance sector and was announced just before global markets were roiled by the decisive July 5 referendum in Greece which rejected additional harsh austerity measures and China's attempts to stabilize its ailing stock market.These macroeconomic developments and slumping oil and iron ore prices have the potential to disrupt the syndicated loan market, but dislocation is more likely to be felt by non-investment grade companies rather than high-grade issuers, one analyst said. Highly rated companies are in a relatively strong position to attract financing because of their credit profiles, he noted, and tend to benefit from any flight to quality in a risk-off environment.""I won't say it's not going to be somewhat choppy. The marketplace always tends to be somewhat choppier when you have these big geopolitical issues popping up. It's just one of several things they're going to need to navigate over the next six months,"" the analyst said.HEALTHY BRIDGE  Citigroup and UBS are providing the 364-day senior unsecured bridge facility, according to regulatory filings. The bridge loan is expected to be taken out with permanent financing that could include a mix of term debt, bonds and commercial paper, sources said. Citigroup and UBS are currently syndicating a $3.2 billion, three-year term loan, the sources added.If the merger clears antitrust scrutiny, it will dwarf the previous largest ever insurance deal announced in early July, when Swiss property and casualty giant ACE Ltd said it was buying Chubb Corp for $28 billion, Reuters reported.In the past two weeks, Anthem also has offered to buy Cigna Corp to create the largest insurer in the country, toppling UnitedHealth Group Inc, according to Reuters, as U.S. insurers grapple with the issue of providing universal coverage, which is a key policy of Barak Obama's presidency. ""We're through this tunnel of managing through at least the initial implementation phase of the ACA [Affordable Care Act],"" said the analyst. ""Companies are now thinking more strongly about how they want to position in the next 3-5 years, and I think M&A will increasingly be a part of that thought process.""The acquisition gives Aetna a strong leg up in government-sponsored managed Medicare, a growth market in the health insurance sector, the analyst added. ""This will vault them into a leadership position, assuming the deal goes through.""The bridge loan pricing is tied to a ratings grid, ranging from 75bp-125bp over Libor.Pricing opens at 100bp over Libor based on Aetna's senior unsecured debt ratings of Baa1/A/A- and the loan pays a 10bp commitment fee. Pricing includes 25bp margin step-ups at 90, 180 and 270 days, respectively, after closing. The loan also pays duration fees, a periodic fee on the outstanding balance of the bridge loan, of 50bp, 75bp and 100bp, according to the same schedule.The deal, which is expected to close in the second half of 2016, is also being financed through $3.4 billion of available cash, and $16 billion of new shares. Humana's existing debt of $3.8 billion will be assumed.Aetna expects to maintain a solid investment grade rating and access to short-term debt markets. The company also expects to deleverage rapidly thanks to strong cash flow.   (Editing By Tessa Walsh and Jon Methven)",2015-07-09,HUM,"Thu Jul 9, 2015 | 3:25pm EDT",TRLPC: Aetna's $16.2B bridge loan is second-biggest this year,http://www.reuters.com//article/aetna-bridge-idUSL1N0ZP1TV20150709?type=companyNews
98,"   By Caroline Humer, Karen Freifeld and Diane Bartz | NEW YORK/WASHINGTON  NEW YORK/WASHINGTON U.S. insurance regulators and state attorneys general are lining up to scrutinize Aetna Inc's proposed $33 billion takeover of rival Humana Inc for potential harm to consumers, complicating what is already expected to be a tough and lengthy review by federal antitrust authorities.Insurance commissioners in 18 states including Texas, Kentucky and Florida will study merger documents provided by Humana to determine whether the deal will harm competition and lead to higher insurance premiums or diminished access to healthcare providers, according to Reuters interviews with regulators and insurance experts.At least three state attorneys general - in Florida, Mississippi and Massachusetts - said they will look at the proposed acquisition. Local politicians and medical industry groups such as the American Medical Association have also voiced concerns about the biggest deal ever in the U.S. health insurance industry.The Department of Justice is taking the lead on the transaction and may ask for asset sales or challenge a deal in court. But the concerns of state insurance commissioners are likely to have added weight since health insurance is heavily regulated at the local level, antitrust experts said. State regulators are also expected to provide the DOJ with their own data on how the deal will affect insurance markets.""The antitrust division makes the final decision on the competitive analysis but will take into account the information provided by the states,"" said Andre Barlow, an antitrust lawyer at Doyle, Barlow and Mazard PLLC, who's not involved in the inquiry.The proposed acquisition comes after years of health insurance change driven by the politically divisive Affordable Care Act, often called Obamacare. Republicans say the new law has driven insurance costs higher and hurt consumers, while Democrats say it is insuring more people. Aetna and Humana have said that because the health insurance market is now more focused on consumers, being bigger will let them offer more competitive products.When the nation's largest insurer, UnitedHealth Group , bought Nevada's Sierra Health Services in 2008, the Nevada Attorney General and the DOJ both filed antitrust complaints and signed off on a settlement requiring UnitedHealth to divest administration and sales of Medicare Advantage plans for seniors and the disabled in two counties.In 2004, California's state regulator first rejected the acquisition of WellPoint Health Networks by Anthem. The companies challenged the move in court and eventually agreed to concessions, including putting $265 million towards California health projects that would benefit consumers. The Humana purchase would create a company with more than 33 million customers in two-thirds of the United States. In individual states, their footprint is much bigger.In a combined Medicare Advantage business, Aetna and Humana would have an 88 percent market share in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri, according to data from the Kaiser Family Foundation. In commercial insured plans, the new company would have more than a third of individual customers in Florida, Illinois and Kansas and 68 percent of Georgia, according to SG Cowen and SNL Financial.Healthcare investors already have concerns over the Humana deal passing muster at the federal level, particularly after antitrust objections scuttled several other major transactions this year, including Sysco Corp's proposed purchase of US Foods and Comcast Corp's planned acquisition of Time Warner Cable Inc. They are also weighing the risk of another major health insurance merger being forged, possibly between Anthem Inc  and Cigna Corp. In that case, antitrust authorities would have to account for the market effect of both deals when raising any objections. The value of Aetna's cash and stock offer has dropped 10 percent since it was announced on July 3, as its share price fell over antitrust risk and other concerns. Aetna and Humana have said they view the regulatory process as ""manageable,"" targeting a deal closing in the second half of 2016 to account for a lengthy review. Aetna and Humana both declined to comment on antitrust issues for this story.STATE BY STATE California Insurance Commissioner Dave Jones plans to talk to antitrust authorities and other states through the National Association of Insurance Commissioners about the Humana deal's impact on California, where he sees even their combined 5 percent share as an issue. ""I will be raising whatever concerns I have on behalf of California consumers,"" Jones said in an interview. ""I am generally concerned that historically health insurance company mergers have resulted in higher, not lower, premiums for consumers.""For example, insurance premiums rose 13.7 percent in Nevada in the year after UnitedHealth Group's acquisition of Sierra Health Services compared to health plans in a similar market that was not affected, according to a 2013 study published in the journal Health Management, Policy and Innovation.In Kentucky, where Humana is based, Insurance Commissioner Sharon Clark said her department would work with federal regulators as they evaluate the transaction as well as conduct its own review, which could take six months to a year to complete.Georgia state commissioner Charles Hudgens said in a statement he will perform an in-depth analysis of the proposed transaction's effect on competition in the state. Texas, Illinois and Florida said they are also awaiting filings from Humana.State attorneys general may also look at the deal, but often don't disclose if they have opened an investigation.In Connecticut, where Aetna is based, a spokesman for Connecticut Attorney General George Jepsen declined to comment on whether the office plans to probe the deal. ""In Connecticut, the AG has the independent authority to look into mergers and to challenge them if it will lessen competition under the state's antitrust laws,"" Robert Blanchard said.In Kentucky, where Humana is based, a spokesman for Attorney General Jack Conway said his office will look at the terms of the potential merger when they are released and determine if any action is necessary. In Florida, where Humana has 1.63 million customers, a spokeswoman for Florida Attorney General Pam Bondi said the state would look into the proposed merger for its effect on competition.",2015-07-10,HUM,"Fri Jul 10, 2015 | 5:59pm EDT",States line up to scrutinize Aetna's $33 bln Humana deal,http://www.reuters.com//article/humana-ma-aetna-antitrust-idUSL1N0ZQ2BQ20150710?type=companyNews
99,"   By Caroline Humer, Karen Freifeld and Diane Bartz | NEW YORK/WASHINGTON  NEW YORK/WASHINGTON U.S. insurance regulators and state attorneys general are lining up to scrutinize Aetna Inc's proposed $33 billion takeover of rival Humana Inc for potential harm to consumers, complicating what is already expected to be a tough and lengthy review by federal antitrust authorities.Insurance commissioners in 18 states including Texas, Kentucky and Florida will study merger documents provided by Humana to determine whether the deal will harm competition and lead to higher insurance premiums or diminished access to healthcare providers, according to Reuters interviews with regulators and insurance experts. At least three state attorneys general  in Florida, Mississippi and Massachusetts  said they will look at the proposed acquisition. Local politicians and medical industry groups such as the American Medical Association have also voiced concerns about the biggest deal ever in the U.S. health insurance industry.The Department of Justice is taking the lead on the transaction and may ask for asset sales or challenge a deal in court. But the concerns of state insurance commissioners are likely to have added weight since health insurance is heavily regulated at the local level, antitrust experts said. State regulators are also expected to provide the DOJ with their own data on how the deal will affect insurance markets.""The antitrust division makes the final decision on the competitive analysis but will take into account the information provided by the states,"" said Andre Barlow, an antitrust lawyer at Doyle, Barlow and Mazard PLLC, who's not involved in the inquiry.The proposed acquisition comes after years of health insurance change driven by the politically divisive Affordable Care Act, often called Obamacare. Republicans say the new law has driven insurance costs higher and hurt consumers, while Democrats say it is insuring more people. Aetna and Humana have said that because the health insurance market is now more focused on consumers, being bigger will let them offer more competitive products.When the nation's largest insurer, UnitedHealth Group (UNH.N), bought Nevada's Sierra Health Services in 2008, the Nevada Attorney General and the DOJ both filed antitrust complaints and signed off on a settlement requiring UnitedHealth to divest administration and sales of Medicare Advantage plans for seniors and the disabled in two counties. In 2004, California's state regulator first rejected the acquisition of WellPoint Health Networks by Anthem. The companies challenged the move in court and eventually agreed to concessions, including putting $265 million towards California health projects that would benefit consumers. The Humana purchase would create a company with more than 33 million customers in two-thirds of the United States. In individual states, their footprint is much bigger. In a combined Medicare Advantage business, Aetna and Humana would have an 88 percent market share in Kansas, 80 percent in West Virginia, 58 percent in Iowa and 51 percent in Missouri, according to data from the Kaiser Family Foundation. In commercial insured plans, the new company would have more than a third of individual customers in Florida, Illinois and Kansas and 68 percent of Georgia, according to SG Cowen and SNL Financial. Healthcare investors already have concerns over the Humana deal passing muster at the federal level, particularly after antitrust objections scuttled several other major transactions this year, including Sysco Corp's proposed purchase of US Foods and Comcast Corp's planned acquisition of Time Warner Cable Inc. They are also weighing the risk of another major health insurance merger being forged, possibly between Anthem Inc (ANTM.N) and Cigna Corp (CI.N). In that case, antitrust authorities would have to account for the market effect of both deals when raising any objections.The value of Aetna's cash and stock offer has dropped 10 percent since it was announced on July 3, as its share price fell over antitrust risk and other concerns. Aetna and Humana have said they view the regulatory process as ""manageable,"" targeting a deal closing in the second half of 2016 to account for a lengthy review. Aetna and Humana both declined to comment on antitrust issues for this story.   STATE BY STATE California Insurance Commissioner Dave Jones plans to talk to antitrust authorities and other states through the National Association of Insurance Commissioners about the Humana deals impact on California, where he sees even their combined 5 percent share as an issue. ""I will be raising whatever concerns I have on behalf of California consumers,"" Jones said in an interview. ""I am generally concerned that historically health insurance company mergers have resulted in higher, not lower, premiums for consumers.""For example, insurance premiums rose 13.7 percent in Nevada in the year after UnitedHealth Group's acquisition of Sierra Health Services compared to health plans in a similar market that was not affected, according to a 2013 study published in the journal Health Management, Policy and Innovation. In Kentucky, where Humana is based, Insurance Commissioner Sharon Clark said her department would work with federal regulators as they evaluate the transaction as well as conduct its own review, which could take six months to a year to complete.Georgia state commissioner Charles Hudgens said in a statement he will perform an in-depth analysis of the proposed transaction's effect on competition in the state. Texas, Illinois and Florida said they are also awaiting filings from Humana.State attorneys general may also look at the deal, but often don't disclose if they have opened an investigation. In Connecticut, where Aetna is based, a spokesman for Connecticut Attorney General George Jepsen declined to comment on whether the office plans to probe the deal. ""In Connecticut, the AG has the independent authority to look into mergers and to challenge them if it will lessen competition under the state's antitrust laws,"" Robert Blanchard said. In Kentucky, where Humana is based, a spokesman for Attorney General Jack Conway said his office will look at the terms of the potential merger when they are released and determine if any action is necessary. In Florida, where Humana has 1.63 million customers, a spokeswoman for Florida Attorney General Pam Bondi said the state would look into the proposed merger for its effect on competition. (Reporting by Caroline Humer and Karen Freifeld in New York, Susan Kelly in Chicago and Diane Bartz in Washington D.C. Editing by Michele Gershberg and John Pickering.)",2015-07-10,HUM,"Fri Jul 10, 2015 | 5:44pm EDT",States line up to scrutinize Aetna's $33 billion Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-antitrust-idUSKCN0PK2II20150710?type=companyNews
100,"  * Combined company would be No. 1 insurer, cover 53 mln members* Antitrust review would include proposed Aetna buy of Humana* U.S. lawmakers, medical group express concern for consumers   (Adds details on antitrust review, concerns from lawmakers, Breakingviews link)By Ankur Banerjee and Ransdell PiersonJuly 24 Anthem Inc said on Friday it would buy Cigna Corp for about $54.2 billion, creating the largest U.S. health insurer by membership and accelerating the industry's consolidation from five national players to three.The proposed acquisition, the health insurance industry's largest, comes three weeks after Aetna Inc agreed to buy Humana Inc for $37 billion.Health insurers are finding it tougher to raise prices following the roll-out of President Barack Obama's healthcare law, while grappling with soaring expenses of medications including cancer drugs that can cost each patient more than $100,000 a year. Anthem said buying Cigna would help it reduce costs and negotiate lower prices with doctors and hospitals.State insurance regulators and federal antitrust authorities are expected to scrutinize how the Anthem-Cigna and Aetna-Humana deals would affect competition for Medicare and individual and commercial insurance.Within a few hours of the announcement, several U.S. lawmakers and a leading physicians group said they feared the pending acquisitions would hurt consumers by raising prices or limiting access to healthcare providers.""The lack of a competitive health insurance market allows the few remaining companies to exploit their market power, dictate premium increases and pursue corporate policies that are contrary to patient interests,"" the American Medical Association (AMA) said in a statement.Under the deal, which the companies expect to close in the second half of 2016, Anthem Chief Executive Joseph Swedish would serve as CEO and chairman. Cigna CEO David Cordani would be president and chief operating officer.In a joint conference call, Swedish told analysts Anthem had no prior discussions ""at all"" with regulators about the deal, but was confident about approval.Shares of Cigna on Friday fell 5.6 percent to $145.72, far below the $188 offered in the buyout, suggesting major Wall Street concern over the antitrust risk. ""Strategically and financially it's very attractive, but they will face regulatory scrutiny,"" said Ana Gupte, analyst with Leerink Partners. ""They also both possibly face divestitures and may have to make concessions to consumers to make the merger go through.""The AMA said its own analysis shows 41 percent of U.S. metropolitan areas already have a single health insurer with a commercial market share of 50 percent or more. It believes the Anthem-Cigna merger would be presumed anticompetitive in at least nine of the states where Anthem operates.""It is imperative that we closely examine changes in the healthcare market, and what has caused these changes, to ensure that consumers are not harmed,"" said Senator Mike Lee, a Republican from Utah who is chairman of the Senate's antitrust panel.Apparent worries about regulatory scrutiny have also hit Humana shares, which closed at $181.76 on Friday, well below the value of Aetna's cash-and-stock offer of $230 per share when it was announced on July 3. BIGGER THAN UNITEDHEALTH Cigna has 15 million members, and about 80 percent of its business is with self-insured companies which pay it a management fee, according to Leerink. It also serves large and small employers, Medicare Advantage customers and individuals.About 61 percent of Anthem's 39 million members are served through self-insured companies, while 15 percent have Medicaid coverage. Large and small group policies make up about 12 percent of its business, while Medicare Advantage accounts for 1 percent.The combined company would have about 53 million members, surpassing UnitedHealth Group's 45.86 million as of June 30.Anthem said it will pay $103.40 in cash and 0.5152 of its shares for each Cigna share. The deal is valued at $181.12 per share based on Anthem's Friday close of $150.86. Anthem said on Friday the offer was valued at $188 per share based on its stock price on May 28 before media reports surfaced that the two companies were in talks.The offer's equity portion is valued at $49.11 billion, according to Reuters calculations based on 261.2 million Cigna shares outstanding as of March 31.Another question is whether Anthem would violate rules of  the Blue Cross and Blue Shield Association, a federation of 36 independent insurers of which it is the biggest member.The association collectively insures 106 million Americans. Anthem provides coverage to the most people and operates in 14 states. No other Blue Cross member operates in more than five states.Blue Cross operators are not supposed to compete with one another, but Cigna does compete against Blue Cross members in a handful of states, which could cause controversy in the association.""There will no doubt be debate among the board of directors,"" said a person knowledgeable about Blue Cross who requested anonymity to protect business relationships.""We will remain Blue,"" Swedish said on the conference call, adding that Anthem feels confident that even after acquiring Cigna, the combined company will satisfy ""the Blue rules.""Swedish said he would serve as CEO for only two years, and remain as chairman afterward. Cordani could be a contender for the CEO role at that point, but no guarantees were provided, said a source familiar with the matter who requested anonymity because the person was unauthorized to publicly discuss details of the transaction.Both Anthem and Cigna would be liable to pay the other a fee equivalent to 3.8 percent of the deal's value if either walks away from the planned merger.Anthem's lead financial adviser is UBS Investment Bank. Credit Suisse also served as financial adviser, and White & Case LLP as legal adviser.Morgan Stanley is Cigna's financial adviser and Cravath, Swaine & Moore LLP its legal adviser.   (Additional reporting by Caroline Humer and Kylie Gumpert in New York and Diane Bartz in Washington; Editing by Alan Crosby and Richard Chang)",2015-07-24,HUM,"Fri Jul 24, 2015 | 4:49pm EDT","UPDATE 5-Anthem to buy Cigna, creating biggest U.S. health insurer",http://www.reuters.com//article/cigna-ma-anthem-idUSL1N1041DO20150724?type=companyNews
101,"   By Diane Bartz  The U.S. House of Representatives Judiciary Committee is planning two hearings for September to discuss concerns about reduced competition in the healthcare industry, lawmakers from both parties said. In July, insurer Aetna said it would buy rival Humana for $33 billion, while Anthem said it would buy Cigna for $54.2 billion. The dual deals would effectively lower the number of major U.S. health insurers from five to three.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1Ipsome",2015-07-27,HUM,"Mon Jul 27, 2015 | 7:15am EDT",U.S. House panel to hold hearings on competition in healthcare,http://www.reuters.com//article/congress-healthcare-antitrust-idUSL1N1070E420150727?type=companyNews
102,"  (Adds Saunders interview)By Caroline HumerNEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, ""transformational"" merger.The readiness for a new transaction just after the Teva deal was announced on Monday represents what Saunders calls a strategy to remain nimble and open to opportunity as the healthcare sector remakes itself.Saunders has already shown a penchant for quick deal-making. Just last year, he helped orchestrate the $25 billion sale of Forest Laboratories Inc, where he was CEO, to Actavis Plc.As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant Pharmaceuticals and its acquisition partner, hedge fund billionaire William Ackman.The latest deal had just closed in March and Saunders was busy integrating the two companies under the Allergan name. At the time, he did not consider unloading the generics assets of Actavis.""While I had a different strategy a few months ago, the thing that sets us apart ... is our strategy to be nimble,"" Saunders said in an interview. Saunders now plans to use the proceeds from its $40.5 billion asset sale to Teva to increase the size of existing drug businesses, expand into new therapy areas and pursue larger deals.He declined to discuss any specific targets, a list Wall Street that analysts speculated may include Biogen Inc, AbbVie Inc and Amgen Inc.""Clearly we are watching many companies - we have been for some time - but what has changed is our timeline for being able to execute has accelerated, if the opportunity presents itself,"" Saunders said.The $40.5 billion cash-and-stock sale of generic drugs business to Teva is expected to close in the first quarter of 2016. That will essentially ""reload"" Allergan's balance sheet for more acquisitions, Saunders added. When asked if Allergan planned to spend the cash within 18 months, he replied that the company would, as long as it could maintain its investment-grade credit rating.CONSOLIDATION AHEAD Saunders said his change of direction for Allergan came only a few weeks ago when Teva CEO Erez Vigodman called to make an offer. Vigodman had already approached Actavis earlier in the year, but the company was not interested at that time. ""To be fair, I didn't think it was a good idea to sell it until Erez called me and put a compelling offer on the table,"" Saunders said. ""It caused me to step back and think about the industry and the dynamics.""The healthcare industry has consolidated in the past year, with pharmacies and distributors aligning through merger deals or purchasing agreements that give them more leverage over prices for generic drugs.These deals, such as CVS Health's purchases of Target Corp's pharmacies and the Omnicare specialty pharmacies and distributor McKesson Corp's purchasing agreement with pharmacy Rite Aid Corp, will force more consolidation among generics makers so they can compete, Saunders said.Two of the largest U.S. health insurers - Humana Inc  and Cigna Corp - have also agreed to be bought in the past month, signaling fresh pressure on prices, Saunders said.Of the seven main therapeutic areas that Allergan will focus on after the generics sale, he said there are four with the strongest opportunities in terms of unmet medical care: aesthetics, eye care, central nervous system therapies and gastrointestinal therapies.Les Funtleyder, healthcare portfolio manager for E Squared Asset Management, which owns Allergan shares, said Saunders should look for something with a reasonable risk versus reward profile.""If it were my $40 billion, I would probably do four or five deals in the $10 billion range, aiming for late-stage drug programs where you have some idea if the drug works,"" Funtleyder said. If two of those deals panned out, ""that would be a good use of capital.""   (Additional reporting by Ransdell Pierson in New York; editing by Michele Gershberg, Nick Zieminski and G Crosse)",2015-07-27,HUM,"Mon Jul 27, 2015 | 5:12pm EDT","UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others",http://www.reuters.com//article/allergan-ceo-idUSL1N1071MC20150727?type=companyNews
103,"  Health insurer Humana Inc (HUM.N), which earlier this month agreed to be bought by Aetna Inc (AET.N) for $37 billion, on Wednesday reported a rise in a key medical cost metric that missed analyst expectations.Humana's consolidated benefit ratio, or the ratio of its spending on medical claims versus premium revenue it takes in, was 85.2 percent compared with 83.1 percent a year ago.   Leerink Partners analyst Ana Gupte said in a research note that the ratio was 50 basis points worse than Wall Street consensus.Investors closely watch this ratio as a sign of whether insurers, who have benefited from years of low medical use and claims, will be caught out by sudden shifts in demand. Humana first said in early July that costs related to the rate of hospital admissions among Medicare customers were higher than it had anticipated. It cut its 2015 outlook by 8 percent and shares fell at that time. On Wednesday, Humana said medical costs have not worsened since it issued that outlook earlier this month. It reiterated that it believes it has priced its 2016 premium rates to cover these costs, indicating that this key metric should improve. Humana had missed analyst expectations several quarters in a row because of cost issues, contributing to investor skepticism about the Aetna deal. The deal is also expected to face antitrust scrutiny as regulators weigh the impact of the combination on competition. Authorities are also expected to closely look at Anthem Inc's (ANTM.N) $54 billion purchase of Cigna Corp (CI.N) and require some asset sales.    The managed care sector is consolidating as insurers seek to cut costs and negotiate with doctors and hospitals over pricing. Humana shares were off 0.5 percent at $183.59 in Wednesday morning trade. Aetna was off 2 cents at $112.29.Excluding tax benefits from the sale of Concerta Inc, Humana earned $1.67 per share, compared with the average analyst estimate of $1.63 per share, according to Thomson Reuters I/B/E/S. On that basis, it had reported earnings of $2.19 per share in the year-ago quarter. In early July, the company told analysts to expect earnings of $1.60 to $1.65 per share on an adjusted basis.Net income rose to $431 million, or $2.85 per share, in the second quarter, from $344 million, or $2.19 per share, a year earlier.The company reported revenue of $13.73 billion, which missed the average analyst estimate of $13.81 billion. (Reporting by Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Anil D'Silva and Meredith Mazzilli)",2015-07-29,HUM,"Wed Jul 29, 2015 | 11:45am EDT",Humana says medical costs cut into second-quarter profit,http://www.reuters.com//article/us-humana-results-idUSKCN0Q31GK20150729?type=companyNews
104,"  (New throughout)July 29 Health insurer Humana Inc, which earlier this month agreed to be bought by Aetna Inc for $37 billion, on Wednesday reported a rise in a key medical cost metric that missed analyst expectations.Humana's consolidated benefit ratio, or the ratio of its spending on medical claims versus premium revenue it takes in, was 85.2 percent compared with 83.1 percent a year ago.Leerink Partners analyst Ana Gupte said in a research note that the ratio was 50 basis points worse than Wall Street consensus.Investors closely watch this ratio as a sign of whether insurers, who have benefited from years of low medical use and claims, will be caught out by sudden shifts in demand.Humana first said in early July that costs related to the rate of hospital admissions among Medicare customers were higher than it had anticipated. It cut its 2015 outlook by 8 percent and shares fell at that time. On Wednesday, Humana said medical costs have not worsened since it issued that outlook earlier this month. It reiterated that it believes it has priced its 2016 premium rates to cover these costs, indicating that this key metric should improve.Humana had missed analyst expectations several quarters in a row because of cost issues, contributing to investor skepticism about the Aetna deal. The deal is also expected to face antitrust scrutiny as regulators weigh the impact of the combination on competition. Authorities are also expected to closely look at Anthem Inc's  $54 billion purchase of Cigna Corp and require some asset sales.The managed care sector is consolidating as insurers seek to cut costs and negotiate with doctors and hospitals over pricing.Humana shares were off 0.5 percent at $183.59 in Wednesday morning trade. Aetna was off 2 cents at $112.29. Excluding tax benefits from the sale of Concerta Inc, Humana earned $1.67 per share, compared with the average analyst estimate of $1.63 per share, according to Thomson Reuters I/B/E/S. On that basis, it had reported earnings of $2.19 per share in the year-ago quarter.In early July, the company told analysts to expect earnings of $1.60 to $1.65 per share on an adjusted basis.Net income rose to $431 million, or $2.85 per share, in the second quarter, from $344 million, or $2.19 per share, a year earlier.The company reported revenue of $13.73 billion, which missed the average analyst estimate of $13.81 billion.       (Reporting by Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Anil D'Silva and Meredith Mazzilli)",2015-07-29,HUM,"Wed Jul 29, 2015 | 11:38am EDT",UPDATE 2-Humana says medical costs cut into second-quarter profit,http://www.reuters.com//article/humana-results-idUSL3N10949A20150729?type=companyNews
105,"  July 29 Health insurer Humana Inc  reported a 12.4 percent rise in quarterly revenue as it added more members to its Medicare Advantage business for individuals. Net income rose to $431 million, or $2.85 per share, in the second quarter ended June 30, from $344 million, or $2.19 per share, a year earlier.    (Reporting by Vidya L Nathan in Bengaluru, Editing by Anil D'Silva)  ",2015-07-29,HUM,"Wed Jul 29, 2015 | 7:41am EDT",Health insurer Humana's revenue rises on higher memberships,http://www.reuters.com//article/humana-results-idUSL3N1084TR20150729?type=companyNews
106,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc (AET.N) Chief Executive Mark Bertolini said on Tuesday the company is talking to federal and state officials on its $37 billion acquisition of Humana Inc (HUM.N) and that there is enough insurance competition for it to receive approval.""The process is underway. We've engaged in conversations with insurance commissioners, with governors, with Washington,"" Bertolini told investors during a conference call to announce the company's earnings. ""We're doing deep analysis, even deeper than we did before the deal on the number of competitors by market,"" he said. If Aetna or Humana need to divest in a market because of the competitive dynamics, ""there will be plenty of competitors in each market,"" he added.    Investors expect regulators and states to push back on the combination of the company's Medicare Advantage offerings. It will become the largest provider of these plans and in some states, will have dominant market share.Aetna shares were unchanged in late morning trading after it announced second-quarter profit rose beyond Wall Street expectations, suggesting that investor worries about the antitrust prospect are still at the front of their minds. ""I think people are looking for more than just assurances from management,"" said Ana Gupte, analyst at Leerink Partners. ""They want to see some actual progress on the regulatory process"" which could take until next year, she said. Aetna has filed its initial antitrust documents with federal regulators and has begun to make the needed filings with state insurance regulators in about 20 states, Bertolini said.  Aetna has spoken with many governors and generally those conversations have been positive, Chief Financial Officer Shawn Guertin said in an interview.Governors of states have a variety of concerns, from jobs to insurance offerings to price stability, he said. The regulatory process is expected to take at least a year. Aetna's acquisition will be reviewed by the Department of Justice as well as state insurance regulators who oversee the commercial insurance industry. Aetna expects to close the deal in the second half of 2016. Bertolini said Aetna will likely need to divest assets in some markets - as Wall Street analysts have suggested - but that in all, the company will have about 8 percent market share of the overall Medicare market, which includes both Medicare Advantage and Medicare fee for service. Antitrust regulators will also be looking at Blue Cross Blue Shield insurer Anthem Inc's (ANTM.N) acquisition of Cigna Corp's (CI.N) at the same time as Aetna's Humana purchase.  (Reporting by Caroline Humer; Editing by Meredith Mazzilli and Alan Crosby)",2015-08-04,HUM,"Tue Aug 4, 2015 | 12:35pm EDT",Aetna CEO says antitrust process underway in Humana deal,http://www.reuters.com//article/us-aetna-results-cfo-idUSKCN0Q91D720150804?type=companyNews
107,"   By Caroline Humer  Aetna Inc Chief Executive Mark Bertolini said on Tuesday the company is talking to federal and state officials on its $37 billion acquisition of Humana Inc  and that there is enough insurance competition for it to receive approval.""The process is underway. We've engaged in conversations with insurance commissioners, with governors, with Washington,"" Bertolini told investors during a conference call to announce the company's earnings.""We're doing deep analysis, even deeper than we did before the deal on the number of competitors by market,"" he said. If Aetna or Humana need to divest in a market because of the competitive dynamics, ""there will be plenty of competitors in each market,"" he added.Investors expect regulators and states to push back on the combination of the company's Medicare Advantage offerings. It will become the largest provider of these plans and in some states, will have dominant market share. Aetna shares were unchanged in late morning trading after it announced second-quarter profit rose beyond Wall Street expectations, suggesting that investor worries about the antitrust prospect are still at the front of their minds.""I think people are looking for more than just assurances from management,"" said Ana Gupte, analyst at Leerink Partners. ""They want to see some actual progress on the regulatory process"" which could take until next year, she said. Aetna has filed its initial antitrust documents with federal regulators and has begun to make the needed filings with state insurance regulators in about 20 states, Bertolini said.Aetna has spoken with many governors and generally those conversations have been positive, Chief Financial Officer Shawn Guertin said in an interview. Governors of states have a variety of concerns, from jobs to insurance offerings to price stability, he said.The regulatory process is expected to take at least a year. Aetna's acquisition will be reviewed by the Department of Justice as well as state insurance regulators who oversee the commercial insurance industry. Aetna expects to close the deal in the second half of 2016.Bertolini said Aetna will likely need to divest assets in some markets - as Wall Street analysts have suggested - but that in all, the company will have about 8 percent market share of the overall Medicare market, which includes both Medicare Advantage and Medicare fee for service.Antitrust regulators will also be looking at Blue Cross Blue Shield insurer Anthem Inc's acquisition of Cigna Corp's  at the same time as Aetna's Humana purchase.",2015-08-04,HUM,"Tue Aug 4, 2015 | 12:35pm EDT",Aetna CEO says antitrust process underway in Humana deal,http://www.reuters.com//article/aetna-results-ceo-idUSL1N10F1Y420150804?type=companyNews
108,"  (Adds CEO quotes, CFO comment, analyst)By Caroline HumerNEW YORK Aug 4 Aetna Inc Chief Executive Mark Bertolini said on Tuesday the company is talking to federal and state officials on its $37 billion acquisition of Humana Inc and that there is enough insurance competition for it to receive approval.""The process is underway. We've engaged in conversations with insurance commissioners, with governors, with Washington,"" Bertolini told investors during a conference call to announce the company's earnings.""We're doing deep analysis, even deeper than we did before the deal on the number of competitors by market,"" he said. If Aetna or Humana need to divest in a market because of the competitive dynamics, ""there will be plenty of competitors in each market,"" he added. Investors expect regulators and states to push back on the combination of the company's Medicare Advantage offerings. It will become the largest provider of these plans and in some states, will have dominant market share.Aetna shares were unchanged in late morning trading after it announced second-quarter profit rose beyond Wall Street expectations, suggesting that investor worries about the antitrust prospect are still at the front of their minds.""I think people are looking for more than just assurances from management,"" said Ana Gupte, analyst at Leerink Partners. ""They want to see some actual progress on the regulatory process"" which could take until next year, she said. Aetna has filed its initial antitrust documents with federal regulators and has begun to make the needed filings with state insurance regulators in about 20 states, Bertolini said.Aetna has spoken with many governors and generally those conversations have been positive, Chief Financial Officer Shawn Guertin said in an interview. Governors of states have a variety of concerns, from jobs to insurance offerings to price stability, he said.The regulatory process is expected to take at least a year. Aetna's acquisition will be reviewed by the Department of Justice as well as state insurance regulators who oversee the commercial insurance industry. Aetna expects to close the deal in the second half of 2016.Bertolini said Aetna will likely need to divest assets in some markets - as Wall Street analysts have suggested - but that in all, the company will have about 8 percent market share of the overall Medicare market, which includes both Medicare Advantage and Medicare fee for service.Antitrust regulators will also be looking at Blue Cross Blue Shield insurer Anthem Inc's acquisition of Cigna Corp's  at the same time as Aetna's Humana purchase.    (Reporting by Caroline Humer; Editing by Meredith Mazzilli and Alan Crosby)",2015-08-04,HUM,"Tue Aug 4, 2015 | 12:13pm EDT",UPDATE 1-Aetna CEO says antitrust process underway in Humana deal,http://www.reuters.com//article/aetna-results-ceo-idUSL1N10F1LQ20150804?type=companyNews
109,"  NEW YORK Aug 4 Aetna Inc chief executive Mark Bertolini said on Tuesday that the company had begun making regulatory filings with both federal and state authorities related to its acquisition of Humana Inc. Bertolini said the company had also begun talking to state insurance commissioners and officials in Washington D.C. about the $37 billion deal, which he said will leave ""plenty of competitors"" in the Medicare markets where the combined company will operate.   (Reporting by Caroline Humer; Editing by Meredith Mazzilli)  ",2015-08-04,HUM,"Tue Aug 4, 2015 | 9:10am EDT",Aetna CEO says has begun antitrust work on Humana deal,http://www.reuters.com//article/aetna-results-ceo-idUSL1N10F16820150804?type=companyNews
110,  NEW YORK Aug 4 Aetna Inc Chief Financial Officer Shawn Guertin said on Tuesday that the health insurer expects 2015 medical cost trend to increase at the low end of a range of 6 percent to 7 percent.The trend reflects spending on medical services like doctor visits and hospitals.  Guertin also reaffirmed that the company expects to close its $37 billion Humana Inc acquisition in the second half of 2016. Investors have reacted skeptically to the deal as they worry that the combination of the two Medicare Advantage providers will run into resistance from regulators.   (Reporting by Caroline Humer; Editing by Chizu Nomiyama) ,2015-08-04,HUM,"Tue Aug 4, 2015 | 9:00am EDT",Aetna CFO says expects 2015 medical cost trend at low end,http://www.reuters.com//article/aetna-results-cfo-idUSL1N10F14R20150804?type=companyNews
111,"  Health insurer Aetna's (AET.N) proposed $37 billion acquisition of smaller rival Humana Inc (HUM.N) was approved by the shareholders of both companies.The companies continue to expect the deal to close in the second half of 2016, they said in separate statements on Monday.Aetna in July said it would buy Humana to become the largest provider of Medicare plans for the elderly.Three weeks later, rival Anthem Inc (ANTM.N) proposed to acquire Cigna Corp (CI.N) for about $47 billion in a deal that would make it the largest U.S. health insurer by membership. The proposed mergers follow the implementation of President Barack Obama's healthcare overhaul, the Affordable Care Act, which extended health insurance to millions of people. Insurers say joining forces will help them better compete as the government tries to rein in healthcare spending.However, federal antitrust authorities are expected to closely scrutinize these proposed deals for potential harm to consumers.  (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-10-19,HUM,"Mon Oct 19, 2015 | 5:21pm EDT","Aetna, Humana shareholders approve proposed merger",http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0SD2FD20151019?type=companyNews
112,"  (Adds context)Oct 19 Health insurer Aetna's proposed $37 billion acquisition of smaller rival Humana Inc was approved by the shareholders of both companies.The companies continue to expect the deal to close in the second half of 2016, they said in separate statements on Monday. Aetna in July said it would buy Humana to become the largest provider of Medicare plans for the elderly.Three weeks later, rival Anthem Inc proposed to acquire Cigna Corp for about $47 billion in a deal that would make it the largest U.S. health insurer by membership. The proposed mergers follow the implementation of President Barack Obama's healthcare overhaul, the Affordable Care Act, which extended health insurance to millions of people. Insurers say joining forces will help them better compete as the government tries to rein in healthcare spending.However, federal antitrust authorities are expected to closely scrutinize these proposed deals for potential harm to consumers.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-10-19,HUM,"Mon Oct 19, 2015 | 5:18pm EDT","UPDATE 1-Aetna, Humana shareholders approve proposed merger",http://www.reuters.com//article/humana-ma-aetna-idUSL3N12J5JN20151019?type=companyNews
113,"  Oct 19 Health insurer Aetna's proposed acquisition of smaller rival Humana Inc was approved by the shareholders of both companies.Aetna continues to expect the deal to close in the second half of 2016, it said on Monday.  Aetna in July said it would buy Humana for about $37 billion.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza) ",2015-10-19,HUM,"Mon Oct 19, 2015 | 4:54pm EDT","Aetna, Humana shareholders approve proposed merger",http://www.reuters.com//article/humana-ma-aetna-idUSL3N12J5J120151019?type=companyNews
114,"  * 3rd-qtr M&A and other advisory fees rise 19 pct to $288 mln* 3rd-qtr operating revenue $594 mln, a record* Advised on Kraft-Heinz, AT&T-DirecTV deal* 3rd-qtr adjusted EPS $0.93 vs est. $0.90   (Adds CEO comment, details; updates shares)By Rachel Chitra and Olivia OranOct 22 Lazard Ltd, a financial advisory and asset management firm, reported a better-than-expected profit and record quarterly operating revenue after advising on several billion-dollar deals.Low U.S. interest rates have helped to push merger activity to levels last seen before the financial crisis in 2008, driving a 19 percent jump in Lazard's quarterly fees from takeovers. The company's shares rose 1.6 percent to $45.98 in premarket trading on Thursday.""The M&A environment feels pretty good to us. Valuations are more reasonable than they were,"" Lazard Chief Executive Kenneth Jacobs said in an interview.Lazard earned $288 million in M&A, capital and sovereign advisory fees in the third quarter ended Sept. 30, nearly half of its total operating revenue. During the period, it advised on several high-profile deals during the period, including the merger that created food industry giant Kraft Heinz Co and AT&T Inc's  acquisition of satellite TV provider DirecTV.The firm is also advising on Anheuser-Busch InBev's  $100 billion-plus bid for SABMiller Plc and health insurer Aetna Inc's deal to buy Humana Inc.""It's a good environment for financing,"" said Jacobs. ""Sentiment is a little rocked by volatility but long-term trends are as strong as they've been in a long time."" Lazard ranked seventh in global M&A rankings for financial advisers, with a 12.9 percent market share as of Oct. 19, according to capital markets data firm Dealogic.Net income attributable to Lazard more than quadrupled to $398.5 million, or $2.99 per share. Excluding items, the company earned 93 cents per share.Total operating revenue rose 2 percent to about $594 million.Analysts on average had expected a profit of 90 cents and revenue of $589.4 million, according to Thomson Reuters I/B/E/S.To Wednesday's close, Lazard's stock had fallen 7.7 percent this year. Shares of peers Moelis & Co and Greenhill & Co Inc had fallen 20 percent and 37 percent respectively.   (Reporting by Rachel Chitra in Bengaluru and Olivia Oran in New York, additional reporting by Richa Naidu; Editing by Maju Samuel and Robin Paxton)",2015-10-22,HUM,"Thu Oct 22, 2015 | 9:15am EDT",UPDATE 2-Lazard profit beats forecast after busy quarter for M&A,http://www.reuters.com//article/lazard-results-idUSL3N12M3UA20151022?type=companyNews
115,"  (Adds Hillary Clinton comment, updates shares)By Bill Berkrot and Ransdell PiersonOct 29 Pfizer Inc, the No. 1 U.S. drugmaker, and Botox maker Allergan Plc said they were in friendly talks to create a pharmaceutical colossus but the prospect that the company would seek to avoid U.S. taxes sounded political alarm bells.Both New York-based Pfizer and Dublin-based Allergan said no agreement has been reached and declined to discuss any terms of the deal, which would potentially set up Pfizer to take advantage of Ireland's lower tax rates.Allergan shares rose 6 percent to $304.38 in U.S. trading, while Pfizer closed off 1.9 percent at $34.77.Pfizer is already facing political pushback at home that is only likely to intensify with the U.S. presidential campaign underway, as candidates take aim at high prescription drug prices and companies looking to avoid paying U.S. taxes.A spokesman for Democratic front-runner Hillary Clinton said the candidate had not seen details of the proposed merger, but is against tax inversion maneuvers, in which U.S. companies relocate overseas to take advantage of lower tax rates.""Clinton is committed to cracking down on so-called 'inversions,' where a company chooses to leave the U.S. on paper to game the tax system, and believes we should reform our tax code to encourage investment in the U.S., rather than shipping earnings and jobs overseas,"" Clinton spokesman Ian Sams said.Democratic U.S. Senator Charles Schumer of New York said in a statement: ""The continued pursuit of inversions, mergers and foreign acquisitions of major U.S. companies for purely tax purposes shows there is a lot more work to be done to stop them.""From the right, developer and Republican presidential candidate Donald Trump said the deal was a reminder that the U.S. tax code needed an overhaul.SMOOTHER PATH ""These corporate inversions take capital and, more importantly, jobs offshore,"" he said in a statement. ""We need leadership in Washington to get the tax code changed so companies will be coming to America, not looking for ways to leave."" Billionaire investor Carl Icahn, who has endorsed Trump and launched a $150 million political action committee advocating tax reform to eliminate inversions, said a Pfizer-Allergan deal would result in the loss of the country's 10th largest company to Ireland.Analysts speculated a deal could be all or primarily done with stock because under new U.S. rules aimed at curtailing tax inversions, shareholders of the overseas company must own at least 40 percent of the combined entity.Credit Suisse analyst Vamil Divan suggested a price of $390 per Allergan share, funded by equity and debt. Allergan's U.S.-traded shares soared as high as $316.80 on Thursday.Earlier Thursday before the companies confirmed the talks, Pfizer Chief Executive Officer Ian Read reiterated his criticism of U.S. corporate taxes.""Our tax rate highly disadvantages American multinational high-tech businesses,"" Read said at a Wall Street Journal event. ""I am fighting with one hand tied behind my back.""Pfizer's effective tax rate is 25 percent, while Allergan's is 15 percent. Given that both sides characterized the talks as ""friendly,"" Pfizer is likely to have a much smoother path outside of the United States after running into intense political opposition in Britain and from AstraZeneca Plc's  board in its failed, unsolicited bid last year.""It's definitely a far easier target for Pfizer than AstraZeneca,"" said Christophe Eggmann, investment director at GAM, who holds shares in both companies. ""The hurdle will really be the price.""Moody's Investor Service said the deal would have ""credit positive implications for both companies.""A tax inversion is being discussed in the current talks, a person familiar with the matter told Reuters. In its pursuit of AstraZeneca, Pfizer had hoped to employ such a strategy.Read said Thursday he was open to any moves that produce the best long-term value for the company and shareholders. He said he was looking at various growth strategies, including a deal.Pfizer is expected to decide by late next year whether to sell or spin off its older, off-patent products unit to pare the business and focus on innovative, patent-protected medicines. Allergan, the product of a recent merger with generic drugmaker Actavis, is selling a large portfolio of generic medicines to Teva Pharmaceutical Industries Ltd   for $40.5 billion.CASH FROM BOTOX A purchase of Allergan, with a market value of more than $113 billion, would be the biggest in Pfizer's long history of huge deals, eclipsing the $90 billion Warner-Lambert acquisition through which it gained control of Lipitor, once the world's top-selling medicine.It would also restore the Viagra maker as the world's largest pharmaceutical company, worth about $330 billion, a position it relinquished after Lipitor went off-patent.Allergan expects revenue of more than $8 billion in the second half of 2015, not including generic drugs it is selling to Teva.Pfizer has annual sales of about $48 billion, with about $27 billion from patent-protected drugs, consumer products and vaccines, and about $21 billion from the business it is considering selling.Since the Warner-Lambert purchase, Pfizer has acquired Pharmacia and Wyeth, each deal under a different CEO.The deals have led to many thousands of job cuts. It is not known how many cuts would result from a tie-up with Allergan.Apart from the tax considerations, the deal would give Pfizer access to Allergan's wrinkle treatment Botox, with $2.4 billion in annual sales, and its $1.3 billion Restasis dry eye treatment.By Sept. 10, deal-making in all sectors of healthcare this year had reached a record $447.5 billion, according to Thomson Reuters data.Other large pending tie-ups include pharmacy chain Walgreens Boots Alliance Inc's planned purchase of smaller rival Rite Aid Corp announced this week, and pending mergers of health insurers Aetna Inc with Humana Inc, and Anthem Inc with Cigna Corp.(Additional reporting by Gregory Roumeliotis and Caroline Humer in New York, Vidya L Nathan in Bengaluru, Ben Hirschler in London and Amanda Becker in Littleton, N.H.; Editing by Jeffrey Benkoe and Christian Plumb)",2015-10-29,HUM,"Thu Oct 29, 2015 | 6:02pm EDT","UPDATE 5-Pfizer, Allergan drug merger talks raise tax hackles in U.S.",http://www.reuters.com//article/allergan-ma-pfizer-idUSL3N12T51K20151029?type=companyNews
116,"  Health insurer Humana Inc (HUM.N), which agreed to be bought by Aetna Inc (AET.N) for $37 billion in July, reported a better-than-expected quarterly profit as it added more members to its individual Medicare Advantage business.Humana, which manages large Medicare Advantage health plans for the elderly and disabled, said individual Medicare Advantage membership increased 14 percent to 2.74 million at the end of September.However, individual commercial membership decreased 11 percent to 963,700 as of Sept. 30.""We remain cautious with regard to our expectations around 2016 earnings growth due to the ongoing challenges in the individual commercial business,"" Humana's Chief Financial Officer Brian Kane said in a statement on Friday.Larger rival Anthem Inc (ANTM.N) said last month its Obamacare insurance business is being hampered by lower-than-anticipated enrollment due to fewer applicants than expected and cheaper premium rates at competitors. Cigna Corp (CI.N), which also reported a better-than-expected quarterly profit on Friday, said it expected 2016 revenue growth to be hurt by reduction in customers in its individual plans.    President Barack Obama's signature healthcare law, the Affordable Care Act, in 2014 overhauled the individual market with new government subsidized plans sold through newly created exchanges.Insurers are betting on mergers to help them compete better, as the government tries to rein in healthcare spending following the implementation of Obamacare. Anthem agreed over the summer to acquire Cigna in a $47 billion deal that would make it the largest U.S. health insurer by membership.       Humana said it expected the Aetna transaction to close in the second half of 2016, as previously forecast.      The company's consolidated benefit ratio, or the ratio of its spending on medical claims versus premium revenue it takes in, was 83.9 percent in the quarter, compared with 83.3 percent a year earlier.  Net income rose to $314 million, or $2.09 per share, in the third quarter ended Sept. 30, from $290 million, or $1.85 per share, a year earlier. On an adjusted basis, the company earned $2.16 per share, above the average analyst estimate of $2.13, according to Thomson Reuters I/B/E/S.Revenue rose 9.2 percent to $13.36 billion, but missed analysts' estimate of $13.64 billion. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2015-11-06,HUM,"Fri Nov 6, 2015 | 7:43am EST",Humana profit beats on individual Medicare Advantage strength,http://www.reuters.com//article/us-humana-results-idUSKCN0SV1CZ20151106?type=companyNews
117,"  * Q3 adjusted profit $2.16/share vs est $2.13* Revenue $13.36 bln vs est $13.64 bln* Individual Medicare Advantage membership up 14 pct   (Adds details)Nov 6 Health insurer Humana Inc, which agreed to be bought by Aetna Inc for $37 billion in July, reported a better-than-expected quarterly profit as it added more members to its individual Medicare Advantage business.Humana, which manages large Medicare Advantage health plans for the elderly and disabled, said individual Medicare Advantage membership increased 14 percent to 2.74 million at the end of September.However, individual commercial membership decreased 11 percent to 963,700 as of Sept. 30. ""We remain cautious with regard to our expectations around 2016 earnings growth due to the ongoing challenges in the individual commercial business,"" Humana's Chief Financial Officer Brian Kane said in a statement on Friday.Larger rival Anthem Inc said last month its Obamacare insurance business is being hampered by lower-than-anticipated enrollment due to fewer applicants than expected and cheaper premium rates at competitors.Cigna Corp, which also reported a better-than-expected quarterly profit on Friday, said it expected 2016 revenue growth to be hurt by reduction in customers in its individual plans. President Barack Obama's signature healthcare law, the Affordable Care Act, in 2014 overhauled the individual market with new government subsidized plans sold through newly created exchanges.Insurers are betting on mergers to help them compete better, as the government tries to rein in healthcare spending following the implementation of Obamacare.Anthem agreed over the summer to acquire Cigna in a $47 billion deal that would make it the largest U.S. health insurer by membership. Humana said it expected the Aetna transaction to close in the second half of 2016, as previously forecast.The company's consolidated benefit ratio, or the ratio of its spending on medical claims versus premium revenue it takes in, was 83.9 percent in the quarter, compared with 83.3 percent a year earlier.Net income rose to $314 million, or $2.09 per share, in the third quarter ended Sept. 30, from $290 million, or $1.85 per share, a year earlier.On an adjusted basis, the company earned $2.16 per share, above the average analyst estimate of $2.13, according to Thomson Reuters I/B/E/S.Revenue rose 9.2 percent to $13.36 billion, but missed analysts' estimate of $13.64 billion.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2015-11-06,HUM,"Fri Nov 6, 2015 | 7:40am EST",UPDATE 2-Humana profit beats on individual Medicare Advantage strength,http://www.reuters.com//article/humana-results-idUSL3N1314D620151106?type=companyNews
118,"  Nov 6 Health insurer Humana Inc, which agreed to be bought by Aetna Inc for $37 billion in July, reported a 9.2 percent rise in quarterly revenue as it added more members to its individual Medicare Advantage business.The company's net income rose to $314 million, or $2.09 per share, in the third quarter ended Sept. 30, from $290 million, or $1.85 per share, a year earlier.  Revenue rose to $13.36 billion from $12.24 billion.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila) ",2015-11-06,HUM,"Fri Nov 6, 2015 | 6:07am EST",Health insurer Humana's revenue rises 9.2 pct,http://www.reuters.com//article/humana-results-idUSL3N1313W820151106?type=companyNews
119,"   By Karen Brettell, David Gaffen and David Rohde | NEW YORK  NEW YORKWhen health insurer Humana Inc reported worse-than-expected quarterly earnings in late 2014  including a 21 percent drop in net income  it softened the blow by immediately telling investors it would make a $500 million share repurchase.In addition to soothing shareholders, the surprise buyback benefited the companys senior executives. It added around two cents to the companys annual earnings per share, allowing Humana to surpass its $7.50 EPS target by a single cent and unlocking higher pay for top managers under terms of the companys compensation agreement.Thanks to Humana hitting that target, Chief Executive Officer Bruce Broussard earned a $1.68 million bonus for 2014.Most publicly traded U.S. companies reward top managers for hitting performance targets, meant to tie the interests of managers and shareholders together. At many big companies, those interests are deemed to be best aligned by linking executive performance to earnings per share, along with measures derived from the companys stock price.But these metrics may not be solely a reflection of a companys operating performance. They can be, and often are, influenced through stock repurchases. In addition to cutting the number of a companys shares outstanding, and thus lifting EPS, buybacks also increase demand for the shares, usually providing a lift to the share price, which affects other performance markers.As corporate America engages in an unprecedented buyback binge, soaring CEO pay tied to short-term performance measures like EPS is prompting criticism that executives are using stock repurchases to enrich themselves at the expense of long-term corporate health, capital investment and employment.Weve accepted a definition of performance that is narrow and quite possibly inappropriate, said Rosanna Landis Weaver, program manager of the executive compensation initiative at As You Sow, a Washington, D.C., nonprofit that promotes corporate responsibility. Pay for performance as it is often structured creates very troublesome, problematic incentives that can potentially drive very short-term thinking.A Reuters analysis of the companies in the Standard & Poors 500 Index found that 255 of those companies reward executives in part by using EPS, while another 28 use other per-share metrics that can be influenced by share buybacks.In addition, 303 also use total shareholder return, essentially a companys share price appreciation plus dividends, and 169 companies use both EPS and total shareholder return to help determine pay.STANDARD PRACTICE EPS and share-price metrics underpin much of the compensation of some of the highest-paid CEOs, including those at Walt Disney Co, Viacom Inc, 21st Century Fox Inc, Target Corp and Cisco Systems Inc.Fewer than 20 of the S&P 500 companies disclose in their proxies whether they exclude the impact of buybacks on per-share metrics that determine executive pay.Humana would not say whether it adjusted targets to account for its buyback last year. In a statement to Reuters, the company said it sets annual per-share targets for executives that take into account the companys capital allocation strategy, which includes buybacks, dividends, acquisitions and investments.Experts said Humana would not have reached the target without the $500 million buyback. The company told analysts at the time of the repurchase announcement in November 2014 that it expected to report annual earnings per share of between $7.40 and $7.60 for the full year.Given the magnitude of the repurchase, the EPS would have been below $7.50 had it not been for the repurchase, said Heitor Almeida, a professor of finance with the College of Business at the University of Illinois in Champaign.As reported in the first article in this series, share buybacks by U.S. non-financial companies reached a record $520 billion in the most recent reporting year. A Reuters analysis of 3,300 non-financial companies found that together, buybacks and dividends have surpassed total capital expenditures and are more than double research and development spending.Companies buy back their shares for various reasons. They do it when they believe their shares are undervalued, or to make use of cash or cheap debt financing when business conditions dont justify capital or R&D spending. They also do it to meet the expectations of increasingly demanding investors.Lately, the sheer volume of buybacks has prompted complaints among academics, politicians and investors that massive stock repurchases are stifling innovation and hurting U.S. competitiveness - and contributing to widening income inequality by rewarding executives with ever higher pay, often divorced from a companys underlying performance.Theres been an over-focus on buybacks and raising EPS to hit share option targets, and we know that those are concentrated in the hands of the few, and that the few is in the top 1 percent, said James Montier, a member of the asset allocation team at global investment firm GMO in London, which manages more than $100 billion in assets.The introduction of performance targets has been a driver of surging executive pay, helping to widen the gap between the richest in America and the rest of the country. Median CEO pay among companies in the S&P 500 increased to a record $10.3 million last year, up from $8.6 million in 2010, according to data firm Equilar.At those levels, CEOs last year were paid 303 times what workers in their industries earned, compared with a ratio of 59 times in 1989, according to the Economic Policy Institute, a Washington-based nonprofit.SALARY AND A LOT MORE Today, the bulk of CEO compensation comes from cash and stock awards, much of it tied to performance metrics. Last year, base salary accounted for just 8 percent of CEO pay for S&P 500 companies, while cash and stock incentives made up more than 45 percent, according to proxy advisory firm Institutional Shareholder Services.Thomson Reuters Corp, owner of Reuters News, used EPS to determine half of the performance awards in the three-year pay cycle ended in 2014 for CEO Jim Smith and other executives. Smith last year took home $6.6 million in compensation. The companys three-year performance awards going forward are based on both EPS and free cash flow per share. A company spokesman said Thomson Reuters does not adjust for the impact of stock buybacks on those metrics. Share repurchases can make the difference in meeting preset targets, according to a Reuters review of corporate proxies.At Xerox Corp, revenue, net income and spending on research and development all declined last year. But the printer and copier makers EPS target of $1.12 was unchanged from the prior year, and managers hit it exactly after $1.1 billion in share repurchases.Half of CEO Ursula Burnss annual bonus target was predicated on hitting that EPS level; ultimately, she received a bonus of $1.98 million out of a possible $2.2 million. EPS is also a major determinant of even bigger bonuses for a three-year performance cycle ending this year.Xerox repurchased $1.35 billion of its shares in the first three quarters of this year. The company declined to comment. Its proxy statement does not indicate whether it adjusts targets to account for buybacks.Managers at information technology company EMC Corp hit their EPS target for 2014 of $1.90 with the help of $3.7 billion in share repurchases. Based on the share count before the buybacks, EPS last year would have been only $1.81, little changed from $1.80 a year earlier, according to a Reuters calculation.The EPS target accounted for half of CEO Joseph Tuccis annual $1.01 million bonus. It also is used to determine 45 percent of bonus share awards for the companys future three-year targets.EMC declined to comment. Its proxy statement does not address whether it makes adjustments to account for buybacks. It has bought back $3.11 billion in shares so far this year.Buybacks can boost a companys share price to benefit executives whose shares vest over a period of years. Activision Blizzard Inc, purveyor of Guitar Hero, Call of Duty and other well-known video games, signed Chief Executive Robert Kotick to a contract in 2012 that included $56 million in share awards that vest over time, depending in part on the share price and EPS.Last year, Kotick ended up getting about $22 million in performance-based cash and stock awards, about the same as the year prior, even as net income dropped 17 percent. How? The stock rose substantially, meeting goals for total shareholder return and increasing the value of share awards.Total shareholder return was helped by an $8.2 billion repurchase made in late 2013  when the company and a group of investors led by Kotick and Activision Chairman Brian Kelly bought out a stake held by then-majority shareholder Vivendi. The company said the deal allowed Activision to operate with more flexibility.The shares rose 33 percent from the date of the buyback announcement in July 2013 through the end of 2014. The share price has continued to rise this year, making the awards even more valuable.Activision declined to comment.In 1992, Congress changed the tax code to curb rising executive pay and encourage performance-based compensation. It didnt work. Instead, the shift is widely blamed for soaring executive pay and a heavier emphasis on short-term results. Companies started tying performance pay to short-term metrics, and suddenly all the things we dont want to happen start happening, said Lynn Stout, a professor of corporate and business law at Cornell Law School in Ithaca, New York. Despite 20 years of trying, we have still failed to come up with an objective performance metric that cant be gamed.Shareholder expectations have changed, too. The individuals and other smaller, mostly passive investors who dominated equity markets during the postwar decades have given way to large institutional investors. These institutions tend to want higher returns, sooner, than their predecessors. Consider that the average time investors held a particular share has fallen from around eight years in 1960 to a year and a half now, according to New York Stock Exchange data.TOO EASY TO MANIPULATE Companies like to use EPS as a performance metric because it is the primary focus of financial analysts when assessing the value of a stock and of investors when evaluating their return on investment.But it is not an appropriate target, its too easy to manipulate, said Almeida, the University of Illinois finance professor.In 2011, Amgen Inc CEO Kevin Sharer oversaw $8.32 billion of buybacks, by far the largest in the pharmaceutical makers history. More than $5 billion of those repurchases came in the fourth quarter of the year.Soon after, Amgen reported that net income was lower than it had been in the three preceding years. At the same time, the buybacks lifted EPS far above the target level that determined 30 percent of Sharers bonus, doubling the amount he earned for that portion of his $4.88 million annual bonus. Without the buyouts, EPS would have fallen below the target level.Sharer left the company in May 2012 and is now on the faculty of Harvard Business School. He did not respond to requests for comment.The Amgen boards compensation committee removed EPS as a performance metric the next year. It opted, instead, to begin using net income, saying in a 2012 proxy statement that doing so would align compensation with a measure that more directly correlates with the underlying performance of our operations.Members of Amgens 2011 compensation committee declined to comment.Some companies, including software developer Citrix Systems Inc and kidney dialysis company DaVita Inc, say they avoid EPS in pay calculations because it is too vulnerable to manipulation.Most companies that use per-share metrics for executive awards, however, say little about whether they adjust results to account for buybacks. A select few, including Johnson & Johnson, FedEx, Time Warner Inc and IBM, do disclose that they strip out the potential effect of buybacks on performance metrics. FedEx, in its most recent filing, said it excluded the effect of buybacks because the positive effect on EPS did not reflect core business performance. Time Warner Inc said it adjusts for buybacks so that payouts were not advantaged if the media company repurchased more shares than it initially anticipated when setting performance goals.Steve Pakela, managing partner at Pay Governance LLC in Pittsburgh, Pennsylvania, which advises more than 40 S&P 500 companies on executive pay, said some directors believe you shouldnt strip out the effect because share buybacks may be the best use of capital.In addition to EPS, there is total shareholder return, which typically comprises a companys share price appreciation plus dividends over time. Total return, often used to compare performance among peer companies, has also become a popular performance measure for executive pay.By providing a lift to a stocks price, buybacks can increase total shareholder return to target levels, resulting in more stock awards for executives. And of course, the higher stock price lifts the value of company stock they already own.It can goose the price at time when the high price means they earn performance shares  even if the stock price later goes back down, they got their shares, said Michael Dorff, a law professor at the Southwestern Law School in Los Angeles.Exxon Corp, the largest repurchaser of shares over the past decade, has rejected shareholder proposals that it add three-year targets based on shareholder return to its compensation program. In its most recent proxy, the energy company said doing so could increase risk-taking and encourage underinvestment to achieve short-term results.The energy giant makes half of its annual executive bonus payments contingent on meeting longer-term EPS thresholds. Since 2005, the company has spent more than $200 billion on buybacks.ADDITIONAL TWEAKS While performance targets are specific, they arent necessarily fixed. Corporate boards often adjust them or how they are calculated in ways that lift executive pay.Humana specifies EPS ranges to determine annual bonuses paid to its executives. For the past three years, buybacks of more than $500 million a year increased EPS. That wasnt all, however. For each of those years, the board altered calculations in ways that also bumped EPS higher.For 2012, then-CEO Michael McCallister received a higher bonus than he otherwise would have -- $1.63 million -- after Humanas board removed litigation expenses from its EPS calculation.He was succeeded as CEO at the start of 2013 by Broussard. For that year, Broussards annual bonus was lifted into the maximum range, for a payment $2.44 million, after accounting for the cost of posting additional reserves against long-term insurance policies.For 2014, Humana discounted from its EPS calculation losses from paying down some bonds, even as its overall debt levels increased. That adjustment brought the company just below its EPS target of $7.50.The $500 million buyback the company announced late last year, part of its total $872 million in buybacks in 2014, was an accelerated share repurchase. In this sort of deal, a company buys all the stock from an investment bank in a single transaction. That allows it to book the reduction in shares outstanding immediately, and the bank then buys the shares on the open market over the ensuing months.Humanas accelerated share repurchase lifted EPS to $7.51, just above the target.Susan Young, an associate professor of accounting and taxation at Fordham University in New York, said accelerated buybacks are commonly used to reach compensation targets. I cant think of a good reason for this form of repurchase, she said, noting that the programs restrict a companys flexibility to reduce or stop buybacks if shares become too expensive.Roy Dunbar, a member of the Humana boards compensation committee, declined to comment on Humana specifically. He said the benefit of accelerated repurchases is to, in a controlled way, buy a significant slice of available shares early in the program, before an announced buyback pushes up the share price and increases the cost to the company.He also said an accelerated program allows shareholders to see immediate action, which is important to signal a higher degree of confidence in something shareholders care a great deal about.In general, he said, effective compensation committees are aware of impact of share repurchases on EPS, particularly when EPS is part of the equity compensation of management.In July, Aetna Inc announced that it would acquire Humana in a deal that at the time valued Humana at $37 billion. If Broussard leaves after the deal, he wont go empty-handed.Just before the Aetna deal was announced, Broussards compensation agreement was modified to accelerate equity awards and remove restrictions on exercising some stock options if he leaves or is terminated within two years of any acquisition, a regulatory filing shows.At the end of last year, Broussard held unvested share awards valued at around $12.8 million, which have since increased in value as Humanas share price has climbed 18 percent. (Edited by John Blanton)",2015-12-10,HUM,"Thu Dec 10, 2015 | 2:47pm EST",Special Report: Buybacks enrich the bosses even when business sags,http://www.reuters.com//article/us-usa-buybacks-pay-specialreport-idUSKBN0TT2AH20151210?type=companyNews
120,"   By Karen Brettell, David Gaffen and David Rohde | NEW YORK  NEW YORKWhen health insurer Humana Inc reported worse-than-expected quarterly earnings in late 2014  including a 21 percent drop in net income  it softened the blow by immediately telling investors it would make a $500 million share repurchase.In addition to soothing shareholders, the surprise buyback benefited the companys senior executives. It added around two cents to the companys annual earnings per share, allowing Humana to surpass its $7.50 EPS target by a single cent and unlocking higher pay for top managers under terms of the companys compensation agreement.Thanks to Humana hitting that target, Chief Executive Officer Bruce Broussard earned a $1.68 million bonus for 2014.Most publicly traded U.S. companies reward top managers for hitting performance targets, meant to tie the interests of managers and shareholders together. At many big companies, those interests are deemed to be best aligned by linking executive performance to earnings per share, along with measures derived from the companys stock price.But these metrics may not be solely a reflection of a companys operating performance. They can be, and often are, influenced through stock repurchases. In addition to cutting the number of a companys shares outstanding, and thus lifting EPS, buybacks also increase demand for the shares, usually providing a lift to the share price, which affects other performance markers.As corporate America engages in an unprecedented buyback binge, soaring CEO pay tied to short-term performance measures like EPS is prompting criticism that executives are using stock repurchases to enrich themselves at the expense of long-term corporate health, capital investment and employment.Weve accepted a definition of performance that is narrow and quite possibly inappropriate, said Rosanna Landis Weaver, program manager of the executive compensation initiative at As You Sow, a Washington, D.C., nonprofit that promotes corporate responsibility. Pay for performance as it is often structured creates very troublesome, problematic incentives that can potentially drive very short-term thinking.A Reuters analysis of the companies in the Standard & Poors 500 Index found that 255 of those companies reward executives in part by using EPS, while another 28 use other per-share metrics that can be influenced by share buybacks.In addition, 303 also use total shareholder return, essentially a companys share price appreciation plus dividends, and 169 companies use both EPS and total shareholder return to help determine pay.STANDARD PRACTICE EPS and share-price metrics underpin much of the compensation of some of the highest-paid CEOs, including those at Walt Disney Co, Viacom Inc, 21st Century Fox Inc, Target Corp and Cisco Systems Inc.Fewer than 20 of the S&P 500 companies disclose in their proxies whether they exclude the impact of buybacks on per-share metrics that determine executive pay.Humana would not say whether it adjusted targets to account for its buyback last year. In a statement to Reuters, the company said it sets annual per-share targets for executives that take into account the companys capital allocation strategy, which includes buybacks, dividends, acquisitions and investments.Experts said Humana would not have reached the target without the $500 million buyback. The company told analysts at the time of the repurchase announcement in November 2014 that it expected to report annual earnings per share of between $7.40 and $7.60 for the full year.Given the magnitude of the repurchase, the EPS would have been below $7.50 had it not been for the repurchase, said Heitor Almeida, a professor of finance with the College of Business at the University of Illinois in Champaign.As reported in the first article in this series, share buybacks by U.S. non-financial companies reached a record $520 billion in the most recent reporting year. A Reuters analysis of 3,300 non-financial companies found that together, buybacks and dividends have surpassed total capital expenditures and are more than double research and development spending.Companies buy back their shares for various reasons. They do it when they believe their shares are undervalued, or to make use of cash or cheap debt financing when business conditions dont justify capital or R&D spending. They also do it to meet the expectations of increasingly demanding investors.Lately, the sheer volume of buybacks has prompted complaints among academics, politicians and investors that massive stock repurchases are stifling innovation and hurting U.S. competitiveness - and contributing to widening income inequality by rewarding executives with ever higher pay, often divorced from a companys underlying performance.Theres been an over-focus on buybacks and raising EPS to hit share option targets, and we know that those are concentrated in the hands of the few, and that the few is in the top 1 percent, said James Montier, a member of the asset allocation team at global investment firm GMO in London, which manages more than $100 billion in assets.The introduction of performance targets has been a driver of surging executive pay, helping to widen the gap between the richest in America and the rest of the country. Median CEO pay among companies in the S&P 500 increased to a record $10.3 million last year, up from $8.6 million in 2010, according to data firm Equilar.At those levels, CEOs last year were paid 303 times what workers in their industries earned, compared with a ratio of 59 times in 1989, according to the Economic Policy Institute, a Washington-based nonprofit.SALARY AND A LOT MORE Today, the bulk of CEO compensation comes from cash and stock awards, much of it tied to performance metrics. Last year, base salary accounted for just 8 percent of CEO pay for S&P 500 companies, while cash and stock incentives made up more than 45 percent, according to proxy advisory firm Institutional Shareholder Services.Thomson Reuters Corp, owner of Reuters News, used EPS to determine half of the performance awards in the three-year pay cycle ended in 2014 for CEO Jim Smith and other executives. Smith last year took home $6.6 million in compensation. The companys three-year performance awards going forward are based on both EPS and free cash flow per share. A company spokesman said Thomson Reuters does not adjust for the impact of stock buybacks on those metrics. Share repurchases can make the difference in meeting preset targets, according to a Reuters review of corporate proxies.At Xerox Corp, revenue, net income and spending on research and development all declined last year. But the printer and copier makers EPS target of $1.12 was unchanged from the prior year, and managers hit it exactly after $1.1 billion in share repurchases.Half of CEO Ursula Burnss annual bonus target was predicated on hitting that EPS level; ultimately, she received a bonus of $1.98 million out of a possible $2.2 million. EPS is also a major determinant of even bigger bonuses for a three-year performance cycle ending this year.Xerox repurchased $1.35 billion of its shares in the first three quarters of this year. The company declined to comment. Its proxy statement does not indicate whether it adjusts targets to account for buybacks.Managers at information technology company EMC Corp hit their EPS target for 2014 of $1.90 with the help of $3.7 billion in share repurchases. Based on the share count before the buybacks, EPS last year would have been only $1.81, little changed from $1.80 a year earlier, according to a Reuters calculation.The EPS target accounted for half of CEO Joseph Tuccis annual $1.01 million bonus. It also is used to determine 45 percent of bonus share awards for the companys future three-year targets.EMC declined to comment. Its proxy statement does not address whether it makes adjustments to account for buybacks. It has bought back $3.11 billion in shares so far this year.Buybacks can boost a companys share price to benefit executives whose shares vest over a period of years. Activision Blizzard Inc, purveyor of Guitar Hero, Call of Duty and other well-known video games, signed Chief Executive Robert Kotick to a contract in 2012 that included $56 million in share awards that vest over time, depending in part on the share price and EPS.Last year, Kotick ended up getting about $22 million in performance-based cash and stock awards, about the same as the year prior, even as net income dropped 17 percent. How? The stock rose substantially, meeting goals for total shareholder return and increasing the value of share awards.Total shareholder return was helped by an $8.2 billion repurchase made in late 2013  when the company and a group of investors led by Kotick and Activision Chairman Brian Kelly bought out a stake held by then-majority shareholder Vivendi. The company said the deal allowed Activision to operate with more flexibility.The shares rose 33 percent from the date of the buyback announcement in July 2013 through the end of 2014. The share price has continued to rise this year, making the awards even more valuable.Activision declined to comment.In 1992, Congress changed the tax code to curb rising executive pay and encourage performance-based compensation. It didnt work. Instead, the shift is widely blamed for soaring executive pay and a heavier emphasis on short-term results. Companies started tying performance pay to short-term metrics, and suddenly all the things we dont want to happen start happening, said Lynn Stout, a professor of corporate and business law at Cornell Law School in Ithaca, New York. Despite 20 years of trying, we have still failed to come up with an objective performance metric that cant be gamed.Shareholder expectations have changed, too. The individuals and other smaller, mostly passive investors who dominated equity markets during the postwar decades have given way to large institutional investors. These institutions tend to want higher returns, sooner, than their predecessors. Consider that the average time investors held a particular share has fallen from around eight years in 1960 to a year and a half now, according to New York Stock Exchange data.TOO EASY TO MANIPULATE Companies like to use EPS as a performance metric because it is the primary focus of financial analysts when assessing the value of a stock and of investors when evaluating their return on investment.But it is not an appropriate target, its too easy to manipulate, said Almeida, the University of Illinois finance professor.In 2011, Amgen Inc CEO Kevin Sharer oversaw $8.32 billion of buybacks, by far the largest in the pharmaceutical makers history. More than $5 billion of those repurchases came in the fourth quarter of the year.Soon after, Amgen reported that net income was lower than it had been in the three preceding years. At the same time, the buybacks lifted EPS far above the target level that determined 30 percent of Sharers bonus, doubling the amount he earned for that portion of his $4.88 million annual bonus. Without the buyouts, EPS would have fallen below the target level.Sharer left the company in May 2012 and is now on the faculty of Harvard Business School. He did not respond to requests for comment.The Amgen boards compensation committee removed EPS as a performance metric the next year. It opted, instead, to begin using net income, saying in a 2012 proxy statement that doing so would align compensation with a measure that more directly correlates with the underlying performance of our operations.Members of Amgens 2011 compensation committee declined to comment.Some companies, including software developer Citrix Systems Inc and kidney dialysis company DaVita Inc, say they avoid EPS in pay calculations because it is too vulnerable to manipulation.Most companies that use per-share metrics for executive awards, however, say little about whether they adjust results to account for buybacks. A select few, including Johnson & Johnson, FedEx, Time Warner Inc and IBM, do disclose that they strip out the potential effect of buybacks on performance metrics. FedEx, in its most recent filing, said it excluded the effect of buybacks because the positive effect on EPS did not reflect core business performance. Time Warner Inc said it adjusts for buybacks so that payouts were not advantaged if the media company repurchased more shares than it initially anticipated when setting performance goals.Steve Pakela, managing partner at Pay Governance LLC in Pittsburgh, Pennsylvania, which advises more than 40 S&P 500 companies on executive pay, said some directors believe you shouldnt strip out the effect because share buybacks may be the best use of capital.In addition to EPS, there is total shareholder return, which typically comprises a companys share price appreciation plus dividends over time. Total return, often used to compare performance among peer companies, has also become a popular performance measure for executive pay.By providing a lift to a stocks price, buybacks can increase total shareholder return to target levels, resulting in more stock awards for executives. And of course, the higher stock price lifts the value of company stock they already own.It can goose the price at time when the high price means they earn performance shares  even if the stock price later goes back down, they got their shares, said Michael Dorff, a law professor at the Southwestern Law School in Los Angeles.Exxon Corp, the largest repurchaser of shares over the past decade, has rejected shareholder proposals that it add three-year targets based on shareholder return to its compensation program. In its most recent proxy, the energy company said doing so could increase risk-taking and encourage underinvestment to achieve short-term results.The energy giant makes half of its annual executive bonus payments contingent on meeting longer-term EPS thresholds. Since 2005, the company has spent more than $200 billion on buybacks.ADDITIONAL TWEAKS While performance targets are specific, they arent necessarily fixed. Corporate boards often adjust them or how they are calculated in ways that lift executive pay.Humana specifies EPS ranges to determine annual bonuses paid to its executives. For the past three years, buybacks of more than $500 million a year increased EPS. That wasnt all, however. For each of those years, the board altered calculations in ways that also bumped EPS higher.For 2012, then-CEO Michael McCallister received a higher bonus than he otherwise would have -- $1.63 million -- after Humanas board removed litigation expenses from its EPS calculation.He was succeeded as CEO at the start of 2013 by Broussard. For that year, Broussards annual bonus was lifted into the maximum range, for a payment $2.44 million, after accounting for the cost of posting additional reserves against long-term insurance policies.For 2014, Humana discounted from its EPS calculation losses from paying down some bonds, even as its overall debt levels increased. That adjustment brought the company just below its EPS target of $7.50.The $500 million buyback the company announced late last year, part of its total $872 million in buybacks in 2014, was an accelerated share repurchase. In this sort of deal, a company buys all the stock from an investment bank in a single transaction. That allows it to book the reduction in shares outstanding immediately, and the bank then buys the shares on the open market over the ensuing months.Humanas accelerated share repurchase lifted EPS to $7.51, just above the target.Susan Young, an associate professor of accounting and taxation at Fordham University in New York, said accelerated buybacks are commonly used to reach compensation targets. I cant think of a good reason for this form of repurchase, she said, noting that the programs restrict a companys flexibility to reduce or stop buybacks if shares become too expensive.Roy Dunbar, a member of the Humana boards compensation committee, declined to comment on Humana specifically. He said the benefit of accelerated repurchases is to, in a controlled way, buy a significant slice of available shares early in the program, before an announced buyback pushes up the share price and increases the cost to the company.He also said an accelerated program allows shareholders to see immediate action, which is important to signal a higher degree of confidence in something shareholders care a great deal about.In general, he said, effective compensation committees are aware of impact of share repurchases on EPS, particularly when EPS is part of the equity compensation of management.In July, Aetna Inc announced that it would acquire Humana in a deal that at the time valued Humana at $37 billion. If Broussard leaves after the deal, he wont go empty-handed.Just before the Aetna deal was announced, Broussards compensation agreement was modified to accelerate equity awards and remove restrictions on exercising some stock options if he leaves or is terminated within two years of any acquisition, a regulatory filing shows.At the end of last year, Broussard held unvested share awards valued at around $12.8 million, which have since increased in value as Humanas share price has climbed 18 percent. (Edited by John Blanton)",2015-12-11,HUM,"Thu Dec 10, 2015 | 7:53pm EST",Special Report: Buybacks enrich the bosses even when business sags,http://www.reuters.com//article/us-usa-buybacks-pay-specialreport-idUSKBN0TT2AH20151211?type=companyNews
121,  Dec 14 Kontigo Care AB :* Signs framework agreement with companies within Humana group * Agreement runs for one year with option for yearly extension Source text for Eikon: Further company coverage:    (Gdynia Newsroom),2015-12-14,HUM,"Mon Dec 14, 2015 | 6:06am EST",BRIEF-Kontigo Care signs deal within Humana group,http://www.reuters.com//article/idUSFWN14004X20151214?type=companyNews
122,"   By Caroline Humer | SAN FRANCISCO  SAN FRANCISCO Aetna Inc (AET.N) Chief Executive Mark Bertolini said on Tuesday that he still expects the company's $37 billion acquisition of rival Humana Inc (HUM.N) to close this year.The deal is being reviewed by the U.S. Department of Justice, which has been seeking documents about Aetna's and Humana's business as it assesses how the deal, and a pending $47 billion combination of Anthem Inc (ANTM.N) and Cigna Corp (CI.N), could affect consumers. ""So far, we have nothing to believe it will be any slower than that, or any faster,"" Bertolini said in an interview at the JP Morgan Healthcare conference.The two proposed mergers would be an unprecedented consolidation of the U.S. health insurance industry, and critics have warned it could lead to higher prices for consumers. Insurers say the combinations will give them greater leverage to control rising healthcare costs. Aetna said it expects the regulators to wrap up their document requests in the next month, and then the company will move onto discussions with them and consider any divestitures that might be needed.Aetna and Humana sell health plans for individuals as well as Medicare Advantage plans for seniors. Humana's operations  does not overlap with Aetnas large corporate business. U.S. antitrust regulators have recently blocked large mergers in a variety of industries, raising questions among investors about whether Aetna's and Anthem's acquisitions will close. Reuters reported on Monday that about 15 state attorneys general have joined the Justice Department's probe into the insurance mergers, potentially complicating what is already expected to be a tough and lengthy review.The government's joint review of both deals has probably increased the breadth and volume of information that Aetna has supplied, Bertolini said. ""If we were to look at 2016 we have two things to do. Deliver our results, and close our deal,"" he said.  (Reporting by Caroline Humer; Editing by Michele Gershberg and Steve Orlofsky)",2016-01-12,HUM,"Tue Jan 12, 2016 | 3:52pm EST",Aetna CEO sees Humana deal on track to close this year,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0UQ2FV20160112?type=companyNews
123,"   By Diane Bartz  Aetna Inc's plan to buy smaller insurer Humana Inc for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP).Aetna's proposed deal for Humana would combine Aetna's 7 percent of the Medicare Advantage market with Humana's 19 percent, and make it the largest provider, according to CAP, which was founded by John Podesta who worked in the White House under Presidents Bill Clinton and Barack Obama.Medicare Advantage is an insurance plan for seniors that is largely paid for by the government but administered by private insurers. The deal is one of two giant insurance mergers announced in July. The other was Anthem's $45 billion bid for Cigna Corp. Deal values were calculated based on Wednesday's closing stock prices.CAP said in one analysis it found that in counties where Aetna competed with Humana, Aetna's average annual premiums were $302 lower. Using a more conservative approach, it determined that Aetna's average annual premiums were $155 less if it competed against Humana, while Humana's premiums were $43 less if it competed against Aetna, CAP said. Aetna said that seniors who are hit with price increases with Medicare Advantage could always switch to traditional Medicare, and that two-thirds of seniors are on traditional Medicare. ""This keeps downward pressure on prices and upward pressure on quality,"" said Aetna spokeswoman Kristine Grow in an email.She also said that Aetna and Humana combined have 4.4 million Medicare Advantage enrollees, about 8 percent of the 54 million people enrolled in Medicare. ""There will continue to be significant competition in Medicare Advantage, with many health plans and other new industry entrants,"" she said in the email.Despite the predicted price increase, CAP stopped short of asking the U.S. Justice Department outright to sue to stop the proposed deal.""All of the available evidence suggests that the bar should be very high for approving these mergers and that they should be stopped absent clear and compelling evidence that they will benefit consumers,"" the think tank said in its report.   (Additional reporting by Caroline Humer)",2016-01-21,HUM,"Thu Jan 21, 2016 | 12:04pm EST",Aetna's deal for Humana will push up costs for seniors - think tank,http://www.reuters.com//article/humana-aetna-cap-idUSL2N1551RQ?type=companyNews
124,"   By Diane Bartz | WASHINGTON  WASHINGTON Aetna Inc's (AET.N) plan to buy smaller insurer Humana Inc (HUM.N) for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP).Aetna's proposed deal for Humana would combine Aetna's 7 percent of the Medicare Advantage market with Humana's 19 percent, and make it the largest provider, according to CAP, which was founded by John Podesta who worked in the White House under Presidents Bill Clinton and Barack Obama.Medicare Advantage is an insurance plan for seniors that is largely paid for by the government but administered by private insurers.The deal is one of two giant insurance mergers announced in July. The other was Anthem's (ANTM.N) $45 billion bid for Cigna Corp (CI.N). Deal values were calculated based on Wednesday's closing stock prices. CAP said in one analysis it found that in counties where Aetna competed with Humana, Aetna's average annual premiums were $302 lower. Using a more conservative approach, it determined that Aetna's average annual premiums were $155 less if it competed against Humana, while Humana's premiums were $43 less if it competed against Aetna, CAP said.Aetna said that seniors who are hit with price increases with Medicare Advantage could always switch to traditional Medicare, and that two-thirds of seniors are on traditional Medicare. ""This keeps downward pressure on prices and upward pressure on quality,"" said Aetna spokeswoman Kristine Grow in an email. She also said that Aetna and Humana combined have 4.4 million Medicare Advantage enrollees, about 8 percent of the 54 million people enrolled in Medicare.""There will continue to be significant competition in Medicare Advantage, with many health plans and other new industry entrants,"" she said in the email. Despite the predicted price increase, CAP stopped short of asking the U.S. Justice Department outright to sue to stop the proposed deal.""All of the available evidence suggests that the bar should be very high for approving these mergers and that they should be stopped absent clear and compelling evidence that they will benefit consumers,"" the think tank said in its report. (Additional reporting by Caroline Humer; Editing by Jeffrey Benkoe)",2016-01-21,HUM,"Thu Jan 21, 2016 | 12:03pm EST",Aetna's deal for Humana will push up costs for seniors: think tank,http://www.reuters.com//article/us-humana-aetna-cap-idUSKCN0UZ2CV?type=companyNews
125,"   By Diane Bartz | WASHINGTON  WASHINGTON Aetna Inc's (AET.N) plan to buy smaller insurer Humana Inc (HUM.N) for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP).Aetna's proposed deal for Humana would combine Aetna's 7 percent of the Medicare Advantage market with Humana's 19 percent, and make it the largest provider, according to CAP, which was founded by John Podesta who worked in the White House under Presidents Bill Clinton and Barack Obama.Medicare Advantage is an insurance plan for seniors that is largely paid for by the government but administered by private insurers.The deal is one of two giant insurance mergers announced in July. The other was Anthem's (ANTM.N) $45 billion bid for Cigna Corp (CI.N). Deal values were calculated based on Wednesday's closing stock prices. CAP said in one analysis it found that in counties where Aetna competed with Humana, Aetna's average annual premiums were $302 lower. Using a more conservative approach, it determined that Aetna's average annual premiums were $155 less if it competed against Humana, while Humana's premiums were $43 less if it competed against Aetna, CAP said.Aetna said that seniors who are hit with price increases with Medicare Advantage could always switch to traditional Medicare, and that two-thirds of seniors are on traditional Medicare. ""This keeps downward pressure on prices and upward pressure on quality,"" said Aetna spokeswoman Kristine Grow in an email. She also said that Aetna and Humana combined have 4.4 million Medicare Advantage enrollees, about 8 percent of the 54 million people enrolled in Medicare.""There will continue to be significant competition in Medicare Advantage, with many health plans and other new industry entrants,"" she said in the email. Despite the predicted price increase, CAP stopped short of asking the U.S. Justice Department outright to sue to stop the proposed deal.""All of the available evidence suggests that the bar should be very high for approving these mergers and that they should be stopped absent clear and compelling evidence that they will benefit consumers,"" the think tank said in its report. (Additional reporting by Caroline Humer; Editing by Jeffrey Benkoe)",2016-01-21,HUM,"Thu Jan 21, 2016 | 12:03pm EST",Aetna's deal for Humana will push up costs for seniors - think tank,http://www.reuters.com//article/humana-aetna-cap-idUSL2N1542CY?type=companyNews
126,"  Health insurer Humana Inc (HUM.N), which is being bought by rival Aetna Inc (AET.N), on Wednesday said that it had set aside 74 cents per share in the fourth quarter to cover anticipated shortfalls in its 2016 individual health plan business. Humana had said last month that it would book anticipated losses on the money-losing business but had not given details on the amount. Wall Street analysts had estimated last month that the set aside would be about 70 cents per share.It made the disclosure as part of its quarterly earnings report.Humana also said that it continues to evaluate its participation in the individual commercial business for 2017.Other insurers including UnitedHealth Group (UNH.N) are considering the extent of their individual business in 2017 and have also taken losses, saying that some members are costing more than they expected.Humana said that many of its high cost members from 2015 had renewed their 2016 plans through Obamacare, a new type of individual insurance created under President Barack Obama's national healthcare reform law. The company said it had 899,100 individual customers at the end of 2015 and expects that number to decline 200,000 to 300,000 people in 2016.In addition to Obamacare plans, Humana also has individual customers in plans that do not comply with the Affordable Care Act but that were grandfathered through this year.Humana said that it had set aside a total reserve of $176 million in the fourth quarter, saying it set premium prices too low for the medical services use. Humana, whose business is primarily managing Medicare Advantage health plans for the elderly and disabled and also runs individual plans under Obamacare, said it expects growth in both earnings per share and revenue in 2017.Humana said it continues to expect its deal to be bought by Aetna to close by the end of the year.The company said it expects adjusted earnings of at least $8.85 in 2016, well above the average analysts' estimate of $8.73 per share, according to Thomson Reuters I/B/E/S. The company's net income fell to $101 million, or 67 cents per share, for the fourth quarter ended Dec. 31, from $145 million, or 94 cents per share, a year earlier. On an adjusted basis, Humana earned $1.45 per share, beating the average analysts' estimate of $1.44 per share.Total revenue rose 8.4 percent to $13.36 billion, missing average analysts' estimate of $13.51 billion. (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Shounak Dasgupta)",2016-02-10,HUM,"Wed Feb 10, 2016 | 9:05am EST",Health insurer Humana takes fourth-quarter charge for 2016 individual losses,http://www.reuters.com//article/us-humana-results-idUSKCN0VJ1BM?type=companyNews
127,"  Health insurer Humana Inc (HUM.N), which is being bought by rival Aetna Inc (AET.N), on Wednesday said that it had set aside 74 cents per share in the fourth quarter to cover anticipated shortfalls in its 2016 individual health plan business. Humana had said last month that it would book anticipated losses on the money-losing business but had not given details on the amount. Wall Street analysts had estimated last month that the set aside would be about 70 cents per share.It made the disclosure as part of its quarterly earnings report.Humana also said that it continues to evaluate its participation in the individual commercial business for 2017.Other insurers including UnitedHealth Group (UNH.N) are considering the extent of their individual business in 2017 and have also taken losses, saying that some members are costing more than they expected.Humana said that many of its high cost members from 2015 had renewed their 2016 plans through Obamacare, a new type of individual insurance created under President Barack Obama's national healthcare reform law. The company said it had 899,100 individual customers at the end of 2015 and expects that number to decline 200,000 to 300,000 people in 2016.In addition to Obamacare plans, Humana also has individual customers in plans that do not comply with the Affordable Care Act but that were grandfathered through this year.Humana said that it had set aside a total reserve of $176 million in the fourth quarter, saying it set premium prices too low for the medical services use. Humana, whose business is primarily managing Medicare Advantage health plans for the elderly and disabled and also runs individual plans under Obamacare, said it expects growth in both earnings per share and revenue in 2017.Humana said it continues to expect its deal to be bought by Aetna to close by the end of the year.The company said it expects adjusted earnings of at least $8.85 in 2016, well above the average analysts' estimate of $8.73 per share, according to Thomson Reuters I/B/E/S. The company's net income fell to $101 million, or 67 cents per share, for the fourth quarter ended Dec. 31, from $145 million, or 94 cents per share, a year earlier. On an adjusted basis, Humana earned $1.45 per share, beating the average analysts' estimate of $1.44 per share.Total revenue rose 8.4 percent to $13.36 billion, missing average analysts' estimate of $13.51 billion. (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Shounak Dasgupta)",2016-02-10,HUM,"Wed Feb 10, 2016 | 9:05am EST",UPDATE 2-Health insurer Humana takes 4Q charge for 2016 individual losses,http://www.reuters.com//article/humana-results-idUSL3N15P269?type=companyNews
128,"  Feb 10 Health insurer Humana Inc, which is being bought by rival Aetna Inc, reported an 8.4 percent rise in quarterly total revenue, helped by strength in its Medicare Advantage business.The company's net income fell to $101 million, or 67 cents per share, for the fourth quarter ended Dec. 31, from $145 million, or 94 cents per share, a year earlier. (bit.ly/1T70NLr)  Humana, which manages large Medicare Advantage health plans for the elderly and disabled and also runs individual plans under Obamacare, said total revenue rose to $13.36 billion from $12.33 billion a year ago.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak Dasgupta) ",2016-02-10,HUM,"Wed Feb 10, 2016 | 7:42am EST",Health insurer Humana's quarterly revenue rises,http://www.reuters.com//article/humana-results-idUSL3N15P263?type=companyNews
129,"  Health insurer Aetna Inc (AET.N) said on Monday Florida's insurance regulator approved its acquisition of Humana Inc (HUM.N). The company said that with the approval from Florida's Office of Insurance Regulation, it has secured 10 of the 20 state approvals required.Aetna said in July it would buy smaller rival Humana for about $37 billion in cash and stock, the largest deal ever in the insurance industry. The announced mergers of Aetna and Humana, as well as Anthem Inc's (ANTM.N) bid for Cigna Corp (CI.N), have come under increased scrutiny as the deals would reduce the number of nationwide health insurers to three from five.About 15 state attorneys general have joined the U.S. Justice Department's probe of the two mergers, Reuters reported last month, citing people familiar with the matter.  Aetna said it continued to cooperate with the Department of Justice in its probe and said it was possible DoJ would require divestitures in some regions.      (Reporting by Kshitiz Goliya in Bengaluru; Editing by Dan Grebler)",2016-02-16,HUM,"Mon Feb 15, 2016 | 10:38pm EST",Aetna gets Florida insurance regulator's approval for Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0VP09X?type=companyNews
130,"  Health insurer Aetna Inc (AET.N) said on Monday Florida's insurance regulator approved its acquisition of Humana Inc (HUM.N). The company said that with the approval from Florida's Office of Insurance Regulation, it has secured 10 of the 20 state approvals required.Aetna said in July it would buy smaller rival Humana for about $37 billion in cash and stock, the largest deal ever in the insurance industry. The announced mergers of Aetna and Humana, as well as Anthem Inc's (ANTM.N) bid for Cigna Corp (CI.N), have come under increased scrutiny as the deals would reduce the number of nationwide health insurers to three from five.About 15 state attorneys general have joined the U.S. Justice Department's probe of the two mergers, Reuters reported last month, citing people familiar with the matter.  Aetna said it continued to cooperate with the Department of Justice in its probe and said it was possible DoJ would require divestitures in some regions.      (Reporting by Kshitiz Goliya in Bengaluru; Editing by Dan Grebler)",2016-02-16,HUM,"Mon Feb 15, 2016 | 10:38pm EST",Aetna gets Florida insurance regulator's approval for Humana deal,http://www.reuters.com//article/humana-ma-aetna-idUSL3N15V05D?type=companyNews
131,"  STOCKHOLM, March 10 Swedish care provider Humana intends to float its shares in Stockholm, giving it a market capitalisation of up to 3.3 billion Swedish crowns ($391 million), it said on Thursday.The listing, pencilled in for Mar. 22, is set to become the second on the main list of the Stockholm bourse this year after a bumper 2015 with 18 IPOs. But volatile equity markets have meant a tentative start of 2016 for new listings.At this point last year, two companies had already been listed in Stockholm and two more announced IPO plans.Humana, majority-owned by private equity fund Argan Capital, said its shares would cost 54 to 62 crowns apiece, giving it a market capitalisation of 2.9 to 3.3 billion crowns. As much as 16.4 million shares will be sold in the offering if an over-allotment option is fully exercised, Humana said, adding it would raise around 450 million crowns in newly issued shares. Six institutional investors, among them Handelsbanken Fonder and Swedbank Robur, have committed to buy around half of the shares in the offering.The listing of Humana follows that of peer Attendo  whose shares have outperformed the wider Stockholm market by some 45 percentage points, including a 40 percent rise on its first day of trading in November. Banks Carnegie and SEB are leading the offering as global coordinators.($1 = 8.4312 Swedish crowns)   (Reporting by Sven Nordenstam; editing by Alistair Scrutton)",2016-03-10,HUM,"Thu Mar 10, 2016 | 10:02am EST",Swedish care provider Humana plans IPO at market cap up to 3.3 bln SEK,http://www.reuters.com//article/humana-ipo-idUSL5N16I4VR?type=companyNews
132,"  STOCKHOLM, March 22 Swedish care provider Humana  priced its initial public offering (IPO) at the top end of an indicative range, giving it a market value of 3.3 billion crowns ($401 million) ahead of its market debut on Tuesday, it said in a statement.The price was set at 62 crowns per share, compared with an indicative range of 54-62 crowns, said the company, which had sales of 5.6 billion crowns last year.Humana's IPO is the second on the main list of the Stockholm bourse this year and comes after last week's debut of electrical installation firm Garo. Carnegie and SEB led the offering of Humana, whose largest shareholder is private equity fund Argan Capital. The value of shares sold in the offering will be 887 million crowns if an over-allotment option is exercised in full, Humana said. ($1 = 8.2232 Swedish crowns)   (Reporting by Sven Nordenstam; Editing by Mark Potter)",2016-03-22,HUM,"Tue Mar 22, 2016 | 3:19am EDT",Swedish care provider Humana valued at $400 mln in IPO,http://www.reuters.com//article/humana-ipo-idUSFWN16U05R?type=companyNews
133,"   By Caroline Humer | NEW YORK, April 19  NEW YORK, April 19 UnitedHealth Group Inc's  decision to exit most of its Obamacare health insurance exchanges next year means rivals will need to raise prices further to prop up an unprofitable business, healthcare analysts and policy experts said on Tuesday.The largest U.S. health insurer's move would likely reduce consumer choices, particularly in states where UnitedHealth has been one of only a handful of players to offer insurance under President Barack Obama's healthcare law, they said.Large pullbacks by providers like Anthem Inc and Aetna Inc are unlikely as they each await approval from the administration for proposed merger deals with smaller rivals, some analysts said.Spokespeople for Aetna and Anthem declined to comment on Tuesday.UnitedHealth is one of the biggest sellers of Obamacare plans, offering them in 34 states in 2016. The company warned in November that it was losing too much money on the business due to low enrollment and high service costs. On Tuesday, it said it would exit all but a handful of those markets.Many of the estimated 650,000 UnitedHealth plan members at the end of 2016 would need to find another insurer.""You will see significant rate increases for 2017 as the (health) plans try to figure out what is a premium at which (they) can make money,"" said Caroline Pearson, senior vice president at research firm Avalere Health. The government provides income-based tax credits to most exchange users, which would help soften the blow from any higher premiums, she said.""In terms of viability of the exchanges, I don't think that this is going to affect that in the long term,"" said Yevgeniy Feyman, deputy director of health policy at the Manhattan Institute for Policy Research.Even if other insurers decided to leave, he said, he could not envision the exchanges being so unprofitable that they ceased to work.A recent Kaiser Family Foundation study found UnitedHealth's departure would leave only one insurer in 29 percent of the 1,855 counties where it offered health plans. The report found that if United had not participated in the exchanges in 2016, the national weighted average benchmark ""silver"" plan would have been about 1 percent higher in 2016. Republican lawmakers have repeatedly sought to repeal the Affordable Care Act, also known as Obamacare, which provides tax credits to help uninsured individuals buy medical coverage. They have said it creates unwarranted government intervention in personal healthcare and have warned that insurers would be left to cover sicker and older individuals.TOUGH BUSINESS U.S. health insurers including Aetna and Anthem have also lost money on the exchanges, but have not said they would exit. The Obama administration estimates more than 12 million people signed up for private insurance on the exchanges for 2016.Insurers are in the midst of submitting proposed premium rates for 2017 ahead of mid-May deadlines set by state exchanges and insurance regulators. Aetna Chief Executive Officer Mark Bertolini has questioned whether the Obamacare business was sustainable, but said he was working with the government to improve it. Anthem CEO Joseph Swedish has said that the company was committed to the exchanges.""I would still be surprised if other major insurers followed United's lead. United was in some sense in a category all its own,"" Kaiser Family Foundation Senior Vice President Larry Levitt said.Health plans sold to individual members represented a small part of UnitedHealth's revenue compared to large-scale contracts with employers, while Aetna and Anthem both had substantial business serving individuals.Aetna and Anthem are undergoing a U.S. Department of Justice review of what would be an historic consolidation in the health insurance industry. Aetna has proposed buying rival Humana Inc , while Anthem has agreed to buy Cigna Corp.(Reporting by Caroline Humer; Editing by Michele Gershberg and Richard Chang)",2016-04-19,HUM,"Tue Apr 19, 2016 | 6:30pm EDT",UnitedHealth's Obamacare exit adds pricing pressure on rivals,http://www.reuters.com//article/usa-healthcare-insurers-idUSL2N17M176?type=companyNews
134,  April 21 Humana Inc : * Sets quarterly cash dividend of $0.29per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ,2016-04-21,HUM,"Thu Apr 21, 2016 | 5:24pm EDT",BRIEF-Humana sets quarterly cash dividend of $0.29/share,http://www.reuters.com//article/idUSFWN17O0TV?type=companyNews
135,"   By Amrutha Penumudi  Aetna Inc (AET.N) said more customers opted for its Obamacare plans in the first quarter than it had expected, but added that the program needed to be more flexible to become sustainable.The health insurer hopes that the next government would allow companies to tailor Obamacare individual plans every year, just like it does with Medicare and Medicaid, Chief Executive Mark Bertolini said.Many insurers have lost money on the healthcare exchanges, which were set up under the Affordable Care Act, because total enrollment has fallen sharply, while some patient costs have been higher than expected.""We have not been able to touch this product because of the politics, but if we can get to that point, we believe, we are in a very good place to make this a sustainable program,"" he said on a call with analysts. Aetna said it had ended the quarter with 1.2 million individual members, which exceeded their previous membership estimates. Anthem Inc (ANTM.N), another big player in the industry, said on Wednesday it planned to stick to the business and was planning to grow in that market.However, UnitedHealth Group Inc (UNH.N), the biggest U.S. health insurer, confirmed last week that it was exiting the business in 2017.Aetna, which is in the process of buying smaller rival Humana Inc (HUM.N), reported first-quarter operating earnings that topped analysts' estimates.  The company said it was on track to close the Humana acquisition by the second half of the year and that it had obtained about two-thirds of the necessary state approvals required to close the deal.Aetna's medical benefit ratio, which compares the amount spent on medical claims with income from premiums, deteriorated to 80.5 percent from 79.1 percent a year ago.  The company's operating earnings of $2.30 per share was above the average analyst estimate of $2.23, according to Thomson Reuters I/B/E/S.Total revenue rose 4 percent to $15.69 billion, beating estimates of $15.45 billion.Aetna shares were up 1.5 percent at $115.52 in morning trading on the New York Stock Exchange. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel and Anil D'Silva)",2016-04-28,HUM,"Thu Apr 28, 2016 | 11:10am EDT",UPDATE 2-Aetna adds more individual Obamacare customers than projected,http://www.reuters.com//article/aetna-results-idUSL3N17V42C?type=companyNews
136,"  U.S. health insurer Humana Inc (HUM.N), which plans to be bought by larger Aetna Inc (AET.N), is considering ending the sale of Obamacare individual plans in some states in 2017 to stem losses there.Humana's individual business, which sells plans under President Barack Obama's Affordable Care Act, has been a drag on results, and the company still expects to lose money this year. Humana sells plans in 15 states.The company said on Wednesday that first-quarter earnings fell 46 percent due to higher costs in individual plans, including Obamacare, and its direct-to-customer Medicare Advantage plans.UnitedHealth Group Inc (UNH.N) said last month it was losing money and would largely exit the 34 states where it sells plans. Aetna said it is reviewing 2017 exchange participation state by state and that changes are needed to stabilize the exchanges.More than 12 million people have signed up for health insurance on the exchanges, but insurers say they are enrolling only when they need to use services. Because the market is smaller than foreseen, there is not a big enough pool of healthy users to cover the costs, they say. Humana said it is in the process of finalizing the sort of insurance plans it will offer in the business next year, but is considering a number of changes, including exiting certain states or products. It also said it may raise premium prices.Humana said there is higher use of medical services and prescriptions among 2015 members who renewed 2016 plans versus those who canceled them. New members in Obamacare plans sold outside the exchanges also had higher use than those who renewed, Humana said.In late 2015 the company set aside $176 million in reserves to cover losses on the individual business. This quarter, it earned money on the operation but increased reserves by that amount to cover additional anticipated losses, it said. Humana said it had 875,700 individual members as of March 31, a decline of 150,000 from a year earlier. Net income fell to $234 million, or $1.56 per share, in the first quarter, from $430 million, or $2.82 per share, a year earlier. It earned $1.86 per share on an adjusted basis and revenue was $13.80 billion versus $13.83 billion. Analysts expected profit of $1.81 per share on revenue of $13.76 billion, according to Thomson Reuters I/B/E/S.Shares fell 0.5 percent to $176.01. (Reporting by Amrutha Penumudi in Bengaluru and Caroline Humer in New York; Editing by Savio D'Souza and Jeffrey Benkoe)",2016-05-04,HUM,"Wed May 4, 2016 | 9:36am EDT",Humana may exit Obamacare individual plans in some states,http://www.reuters.com//article/us-humana-results-idUSKCN0XV1BH?type=companyNews
137,"  May 4 Humana Inc* Humana reports first quarter 2016 financial results; reaffirms 2016 financial guidance* Q1 adjusted earnings per share $1.86* Q1 earnings per share $1.56* Q1 earnings per share view $1.81 -- Thomson Reuters I/B/E/S* Sees q2 2016 adjusted earnings per share at least $2.15 * Fy2016 earnings per share view $8.86, revenue view $54.56 billion -- Thomson Reuters I/B/E/S* Humana Inc says consolidated revenues (including investment income) for 1q 2016 were $13.80 billion, a decrease of $33 million* Humana reaffirmed adjusted EPS for year ending december 31, 2016 * 1Q 2016 consolidated benefit ratio of 84.8 percent increased by 170 basis points from 83.1 percent for the prior year's quarter* Humana is in process of finalizing plans for its ACA-compliant individual commercial medical market offerings in 2017 * Q2 earnings per share view $2.26 -- Thomson Reuters I/B/E/S* Individual medicare advantage membership was 2,807,200 as of march 31, 2016, up 5 percent, from 2,685,900 at March 31, 2015* Group medicare advantage membership was 349,200 as of march 31, 2016, a decrease of 121,700, or 26 percent, from 470,900 at march 31, 2015* Q1 revenue view $13.76 billion -- Thomson Reuters I/B/E/S* Humana inc says continue to anticipate closing pending transaction with Aetna in second half of 2016  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-04,HUM,"Wed May 4, 2016 | 8:00am EDT",BRIEF-Humana Q1 earnings per share $1.56,http://www.reuters.com//article/idUSASC08MN1?type=companyNews
138,  May 10 Humana Inc* Humana invests in livongo to transform diabetes management  * Humana's strategic investment completes livongo's $49.5 million series C financing round  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-10,HUM,"Tue May 10, 2016 | 7:51am EDT",BRIEF-Humana invests in Livongo to transform diabetes management,http://www.reuters.com//article/idUSFWN1870PH?type=companyNews
139,"  May 12 Extendicare Inc* Qtrly revenue of $262.4 million, up $60.2 million  * Qtrly  affo from continuing operations $0.139 per basic share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-05-12,HUM,"Thu May 12, 2016 | 5:23pm EDT",BRIEF-Extendicare qtrly revenue of $262.4 mln,http://www.reuters.com//article/idUSFWN18916B?type=companyNews
140,"  NEW YORK May 25 A tie-up of Aetna Inc  and Humana Inc would be anti-competitive in Missouri for several types of insurance, including individual Medicare Advantage plans where the combined company would have more than a 50 percent market share, the Missouri Department of Insurance said.The department said in an order, dated May 24 and posted on its website, that if the proposed acquisition of Humana by Aetna were to go forward, the companies would need to stop selling individual insurance, small group and certain Medicare Advantage plans in its state.The combination would exacerbate a consolidation trend that has contributed to higher insurance prices, the department said. Aetna announced plans last year to buy smaller rival Humana.The deal is being reviewed by the U.S. Department of Justice as well as state insurance regulators and antitrust authorities.   Investors have been uncertain that the purchase will close, in part because anti-trust regulators are also reviewing competitor Anthem Inc's plan to buy Cigna Corp.. ""This order does not impede the DOJ approval process. We are disappointed with the Missouri order but expect to have a constructive dialogue with the state to address their concerns,"" Aetna spokesman T.J. Crawford said in a statement. According to the order, Aetna can submit a plan to the insurance regulator to address the impact of the acquisition.(Reporting by Caroline Humer; Editing by Alan Crosby)",2016-05-25,HUM,"Wed May 25, 2016 | 12:41pm EDT",Aetna-Humana tie-up is anti-competitive in Missouri - state regulator,http://www.reuters.com//article/humana-ma-aetna-idUSL2N18M14X?type=companyNews
141,"   By Caroline Humer  A tie-up of Aetna Inc and Humana Inc would be anti-competitive in Missouri for several types of insurance, including individual Medicare Advantage plans where the combined company would have more than a 50 percent market share, the Missouri Department of Insurance said.The department said in an order, dated May 24 and posted on its website, that if the proposed acquisition of Humana by Aetna were to go forward, the companies would need to stop selling individual insurance, small group and certain Medicare Advantage plans in its state. Missouri is the first state regulator to release findings against the $33 billion deal announced last year.The deal is being reviewed by the U.S. Department of Justice, as well as state regulators and antitrust authorities, who are also reviewing competitor Anthem Inc's plan to buy Cigna Corp.. Because the deals will reduce major health insurers to three from five, investors are uncertain they will close.Missouri's findings should not influence the Justice Department review, said Dan Mendelson, chief executive of Avalere Health, a Washington D.C. healthcare consulting firm.But, he said, a similar ruling from a large state such as California could. Other states are also likely to go public with issues they want Aetna and Humana to address through asset sales or other concessions, Mendelson said.The American Medical Association, which has expressed reservations about the potential anti-competitive impact of both deals, applauded the Missouri move.""The Missouri order strongly validates concerns that AMA has expressed to Missouri regulators, as well as the U.S. Department of Justice, and officials in other states impacted by the proposed health insurer mergers,"" AMA President Steven Stack said in a statement.  California's insurance commissioner has held a hearing on the merger's impact but has not commented. According to the order, Aetna can submit a plan to the insurance regulator to address the impact of the acquisition.""This order does not impede the DOJ approval process. We are disappointed with the Missouri order but expect to have a constructive dialogue with the state to address their concerns,"" Aetna spokesman T.J. Crawford said.Aetna has filed for regulatory approval in the 20 states where Humana is domiciled and of those, 15 have approved the deal. In other states where the companies sell insurance, including Missouri, state regulators can choose to review the deal's impact. Federal regulators are also examining local insurance competition. The Missouri insurance regulator said that Aetna held a 36.88 percent share in the comprehensive individual insurance market in 2015 while Humana had 1.93 percent. In individual Medicare Advantage, Aetna and Humana have more than 70 percent market share in 33 county markets, the department said. Aetna has the largest market share at 33 percent.Aetna shares rose 1.8 percent to close at $113.69, while Humana shares rose 2.3 percent to $174.70 in New York Stock Exchange trading. (Reporting by Caroline Humer and Bill Berkrot; Editing by Alan Crosby)",2016-05-25,HUM,"Wed May 25, 2016 | 6:11pm EDT",Aetna-Humana tie-up is anti-competitive in Missouri-state regulator,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0YG2GI?type=companyNews
142,"   By Caroline Humer  A tie-up of Aetna Inc and Humana Inc would be anti-competitive in Missouri for several types of insurance, including individual Medicare Advantage plans where the combined company would have more than a 50 percent market share, the Missouri Department of Insurance said.The department said in an order, dated May 24 and posted on its website, that if the proposed acquisition of Humana by Aetna were to go forward, the companies would need to stop selling individual insurance, small group and certain Medicare Advantage plans in its state. Missouri is the first state regulator to release findings against the $33 billion deal announced last year.The deal is being reviewed by the U.S. Department of Justice, as well as state regulators and antitrust authorities, who are also reviewing competitor Anthem Inc's plan to buy Cigna Corp.. Because the deals will reduce major health insurers to three from five, investors are uncertain they will close.Missouri's findings should not influence the Justice Department review, said Dan Mendelson, chief executive of Avalere Health, a Washington D.C. healthcare consulting firm.But, he said, a similar ruling from a large state such as California could. Other states are also likely to go public with issues they want Aetna and Humana to address through asset sales or other concessions, Mendelson said.The American Medical Association, which has expressed reservations about the potential anti-competitive impact of both deals, applauded the Missouri move.""The Missouri order strongly validates concerns that AMA has expressed to Missouri regulators, as well as the U.S. Department of Justice, and officials in other states impacted by the proposed health insurer mergers,"" AMA President Steven Stack said in a statement.  California's insurance commissioner has held a hearing on the merger's impact but has not commented. According to the order, Aetna can submit a plan to the insurance regulator to address the impact of the acquisition.""This order does not impede the DOJ approval process. We are disappointed with the Missouri order but expect to have a constructive dialogue with the state to address their concerns,"" Aetna spokesman T.J. Crawford said.Aetna has filed for regulatory approval in the 20 states where Humana is domiciled and of those, 15 have approved the deal. In other states where the companies sell insurance, including Missouri, state regulators can choose to review the deal's impact. Federal regulators are also examining local insurance competition. The Missouri insurance regulator said that Aetna held a 36.88 percent share in the comprehensive individual insurance market in 2015 while Humana had 1.93 percent. In individual Medicare Advantage, Aetna and Humana have more than 70 percent market share in 33 county markets, the department said. Aetna has the largest market share at 33 percent.Aetna shares rose 1.8 percent to close at $113.69, while Humana shares rose 2.3 percent to $174.70 in New York Stock Exchange trading. (Reporting by Caroline Humer and Bill Berkrot; Editing by Alan Crosby)",2016-05-25,HUM,"Wed May 25, 2016 | 6:11pm EDT",UPDATE 2-Aetna-Humana tie-up is anti-competitive in Missouri-state regulator,http://www.reuters.com//article/humana-ma-aetna-idUSL2N18M1BT?type=companyNews
143,  June 7 Aetna Inc* Reaffirm full-year 2016 operating earnings per share projection of $7.90 to $8.10 * Continue to expect to complete proposed acquisition of humana inc. In second half of 2016  * Fy2016 earnings per share view $8.03 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780),2016-06-07,HUM,"Tue Jun 7, 2016 | 5:17pm EDT",BRIEF-Aetna says continues to expect to complete Humana deal in 2nd half of 2016,http://www.reuters.com//article/idUSFWN18Z0JF?type=companyNews
144,"  NEW YORK/WASHINGTON The California Department of Managed Health Care approved Aetna Inc's (AET.N) acquisition of Humana Inc (HUM.N) with conditions including the insurer's commitment to keeping premium increases at a minimum in the small group HMO business and to making about $50 million in community investments.The managed healthcare department's director, Shelley Rouillard, said in a statement that the actions will help control healthcare costs in the state. Aetna has also committed to keeping key functions and operations in the state.Aetna spokesman T.J. Crawford said that the company has agreed to the conditions outlined by the regulator and that it continues to expect the transaction to close in the second half of 2016. In addition to state regulators, national antitrust regulators are also reviewing the proposed deal which was originally announced in July 2015. Aetna said it would invest over the next three years $6 million in consumer assistance programs for seniors and people with disabilities, $3 million for dental services in low-income or underserved communities, $23 million for a service center in Fresno, $1 million to expand telehealth services, and $16.5 million to support pay for performance medical programs. ""While California is not a critical State for the deal given (Humana's) small presence, it is another indication that the merger anti-trust review is on track with only four states remaining for approval,"" Leerink analyst Ana Gupte said in a research note.Aetna shares were up 1.7 percent at $123.10 and Humana shares were up 2 percent at $190.91 on Monday afternoon, both lifted by the news.  (Reporting by Caroline Humer in New York and Diane Bartz in Washington D.C.; Editing by Chris Reese and Matthew Lewis)",2016-06-20,HUM,"Mon Jun 20, 2016 | 1:42pm EDT",California regulator approves Aetna-Humana deal with conditions,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0Z61ZG?type=companyNews
145,"  NEW YORK/WASHINGTON The California Department of Managed Health Care approved Aetna Inc's (AET.N) acquisition of Humana Inc (HUM.N) with conditions including the insurer's commitment to keeping premium increases at a minimum in the small group HMO business and to making about $50 million in community investments.The managed healthcare department's director, Shelley Rouillard, said in a statement that the actions will help control healthcare costs in the state. Aetna has also committed to keeping key functions and operations in the state.Aetna spokesman T.J. Crawford said that the company has agreed to the conditions outlined by the regulator and that it continues to expect the transaction to close in the second half of 2016. In addition to state regulators, national antitrust regulators are also reviewing the proposed deal which was originally announced in July 2015. Aetna said it would invest over the next three years $6 million in consumer assistance programs for seniors and people with disabilities, $3 million for dental services in low-income or underserved communities, $23 million for a service center in Fresno, $1 million to expand telehealth services, and $16.5 million to support pay for performance medical programs. ""While California is not a critical State for the deal given (Humana's) small presence, it is another indication that the merger anti-trust review is on track with only four states remaining for approval,"" Leerink analyst Ana Gupte said in a research note.Aetna shares were up 1.7 percent at $123.10 and Humana shares were up 2 percent at $190.91 on Monday afternoon, both lifted by the news.  (Reporting by Caroline Humer in New York and Diane Bartz in Washington D.C.; Editing by Chris Reese and Matthew Lewis)",2016-06-20,HUM,"Mon Jun 20, 2016 | 1:42pm EDT",UPDATE 1-California regulator approves Aetna-Humana deal with conditions,http://www.reuters.com//article/humana-ma-aetna-idUSL1N19C138?type=companyNews
146,"  NEW YORK, June 20 The California Department of Managed Health Care approved Aetna Inc's acquisition of Humana Inc with conditions that it says will control health care costs in the state, such as minimum premium rate increases in the small group HMO business and about $50 million in community investments. The managed health care department's director, Shelley Rouillard, has regulatory oversight for the deal in California. She said in a statement that Aetna has also committed to keeping key functions and operations in the state.   (Reporting by Caroline Humer and Diane Bartz; Editing by Chris Reese)  ",2016-06-20,HUM,"Mon Jun 20, 2016 | 1:02pm EDT",California regulator approves Aetna-Humana deal with conditions,http://www.reuters.com//article/humana-ma-aetna-idUSL1N19C11A?type=companyNews
147,  June 23 Fitch: * Fitch maintains Humana's ratings on positive watch  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-06-23,HUM,"Thu Jun 23, 2016 | 6:05pm EDT",BRIEF-Fitch maintains Humana's ratings on positive watch,http://www.reuters.com//article/idUSFWN19F0MA?type=companyNews
148,"  NEW YORK California's insurance commissioner on Thursday urged national antitrust regulators to block health insurer Aetna Inc's proposed $34 billion acquisition of Humana Inc.David Jones, whose state Department of Insurance does not have authority to block the deal, said the acquisition would be anti-competitive in California and nationwide and contribute to higher prices for insurance.Jones' comments came just days after California's other  insurance regulator said it had approved the Aetna-Humana deal with conditions, including that Aetna keep down premium increases and invest $50 million in communities.""We received approval earlier this week from the California Department of Managed Health Care, the only regulatory agency in the state with official oversight of our acquisition,"" Aetna spokesman T.J. Crawford said. Jones a week ago also called for the U.S. Justice Department to stand against Anthem Inc's proposed acquisition of  Cigna Corp. He said that one of his concerns is the shrinking number of commercial insurers available to enter new markets. ""If Humana disappears into this merger, it's one less company that has the realistic possibility of entering the market,"" Jones said. He said the agreement reached between Aetna and the California Department of Managed Health Care did not address antitrust concerns detailed in a 24-page letter his insurance department sent to the U.S. Department of Justice. Aetna shares were up 0.3 percent at $120.49 and those of Humana was off 0.1 percent at $187.41 in mid-afternoon trading having fallen slightly after Jones' comments. (Reporting by Caroline Humer; Editing by Cynthia Osterman and Steve Orlofsky)",2016-06-23,HUM,"Thu Jun 23, 2016 | 2:57pm EDT",California insurance chief urges U.S. to block Aetna-Humana deal,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0Z920Y?type=companyNews
149,"  June 24 Aetna Inc : * Co, Humana delivered written notice to each other to extend ""end date"" with respect to merger from June 30, 2016 to Dec 31, 2016 - sec filing  Source text: 1.usa.gov/28SE5YM  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ",2016-06-24,HUM,"Fri Jun 24, 2016 | 4:53pm EDT","BRIEF-Aetna, Humana delivered written notice to each other to extend ""end date"" with respect to merger from June 30-Dec 31",http://www.reuters.com//article/idUSFWN19G0H4?type=companyNews
150,"  NEW YORK The Illinois Department of Insurance has approved Aetna Inc's (AET.N) proposed $34 billion acquisition of Humana Inc (HUM.N) provided it is approved by the U.S. Department of Justice, according to an order dated June 23 posted on the department's website. Aetna announced the deal last summer and it is under review by the Justice Department, which is looking at competition concerns around its combined Medicare Advantage business for older people and the disabled.In Illinois, Medicare Advantage plans, in which private insurers manage a customer's health benefits for the government, have enough competition because members can always turn to the traditional Medicare program if they are not happy, the state Department of Insurance said in its June 23 order.""We now have change of control approvals in 17 of the 20 states required and continue to cooperate with the Department of Justice on its review,"" Aetna spokesman T.J. Crawford said.  The company continues to expect the transaction to close in the second half of 2016, he said. (This version of the story corrects first sentence to show that Illinois approval is conditional upon U.S. Justice Department approval, instead of that Illinois approval has no conditions)  (Reporting by Caroline Humer; Editing by Tom Brown)",2016-06-27,HUM,"Mon Jun 27, 2016 | 1:13pm EDT",Illinois insurance regulator approves Aetna purchase of Humana,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKCN0ZD26P?type=companyNews
151,"  NEW YORK The Illinois Department of Insurance has approved Aetna Inc's (AET.N) proposed $34 billion acquisition of Humana Inc (HUM.N) provided it is approved by the U.S. Department of Justice, according to an order dated June 23 posted on the department's website. Aetna announced the deal last summer and it is under review by the Justice Department, which is looking at competition concerns around its combined Medicare Advantage business for older people and the disabled.In Illinois, Medicare Advantage plans, in which private insurers manage a customer's health benefits for the government, have enough competition because members can always turn to the traditional Medicare program if they are not happy, the state Department of Insurance said in its June 23 order.""We now have change of control approvals in 17 of the 20 states required and continue to cooperate with the Department of Justice on its review,"" Aetna spokesman T.J. Crawford said.  The company continues to expect the transaction to close in the second half of 2016, he said. (This version of the story corrects first sentence to show that Illinois approval is conditional upon U.S. Justice Department approval, instead of that Illinois approval has no conditions)  (Reporting by Caroline Humer; Editing by Tom Brown)",2016-06-27,HUM,"Mon Jun 27, 2016 | 1:13pm EDT",CORRECTED-Illinois insurance regulator approves Aetna purchase of Humana,http://www.reuters.com//article/humana-ma-aetna-idUSL1N19J0ZQ?type=companyNews
152,"   By Carl O'Donnell and Caroline Humer  Aetna Inc has launched an auction to sell a portfolio of Medicare Advantage assets as it seeks antitrust approval for its $37 billion acquisition of U.S. health insurance peer Humana Inc, according to people familiar with the matter.The company is hoping the move will help ease antitrust concerns. Merging Aetna's and Humana's Medicare Advantage businesses would make the combined company the largest U.S. manager of the healthcare insurance for seniors and the disabled.Aetna has sent out pitchbooks to potential buyers and will begin collecting bids as soon as next week, the people said on Friday. The assets will likely be valued around the $1 billion range, the people added. The sale process may take several months, and there is no certainty that it will result in Aetna securing all the necessary regulatory approvals for its deal with Humana, the people said. The sources asked not to be identified because the sale process is confidential. Aetna declined to comment, while Humana did not respond to a request for comment.In addition to the Aetna-Humana deal, the U.S. Department of Justice has been scrutinizing Anthem Inc's acquisition of Cigna Corp, announced less than a month after Aetna's deal last July. The Department of Justice has been looking at the two deals closely, in part because the move from five national insurers to three has raised concerns among hospitals, doctors and consumers that it will result in higher prices.Wall Street has been less concerned about Aetna making it past antitrust regulators. On Thursday, Leerink Partners analyst Ana Gupte said in a research note that she believed there was an 80 percent chance of Aetna closing on its acquisition of Humana, and noted that it was in dialogue with both the Department of Justice and potential buyers for assets. She estimated that the divestments would cover about 350,000 members.",2016-07-01,HUM,"Fri Jul 1, 2016 | 5:12pm EDT",Aetna launches Medicare Advantage asset sale -sources,http://www.reuters.com//article/aetna-medicareadvantage-idUSL1N19N23W?type=companyNews
153,"   By Carl O'Donnell and Caroline Humer  Aetna Inc has launched an auction to sell a portfolio of Medicare Advantage assets as it seeks antitrust approval for its $37 billion acquisition of U.S. health insurance peer Humana Inc, according to people familiar with the matter. The company is hoping the move will help ease antitrust concerns. Merging Aetna's and Humana's Medicare Advantage businesses would make the combined company the largest U.S. manager of the healthcare insurance for seniors and the disabled.Aetna has sent out pitchbooks to potential buyers and will begin collecting bids as soon as next week, the people said on Friday. The assets will likely be valued around the $1 billion range, the people added.  The sale process may take several months, and there is no certainty that it will result in Aetna securing all the necessary regulatory approvals for its deal with Humana, the people said. The sources asked not to be identified because the sale process is confidential. Aetna declined to comment, while Humana did not respond to a request for comment.  In addition to the Aetna-Humana deal, the U.S. Department of Justice has been scrutinizing Anthem Inc's acquisition of Cigna Corp, announced less than a month after Aetna's deal last July.The Department of Justice has been looking at the two deals closely, in part because the move from five national insurers to three has raised concerns among hospitals, doctors and consumers that it will result in higher prices. Wall Street has been less concerned about Aetna making it past antitrust regulators. On Thursday, Leerink Partners analyst Ana Gupte said in a research note that she believed there was an 80 percent chance of Aetna closing on its acquisition of Humana, and noted that it was in dialogue with both the Department of Justice and potential buyers for assets. She estimated that the divestments would cover about 350,000 members. (Reporting by Carl O'Donnell and Caroline Humer in New York; Editing by Marguerita Choy)",2016-07-01,HUM,"Fri Jul 1, 2016 | 5:09pm EDT",Aetna launches Medicare Advantage asset sale: sources,http://www.reuters.com//article/us-aetna-medicareadvantage-idUSKCN0ZH5Z6?type=companyNews
154,"   By Carl O'Donnell and Caroline Humer  Aetna Inc has launched an auction to sell a portfolio of Medicare Advantage assets as it seeks antitrust approval for its $37 billion acquisition of U.S. health insurance peer Humana Inc, according to people familiar with the matter. The company is hoping the move will help ease antitrust concerns. Merging Aetna's and Humana's Medicare Advantage businesses would make the combined company the largest U.S. manager of the healthcare insurance for seniors and the disabled.Aetna has sent out pitchbooks to potential buyers and will begin collecting bids as soon as next week, the people said on Friday. The assets will likely be valued around the $1 billion range, the people added.  The sale process may take several months, and there is no certainty that it will result in Aetna securing all the necessary regulatory approvals for its deal with Humana, the people said. The sources asked not to be identified because the sale process is confidential. Aetna declined to comment, while Humana did not respond to a request for comment.  In addition to the Aetna-Humana deal, the U.S. Department of Justice has been scrutinizing Anthem Inc's acquisition of Cigna Corp, announced less than a month after Aetna's deal last July.The Department of Justice has been looking at the two deals closely, in part because the move from five national insurers to three has raised concerns among hospitals, doctors and consumers that it will result in higher prices. Wall Street has been less concerned about Aetna making it past antitrust regulators. On Thursday, Leerink Partners analyst Ana Gupte said in a research note that she believed there was an 80 percent chance of Aetna closing on its acquisition of Humana, and noted that it was in dialogue with both the Department of Justice and potential buyers for assets. She estimated that the divestments would cover about 350,000 members. (Reporting by Carl O'Donnell and Caroline Humer in New York; Editing by Marguerita Choy)",2016-07-01,HUM,"Fri Jul 1, 2016 | 5:09pm EDT",Aetna launches Medicare Advantage asset sale -sources,http://www.reuters.com//article/aetna-medicareadvantage-idUSL1N19N1WP?type=companyNews
155,"  (Adds Aetna, Humana, Kyrgyzaltyn, London Stock Exchange, Liberty House, British Land)July 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** The U.S. Department of Justice has significant concerns about Aetna Inc's proposed acquisition of health insurer Humana Inc, a source familiar with the situation said, and shares of Humana fell more than 11 percent.** Kyrgyzstan's state gold company Kyrgyzaltyn has voted against a planned $1.1 billion takeover of Thompson Creek Metals TCM.TO by Canadian miner Centerra Gold.**  London Stock Exchange Group said that U.S. and Russian authorities had approved its $27 billion merger with Deutsche Boerse, giving it the first set of regulatory clearances needed to create a European exchange giant.** Property company British Land said it had exchanged contracts to sell a Debenhams store located in London's West End shopping district to a private investor, a sign that deals were still being struck in a sector gripped with concerns around the impact of Brexit. ** Liberty House Group plans to bid for two units of Tata Steel's British business - specialty steels and pipeline tubes - which operate independently of its Port Talbot plant and related assets that were put up for sale earlier this year, an industry source told Reuters.** France's Danone said it would double the size of its U.S. business by buying organic foods producer WhiteWave Foods Co in a deal worth $12.5 billion, including some $2.1 billion of debt and ""other"" liabilities.** Canadian oil producer Paramount Resources Ltd  agreed to sell some of its Deep Basin oil and gas properties in Alberta to Seven Generations Energy Ltd for about C$1.9 billion ($1.47 billion). ** Security software company Avast Software said it would buy Dutch rival AVG Technologies for $1.3 billion in cash to expand in emerging markets.** Bankrupt renewable power plant developer SunEdison Inc  has asked a U.S. bankruptcy court judge to approve the sale of its stake in a California solar project to an affiliate of hedge fund D.E. Shaw. ** British waste manager Shanks Group Plc said it was in talks to buy Dutch recycler van Gansewinkel Groep BV (VGG) for about 440 million euros ($487.4 million) in cash and stock, on a debt-free, cash-free basis.** BM&FBovespa SA, Latin America's largest financial exchange operator, has paid 44 million reais ($13.2 million) for a 10 percent stake in the Colombian stock exchange, the company said in a securities filing on Wednesday.** General Electric and German wind turbine maker Senvion are preparing bids for French wind power group Adwen, which is jointly owned by Spain's Gamesa and France's Areva, people familiar with the matter said.** China's HNA Group and a firm backed by Hong Kong tycoon Li Ka-shing are among the suitors advancing to a second round of bidding for CIT Group's aircraft leasing assets valued at between $3 billion and $4 billion, people familiar with the situation said.** China's HNA Group said that the 63.6 percent of the voting rights and shares in Gategroup it now owned are sufficient for its takeover bid for the Swiss airline catering firm to succeed, waiving the minimum acceptance level it had set previously.(Compiled by Arunima Banerjee and Amrutha Penumudi in Bengaluru)",2016-07-07,HUM,"Thu Jul 7, 2016 | 4:03pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N19T4FX?type=companyNews
156,"  July 7 Shares in health insurer Humana  fell nearly 10 percent following a report that antitrust regulators were due to discuss ""significant concerns"" over its proposed buyout by rival Aetna IncAntitrust trade publication MLex said officials from both insurers were due to meet with U.S. Department of Justice reviewers on Friday about their proposed merger. Justice Department investigators are mainly concerned whether the deal will limit consumer choices for Medicare Advantage health plans for the elderly.  Reuters previously reported that Aetna has begun a process to divest about $1 billion of Medicare Advantage assets to address antitrust concerns.   (Reporting by Carl O'Donnell; Editing by James Dalgleish) ",2016-07-07,HUM,"Thu Jul 7, 2016 | 1:28pm EDT",Humana shares drop on report of DOJ meeting over Aetna deal,http://www.reuters.com//article/humana-ma-aetna-idUSL1N19T1JE?type=companyNews
157,"   By Mark Miller | CHICAGO  CHICAGO Medicare enrollees are moving in greater numbers than ever to the programs managed care option as a way to save money. But the tradeoff is much less ability to use their preferred doctors and hospitals.Seniors can choose between traditional fee-for-service Medicare - which is accepted by most healthcare providers - or a Medicare Advantage plan. The latter encompasses health maintenance organizations (HMOs) or preferred provider organizations (PPOs), which control costs by creating healthcare provider networks that enrollees must use.In theory, prospective Advantage enrollees can review lists of in-network providers before opting into a plan. But a new study by the Kaiser Family Foundation (KFF) finds that provider data often is very difficult to review, can be out of date and frequently contain inaccurate information.KFFs review also found shortcomings in the quality of providers in some Medicare Advantage provider networks. One out of every five plans did not include a regional academic medical center - institutions which usually offer the highest quality care and top specialists. And only 40 percent of Advantage provider networks included top-quality cancer centers, as indicated by membership in the National Cancer Institutes network.NCI-designated cancer centers offer cutting-edge treatments and tend to have greater access to clinical trials. They are especially important for patients with rare and advanced cancers, or other complicating conditions, said Gretchen Jacobson, KFFs associate director of the program on Medicare policy and co-author of the study. The upshot: Medicare Advantage may be just fine if you are  healthy, but problems may crop up if your healthcare needs become more complex and you have very specific healthcare provider preferences. This year, 31 percent of Medicare enrollees are in Advantage plans, up from 11 percent in 2010. That number is expected to hit 41 percent by 2026, according to a forecast by the Congressional Budget Office.When Medicare enrollees join Medicare Advantage plans, their Part B premiums continue to be paid to Medicare, which then makes a monthly capitated payment to the Advantage plan. The payment is based on the plans estimated cost per enrollee, the plans quality rating and the health status of the enrollee.The largest providers are UnitedHealthcare, Humana Inc and Blue Cross Blue Shield. One often hears critics claim that healthcare providers are bailing out of traditional Medicare in large numbers - but that is not actually the case. Last year, 14 percent of Medicare enrollees who were seeking a new primary care doctor reported major problems in finding a physician who would treat them, according to survey data from the Medicare Payment Advisory Commission, an independent congressional agency. Among those seeking a new specialist, 6 percent reported major problems. In both cases, that represents 1 percent of the total Medicare population. ADVANTAGES, PITFALLS  Advantage plans often offer extra benefits, such as health club memberships, vision care and some limited dental care. Cost-sharing is often lower, and many plans provide prescription drug coverage with no extra premium. It can be very attractive to many seniors who are living on a fixed budget, Jacobson said. The trade-off is limited provider networks - and the challenges prospective enrollees face in determining who they are allowed to see for healthcare, and who is off-limits. KFF reviewed 409 Advantage plans, including 307 HMOs and 102 PPOs. Researchers found provider directories often were riddled with errors, omissions and outdated information.Theres no reason in this era of technology why this needs to be as difficult as it is, Jacobson said. People should be able to simply tell the system who their doctors are, the illnesses they have, and get a recommendation for a plan that will work for them.KFF also found that Advantage provider network quality differs significantly. For example, Los Angeles has three NCI-designated cancer centers. Most of the Advantage plans there do not include any of them, but one plan includes all three.A report last year by the U.S. Government Accountability Office found that the Centers for Medicare & Medicaid Services (CMS), which runs Medicare, needs to improve its oversight of Advantage plans to assure that provider networks are robust. The report also criticized CMS for doing too little to assess the accuracy of Advantage plan provider lists.Even when Advantage enrollees are able to confirm participation by their healthcare providers, there is no guarantee that will continue. Advantage plans are free to add or drop health providers during the course of an enrollment season.  That became an especially hot issue in 2014 when UnitedHealthcare dropped providers who covered thousands of the insurer's patients, including the prominent Yale-New Haven Hospital system.Democrats in Congress have proposed legislation that would prohibit Advantage plans from dropping providers without cause during the middle of an enrollment year.Under current rules, plans must provide 30 days notice to enrollees when providers are dropped. Enrollees who lose access to a provider can make a midyear plan change only under very limited circumstances. You can do it only if you are receiving ongoing care from a provider that is terminated, Jacobson said. Otherwise you need to wait until the next open enrollment period.The annual enrollment period for Advantage and Part D prescription drug plans are held from Oct. 15 to Dec. 7 each year. At that point, a beneficiary could switch to a different Advantage plan, or shift back to traditional Medicare. But a serious diagnosis in January would leave you hamstrung until the following year.Said Jacobson: ""It can be a roll of the dice.""(This version of the July 7 story corrects paragraph 8. An earlier version of this column said that the enrollee's Part B premium ""goes to the insurance company providing the plan"".) (Editing by Matthew Lewis)",2016-07-11,HUM,"Mon Jul 11, 2016 | 1:38pm EDT","Medicare Advantage grows, but provider choice is limited",http://www.reuters.com//article/column-miller-medicare-idUSL1N19S1DA?type=companyNews
158,"   By Caroline Humer and Carl O'Donnell | NEW YORK  NEW YORK While Wall Street is largely betting that antitrust regulators will stop Humana Inc's (HUM.N) takeover by larger rival Aetna Inc (AET.N), shares of Humana could still fall as much as 18 percent if the deal unravels, investors and analysts say.    Doubts over Aetna's purchase of Humana and over a second proposed transaction in which Anthem Inc (ANTM.N) would buy rival Cigna Inc (CI.N) have run high since both deals were announced about a year ago.Shares of Humana and Cigna have traded well below their buyout agreements. Antitrust regulators at the U.S. Department of Justice have concerns over how both deals would affect competition and prices in the healthcare market.    Of the two transactions, the Humana deal is still seen as having a higher probability of gaining approval.Equity analyst Ana Gupte at Leerink Partners has forecast a chance of less than 50 percent that the Anthem-Cigna deal will close, but expects that Aetna will receive a green light to buy Humana by the third quarter of this year.    ""The Aetna-Humana deal always seemed more realistic and likely that they can divest certain parts more easily and we still think that's the case,"" said Oliver Marti, portfolio manager at Columbus Circle Investors' Healthcare Strategies fund. CCI did not own any of the insurer shares as of April 30 according to regulatory filings.     Aetna and Humana's overlap is primarily in managing Medicare Advantage health programs for the elderly, a position Aetna hopes to strengthen through the merger. However, Aetna has outlined plans to sell some Medicare Advantage assets in the transaction where there is regional overlap, and has told the Justice Department it has several willing buyers, Reuters reported last week.    Humana shares now trade around $159, far below Aetna's buyout offer worth about $224 per share. They could fall an additional 9 percent to $145 if the Justice Department sues to block the deal, and sink as much as 15 percent to $135 if Aetna decides to immediately walk away or does not ultimately reach a settlement, according to four investors who focus on deal arbitrage.      Leerink's Gupte has also said Humana stock would trade at $140 to $150 if the Justice Department sues to block the deal, while Marti sees it falling as low as $130 if the acquisition is scrapped entirely.     The investors, who rank among the 125 largest shareholders in Humana, spoke on condition of anonymity because they are not authorized to discuss investments. They said the estimated downside represents a view shared among many investors, who expect a decision from the Justice Department sometime this month.      Another investor, Joel Emery, chief investment officer at an investment fund called Tareo Capital, said he is in the camp that still sees a possible deal between Aetna and Humana. If either that transaction or Anthem's purchase of Cigna are blocked, he expects the insurers to boost profit growth through share buybacks, and to seek smaller acquisitions. Tareo holds Cigna shares.    ""I think the sector still has the ability to consolidate,"" Emery said.        (Editing by Michele Gershberg and Matthew Lewis)",2016-07-18,HUM,"Mon Jul 18, 2016 | 7:05am EDT",Humana shares still have room to fall if Aetna buyout blocked,http://www.reuters.com//article/humana-ma-investors-idUSL1N1A1215?type=companyNews
159,"  July 21 S&P on Aetna and Humana:* Intend to resolve the creditwatch placements after we evaluate  additional details surrounding the suit and assess potential courses of  action * Aetna Inc., Humana Inc. and core subsidiaries ratings placed on creditwatch following U.S. department. Of justice announcement  Source (bit.ly/29XoZD7)   (Reporting by Parikshit Mishra)",2016-07-21,HUM,"Thu Jul 21, 2016 | 7:24pm EDT",BRIEF-S&P says Aetna and Humana placed on creditwatch following U.S. DOJ announcement,http://www.reuters.com//article/idUSFWN1A70XJ?type=companyNews
160,"  WASHINGTON Humana Government Business Inc, a unit of Humana Inc, and Health Net Federal Services LLC have been selected to provide managed care support to the U.S. Defense Department's TRICARE healthcare program, the Pentagon said on Thursday.The total potential value of Humana's contract, including all option periods, is estimated at $40.5 billion. The instant award, which comprises the nine-month base period, is valued at $67.4 million, the Pentagon said in a statement.The total potential value of Health Net's contract, including all option periods, is estimated at $17.7 billion. The instant award, which comprises the nine month base period, is valued at $49.3 million, the statement said.    (Reporting by Eric Beech)",2016-07-21,HUM,"Thu Jul 21, 2016 | 5:31pm EDT","Humana, Health Net win U.S. defense contracts: Pentagon",http://www.reuters.com//article/us-pentagon-healthcare-idUSKCN1012Y7?type=companyNews
161,"  WASHINGTON Humana Government Business Inc, a unit of Humana Inc, and Health Net Federal Services LLC have been selected to provide managed care support to the U.S. Defense Department's TRICARE healthcare program, the Pentagon said on Thursday.The total potential value of Humana's contract, including all option periods, is estimated at $40.5 billion. The instant award, which comprises the nine-month base period, is valued at $67.4 million, the Pentagon said in a statement.The total potential value of Health Net's contract, including all option periods, is estimated at $17.7 billion. The instant award, which comprises the nine month base period, is valued at $49.3 million, the statement said.    (Reporting by Eric Beech)",2016-07-21,HUM,"Thu Jul 21, 2016 | 5:31pm EDT","Humana, Health Net win U.S. defense contracts -Pentagon",http://www.reuters.com//article/pentagon-healthcare-idUSW1N1A002U?type=companyNews
162,"  July 21 Humana Inc :* Under terms of award, Humana's service area would cover approximately 6 million beneficiaries in a 30-state region * Informed by U.S. Department of Defense it has been awarded contract for Tricare East region  * Tricare contract provides five, one-year options exercisable by department of defense  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-21,HUM,"Thu Jul 21, 2016 | 5:12pm EDT",BRIEF-Humana awarded Department of Defense TRICARE East Region contract,http://www.reuters.com//article/idUSFWN1A70XC?type=companyNews
163,"  July 21 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:**  MasterCard Inc said it would buy 92.4 percent stake in London-based VocaLink Holdings Ltd for about $920 million (700 million pounds) as the world's No.2 payment network provider looks to strengthen its presence in the UK market.** Liberty Media Corp LMCA.O Chief Executive Greg Maffei made an offer to buy internet radio company Pandora Media Inc P.N in recent months, valuing the company at more than $3.4 billion, the Wall Street Journal reported on Thursday.** The chairman of SABMiller said the brewer would consider the attractiveness of a $107 billion offer by Anheuser Busch InBev after the merger had undergone the regulatory process.** The U.S. Justice Department sued to challenge two separate health insurance mergers, Anthem Inc's  purchase of Cigna Corp and Aetna Inc's  acquisition of Humana Inc.** U.S. regional lender FNB Corp said it would acquire peer Yadkin Financial Corp YDKN.N in an all-stock deal valued at about $1.4 billion, the latest sign that community bank mergers are picking up following a drought in dealmaking after the 2008 financial crisis. ** Mexican breadmaker Grupo Bimbo said it had completed the purchase of Spain's Panrico after getting approval from Spanish and Portuguese competition authorities.** Mexican glass manufacturer Vitro said it had agreed to purchase the flat glass unit of U.S. company PPG  for around $750 million, giving it a foothold in the U.S. and Canadian markets.** Japanese mining equipment maker Komatsu Ltd has agreed to buy its smaller U.S. rival Joy Global Inc for about $3.7 billion including debt, its biggest ever acquisition, to increase its clout in the mining industry. ** U.S. investor Oaktree has reduced its stake in German real estate group Alstria Office by placing 10.72 million shares, a stake of 7 percent, with institutional investors, two people familiar with the transaction said.** Australia's antitrust watchdog gave the green light to a A$9.1 billion ($6.8 billion) buyout of rail freight giant Asciano Ltd by a global consortium led by Canada's Brookfield Asset Management Inc.** Australia's Oil Search Ltd cleared the way for ExxonMobil Corp to take over InterOil Corp for $2.2 billion, opting not to raise its rival offer for its partner in a rich Papua New Guinea gas field. ** Galenica said it agreed to buy U.S. biopharma company Relypsa for $1.53 billion in cash to strengthen its Vifor Pharma unit.** Promoted Hull City have put takeover talks on hold to focus on strengthening their squad as a host of injuries has left the club with just 13 fit players for the new Premier League season.** A state tender for a company to build and operate a power plant in southern Russia attracted no bids partly because firms feared falling foul of EU sanctions should any electricity be diverted to nearby Crimea, industry sources said.** Developer China Vanke Co Ltd said it and its partners have sealed a $1.9 billion deal with Blackstone Group LP and third parties, with the company putting in 3.89 billion yuan ($583 million) to buy their property firms.** China Minsheng Banking Corp's Vice Chairman Lu Zhiqiang spent $1.1 billion last week to buy its shares, the bank has disclosed, raising speculation of a looming power struggle at the country's biggest private lender.    (Compiled by Gayathree Ganesan in Bengaluru)",2016-07-21,HUM,"Thu Jul 21, 2016 | 3:59pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N1A738H?type=companyNews
164,"  (The following statement was released by the rating agency) CHICAGO, July 21 (Fitch) Fitch Ratings said today that its ratings on Anthem  Inc. (ANTM), Aetna Inc. (AET), Cigna Corp. (CI) and Humana Inc. (HUM) remain on  Rating Watch following ANTM's and AET's separate announcements that they intend  to challenge today's decisions by the Department of Justice's (DOJ) to block  their respective acquisitions of CI and HUM.  Fitch anticipates the companies' ratings remaining on rating watch pending the  ultimate outcome of the lawsuits. If ANTM and AET ultimately prove unsuccessful  in challenging the DOJ's lawsuits, Fitch expects to complete a review of the  insurers' then current capital and operational strategies. Assuming these  capital and operational strategies are broadly consistent with those the  insurers maintained prior to entering into their respective merger agreements,  Fitch, consistent with previous comments, would likely affirm the insurers'  ratings at their current ratings levels.   Should the challenge prove successful, Fitch, consistent with previous comments,  expects to affirm ANTM's ratings at their current levels with a Negative Outlook  once the company accesses the capital markets to fund its acquisition. Fitch  would also expect to downgrade the ratings on CI's senior notes one notch upon  the acquisition's close. Similarly Fitch would expect to downgrade AET's ratings  and to upgrade HUM's ratings upon the close of their transaction. These  anticipated rating actions would be subject to a review of potential asset  divestiture required by the DOJ and the extent to which they would alter the  profiles of the combined organizations. This is an area of heightened concern  given the DOJ's assertion that divestitures proposed by the companies to date  have fallen short of those required to prevent the DOJ from filing suits to  block the transactions.  Fitch's ratings on ANTM and AET, the acquiring companies in their respective  transactions, are on Rating Watch Negative reflecting the higher leverage and  lower interest coverage that would result from the transactions' completion and  integration risks. In Fitch's view, these risks are outweighed from a ratings  perspective by the size and scale benefits that would result from the completion  of the transactions.  Fitch's ratings on CI and HUM, the companies to be acquired in their respective  transactions, are also on Rating Watch. Ratings on CI's senior unsecured  securities are on Rating Watch Negative, reflecting concerns about a combined  ANTM-CI organization's leverage, interest coverage and integration risks. HUM's  ratings are on Rating Watch Positive reflecting anticipated ratings benefits  from a combined AET-HUM organization's more diverse product portfolio as well as  the fact that HUM's current ratings are two notches lower than AET's current  ratings.        Contact: Mark Rouck, CPA, CFA Senior Director  +1-312-368-2085 Fitch Ratings, Inc.  70 West Madison St. Chicago, IL 60602 Brad Ellis, CFA Director  +1-312-368-3158 Media Relations: Hannah James, New York, Tel: + 1 646 582 4947, Email:  hannah.james@fitchratings.com. Additional information is available at www.fitchratings.com ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2016-07-21,HUM,"Thu Jul 21, 2016 | 2:48pm EDT",Fitch: Anthem & Aetna to Challenge DOJ Merger Block; Ratings Remain on Watch,http://www.reuters.com//article/idUSFit968242?type=companyNews
165,"  July 21 Humana Inc :* Humana increases earnings guidance* Sees Q2 2016 adjusted earnings per share about $2.28* Sees FY 2016 adjusted earnings per share at least $9.25* says  updated guidance for FY16 adjusted eps of at least $9.25 compares to its previous guidance for FY16 adjusted eps of at least $8.85* Higher guidance due to better-than-expected performance YTD for individual medicare advantage and healthcare services businesses * ""Individual business remains very challenging""* Experiencing better-than-expected performance across several of its businesses resulting in an increase in its FY16 earnings guidance for these businesses * sees Q2 gaap earnings per share $2.03* Due to pending transaction with Aetna, company is not planning to host a conference call in conjunction with Q2 earnings release* Says expects 2017 premiums associated with ACA-compliant offerings in range of $750 million to $1 billion * Notified relevant departments of insurance of intent to discontinue certain on-exchange individual products across various geographies for 2017* Guidance for FY16 adjusted to reflect lower projected tax rate, raising co's eps guidance by approximately $0.12 per diluted common share* Together with Aetna, company intends to ""vigorously defend"" Aetna transaction in response to DOJ lawsuit* 2017 individual offerings geographic presence to now cover no more than 156 counties across 11 states versus 1,351 counties across 19 states in 2016    Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-07-21,HUM,"Thu Jul 21, 2016 | 11:57am EDT",BRIEF-Humana increases FY 2016 earnings guidance,http://www.reuters.com//article/idUSASC08XQ0?type=companyNews
166,"  NEW YORK, July 21 U.S. antitrust regulators will announce on Thursday plans to file lawsuits to block two separate health insurance mergers, Anthem Inc.'s  purchase of Cigna Corp. and Aetna Inc.'s  acquisition of Humana Inc., according to a source familiar with the matter. The U.S. Department of Justice has been reviewing the deals for the past year.   (Reporting by Caroline Humer and Diane Bartz in Washington DC; Editing by Chizu Nomiyama)  ",2016-07-21,HUM,"Thu Jul 21, 2016 | 9:26am EDT","U.S. regulators to block Anthem-Cigna, Aetna-Humana deals Thursday-source",http://www.reuters.com//article/usa-healthcare-antitrust-idUSL1N1A70NQ?type=companyNews
167,"  July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday.                HIGHLIGHTS      * Chicago Bridge & Iron Co        : Baird cuts to neutral      * D.R. Horton Inc        : BofA Merrill cuts to neutral from buy        * Humana Inc        : Wolfe Research raises to outperform        * Community Bank System Inc        : Sandler O'Neill cuts to hold rating      * Packaging Corp of America        : Deutsche Bank cuts to hold from buy                     Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical order.        * 1st Source Corp         : KBW raises target price to $33 from $32        * 8X8 Inc         : Barclays raises price target to $17 from $13; rating overweight        * 8X8 Inc         : Craig Hallum raises target price to $17 from $15; rating buy        * 8X8 Inc         : Deutsche Bank raises target price to $22 from $20        * 8X8 Inc         : Needham raises target price to $17 from $15; rating buy        * 8X8 Inc         : Northland Capital raises target price to $17 from $16        * A. O. Smith Corp        : BMO raises target price to $105 from $93        * Acxiom Corp         : Dougherty starts with buy; price target $28        * Adeptus Health Inc         : Goldman Sachs cuts target price to $80 from $89        * Adeptus Health Inc         : Jefferies cuts price target to $100 from $113        * Adeptus Health Inc         : Keybanc Capital cuts target price to $67 from $85        * Advanced Micro Devices        : BMO raises target price to $5 from $4.50        * Advanced Micro Devices        : Canaccord Genuity raises target price to $6.50 from $6        * Advanced Micro Devices        : Citigroup raises price target to $2.50 from $2        * Advanced Micro Devices        : Craig Hallum raises price target to $7.50 from $6; buy        * Advanced Micro Devices        : Credit Suisse raises target price to $5.50 from $3.50        * Advanced Micro Devices        : Deutsche Bank raises target price to $4 from $3        * Advanced Micro Devices        : Jefferies raises price target to $6.75 from $5.50        * Advanced Micro Devices        : Mizuho raises target price to $5.50; rating neutral        * Aetna Inc        : UBS cuts target price to $135.0 from $145        * Aetna Inc        : Wolfe Research cuts to peer perform        * Agilent Technologies Inc      : BTIG raises target price to $55 from $50; rating buy        * AK Steel Holding Corp        : Credit Suisse raises target price to $8 from $7        * Akamai         : SunTrust Robinson starts with buy      * Alexion Pharmaceuticals Inc         : Jefferies cuts target price to $140 from $159        * Alibaba Group Holding Ltd         : Jefferies raises target price to $101; rating buy        * Alliance Data Systems Corp        : Barclays raises target price to $250 from $240        * Alliance Data Systems Corp        : BMO cuts to market perform rating       * Alliance Data Systems Corp        : Goldman Sachs raises target price to $210 from $195        * Allstate Corp        : Deutsche Bank raises target price to $77 from $76        * AMC Networks Inc         : Goldman Sachs cuts target price to $84 from $91        * American Airlines Group        : Wolfe Research cuts target to $45 from $48; outperform        * American Electric Power Company        : Deutsche Bank raises target to $72 from $66        * American National Bankshares Inc         : KBW raises target price to $27 from $26        * American National Bankshares Inc         : Raymond James raises target to $28 from $27        * American River Bankshares         : Sandler O'Neill raises target price to $12; buy        * Associated Banc-Corp        : Deutsche Bank raises target price to $20 from $19        * Associated Banc-Corp        : KBW raises target price to $19.5 from $19        * Asterias Biotherapeutics Inc        : Raymond James starts with outperform; target $5        * AT&T Inc      : Cowen and Company raises target price to $45 from $44        * AT&T Inc      : Jefferies raises target price to $48 from $44        * AT&T Inc      : Oppenheimer raises target price to $46 from $40        * AT&T Inc      : Raymond James raises target price to $44 from $41        * AT&T Inc      : RBC raises price target to $44 from $41        * Athenahealth Inc         : Cowen and Company cuts target price to $158 from $162        * Athenahealth Inc         : Deutsche Bank cuts to hold from buy        * Athenahealth Inc         : Deutsche Bank cuts to hold; target price to $147 from $165        * Athenahealth Inc         : Oppenheimer cuts price target to $170 from $186; outperform        * Banc of California Inc         : D.A. Davidson raises price target to $22 from $20.50        * Banc of California Inc         : UBS raises target price to $25 from $24        * BancorpSouth Inc        : Jefferies raises target price to $25        * Bank of New York Mellon Corp       : CLSA cuts target price to $45 from $46        * Bank of New York Mellon Corp       : Raymond James raises target price to $45 from $44        * Bank of New York Mellon Corp       : UBS cuts target price to $45 from $46.0        * Benchmark Electronics Inc        : B.Riley raises target price to $23 from $19        * Benchmark Electronics Inc        : Needham raises target price to $26 from $23; buy        * Biogen Inc         : Goldman Sachs raises price target to $275 from $267; rating neutral        * Biogen Inc         : Leerink raises target price to $360 from $319        * Black Knight Financial Services Inc         : KBW raises target price to $38 from $37        * Blackstone Group       : Deutsche Bank raises target price to $26 from $24        * Blackstone Group       : Goldman Sachs raises target price to $31; rating buy        * Blue Bird Corp         : Craig Hallum raises target price to $19        * Blue Bird Corp         : Stifel raises target price to $15 from $14        * Blue Hills Bancorp         : Compass Point raises target price to $18 from $17.5; buy        * Blueknight Energy Partners LP         : SunTrust Robinson raises target to $8 from $5        * Blueknight Energy Partners LP         : SunTrust Robinson raises to buy from neutral        * Boston Beer Co Inc        : CLSA raises target price to $175 from $160        * Boston Beer Co Inc        : Cowen and Company raises target price to $170 from $151        * Boston Beer Co Inc        : Jefferies raises target price to $151 from $145        * Boston Beer Co Inc        : Susquehanna raises target price to $175 from $154        * Boston Private Financial Holdings Inc         : Jefferies raises target price to $13.50        * Boston Private Financial Holdings Inc         : KBW raises target to $12 from $11.5        * Brandywine Realty Trust        : JP Morgan raises target price to $17 from $16        * Brandywine Realty Trust        : Mizuho Securities cuts to neutral        * Brandywine Realty Trust        : SunTrust Robinson raises target price to $18 from $17        * Bruker Corp         : Btig's Karen Koski assumes coverage with neutral rating        * Buffalo Wild Wings Inc         : Goldman Sachs raises price target to $170 from $166        * Calpine Corp        : Deutsche Bank raises price target to $18 from $17        * Capital One Financial        : Barclays cuts target price to $80 from $87; overweight        * Capital One Financial Corp        : BMO cuts target price to $102 from $108        * Capital One Financial Corp        : CLSA cuts target price to $83 from $90        * Capital One Financial Corp        : Credit Suisse cuts target price to $85 from $90        * Capital One Financial Corp        : Goldman Sachs cuts target price to $77 from $83        * Capital One Financial Corp        : Sandler O'Neill cuts target price to $86 from $88      * Capital One Financial Corp        : Stifel cuts target price to $76 from $77        * Cardinal Financial Corp         : KBW raises target price to $24 from $23        * CBS Corp        : Goldman Sachs raises target price to $57 from $56        * Celestica Inc        : Citigroup raises price target to $9.75 from $9        * Celestica Inc        : Canaccord Genuity raises price target to $12 from $11        * Celestica Inc        : Canaccord Genuity raises to buy from hold        * Celsion Corp         : Maxim cuts price target to $4 from $9; rating buy        * CenterPoint Energy Inc        : Deutsche Bank raises target price to $24.5 from $22.5        * Central Valley Community         : D.A. Davidson raises target price to $17 from $13.50        * Central Valley Community         : KBW cuts to Market perform from outperform        * Cheesecake Factory Inc         : Goldman Sachs cuts price target to $49 from $50        * Chicago Bridge & Iron Company NV        : Baird cuts to neutral       * Chicago Bridge & Iron Company NV        : Baird cuts price target to $40        * Chicago Bridge & Iron Company NV        : Baird cuts to neutral; cuts target to $40       * Chipotle Mexican Grill        : Barclays cuts target to $395 from $400; equal weight        * Chipotle Mexican Grill        : Jefferies cuts target price to $330 from $350        * Chipotle Mexican Grill        : Nomura cuts target price to $405 from $420; neutral        * Citizens Financial Group Inc        : Bernstein cuts target price to $28 from $32      * Citizens Financial Group Inc        : Jefferies raises target price to $23; rating hold        * Citizens Financial Group Inc        : KBW raises target price to $24 from $23        * Clearwater Paper Corp        : DA Davidson raises price target by $10 to $75        * Clearwater Paper Corp        : RBC raises target price to $60 from $56        * CMS Energy Corp        : Deutsche Bank raises target price to $46 from $43        * Coca-Cola European Partners Plc        : Bernstein cuts price target to $42 from $57        * Cohen & Steers Inc        : KBW raises target price to $44 from $43        * Community Bank System Inc        : KBW raises target price to $42 from $40        * Community Bank System Inc        : Sandler O'Neill cuts to hold on valuation        * Community Financial Corp         : KBW raises target price to $23 from $22        * Comtech Telecommunications         : Ladenburg starts with buy rating; $19 price target        * Concordia         : Goldman Sachs cuts price target to $26      * Consolidated Edison Inc       : Deutsche Bank raises target price to $74 from $70        * Contango Oil & Gas Co        : RBC raises price target to $15 from $14; outperform        * ContraFect Corp         : Maxim cuts to hold from buy        * Core Laboratories NV        : Iberia Capital raises target price to $150 from $140        * Core Laboratories NV        : Scotia Howard Weil raises target price to $127 from $122        * Coresite Realty        : SunTrust Robinson starts with buy      * Crown Castle International Corp        : Stifel raises target price to $110 from $103        * Crown Holdings Inc        : Credit Suisse raises target price to $60 from $58        * Cyrusone         : SunTrust Robinson starts with buy      * D.R. Horton Inc        : BofA Merrill cuts to neutral from buy        * D.R. Horton Inc        : Deutsche Bank raises target price to $34 from $33        * D.R. Horton Inc        : KBW raises target price to $35 from $33        * D.R. Horton Inc        : S&P cuts target price by $1 to $35        * D.R. Horton Inc        : S&P cuts to hold from buy        * Dana Holding Corp        : JP Morgan raises target price to $14 from $13; rating neutral        * Dana Holding Corp        : RBC raises target price to $14 from $11        * Dana Holding Corp        : Susquehanna raises price target to $14 from $13        * Darden Restaurants Inc        : Goldman Sachs cuts price target to $63 from $64        * Del Frisco's Restaurant Group Inc         : Raymond James cuts target to $19 from $19.5        * Devon Energy Corp        : JP Morgan raises target price to $41 from $38        * Dexcom Inc         : Baird raises price target to $81 from $74; rating neutral        * Dexcom Inc         : Oppenheimer raises target price to $93 from $80        * Dexcom Inc         : Raymond James raises target price to $105 from $81        * Digital Realty        : SunTrust Robinson starts with buy      * Discovery Communications Inc          : Goldman Sachs cuts target price to $24 from $25        * Dish Network         : RBC raises price target to $56 from $50; rating sector perform        * Dish Network         : Wunderlich cuts to sell from hold        * Dominion Resources Inc      : Deutsche Bank raises target price to $78 from $72        * Domino's Pizza Inc        : Barclays raises target price to $132 from $121        * Domino's Pizza Inc        : JP Morgan raises target price to $150 from $123        * Domino's Pizza Inc        : Maxim raises price target to $135 from $127        * Dover Corp        : Baird LOWERS price target to $84 from $86; rating outperform        * Dover Corp        : Bernstein cuts target price to $85 from $87        * Dover Corp        : Goldman Sachs raises price target to $68 from $64        * Dover Corp        : RBC raises target price to $64 from $62        * DTE Energy Co        : Deutsche Bank raises target price to $96 from $90        * Duke Energy Corp        : Deutsche Bank raises target price to $85 from $80        * Dunkin' Brands Group         : JP Morgan raises target price to $50 from $45; neutral        * Dupont Fabros Technology Inc        : SunTrust Robinson starts with buy      * Dynegy Inc        : Deutsche Bank raises target price to $23 from $21        * E*TRADE Financial Corp         : CLSA cuts target price to $29 from $31        * E*TRADE Financial Corp         : Deutsche Bank raises target price to $29 from $28        * E*TRADE Financial Corp         : Goldman Sachs cuts to neutral from buy        * E*TRADE Financial Corp         : Goldman Sachs removes from Americas buy list        * E*TRADE Financial Corp         : Jefferies raises price target to $28 from $25.50        * E*TRADE Financial Corp         : Nomura raises target price to $32 from $30; rating buy        * E*TRADE Financial Corp         : Raymond James raises target price to $31 from $28        * E*TRADE Financial Corp         : SunTrust Robinson raises price target to $27 from $25        * East West Bancorp         : Barclays cuts target to $41 from $42; rating overweight        * East West Bancorp         : D.A. Davidson cuts price target to $38 from $40        * East West Bancorp         : KBW cuts target price to $39 from $40        * Eastgroup Properties Inc        : Sandler O'Neill cuts to hold from buy        * Eastgroup Properties Inc        : Stifel cuts to hold from buy        * Eaton Vance Corp       : Citigroup raises price target by $4 to $39        * EBay Inc         : Benchmark raises target price to $33 from $29        * Edison International        : Deutsche Bank raises target price to $76 from $71        * El Paso Electric Co       : Ladenburg Thalmann raises price target to $52 from $48; buy        * Encana Corp        : Barclays raises target price to $10 from $7       * Encana Corp        : CIBC raises target price to $8 from $6.75        * Encana Corp        : Goldman Sachs raises price target to $9.75 from $9.50        * Entergy Corp        : Deutsche Bank raises target price to $83 from $78        * Equinix         : SunTrust Robinson starts with buy      * Essendant Inc         : Jefferies cuts price target to $23 from $29; rating hold        * Essendant Inc         : Jefferies cuts price target to $23.50; rating hold        * Eversource Energy       : Deutsche Bank raises target price to $61 from $58        * Evolent Health Inc        : Leerink raises target price to $28 from $20        * Exelon Corp        : Deutsche Bank raises target price to $39 from $36        * Exelon Corp        : Deutsche Bank raises to buy from hold        * Expedia Inc         : Cowen and Company cuts price target to $130 from $135        * Facebook Inc       : BTIG cuts to neutral from buy        * FCB Financial Holdings        : Deutsche Bank raises target to $41 from $39; rating buy        * FCB Financial Holdings        : Sandler O'Neill raises target price to $42; rating buy        * Fidelity Southern Corp         : KBW raises target price to $20 from $19        * Fidelity Southern Corp         : KBW raises to outperform from market perform        * First American Financial        : Barclays raises target to $46 from $45; overweight        * First American Financial        : KBW raises target price to $40 from $39        * First Financial Bankshares Inc         : KBW raises target price to $30 from $27        * FirstEnergy Corp       : Deutsche Bank raises target price to $39 from $37        * Flextronics International Ltd         : Craig Hallum lowers target price to $15; buy        * FMC Technologies        : Barclays cuts price target to $30 from $31; equal weight        * FMC Technologies        : Jefferies cuts price target to $27 from $29        * FTI Consulting Inc        : SunTrust Robinson raises target price to $50 from $45        * General Motors Co       : CLSA raises target price to $36 from $35        * General Motors Co       : RBC raises price target to $34 from $32; rating sector perform        * Genesis Energy LP        : Raymond James raises target price to $43        * Gentex Corp         : Craig-Hallum raises price target to $20 from $19; rating buy        * Global Payments Inc        : Citigroup raises price target to $89 from $78        * Graco Inc        : Goldman Sachs cuts target price to $67 from $70        * Graco Inc        : SunTrust Robinson cuts price target to $80 from $85        * Great Southern Bancorp Inc         : KBW raises target price to $42 from $40        * Hancock Holding Co         : BofA Merrill raises to neutral; raises objective to $32        * Hancock Holding Co         : Jefferies raises target price to $30        * Hancock Holding Co         : KBW raises target price to $33 from $26        * Harman International        : Pacific Crest cuts to sector weight from overweight        * Hawaiian Holdings Inc       : Cowen and Company raises price target to $48 from $46        * Hawaiian Holdings Inc       : Deutsche Bank raises target price to $50 from $47        * Heritage Financial Corp         : D. A. Davidson cuts target price to $21 from $22        * Home Bancshares Inc         : KBW raises target price to $23 from $22        * Hudson Pacific Properties        : Mizuho Securities raises target to $37 from $28        * Hudson Pacific Properties        : Mizuho Securities raises to buy from neutral        * Humana Inc        : Jefferies raises target price to $220 from $210        * Humana Inc        : JP Morgan raises target price to $170 from $150        * Humana Inc        : Leerink cuts target price to $200 from $230        * Humana Inc        : RBC raises price target to $224 from $220        * Humana Inc        : RBC raises target price to $224 from $220        * Humana Inc        : Wolfe Research raises to outperform        * Huntington Bancshares Inc         : BMO cuts target price to $10 from $11        * Huntington Bancshares Inc         : Raymond James cuts target price to $11 from $11.50        * Huntington Bancshares Inc         : RBC cuts target price to $11 from $12        * IHS Markit Ltd         : Goldman Sachs reinstates with neutral; price target $38        * IMAX Corp         : Barrington raises price target by $3 to $40; rating outperform        * Incyte Corp         : Guggenheim raises target price to $97 from $85        * Intel Corp         : Exane BNP Paribas raises target price by 12 pct to $37        * Interpublic Group of Companies Inc        : Goldman Sachs cuts target to $21 from $22        * Interxion         : SunTrust Robinson starts with buy      * Invesco Ltd        : JP Morgan cuts target price to $36 from $39        * ITC Holdings Corp        : Deutsche Bank raises target price to $47 from $45        * J M Smucker Co        : Consumer Edge Research assumes coverage with equal weight        * JAKKS Pacific Inc         : B. Riley raises target price to $10 from $8.25; neutral        * JAKKS Pacific Inc         : BMO raises target price to $12 from $11        * JD.com Inc       : Jefferies cuts target price to $31.60 ; rating buy        * Johnson Controls Inc        : Deutsche Bank raises target price to $48 from $47        * Johnson Controls Inc        : JP Morgan raises price target to $48 from $47        * Johnson Controls Inc        : RBC raises price target to $48 from $46      * Joy Global        : Avondale cuts to market perform       * Joy Global Inc        : Avondale cuts price target to $28 from $30        * Joy Global Inc        : BB&T raises to hold from underweight        * Joy Global Inc        : BMO cuts to market perform; raises target price to $28        * Joy Global Inc        : RBC raises target price to $28.3 from $19        * Kaiser Aluminum Corp         : JP Morgan raises target price to $89 from $86        * Kinder Morgan Inc        : SunTrust Robinson raises target price to $25 from $20; buy        * Kite Realty Group Trust        : Barclays starts with overweight rating; $33 target        * Lamar Advertising Co         : Goldman Sachs raises target price to $64 from $59        * Las Vegas Sands Corp        : Susquehanna raises target price to $57 from $54        * LaSalle Hotel Properties        : Barclays raises target price to $25 from $23        * Liberty Media Corp         : Evercore ISI resumes with buy; $28 price target        * Liberty Siriusxm Group          : Evercore ISI resumes with buy; target price $41       * Lions Gate Entertainment Corp        : Goldman Sachs cuts target price to $23 from $24        * LTC Properties Inc        : Canaccord Genuity raises price target to $54 from $49        * ManpowerGroup Inc        : RBC raises target price to $74 from $73        * Marriott Vacations Worldwide        : MKM Partners raises target to $87 from $85        * Marriott Vacations Worldwide        : SunTrust Robinson raises target to $76 from $68        * Marten Transport Ltd         : Avondale cuts to market perform - Trader        * Mattel Inc        : Barclays cuts price target to $34 from $36; rating equal weight        * Maxim Integrated Products         : Credit Suisse cuts target price to $40 from $42        * Maxim Integrated Products         : Jefferies raises target price to $42 from $41        * Maxim Integrated Products         : Pacific Crest raises price target to $42 from $41        * Maxim Integrated Products Inc         : Goldman Sachs raises target to $37 from $35        * Maxim Integrated Products Inc         : Stifel raises target price to $44 from $43        * MB Financial Inc         : KBW raises target price to $40 from $38        * Mead Johnson Nutrition Co        : Deutsche Bank raises target price to $88 from $83        * Medical Properties Trust        : Deutsche Bank starts with buy rating; $17 price target        * Middlefield Banc Corp         : KBW raises target price to $37 from $36        * Mobileye NV         : Berenberg raises target price to $58 from $51        * MSA Safety Inc        : Baird cuts to neutral        * MSA Safety Inc        : Baird raises target price to $57 from $54        * MSA Safety Inc        : Barrington raises target to $65 from $63; rating outperform        * Navigator Holdings Ltd         : Stifel cuts target price to $18 from $25        * NetEase Inc         : Citigroup raises target price to $241 from $185.5        * Newmont Mining Corp        : Deutsche Bank raises target price to $49 from $44        * NextEra Energy Inc        : Deutsche Bank raises target price to $134 from $123        * Nextera Energy Partners LP        : Deutsche Bank raises target price to $30 from $28        * Nielsen Holdings Plc         : BMO cuts to market perform rating       * Northwestern Corp        : Ladenburg Thalmann raises price target to $62 from $60; neutral        * NRG Energy Inc        : Deutsche Bank raises target price to $20 from $19        * Olin Corp        : RBC cuts target price to $24 from $28        * Open Text Corp         : Credit Suisse raises target price to $55 from $49       * Outfront Media Inc        : Goldman Sachs raises target price to $27 from $25        * Outfront Media Inc        : Wedbush starts with neutral; target price $26        * Pacific Continental Corp         : Sandler O'Neill lowers price target to $17.5; buy        * Pacific Premier Bancorp Inc         : Raymond James raises target price to $27 from $25        * Packaging Corp of America        : CLSA raises target price to $83 from $75        * Packaging Corp of America        : D.A. Davidson raises price target to $83 from $75        * Packaging Corp of America        : Deutsche Bank cuts to hold from buy        * Packaging Corp of America        : Deutsche Bank raises target price to $75 from $73        * Pandora Media Inc      : Credit Suisse cuts target price to $16 from $17        * Pandora Media Inc      : Goldman Sachs cuts price target to $15 from $16        * Pandora Media Inc      : Pacific Crest cuts to underweight from sector weight        * Pandora Media Inc      : Stifel cuts target price to $15 from $16        * PayPal Holdings Inc         : Bernstein cuts target price to $41 from $43        * PayPal Holdings Inc         : Cowen and Company raises price target to $39 from $38.        * PayPal Holdings Inc         : Credit Suisse raises price target to $43 from $42      * PayPal Holdings Inc         : Goldman Sachs raises target price to $47 from $46        * PayPal Holdings Inc         : KBW cuts target price to $44 from $46        * PayPal Holdings Inc         : SunTrust Robinson raises target price to $45 from $44; buy        * PayPal Holdings Inc         : Wedbush raises target price to $50; rating outperform        * PayPal Holdings Inc         : Wells Fargo cuts to market perform - Thefly.Com        * Perkinelmer Inc        : BTIG's Karen Koski assumes coverage with neutral rating        * Perrigo Company Plc         : Deutsche Bank raises to buy from hold        * PG&E Corp        : Deutsche Bank raises target price to $68 from $62        * Pinnacle Foods Inc       : Deutsche Bank raises target price to $48 from $44        * Plexus Corp         : B. Riley cuts to neutral rating        * Plexus Corp         : Needham raises target price to $52 from $50        * PPG Industries        : Barclays cuts price target to $120 from $125; rating equal weight        * PPG Industries        : Credit Suisse cuts target price to $115 from $117        * PPG Industries        : Deutsche Bank cuts target price to $122 from $125        * Preferred Bank         : FBR raises target price to $39 from $37        * Procter & Gamble Co       : Stifel raises target price to $92 from $85        * Proofpoint Inc         : Citigroup raises price target to $82 from $77        * Proofpoint Inc         : Deutsche Bank raises target price to $80 from $72        * Proofpoint Inc         : Dougherty raises price target to $85 from $75        * Proofpoint Inc         : Evercore ISI raises target price to $85 from $70        * Proofpoint Inc         : Northland Capital raises target price to $100 from $85        * Proofpoint Inc         : Pacific Crest cuts to sector weight from overweight        * Proofpoint Inc         : Piper Jaffray raises price target to $85 from $76        * Proofpoint Inc         : RBC raises target price to $80 from $70        * Proofpoint Inc         : Stifel raises target price to $85 from $80        * Proofpoint Inc         : Wedbush raises target price to $83 from $78        * Proofpoint Inc         : Wunderlich raises target price to $83 from $75        * Public Service Enterprise Group        : Deutsche Bank raises target to $49 from $47        * Public Storage        : Evercore ISI raises target price to $235 from $234        * PulteGroup Inc        : Citigroup raises price target to $23 from $20        * PulteGroup Inc        : Credit Suisse raises target price to $18 from $16        * PulteGroup Inc        : FBR & CO raises target price to $24 from $20        * PulteGroup Inc        : JP Morgan raises to overweight from neutral;raises target to $26        * PulteGroup Inc        : RBC raises price target to $26 from $23; rating outperform        * PulteGroup Inc        : Susquehanna raises target price to $27 from $23        * PulteGroup Inc        : UBS raises target price to $25 from $22; rating buy        * Puma Biotechnology Inc         : RBC raises target price to $46 from $36        * QCR Holdings Inc         : KBW raises target price to $32 from $31        * Qorvo Inc         : Cowen and Company raises target price to $65 from $55        * QTS Realty Trust Inc        : SunTrust Robinson starts with buy      * Quest Diagnostics        : Barclays raises target price to $85 from $75        * Quest DIAGnostics        : Canaccord Genuity raises price target to $90 from $80; buy        * Quest Diagnostics        : Craig Hallum raises target price to $81; rating hold        * Quest Diagnostics        : Goldman Sachs raises target price to $82 from $74        * Quest Diagnostics        : Jefferies raises price target to $86 from $75        * Rackspace Hosting        : SunTrust Robinson starts with neutral, $25 target price        * Reliance Steel & Aluminum Co       : CLSA raises target price to $77 from $75        * Reliance Steel & Aluminum Co       : Cowen and Company raises target to $86 from $78        * Relypsa Inc         : Brean cuts to hold from buy        * Relypsa Inc         : Citigroup cuts to neutral        * Relypsa Inc         : HC Wainwright cuts to neutral rating        * Relypsa Inc         : Morgan Stanley revises rating to equal weight; ups target to $32        * Roche           : Bernstein cuts target price to $36 from $37      * Rogers Communications Inc        : Barclays raises target price to $41 from $40        * Ryanair          : Raymond James cuts target price to $85 from $100       * S&T Bancorp Inc         : KBW raises target price to $33 from $32        * Sandy Spring Bancorp         : Baird raises price target to $31 from $30; rating neutral        * Sandy Spring Bancorp         : KBW raises target price to $29 from $28; market perform        * Sarepta Therapeutics Inc         : Needham raises target price to $26 from $20        * Schlumberger NV        : UBS raises price target to $100 from $94; rating buy        * Sherwin-Williams Co        : Barclays cuts price target to $305 from $315; equal weight        * Sherwin-Williams Co        : CLSA raises to buy        * Sherwin-Williams Co        : Credit Suisse cuts target price to $318 from $319        * Sherwin-Williams Co        : RBC cuts target price to $335 from $340        * Shire Plc         : Bernstein raises target price to $225 from $222       * Sina Corp         : Jefferies raises to buy; raises target price to $64        * Skechers USA Inc        : BB&T cuts price target to $36 from $40        * Skechers USA Inc        : Citigroup cuts price target to $38 from $42        * Skechers USA Inc        : Cowen and Company cuts price target to $28 from $32        * Skechers USA Inc        : Monness Crespi Hardt cuts to neutral from buy        * Skyworks Solutions         : Barclays cuts price target to $74 from $81; rating overweight        * Skyworks Solutions         : BMO cuts target price to $65 from $69        * Skyworks Solutions         : Canaccord Genuity cuts target price to $92 from $95        * Skyworks Solutions         : CLSA raises target price to $73 from $70        * Skyworks Solutions         : Cowen and Company cuts target price to $72 from $76        * Sonoco Products Co        : Baird raises target price to $55 from $50; rating neutral        * Sonoco Products Co        : D.A. Davidson raises target to $47 from $44        * Sonoco Products Co        : Goldman Sachs raises price target to $52; rating neutral        * Southern Co       : Deutsche Bank raises target price to $54 from $50        * Southwest Airlines Co        : Credit Suisse cuts target price to $48 from $54        * Southwest Airlines Co        : Stifel cuts target price to $50 from $55        * Southwestern Energy Co        : JP Morgan raises price target to $14 from $12        * Southwestern Energy Co        : JP Morgan raises to neutral from underweight        * Southwestern Energy Co        : Nomura raises target price to $15 from $13        * Starbucks Corp         : Barclays cuts price target to $60 from $62; rating equal weight        * Starbucks Corp         : BTIG cuts target price to $64 from $75        * Starbucks Corp         : CLSA cuts target price to $70 from $75        * Starbucks Corp         : Cowen and Company cuts target price to $66 from $69        * Starbucks Corp         : Credit Suisse cuts target price to $58 from $61        * Starbucks Corp         : Jefferies cuts target price to $65 from $70        * Starbucks Corp         : JP Morgan cuts target price to $61 from $68        * Starz          : Goldman Sachs cuts target price to $32 from $33        * Stryker Corp        : Barclays raises price target to $120 from $109; rating underweight        * Stryker Corp        : Brean Capital raises target price to $125 from $121        * Stryker Corp        : Canaccord Genuity raises target price to $130 from $122; buy        * Stryker Corp        : Cowen and Company raises price target to $130 from $120        * Stryker Corp        : Deutsche Bank raises target price to $128 from $125        * Stryker Corp        : Jefferies raises target price to $120 from $113        * Stryker Corp        : JP Morgan raises target price to $119 from $116        * Stryker Corp        : UBS raises target price to $121 from $112       * Stryker Corp        : UBS raises target price to 121. from $112.0        * SVB Financial Group         : D A Davidson cuts price target to $112 from $140        * SVB Financial Group         : D A Davidson cuts to neutral from buy        * SVB Financial Group         : Evercore ISI raises target price to $100 from $98        * SVB Financial Group         : Jefferies cuts target price to $118        * SVB Financial Group         : SunTrust Robinson cuts target price to $120 from $130        * Swift Transportation Co         : Stifel raises target price to $22 from $20        * Syntel Inc         : Barrington cuts price target to $52 from $55        * Texas Roadhouse Inc         : Goldman Sachs cuts price target to $40 from $41        * Thermo Fisher Scientific Inc        : BTIG raises to buy from neutral        * Thermo Fisher Scientific Inc        : BTIG's Karen Koski assumes coverage of the stock        * Time Warner Inc        : Goldman Sachs raises target price to $87 from $86        * Travelers Companies Inc        : RBC raises target price to $125 from $121        * Treehouse Foods Inc        : JP Morgan raises price target to $119 from $98        * Trinity Biotech Plc         : ROTH raises target price to $14 from $13        * TriState Capital Holdings Inc        : KBW raises target price to $16 from $15        * TriState Capital Holdings Inc        : Maxim GROUP raises target price to $17 from $16        * Twitter Inc         : Raymond James cuts to market perform - Trader        * Ultimate Software Group         : Credit Suisse raises target to $260 from $225;outperform        * Ultimate Software Group Inc         : RBC raises target price to $245 from $218        * Ultratech Inc         : Benchmark raises target price to $30; rating buy        * Ultratech Inc         : Canaccord Genuity raises target price to $24 from $19        * Ultratech Inc         : D.A. Davidson raises price target to $26 from $24        * Umpqua Holdings         : Barclays cuts target to $15 from $16; rating equal weight        * Umpqua Holdings         : KBW cuts target price to $17 from $18        * Umpqua Holdings         : Raymond James cuts target price to $16 from $17        * Union Pacific Corp        : Credit Suisse cuts target price to $106 from $107        * Union Pacific Corp        : Deutsche Bank cuts target price to $91 from $94        * Union Pacific Corp        : Raymond James raises target price to $103 from $100        * Union Pacific Corp        : TD Securities raises target price to $98 from $96        * Union Pacific Corp        : UBS raises target price to $95 from $88.        * United Rentals        : Barclays raises price target to $81 from $74; rating overweight        * United Rentals        : Goldman Sachs raises price target to $61 from $58        * United Rentals        : Jefferies raises target price to $88 from $80        * United States Steel Corp      : Credit Suisse raises target price to $29 from $26        * Universal Forest Products         : D.A. Davidson raises target price to $105        * Universal Forest Products         : D.A. Davidson raises to neutral from underperform        * Vipshop Holdings Ltd         : Jefferies cuts target price to $16; rating buy        * Visa Inc      : BMO raises target price to $100 from $98.        * Visa Inc      : Cowen and Company raises price target to $100 from $87       * Visa Inc      : Evercore ISI raises target price to $98 from $85        * Visa Inc      : Goldman Sachs raises target price to $97 from $96        * Visa Inc      : Pacific Crest raises price target to $92 from $80        * Visa Inc      : Stifel raises target price to $91 from $86        * Walt Disney Co        : Goldman Sachs raises target price to $109 from $108        * WEC Energy Group Inc        : Deutsche Bank raises target price to $65 from $61        * Werner Enterprises Inc         : Cowen and Company raises target to $24.00 from $23        * Werner Enterprises Inc         : Credit Suisse raises price target to $22 from $21        * Werner Enterprises Inc         : Susquehanna cuts target price to $22 from $23        * Westamerica Bancorp         : Sandler O'Neill raises price target by $1 to $45        * Williams Companies Inc        : Citigroup resumes with neutral        * Williams Partners LP        : Citigroup resumes with neutral        * Wynn Resorts Ltd         : Susquehanna raises target price to $107 from $105        * Xcel Energy Inc        : Deutsche Bank raises target price to $43 from $40        * Yadkin Financial Corp         : KBW cuts to market perform from outperform        * Yadkin Financial Corp         : KBW raises target price to $28 from $27        * Yadkin Financial Corp         : Raymond James cuts to market perform from outperform        * Yandex         : Goldman Sachs raises target price to $26.9 from $26.5       (Compiled by Geetha Panchaksharam in Bengaluru)   ",2016-07-22,HUM,"Fri Jul 22, 2016 | 2:37pm EDT","U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron",http://www.reuters.com//article/research-us-idUSL4N1A82TX?type=companyNews
168,"   By Carl O'Donnell and Caroline Humer  The potential bust-up of two mega deals among America's largest health insurance companies may have an unintended result - more mergers.The U.S. Department of Justice on Thursday sued to block  Aetna Inc's $37 billion purchase of Humana Inc  and Anthem Inc's proposed $54 billion buyout of Cigna Corp, arguing that they would cut competition and boost rates for patients.If no settlement is reached for one or both deals, the fallback strategy for the four insurers to ensure future growth would likely be a familiar one: Another buying spree, this time of smaller insurers less likely to raise the ire of regulators.""Unless the market changes drastically, I don't see another major deal going through,"" said Norman Armstrong, a partner at King and Spalding LLP who focuses on antitrust. ""But with smaller deals there's more potential to get something done.""The most obvious targets are midsized, national players in government healthcare plans such as Centene Corp, Molina Healthcare Inc, or WellCare Health Plans Inc, according to analysts and investors.Although acquiring these companies would not produce the big boost to earnings sought by the planned mega mergers, they would offer a foothold in markets likely to grow rapidly in coming years, such as Medicaid health plans for the poor and Medicare Advantage coverage for the elderly.Both Molina and Centene have large exposure to private Medicaid plans, a more than $100 billion market that is benefiting as states outsource more responsibility for the government insurance program to private companies.Molina and WellCare were also said to be interested in Medicare Advantage plans that Aetna sought to divest to win approval for its Humana deal, according to a source familiar with the matter. Anthem has already expressed interest in acquiring Medicare and Medicaid members. In 2014, it purchased Simply Healthcare Holdings, a managed care company for government health insurance in Florida.In the case of Centene, the biggest impediment to a deal is that the company is not likely ready to sell.Centene sees itself as an acquirer, not a target, according to spokeswoman Marcela Manjarrez Hawn. Earlier this year, Centene acquired peer HealthNet for $6.3 billion.""We believe it will be difficult for anyone to pay what we will be worth in the next 12 months,"" she said in a statement. Another option would be Magellan Health Inc, an insurer that focuses on niche types of patients, according to Ana Gupte, an equities analyst at Leerink Partners.Buying Magellan could help insurers build out their capabilities in dealing with specialty products, at a time when high prices for specialty drugs are attracting increasing attention, Gupte said.Aetna, Cigna and Magellan declined to comment. Anthem, Molina, Humana, and WellCare did not immediately respond to requests for comment.Even these smaller deals may not clear antitrust approval. For example, WellCare, with a market capitalization of under $5 billion, may be too much for Humana to swallow, largely because both companies have significant presences in the Medicare Advantage space.""The [Justice Department] is on 'high alert' right now, so maybe even a smaller deal is harder than in the past,"" said Gupte.To avoid the most intense regulatory scrutiny, any follow-up deals are likely to be delayed until after the U.S. presidential and congressional elections in November, when the prospect of big health insurance combinations will be less politically charged, according to a shareholder in Humana who asked not to be named because he was not authorized to talk to the media.In the interim, Aetna, Humana, Anthem and Cigna may seek to placate investors with share buybacks.Between them, the health insurance companies could buy back more than $14 billion worth of shares, providing an immediate boost to earnings per share to help offset the impact of the lost mergers, Christine Arnold, an analyst at Cowen and Company, wrote in a research note.",2016-07-22,HUM,"Fri Jul 22, 2016 | 7:24pm EDT",DEALTALK-U.S. government's bid to block insurance mergers could spawn new ones,http://www.reuters.com//article/usa-healthcare-dealtalk-idUSL1N1A81YJ?type=companyNews
169,"   By Carl O'Donnell and Caroline Humer  The potential bust-up of two mega deals among Americas largest health insurance companies may have an unintended result - more mergers.     The U.S. Department of Justice on Thursday sued to block  Aetna Inc's (AET.N) $37 billion purchase of Humana Inc (HUM.N) and Anthem Incs (ANTM.N) proposed $54 billion buyout of Cigna Corp (CI.N), arguing that they would cut competition and boost rates for patients. If no settlement is reached for one or both deals, the fallback strategy for the four insurers to ensure future growth would likely be a familiar one: Another buying spree, this time of smaller insurers less likely to raise the ire of regulators.""Unless the market changes drastically, I don't see another major deal going through,"" said Norman Armstrong, a partner at King and Spalding LLP who focuses on antitrust. ""But with smaller deals there's more potential to get something done.""    The most obvious targets are midsized, national players in government healthcare plans such as Centene Corp (CNC.N), Molina Healthcare Inc (MOH.N), or WellCare Health Plans Inc (WCG.N), according to analysts and investors.Although acquiring these companies would not produce the big boost to earnings sought by the planned mega mergers, they would offer a foothold in markets likely to grow rapidly in coming years, such as Medicaid health plans for the poor and Medicare Advantage coverage for the elderly. Both Molina and Centene have large exposure to private Medicaid plans, a more than $100 billion market that is benefiting as states outsource more responsibility for the government insurance program to private companies.Molina and WellCare were also said to be interested in Medicare Advantage plans that Aetna sought to divest to win approval for its Humana deal, according to a source familiar with the matter.      Anthem has already expressed interest in acquiring Medicare and Medicaid members. In 2014, it purchased Simply Healthcare Holdings, a managed care company for government health insurance in Florida.In the case of Centene, the biggest impediment to a deal is that the company is not likely ready to sell.Centene sees itself as an acquirer, not a target, according to spokeswoman Marcela Manjarrez Hawn. Earlier this year, Centene acquired peer HealthNet for $6.3 billion. ""We believe it will be difficult for anyone to pay what we will be worth in the next 12 months,"" she said in a statement. Another option would be Magellan Health Inc (MGLN.O), an insurer that focuses on niche types of patients, according to Ana Gupte, an equities analyst at Leerink Partners.     Buying Magellan could help insurers build out their capabilities in dealing with specialty products, at a time when high prices for specialty drugs are attracting increasing attention, Gupte said.Aetna, Cigna and Magellan declined to comment. Anthem, Molina, Humana, and WellCare did not immediately respond to requests for comment. Even these smaller deals may not clear antitrust approval.      For example, WellCare, with a market capitalization of under $5 billion, may be too much for Humana to swallow, largely because both companies have significant presences in the Medicare Advantage space.     The [Justice Department] is on high alert right now, so maybe even a smaller deal is harder than in the past, said Gupte.     To avoid the most intense regulatory scrutiny, any follow-up deals are likely to be delayed until after the U.S. presidential and congressional elections in November, when the prospect of big health insurance combinations will be less politically charged, according to a shareholder in Humana who asked not to be named because he was not authorized to talk to the media.In the interim, Aetna, Humana, Anthem and Cigna may seek to placate investors with share buybacks.     Between them, the health insurance companies could buy back more than $14 billion worth of shares, providing an immediate boost to earnings per share to help offset the impact of the lost mergers, Christine Arnold, an analyst at Cowen and Company, wrote in a research note.  (Reporting by Carl O'Donnell and Caroline Humer in New York; Editing by Matthew Lewis)",2016-07-22,HUM,"Fri Jul 22, 2016 | 7:24pm EDT",DEALTALK-U.S. government's bid to block insurance mergers could spawn new ones,http://www.reuters.com//article/usa-healthcare-dealtalk-idUSL1N1A81I8?type=companyNews
170,"   By Caroline Humer and Carl O'Donnell | NEW YORK  NEW YORK U.S. antitrust officials on Thursday moved to block an unprecedented consolidation of the national health insurance market, filing a lawsuit against Anthem Inc's  proposed purchase of Cigna Corp and Aetna Inc's  planned acquisition of Humana Inc.The U.S. Department of Justice said the two multibillion-dollar mergers would reduce competition, raise prices for consumers and stifle innovation if the number of large, national insurers were to fall from five to three.It was the latest example of the Obama administration challenging massive combinations in major industries, from oilfield services to telecommunications.""We will not hesitate to intervene. We will not shy away from complex cases,"" U.S. Attorney General Loretta Lynch told a news conference on Thursday. ""We will protect the interests of the American people.""The deals would hurt consumers in the different markets served by the four companies, from medical coverage provided by large corporations to their employees to Medicare Advantage plans for the elderly and insurance sold to individuals on exchanges created under President Barack Obama's healthcare reform law, the Justice Department said.""We have no doubt that these mergers would reduce competition from what it is today,"" said Principal Deputy Associate Attorney General William Baer, who spearheaded the antitrust reviews.Merging Aetna's and Humana's Medicare Advantage businesses would create the largest U.S. manager of the healthcare insurance for seniors and the disabled.The Anthem deal for Cigna would create the largest U.S. health insurer by membership, with about 53 million members, surpassing UnitedHealth Group's 45.9 million as of June 30, and make it the leader in employer-based health insurance.Aetna and Anthem had each argued their proposed purchases would help lower prices for consumers by giving them greater leverage in negotiating with doctors and hospitals.AETNA VOWS LEGAL FIGHT Aetna and Humana said Thursday they plan ""to vigorously defend the companies' pending merger,"" worth $33 billion. Aetna Chief Executive Mark Bertolini said the company has proposed divesting enough assets to ensure competition in markets where it overlaps with Humana.""If we can't come to a negotiation on what markets to divest, although we have two very complete remedies in front of the Department of Justice now, I think I'm willing to let a judge decide,"" Bertolini told business news channel CNBC. ""We'll go all the way we need to to make this happen.""Anthem had a more muted response, saying it was committed to working toward a settlement with the Justice Department for its $45 billion transaction, but would challenge the lawsuit if necessary. Cigna said it was evaluating its options. It does not believe a deal would close before 2017, ""if at all.""After news of the lawsuit, Humana raised its 2016 earnings forecast, saying its core businesses, Medicare Advantage and Healthcare Services, are performing better than expected. Humana shares rose 8.3 percent.Cigna climbed 5.4 percent, Anthem closed up 2.6 percent and Aetna rose 1.6 percent. Speculation that the U.S. government would block both deals had weighed on shares of all four insurers for several weeks.Humana's raised forecast ""bodes well for the rest of the industry. Now you can expect the other guys to report good numbers and perhaps raise guidance as well,"" said Jeff Jonas, portfolio manager for Gabelli Funds, which holds Cigna and Humana shares. ""There's somewhat of a relief rally, too, given that this has been an overhang for so long, particularly with Anthem and Cigna,"" he said.CONCERN FOR DIFFERENT CONSUMERS In the lawsuit against Aetna, the Justice Department cited specific concerns about damage to 1.6 million people in 364 counties who are customers of Medicare Advantage, the program that serves older people.It also said there were issues for the individual plans sold on Obamacare exchanges, where the government has sought to spur competition and keep prices low.About 20 state insurance departments were required to review the Aetna-Humana deal. Missouri came out firmly against it, while others, including California and New York, approved it after reaching a settlement. In the lawsuit against Anthem-Cigna, antitrust regulators said the combination would substantially lessen competition in an already consolidated industry, harming millions of Americans, doctors and hospitals.The Justice Department said it was concerned about the impact on the national corporate business, which serves large companies and which it said has only four competitors.It also said there were issues with local business markets, the individual Obamacare exchanges and the impact a combined company could have on contracts with doctors.The presidential campaign of Democrat Hillary Clinton, who said when the deals were announced she was ""very skeptical"" they would benefit consumers, said Thursday they ""applaud"" the Justice Department's decision.""Hillary will continue to fight to reduce health costs and strengthen antitrust enforcement to prevent corporations from gaining too much market power,"" Clinton policy adviser Ann O'Leary said in a statement.Doctors and hospitals had urged the Justice Department to try to block the deal, and some large employers were also against the combination.Aetna and Anthem had each proposed asset sales to the regulators, but they did not adequately address the loss of market competition, Baer said.Eleven states and the District of Colombia joined the Justice Department lawsuit against Anthem and Cigna; eight states and DC joined the lawsuit against Aetna and Humana.If the government successfully scuttles the deals, Anthem would owe Cigna $1.85 billion in breakup fees. Aetna would have to pay Humana $1 billion. If the deals fail for other reasons, the breakup fees would be different.The unusual move against two deals in the same industry represents a repeat of history for Baer, who headed the department's Antitrust Division until a short time ago and is now the No. 3 official in the Justice Department.In March 1998, Baer asked a court to stop a major consolidation of the U.S. drug wholesaling business. McKesson Corp had sought to buy AmeriSource Health Corp, and Cardinal Health wanted to buy Bergen Brunswig Corp. A court granted the preliminary injunction.(Reporting by Caroline Humer and Diane Bartz in Washington DC, additional reporting by Jon Stempel, Lewis Krauskopf and Carl O'Donnell and Bill Berktot in New York)",2016-07-22,HUM,"Fri Jul 22, 2016 | 7:46am EDT","U.S. moves to block massive health insurer deals led by Anthem, Aetna",http://www.reuters.com//article/usa-healthcare-antitrust-idUSL1N1A70RV?type=companyNews
171,"   By Caroline Humer and Carl O'Donnell | NEW YORK  NEW YORK Health insurer Aetna Inc (AET.N), whose $33 billion purchase of Humana Inc (HUM.N) has been spurned by the U.S. government, faces a tough but not impossible legal battle to try to reinstate the deal.Aetna vowed to fight to the very end after the Department of Justice filed suit earlier on Thursday to block the merger, which had been in the works for more than a year. Antitrust reviewers say the combination will hurt consumers and the companies' proposed fix - selling some health plans to a competitor - is insufficient. The Justice Department simultaneously sued to block Anthem Incs (ANTM.N) proposed $45 billion deal for Cigna Inc (CI.N), moving against an unprecedented effort to consolidate the U.S. health insurance market.Of the two deals, analysts and investors see Aetna and Humana as having a slight chance to reverse the decision through a court battle. They face a Justice Department empowered by a series of high-profile successes against mega-mergers, scuttling deals in industries from oil services to retail stores and telecommunications.""My initial impression from the complaint ... is that the Justice Department and the states are on much safer ground"" in their argument against an Aetna-Humana tie-up, said Beau Buffier, co-head of the antitrust group at Shearman & Sterling in New York.The Justice Department lawsuit focused on a county-by-county analysis of where Aetna and Humana have what is deemed too much market share in providing Medicare Advantage for elderly people and in the individual health plans created under President Barack Obama's healthcare reform law. Aetna will argue in court that the Justice Department defined the market for Medicare Advantage too narrowly, which has caused it to see competition issues where they do not exist, Chief Executive Officer Mark Bertolini said in an interview. The government has failed to take into account that seniors can not only choose between Medicare Advantage plans sold by private players, but also have the government-run Medicare program as an option.""Let a judge decide. Is Medicare Advantage competitive with Medicare fee-for-service? If that is indeed the case, then there isn't any market we need to divest,"" Bertolini said. ""If we have to divest, can we provide an appropriate remedy? And we have.""The Justice Department has already rejected that argument. However, Aetna will use evidence that the Obama administration envisioned Medicare and Medicare Advantage as direct competitors as it sought support for the Affordable Care Act passed in 2010. Aetna and Humana also have an answer to the concerns over the Obamacare market, since Humana has already announced plans to cut back dramatically on its presence in that business.""We think over time, that becomes less of an issue,"" Humana CEO Bruce Broussard said in an interview. Humana will in 2017 offer Obamacare plans in only about 160 U.S. counties, compared with 1,351 counties this year. The Justice Department has signaled antitrust concerns in 19 counties.Aetna may also gain some leverage if the Anthem-Cigna deal breaks up first, according to some antitrust experts. In that scenario, Anthem could become a buyer of some Medicare Advantage business they need to divest. If Cigna-Anthem craters, I wouldnt be surprised to see the Justice Department agreeing to some kind of divestiture package, said Matthew Cantor, an antitrust lawyer at Constantine Cannon.Bertolini said Aetna has presented a package of assets to sell that nearly matches up with the 364 counties in 21 states where the Justice Department cites a lack of competition. Aetna has two buyers for those health plans that have experience in Medicare Advantage, he said. A source familiar with the situation said the two companies that have offered to buy all the assets are WellCare Health Plans Inc (WCG.N) and Molina HealthCare Inc (MOH.N).The Justice Department has argued that the proposed buyers are not strong enough players on their own. ""Overall, this will be all about litigating the fix,"" said Andrea Murino, co-chair of Goodwin's antitrust group based in Washington D.C. ""What DOJ wants when they come up with a remedy is an immediate and expansive competitive response - to substitute one company in for another without missing a beat."" (Reporting by Caroline Humer; Editing by Matthew Lewis)",2016-07-22,HUM,"Fri Jul 22, 2016 | 12:00am EDT","Aetna, Humana map legal strategy to salvage merger",http://www.reuters.com//article/us-usa-healthcare-aetna-analysis-idUSKCN10136J?type=companyNews
172,"   By Caroline Humer and Carl O'Donnell | NEW YORK  NEW YORK U.S. antitrust officials on Thursday moved to block an unprecedented consolidation of the national health insurance market, filing a lawsuit against Anthem Inc's (ANTM.N) proposed purchase of Cigna Corp (CI.N) and Aetna Inc's (AET.N) planned acquisition of Humana Inc (HUM.N). The U.S. Department of Justice said the two multibillion-dollar mergers would reduce competition, raise prices for consumers and stifle innovation if the number of large, national insurers were to fall from five to three. It was the latest example of the Obama administration challenging massive combinations in major industries, from oilfield services to telecommunications.""We will not hesitate to intervene. We will not shy away from complex cases,"" U.S. Attorney General Loretta Lynch told a news conference on Thursday. ""We will protect the interests of the American people.""The deals would hurt consumers in the different markets served by the four companies, from medical coverage provided by large corporations to their employees to Medicare Advantage plans for the elderly and insurance sold to individuals on exchanges created under President Barack Obama's healthcare reform law, the Justice Department said.""We have no doubt that these mergers would reduce competition from what it is today,"" said Principal Deputy Associate Attorney General William Baer, who spearheaded the antitrust reviews.Merging Aetna's and Humana's Medicare Advantage businesses would create the largest U.S. manager of the healthcare insurance for seniors and the disabled. The Anthem deal for Cigna would create the largest U.S. health insurer by membership, with about 53 million members, surpassing UnitedHealth Group's (UNH.N) 45.9 million as of June 30, and make it the leader in employer-based health insurance.Aetna and Anthem had each argued their proposed purchases would help lower prices for consumers by giving them greater leverage in negotiating with doctors and hospitals.    AETNA VOWS LEGAL FIGHT Aetna and Humana said Thursday they plan ""to vigorously defend the companies' pending merger,"" worth $33 billion. Aetna Chief Executive Mark Bertolini said the company has proposed divesting enough assets to ensure competition in markets where it overlaps with Humana.""If we can't come to a negotiation on what markets to divest, although we have two very complete remedies in front of the Department of Justice now, I think I'm willing to let a judge decide,"" Bertolini told business news channel CNBC. ""We'll go all the way we need to make this happen."" Anthem had a more muted response, saying it was committed to working toward a settlement with the Justice Department for its $45 billion transaction, but would challenge the lawsuit if necessary. Cigna said it was evaluating its options. It does not believe a deal would close before 2017, ""if at all."" After news of the lawsuit, Humana raised its 2016 earnings forecast, saying its core businesses, Medicare Advantage and Healthcare Services, are performing better than expected. Humana shares rose 8.3 percent.Cigna climbed 5.4 percent, Anthem closed up 2.6 percent and Aetna rose 1.6 percent. Speculation that the U.S. government would block both deals had weighed on shares of all four insurers for several weeks.Humana's raised forecast ""bodes well for the rest of the industry. Now you can expect the other guys to report good numbers and perhaps raise guidance as well,"" said Jeff Jonas, portfolio manager for Gabelli Funds, which holds Cigna and Humana shares.""There's somewhat of a relief rally, too, given that this has been an overhang for so long, particularly with Anthem and Cigna,"" he said. CONCERN FOR DIFFERENT CONSUMERS     In the lawsuit against Aetna, the Justice Department cited specific concerns about damage to 1.6 million people in 364 counties who are customers of Medicare Advantage, the program that serves older people. It also said there were issues for the individual plans sold on Obamacare exchanges, where the government has sought to spur competition and keep prices low.About 20 state insurance departments were required to review the Aetna-Humana deal. Missouri came out firmly against it, while others, including California and New York, approved it after reaching a settlement.In the lawsuit against Anthem-Cigna, antitrust regulators said the combination would substantially lessen competition in an already consolidated industry, harming millions of Americans, doctors and hospitals. The Justice Department said it was concerned about the impact on the national corporate business, which serves large companies and which it said has only four competitors.It also said there were issues with local business markets, the individual Obamacare exchanges and the impact a combined company could have on contracts with doctors.The presidential campaign of Democrat Hillary Clinton, who said when the deals were announced she was ""very skeptical"" they would benefit consumers, said Thursday they ""applaud"" the Justice Department's decision.""Hillary will continue to fight to reduce health costs and strengthen antitrust enforcement to prevent corporations from gaining too much market power,"" Clinton policy adviser Ann OLeary said in a statement.Doctors and hospitals had urged the Justice Department to try to block the deal, and some large employers were also against the combination.Aetna and Anthem had each proposed asset sales to the regulators, but they did not adequately address the loss of market competition, Baer said.Eleven states and the District of Colombia joined the Justice Department lawsuit against Anthem and Cigna; eight states and DC joined the lawsuit against Aetna and Humana.If the government successfully scuttles the deals, Anthem would owe Cigna $1.85 billion in breakup fees. Aetna would have to pay Humana $1 billion. If the deals fail for other reasons, the breakup fees would be different.The unusual move against two deals in the same industry represents a repeat of history for Baer, who headed the department's Antitrust Division until a short time ago and is now the No. 3 official in the Justice Department.In March 1998, Baer asked a court to stop a major consolidation of the U.S. drug wholesaling business. McKesson Corp (MCK.N) had sought to buy AmeriSource Health Corp, and Cardinal Health (CAH.N) wanted to buy Bergen Brunswig Corp. A court granted the preliminary injunction. (Reporting by Caroline Humer and Diane Bartz in Washington DC, additional reporting by Jon Stempel, Lewis Krauskopf and Carl O'Donnell and Bill Berktot in New York; Editing by Michele Gershberg, Nick Zieminski and Bernard Orr)",2016-07-22,HUM,"Thu Jul 21, 2016 | 9:04pm EDT","U.S. moves to block massive health insurer deals led by Anthem, Aetna",http://www.reuters.com//article/us-usa-healthcare-antitrust-idUSKCN1011VU?type=companyNews
173,"   By Caroline Humer and Carl O'Donnell | NEW YORK  NEW YORK U.S. antitrust officials on Thursday moved to block an unprecedented consolidation of the national health insurance market, filing a lawsuit against Anthem Inc's (ANTM.N) proposed purchase of Cigna Corp (CI.N) and Aetna Inc's (AET.N) planned acquisition of Humana Inc (HUM.N). The U.S. Department of Justice said the two multibillion-dollar mergers would reduce competition, raise prices for consumers and stifle innovation if the number of large, national insurers were to fall from five to three. It was the latest example of the Obama administration challenging massive combinations in major industries, from oilfield services to telecommunications.""We will not hesitate to intervene. We will not shy away from complex cases,"" U.S. Attorney General Loretta Lynch told a news conference on Thursday. ""We will protect the interests of the American people.""The deals would hurt consumers in the different markets served by the four companies, from medical coverage provided by large corporations to their employees to Medicare Advantage plans for the elderly and insurance sold to individuals on exchanges created under President Barack Obama's healthcare reform law, the Justice Department said.""We have no doubt that these mergers would reduce competition from what it is today,"" said Principal Deputy Associate Attorney General William Baer, who spearheaded the antitrust reviews.Merging Aetna's and Humana's Medicare Advantage businesses would create the largest U.S. manager of the healthcare insurance for seniors and the disabled. The Anthem deal for Cigna would create the largest U.S. health insurer by membership, with about 53 million members, surpassing UnitedHealth Group's (UNH.N) 45.9 million as of June 30, and make it the leader in employer-based health insurance.Aetna and Anthem had each argued their proposed purchases would help lower prices for consumers by giving them greater leverage in negotiating with doctors and hospitals.    AETNA VOWS LEGAL FIGHT Aetna and Humana said Thursday they plan ""to vigorously defend the companies' pending merger,"" worth $33 billion. Aetna Chief Executive Mark Bertolini said the company has proposed divesting enough assets to ensure competition in markets where it overlaps with Humana.""If we can't come to a negotiation on what markets to divest, although we have two very complete remedies in front of the Department of Justice now, I think I'm willing to let a judge decide,"" Bertolini told business news channel CNBC. ""We'll go all the way we need to make this happen."" Anthem had a more muted response, saying it was committed to working toward a settlement with the Justice Department for its $45 billion transaction, but would challenge the lawsuit if necessary. Cigna said it was evaluating its options. It does not believe a deal would close before 2017, ""if at all."" After news of the lawsuit, Humana raised its 2016 earnings forecast, saying its core businesses, Medicare Advantage and Healthcare Services, are performing better than expected. Humana shares rose 8.3 percent.Cigna climbed 5.4 percent, Anthem closed up 2.6 percent and Aetna rose 1.6 percent. Speculation that the U.S. government would block both deals had weighed on shares of all four insurers for several weeks.Humana's raised forecast ""bodes well for the rest of the industry. Now you can expect the other guys to report good numbers and perhaps raise guidance as well,"" said Jeff Jonas, portfolio manager for Gabelli Funds, which holds Cigna and Humana shares.""There's somewhat of a relief rally, too, given that this has been an overhang for so long, particularly with Anthem and Cigna,"" he said. CONCERN FOR DIFFERENT CONSUMERS     In the lawsuit against Aetna, the Justice Department cited specific concerns about damage to 1.6 million people in 364 counties who are customers of Medicare Advantage, the program that serves older people. It also said there were issues for the individual plans sold on Obamacare exchanges, where the government has sought to spur competition and keep prices low.About 20 state insurance departments were required to review the Aetna-Humana deal. Missouri came out firmly against it, while others, including California and New York, approved it after reaching a settlement.In the lawsuit against Anthem-Cigna, antitrust regulators said the combination would substantially lessen competition in an already consolidated industry, harming millions of Americans, doctors and hospitals. The Justice Department said it was concerned about the impact on the national corporate business, which serves large companies and which it said has only four competitors.It also said there were issues with local business markets, the individual Obamacare exchanges and the impact a combined company could have on contracts with doctors.The presidential campaign of Democrat Hillary Clinton, who said when the deals were announced she was ""very skeptical"" they would benefit consumers, said Thursday they ""applaud"" the Justice Department's decision.""Hillary will continue to fight to reduce health costs and strengthen antitrust enforcement to prevent corporations from gaining too much market power,"" Clinton policy adviser Ann OLeary said in a statement.Doctors and hospitals had urged the Justice Department to try to block the deal, and some large employers were also against the combination.Aetna and Anthem had each proposed asset sales to the regulators, but they did not adequately address the loss of market competition, Baer said.Eleven states and the District of Colombia joined the Justice Department lawsuit against Anthem and Cigna; eight states and DC joined the lawsuit against Aetna and Humana.If the government successfully scuttles the deals, Anthem would owe Cigna $1.85 billion in breakup fees. Aetna would have to pay Humana $1 billion. If the deals fail for other reasons, the breakup fees would be different.The unusual move against two deals in the same industry represents a repeat of history for Baer, who headed the department's Antitrust Division until a short time ago and is now the No. 3 official in the Justice Department.In March 1998, Baer asked a court to stop a major consolidation of the U.S. drug wholesaling business. McKesson Corp (MCK.N) had sought to buy AmeriSource Health Corp, and Cardinal Health (CAH.N) wanted to buy Bergen Brunswig Corp. A court granted the preliminary injunction. (Reporting by Caroline Humer and Diane Bartz in Washington DC, additional reporting by Jon Stempel, Lewis Krauskopf and Carl O'Donnell and Bill Berktot in New York; Editing by Michele Gershberg, Nick Zieminski and Bernard Orr)",2016-07-22,HUM,"Thu Jul 21, 2016 | 9:04pm EDT","UPDATE 7-U.S. moves to block massive health insurer deals led by Anthem, Aetna",http://www.reuters.com//article/usa-healthcare-antitrust-idUSL1N1A70P8?type=companyNews
174,"  July 27 Aetna Humana* Moody's affirms aetna's ratings, humana's ratings remain on review following doj lawsuit * The outlook on aetna and its subsidiaries remains stable.  * Ratings reflect that there remains reasonable probability that merger will ultimately be approved despite doj lawsuit  Source text for Eikon:  Further company coverage:",2016-07-27,HUM,"Wed Jul 27, 2016 | 5:16pm EDT",BRIEF-Moody's affirms Aetna's and Humana's ratings,http://www.reuters.com//article/idUSFWN1AD17B?type=companyNews
175,"  Aug 2 Molina Healthcare Inc* Transactions expected to be immediately accretive to earnings following close * Expects to fund transactions with available cash, but has also received a debt commitment letter  * Molina Healthcare to acquire certain medicare advantage assets from Aetna and Humana  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780)",2016-08-02,HUM,"Tue Aug 2, 2016 | 6:45am EDT",BRIEF-Molina Healthcare to acquire certain medicare assets from Aetna and Humana,http://www.reuters.com//article/idUSFWN1AJ0C5?type=companyNews
176,"  Aug 2 Aetna Inc* Aetna Inc says deal valued at $117 million* Transactions contingent on successful closing of Aetna-Humana transaction * Deal for a total estimated $117 million in cash for both transactions* Companies remain committed to defending their pending transaction against a u.s. Department of justice lawsuit seeking to block it * Believe divestitures taken together would address Department Of Justice's perceived ""competitive concerns"" regarding medicare advantage * Aetna and Humana agree to sell certain medicare advantage assets to Molina Healthcare Inc* As a result of transactions, Molina is expected to gain approximately 290,000 medicare advantage members in 21 states  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-08-02,HUM,"Tue Aug 2, 2016 | 6:34am EDT",BRIEF-Aetna and Humana agree to sell certain assets to Molina Healthcare,http://www.reuters.com//article/idUSFWN1AJ07L?type=companyNews
177,"   By Amrutha Penumudi  Humana Inc (HUM.N) reported a 28 percent drop in quarterly profit as it set aside more money to cover losses in its Obamacare business, and the company said it would discontinue next year most of these plans sold off public exchanges.The U.S. health insurer, whose acquisition by rival Aetna Inc (AET.N) has been challenged by U.S. antitrust authorities, said it planned to shrink its individual commercial business to 156 counties next year from 1,351 currently.Under the business, Humana offers individual insurance plans both on and off the public exchanges set up under President Barack Obama's Affordable Care Act. The company said it expected premiums of $750 million-$1 billion in 2017 from its Obamacare plans, way lower than the $3.4 billion estimated for 2016. U.S. health insurers, including Anthem Inc (ANTM.N) and UnitedHealth Group Inc (UNH.N), have been losing money in their Obamacare businesses due to high medical costs. Humana set aside about $208 million more in the second quarter to cover losses in the business, which it currently operates in 15 U.S. states. The company said it would shrink the business to 11 states next year and had already limited memberships in the four states where it no longer intended to offer the plans. Humana had said in May it would exit the Obamacare business in some states.  The company and Aetna announced a deal on Tuesday to sell a portfolio of about 290,000 of their Medicare Advantage members in 21 states to Molina Healthcare Inc (MOH.N) to win U.S. antitrust approval for their merger.Humana's individual commercial memberships fell by nearly a quarter in the three months ended June 30.  Net income fell to $311 million, or $2.06 per share.Excluding items, the company earned $2.30 per share, beating the average analyst estimate of $2.23, according to Thomson Reuters I/B/E/S. Revenue rose 2 percent to $14.01 billion, topping the average estimate of $13.59 billion.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2016-08-03,HUM,"Wed Aug 3, 2016 | 9:24am EDT",Humana profit plunges on higher provisions for Obamacare business,http://www.reuters.com//article/us-humana-results-idUSKCN10E1CG?type=companyNews
178,"   By Amrutha Penumudi  Humana Inc (HUM.N) reported a 28 percent drop in quarterly profit as it set aside more money to cover losses in its Obamacare business, and the company said it would discontinue next year most of these plans sold off public exchanges.The U.S. health insurer, whose acquisition by rival Aetna Inc (AET.N) has been challenged by U.S. antitrust authorities, said it planned to shrink its individual commercial business to 156 counties next year from 1,351 currently.Under the business, Humana offers individual insurance plans both on and off the public exchanges set up under President Barack Obama's Affordable Care Act. The company said it expected premiums of $750 million-$1 billion in 2017 from its Obamacare plans, way lower than the $3.4 billion estimated for 2016. U.S. health insurers, including Anthem Inc (ANTM.N) and UnitedHealth Group Inc (UNH.N), have been losing money in their Obamacare businesses due to high medical costs. Humana set aside about $208 million more in the second quarter to cover losses in the business, which it currently operates in 15 U.S. states. The company said it would shrink the business to 11 states next year and had already limited memberships in the four states where it no longer intended to offer the plans. Humana had said in May it would exit the Obamacare business in some states.  The company and Aetna announced a deal on Tuesday to sell a portfolio of about 290,000 of their Medicare Advantage members in 21 states to Molina Healthcare Inc (MOH.N) to win U.S. antitrust approval for their merger.Humana's individual commercial memberships fell by nearly a quarter in the three months ended June 30.  Net income fell to $311 million, or $2.06 per share.Excluding items, the company earned $2.30 per share, beating the average analyst estimate of $2.23, according to Thomson Reuters I/B/E/S. Revenue rose 2 percent to $14.01 billion, topping the average estimate of $13.59 billion.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2016-08-03,HUM,"Wed Aug 3, 2016 | 9:24am EDT",UPDATE 2-Humana profit plunges on higher provisions for Obamacare business,http://www.reuters.com//article/humana-results-idUSL3N1AK43T?type=companyNews
179,"  Aug 3 Humana Inc's quarterly pretax income fell nearly 20 percent as the U.S. health insurer set aside more money to cover losses in its business that sells individual plans under the Affordable Care Act, known better as Obamacare.Humana said on Wednesday it had limited Obamacare memberships on public exchanges in four states, where it would discontinue coverage altogether next year. The company also said it intended to discontinue nearly all off-exchange individual commercial plans in 2017. Humana, whose acquisition by larger rival Aetna Inc  has been challenged by U.S. antitrust authorities, said pretax income fell to $636 million, or $2.06 per share, in the second quarter ended June 30 from $793 million, or $2.85 per share, a year earlier. Revenue rose 2 percent to $14.01 billion.       (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2016-08-03,HUM,"Wed Aug 3, 2016 | 7:51am EDT",U.S. health insurer Humana's quarterly pretax income falls 20 pct,http://www.reuters.com//article/humana-results-idUSL3N1AK42T?type=companyNews
180,"  Aug 3 Humana Inc :* Humana reports second quarter 2016 financial results; reaffirms recent 2016 financial guidance increase* Consolidated revenues (including investment income) for 2q 2016 were $14.01 billion, an increase of 2 percent 2q 2015* 2Q 2016 consolidated benefit ratio of 84.3 percent decreased by 90 basis points from 85.2 percent for 2q 2015* Company has agreed with Aetna that its quarterly dividend will not exceed $0.29 per share prior to closing transaction* Qtrly adjusted earnings per share $2.30* Expects 2017 geographic presence for individual commercial offerings to cover no more than 156 counties, down from 1,351 counties in 2016* To maintain individual commercial on-exchange coverage options in markets where it expects to offer stable individual commercial health plan* Individual Medicare advantage membership was 2.8 million as of june 30, 2016, an increase of 4 percent, from june 30, 2015 * Individual medicare advantage membership was 2,816,500 as of june 30, 2016, an increase of 107,200, or 4 percent* Group medicare advantage membership was 351,700 as of June 30, 2016, a decrease of 121,400, or 26 percent* ""challenges in our individual commercial business remain""* Ability and intent to continue its quarterly dividend policy is not impacted by pending transaction with Aetna * Together with Aetna, company intends to defend deal in response to lawsuit* Qtrly GAAP earnings per share $2.06* Based on evaluation of claims data received through june 2016, company increased its fy16 PDR by approximately $208 million in 2q 2016* Intends to discontinue substantially all ACA-compliant off-exchange individual commercial plans in 2017 * Company has limited on-exchange membership in four states where it intends to discontinue that coverage in 2017* Expects 2017 geographic presence for individual commercial offerings to cover no more than 156 counties, down from its 2016 presence in 1,351 counties* Expects 2017 geographic presence for individual commercial offerings to cover up to 156 counties, down from 2016 presence in 1,351 counties* Expects 2017 premiums associated with ACA-compliant offerings in range of $750 million to $1 billion versus approximately $3.4 billion projected for fy16* Individual commercial on-exchange plans for 2017 have yet to be finalized* Will continue to evaluate performance of individual commercial business for 2016 as it further develops and corresponding impact on PDR* Q2 earnings per share view $2.23, revenue view $13.59 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-08-03,HUM,"Wed Aug 3, 2016 | 7:43am EDT",BRIEF-Humana qtrly GAAP earnings per share $2.06,http://www.reuters.com//article/idUSASC09086?type=companyNews
181,"   By Diane Bartz  The federal judge hearing the U.S. Justice Department's case to block Aetna Inc's $34 billion purchase of Humana Inc has set a trial date for Dec. 5, later than the companies had requested.Aetna and Humana are fighting the U.S. Department of Justice's lawsuit asserting that combining the two companies will harm consumers and raise prices.Aetna had asked for a trial date in the fall, perhaps October, because of a Dec. 31 deadline for the deal's completion. The Justice Department has said that that deadline can be pushed back. Judge John Bates, who will decide if the merger may go forward, said during a hearing on Wednesday that the companies had failed to define any harm in a later trial. Bates said that the trial would likely end on Dec. 21 and that the case would most likely be decided in mid- to late January.The Justice Department filed lawsuits on July 21 asking a federal court to stop Aetna's planned acquisition of Humana as well as Anthem's planned $45 billion purchase of Cigna. Aetna has argued that a single question will dominate the trial: Does Medicare Advantage, which is managed by insurance companies, compete with Medicare, which is managed by the government? The government says that the two products do not compete while insurers argue that they do.If Medicare Advantage competes against traditional Medicare, then Aetna's MA products compete against the government's Medicare and the deal is much likely to be deemed legal under antitrust law.",2016-08-10,HUM,"Wed Aug 10, 2016 | 1:40pm EDT",Judge sets Aetna-Humana antitrust trial date for Dec. 5,http://www.reuters.com//article/humana-aetna-court-idUSL1N1AR1GI?type=companyNews
182,"  (Add quotes, background on dispute)Washington DC Aug 10 The federal judge hearing the U.S. Justice Department's case to block Aetna Inc's  $34 billion purchase of Humana Inc has set a trial date for Dec. 5, later than the companies had requested.Aetna and Humana are fighting the U.S. Department of Justice's lawsuit asserting that combining the two companies will harm consumers and raise prices.Aetna had asked for a trial date in the fall, perhaps October, because of a Dec. 31 deadline for the deal's completion. The Justice Department has said that that deadline can be pushed back. Judge John Bates, who will decide if the merger may go forward, said during a hearing on Wednesday that the companies had failed to define any harm in a later trial. Bates said that the trial would likely end on Dec. 21 and that the case would most likely be decided in mid- to late January.The Justice Department filed lawsuits on July 21 asking a federal court to stop Aetna's planned acquisition of Humana as well as Anthem's planned $45 billion purchase of Cigna. Aetna has argued that a single question will dominate the trial: Does Medicare Advantage, which is managed by insurance companies, compete with Medicare, which is managed by the government? The government says that the two products do not compete while insurers argue that they do.If Medicare Advantage competes against traditional Medicare, then Aetna's MA products compete against the government's Medicare and the deal is much likely to be deemed legal under antitrust law.   (Reporting by Diane Bartz in Washington D.C.; Editing by Chizu Nomiyama and Alan Crosby)",2016-08-10,HUM,"Wed Aug 10, 2016 | 12:54pm EDT",UPDATE 1-Judge sets Aetna-Humana antitrust trial date for Dec. 5,http://www.reuters.com//article/humana-aetna-court-idUSL1N1AR15X?type=companyNews
183,"  Washington DC The U.S. District Court judge hearing the U.S. Justice Department's case to block Aetna Inc.'s (AET.N) $34 billion purchase of Humana Inc. (HUM.N) has set a trial date for Dec. 5, 2016, later than the companies had requested.Aetna and Humana are fighting the U.S. Department of Justice's lawsuit asserting that combining the two companies will harm consumers and raise prices. The companies were seeking an earlier date for the trial to increase the possibility of closing the deal within their target timeframe. Judge John Bates of the U.S. District Court for the District of Columbia said during a hearing on Wednesday that the companies had failed to define any harm that would be caused by setting the date in December.   (Reporting by Diane Bartz in Washington D.C.; Editing by Chizu Nomiyama)",2016-08-10,HUM,"Wed Aug 10, 2016 | 12:38pm EDT",Judge sets Aetna-Humana antitrust trial date for December 5,http://www.reuters.com//article/us-humana-aetna-court-idUSKCN10L1VH?type=companyNews
184,  Aug 11 Extendicare Inc* Extendicare announces solid 2016 second quarter results * Qtrly AFFO per share $0.206 * Qtrly total revenue $261.4 million versus $234.4 million * Q2 FFO per share view c$0.14 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:,2016-08-11,HUM,"Thu Aug 11, 2016 | 5:27pm EDT",BRIEF-Extendicare Q2 AFFO per share $0.206,http://www.reuters.com//article/idUSL8N1AS76K?type=companyNews
185,"  NEW YORK Aetna Inc, the No. 3 U.S. health insurer, on Monday said that due to persistent financial losses on Obamacare plans, it will sell individual insurance on the government-run online marketplaces in only four states next year, down from the current 15 states.Aetna's decision follows similar moves from UnitedHealth Group Inc. and Humana Inc., which have cited similar concerns about financial losses on these exchanges created under President Barack Obama's national healthcare reform law.Aetna is also trying to buy Humana and is currently fighting a U.S. government lawsuit aimed at blocking the $34 billion deal.Aetna, which earlier this year said it was too soon to give up on the exchanges despite its challenges, this month signaled it was reconsidering. On Aug. 2, the company said it would not expand in 2017 and would review all its individual business.Many insurers last year had said they expected to profit on the exchanges, but now say more exchange rules must be changed for it to be sustainable. Only about 11 million people have signed up through the exchanges, about half as many as expected.Larry Levitt, healthcare economist at the Kaiser Family Foundation, said that if enrollment stagnates, small technical fixes likely will not be enough to bring big insurers back. ""More healthy people need to be encouraged to sign up,"" Levitt said by email.  Aetna said that the current risk adjustment system, in which the government balances out the costs of sicker than typical populations through payments to insurers, is not adequate. Aetna said that it had a second-quarter pretax loss of $200 million on the individual business and has lost $430 million since the plans first went on sale in 2014. Kevin Counihan, Chief Executive of the U.S. government-run individual marketplace, said that the risks of the customer pool is improving. ""Its no surprise that companies are adapting at different rates to a market where they compete for business on cost and quality rather than by denying coverage to people with preexisting conditions,"" Counihan said in a statement.Aetna on Monday said it would continue to sell plans on the exchanges in Delaware, Iowa, Nebraska and Virginia in 2017. The plans, which are eligible for income-based government subsidies, will be sold in 242 counties, down from 778 counties this year. States it is exiting include Florida and Ohio. It will continue to sell individual plans that meet the law's requirements - such as not denying coverage to people with pre-existing conditions - outside of the exchanges where it does now, the company said. (Reporting by Caroline Humer; Editing by Diane Craft)",2016-08-16,HUM,"Mon Aug 15, 2016 | 9:58pm EDT",Aetna pulls back on Obamacare health insurance plans in 2017,http://www.reuters.com//article/us-aetna-exchanges-idUSKCN10R01N?type=companyNews
186,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc warned in July that it would exit much of the individual Obamacare health insurance market if the government challenged its deal to buy rival Humana Inc, according to a letter it sent to the U.S. Department of Justice.The public release of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government-run websites in 11 states, citing financial losses on the business.The company's withdrawal followed similar moves by UnitedHealth Group Inc and Humana, representing a blow to the marketplace for the government-subsidized insurance plans created under President Barack Obama's signature healthcare reform law.In the July 5 letter, Aetna Chief Executive Officer Mark Bertolini said it would have to cut back because it would be some time before the company recouped the investment it had made in this market over the past 2-1/2 years.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote. A copy of the letter was posted on the Huffington Post website, which obtained the document though the Freedom of Information Act. ""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote.Many insurers have said they are losing money because the Obamacare population is sicker than foreseen and the risk-adjustment payments from the government are insufficient. The government has made changes aimed at helping the insurers, which say it has not gone far enough to make the business sustainable.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's purchase of Cigna Corp after an antitrust review, saying the two deals would lead to higher prices. Aetna spokesman TJ Crawford said the letter was a response to the department's written request for information. The company's ultimate decision was based on financial information obtained after the letter was sent, he said.""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said. The release of the documents is unusual in a Justice Department antitrust investigation. So was the review, which was conducted in tandem with the Anthem-Cigna investigation and involved a business in which the Obama administration was deeply invested.In June, ongoing dialogue between Aetna and the department about the exchanges turned to discussions about the potential impact of a failed deal on those markets, according to a person familiar with the situation.Assistant Attorney General William Baer, who was leading the review, sent a June 30 request to Aetna for information on the consequences of not completing the deal.A copy of the government document sent to Aetna shows the Justice Department asked for data on costs such as the breakup fee; the impact on Aetna's business strategy, including participation on the Obamacare exchanges; and documents related to a June board meeting, the Humana deal or the exchanges.Aetna shares rose 1 percent to $120.09. Humana fell 0.5 percent to $178.69.",2016-08-17,HUM,"Wed Aug 17, 2016 | 4:28pm EDT",Aetna warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/humana-aetna-obamacare-idUSL1N1AY0L8?type=companyNews
187,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc (AET.N) warned in July that it would exit much of the individual Obamacare health insurance market if the government challenged its deal to buy rival Humana Inc (HUM.N), according to a letter it sent to the U.S. Department of Justice.The public release of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government-run websites in 11 states, citing financial losses on the business.The company's withdrawal followed similar moves by UnitedHealth Group Inc (UNH.N) and Humana, representing a blow to the marketplace for the government-subsidized insurance plans created under President Barack Obama's signature healthcare reform law.In the July 5 letter, Aetna Chief Executive Officer Mark Bertolini said it would have to cut back because it would be some time before the company recouped the investment it had made in this market over the past 2-1/2 years.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote. A copy of the letter was posted on the Huffington Post website, which obtained the document though the Freedom of Information Act. ""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote. Many insurers have said they are losing money because the Obamacare population is sicker than foreseen and the risk-adjustment payments from the government are insufficient. The government has made changes aimed at helping the insurers, which say it has not gone far enough to make the business sustainable.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's (ANTM.N) purchase of Cigna Corp (CI.N) after an antitrust review, saying the two deals would lead to higher prices. Aetna spokesman TJ Crawford said the letter was a response to the department's written request for information. The company's ultimate decision was based on financial information obtained after the letter was sent, he said. ""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said.The release of the documents is unusual in a Justice Department antitrust investigation. So was the review, which was conducted in tandem with the Anthem-Cigna investigation and involved a business in which the Obama administration was deeply invested.In June, ongoing dialogue between Aetna and the department about the exchanges turned to discussions about the potential impact of a failed deal on those markets, according to a person familiar with the situation.  Assistant Attorney General William Baer, who was leading the review, sent a June 30 request to Aetna for information on the consequences of not completing the deal. A copy of the government document sent to Aetna shows the Justice Department asked for data on costs such as the breakup fee; the impact on Aetna's business strategy, including participation on the Obamacare exchanges; and documents related to a June board meeting, the Humana deal or the exchanges.Aetna shares rose 1 percent to $120.09. Humana fell 0.5 percent to $178.69.     (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2016-08-17,HUM,"Wed Aug 17, 2016 | 3:13pm EDT",Aetna warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/us-humana-aetna-obamacare-idUSKCN10S1D4?type=companyNews
188,"   By Caroline Humer | NEW YORK  NEW YORK Aetna Inc (AET.N) warned in July that it would exit much of the individual Obamacare health insurance market if the government challenged its deal to buy rival Humana Inc (HUM.N), according to a letter it sent to the U.S. Department of Justice.The public release of the letter came after Aetna said on Monday that it would pull out of selling individual insurance on the government-run websites in 11 states, citing financial losses on the business.The company's withdrawal followed similar moves by UnitedHealth Group Inc (UNH.N) and Humana, representing a blow to the marketplace for the government-subsidized insurance plans created under President Barack Obama's signature healthcare reform law.In the July 5 letter, Aetna Chief Executive Officer Mark Bertolini said it would have to cut back because it would be some time before the company recouped the investment it had made in this market over the past 2-1/2 years.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote. A copy of the letter was posted on the Huffington Post website, which obtained the document though the Freedom of Information Act. ""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote. Many insurers have said they are losing money because the Obamacare population is sicker than foreseen and the risk-adjustment payments from the government are insufficient. The government has made changes aimed at helping the insurers, which say it has not gone far enough to make the business sustainable.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's (ANTM.N) purchase of Cigna Corp (CI.N) after an antitrust review, saying the two deals would lead to higher prices. Aetna spokesman TJ Crawford said the letter was a response to the department's written request for information. The company's ultimate decision was based on financial information obtained after the letter was sent, he said. ""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said.The release of the documents is unusual in a Justice Department antitrust investigation. So was the review, which was conducted in tandem with the Anthem-Cigna investigation and involved a business in which the Obama administration was deeply invested.In June, ongoing dialogue between Aetna and the department about the exchanges turned to discussions about the potential impact of a failed deal on those markets, according to a person familiar with the situation.  Assistant Attorney General William Baer, who was leading the review, sent a June 30 request to Aetna for information on the consequences of not completing the deal. A copy of the government document sent to Aetna shows the Justice Department asked for data on costs such as the breakup fee; the impact on Aetna's business strategy, including participation on the Obamacare exchanges; and documents related to a June board meeting, the Humana deal or the exchanges.Aetna shares rose 1 percent to $120.09. Humana fell 0.5 percent to $178.69.     (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2016-08-17,HUM,"Wed Aug 17, 2016 | 3:13pm EDT",UPDATE 2-Aetna warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/humana-aetna-obamacare-idUSL1N1AY0ML?type=companyNews
189,"  NEW YORK Aug 17 Aetna Inc's CEO said in a letter to the U.S. Department of Justice during the review of its deal to buy rival Humana Inc that the insurer would exit much of the individual Obamacare insurance market if the agency challenged the merger.In the July 5 letter, Chief Executive Officer Mark Bertolini said it would be some time before the company recouped the investment it had made over the past 2 1/2 years in the government-subsidized insurance plans created under President Barack Obama's national healthcare reform law.""Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,"" Bertolini wrote, according to a copy of the letter posted on the Huffington Post website, which obtained the document though the Freedom of Information Act.""Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna's ability to continue its support,"" he wrote. UnitedHealth Group Inc and Humana Inc have cited similar concerns about financial losses on the Obamacare exchanges and have also cut back most of their plans for 2017.The Justice Department moved on July 21 to block Aetna's acquisition of Humana and Anthem Inc's purchase of Cigna Corp, saying the two deals would lead to higher prices. Aetna on Monday announced it would pull out of selling individual insurance on the government-run websites in 11 states, saying its losses on the business were too high. Aetna spokesman TJ Crawford said in an e-mailed statement that since the company submitted the letter to the Justice Department, it had a better view of the business line's second-quarter performance.""That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,"" Crawford said.Aetna shares were unchanged in premarket trading.   (Reporting by Caroline Humer; Editing by Lisa Von Ahn)",2016-08-17,HUM,"Wed Aug 17, 2016 | 9:16am EDT",Aetna CEO warned it would cut Obamacare if Humana deal was blocked,http://www.reuters.com//article/humana-aetna-obamacare-idUSL1N1AY0J3?type=companyNews
190,  Aug 25 Humana Inc * Sets quarterly cash dividend of $0.29per share  Source text for Eikon:  Further company coverage:  ,2016-08-25,HUM,"Thu Aug 25, 2016 | 5:17pm EDT",BRIEF-Humana sets quarterly cash dividend of $0.29 per share,http://www.reuters.com//article/idUSFWN1B60FU?type=companyNews
191,"  Sept 23 Humana Inc :* Marketing process for company's 2016 medicare offerings begins on October 1, 2016, with enrollment beginning october 15, 2016  * All of 2017 medicare advantage, prescription drug plan offerings filed with centers for medicare and medicaid services in June approved by CMS  Source text - bit.ly/2dgfAn2 Further company coverage: ",2016-09-23,HUM,"Fri Sep 23, 2016 | 5:00pm EDT","BRIEF-Humana:2017 medicare advantage,prescription drug plan offerings approved by CMS",http://www.reuters.com//article/idUSFWN1BZ0MQ?type=companyNews
192,"  Health insurer Humana Inc (HUM.N) on Wednesday said a U.S. government health department cut its quality rating on Humana Medicare plans that currently enroll more than 1 million people, which could affect how much the government pays the insurer in 2018.Humana said it disagreed with the new quality ratings and that it will ask the government to reconsider its assessment. It also said it would take operational actions to mitigate the financial impact of the ratings drop.The cut could mean at least a $1 billion revenue hole for 2018, JP Morgan analyst Gary Taylor wrote in a research note. He suggested that Humana could cut some benefits and move other enrollees to higher performing plans to protect profits, but that it would be difficult to cover all of the gap.Shares of Humana, whose plan to be bought by larger rival Aetna Inc (AET.N) is being challenged by the U.S. Justice Department in court, fell 5.8 percent, or $10.34, to $167.19. Aetna dropped $2.02, or 1.8 percent, to $110.05.Humana said the government's updated ""Star"" ratings, published on Wednesday, show the number of its members in 4-star plans fell to 1.17 million from 2.15 million.  The government reimburses insurers more for 4-star rated Medicare plans than it does for lower-rated plans.The change in ratings would affect these payments in 2018, but is not expected to impact membership growth in 2017, Humana said.Humana raised its 2016 earnings forecast, citing better-than-projected performance in its Medicare Advantage business. Humana now anticipates earnings of about $8.80 per share on a GAAP basis and about $9.50 on an adjusted basis for the year ending Dec. 31, or $0.25 per share above its previous guidance.Medicare uses a Star rating system to measure how well Medicare Advantage and prescription drug plans perform. Medicare scores are based on several categories including quality of care and customer service. Ratings range from 1 to 5 stars, with five being the highest and one being the lowest score.     (This version of the story corrects to 1.17 million, not 1.7 million, in fifth paragraph) (Reporting by Ankur Banerjee in Bengaluru and Caroline Humer in New York; Editing by Chris Reese, Bernard Orr)",2016-10-12,HUM,"Wed Oct 12, 2016 | 2:07pm EDT",Humana says government cut in Medicare ratings will impact 2018,http://www.reuters.com//article/us-humana-outlook-idUSKCN12C1XI?type=companyNews
193,"  Health insurer Humana Inc (HUM.N) on Wednesday said a U.S. government health department cut its quality rating on Humana Medicare plans that currently enroll more than 1 million people, which could affect how much the government pays the insurer in 2018.Humana said it disagreed with the new quality ratings and that it will ask the government to reconsider its assessment. It also said it would take operational actions to mitigate the financial impact of the ratings drop.The cut could mean at least a $1 billion revenue hole for 2018, JP Morgan analyst Gary Taylor wrote in a research note. He suggested that Humana could cut some benefits and move other enrollees to higher performing plans to protect profits, but that it would be difficult to cover all of the gap.Shares of Humana, whose plan to be bought by larger rival Aetna Inc (AET.N) is being challenged by the U.S. Justice Department in court, fell 5.8 percent, or $10.34, to $167.19. Aetna dropped $2.02, or 1.8 percent, to $110.05.Humana said the government's updated ""Star"" ratings, published on Wednesday, show the number of its members in 4-star plans fell to 1.17 million from 2.15 million.  The government reimburses insurers more for 4-star rated Medicare plans than it does for lower-rated plans.The change in ratings would affect these payments in 2018, but is not expected to impact membership growth in 2017, Humana said.Humana raised its 2016 earnings forecast, citing better-than-projected performance in its Medicare Advantage business. Humana now anticipates earnings of about $8.80 per share on a GAAP basis and about $9.50 on an adjusted basis for the year ending Dec. 31, or $0.25 per share above its previous guidance.Medicare uses a Star rating system to measure how well Medicare Advantage and prescription drug plans perform. Medicare scores are based on several categories including quality of care and customer service. Ratings range from 1 to 5 stars, with five being the highest and one being the lowest score.     (This version of the story corrects to 1.17 million, not 1.7 million, in fifth paragraph) (Reporting by Ankur Banerjee in Bengaluru and Caroline Humer in New York; Editing by Chris Reese, Bernard Orr)",2016-10-12,HUM,"Wed Oct 12, 2016 | 2:07pm EDT",CORRECTED-UPDATE 2-Humana says government cut in Medicare ratings will impact 2018,http://www.reuters.com//article/humana-outlook-idUSL4N1CI459?type=companyNews
194,"  Oct 12 Health insurer Humana Inc on Wednesday raised its full-year earnings forecast, primarily due to better-than-projected performance in its Medicare Advantage business.Humana now anticipates earnings of about $8.80 per share on a GAAP basis and about $9.50 on an adjusted basis for the year ending Dec. 31, or $0.25 per share above its previous guidance. The company said that a decline in memberships in its 4-Star plans does not take into account certain operational actions it intends to take over the coming quarters to mitigate any potential impact of published ratings on Star bonus revenues for 2018. Medicare uses a Star rating system to measure how well Medicare Advantage and prescription drug plans perform. Medicare scores are based on several categories including quality of care and customer service. Ratings range from 1 to 5 stars, with five being the highest and one being the lowest score. Humana said it intends to file for reconsideration of certain of Star ratings for the 2018 bonus year.   (Reporting by Ankur Banerjee in Bengaluru)",2016-10-12,HUM,"Wed Oct 12, 2016 | 11:02am EDT",Humana raises 2016 earnings forecast,http://www.reuters.com//article/humana-outlook-idUSL4N1CI422?type=companyNews
195,"  Oct 14 Humana Inc* Humana Inc - Annual medicare advantage and prescription drug plan open enrollment period runs Oct. 15 through Dec. 7, 2016 * Humana Inc - Humana will expand its telemedicine program in 2017 to 80 counties in 23 states  * Humana - In 2017, most Humana Medicare advantage members will have access to GO365(TM), Humana's wellness and rewards program  Source text for Eikon:  Further company coverage:",2016-10-14,HUM,"Fri Oct 14, 2016 | 10:18am EDT",BRIEF-Humana Offers 2017 Medicare Health Plans,http://www.reuters.com//article/idUSFWN1CK0DS?type=companyNews
196,  Oct 26 Humana Inc * Sets quarterly cash dividend of $0.29 per share  Source text for Eikon:  Further company coverage:  ,2016-10-26,HUM,"Wed Oct 26, 2016 | 4:27pm EDT",BRIEF-Humana sets quarterly cash dividend of $0.29/share,http://www.reuters.com//article/idUSFWN1CW1AW?type=companyNews
197,"  NEW YORK Aetna Inc. (AET.N) is committed to defending its proposed acquisition of Humana Inc. (HUM.N) in court, where the U.S. Department of Justice is seeking to block the acquisition, Chief Executive Officer Mark Bertolini said on a conference call on Thursday.Aetna Chief Financial Officer, also speaking on the call, said that based on continued issues during the third quarter in the Affordable Care Act-compliant individual health insurance plans, the company expects a loss of $350 million on that business in 2016.    (Reporting by Caroline Humer)",2016-10-27,HUM,"Thu Oct 27, 2016 | 8:55am EDT",Aetna CEO is committed to defending Humana acquisition,http://www.reuters.com//article/us-aetna-results-ceo-idUSKCN12R1PE?type=companyNews
198,"  NEW YORK Oct 27 Aetna Inc. is committed to defending its proposed acquisition of Humana Inc. in court, where the U.S. Department of Justice is seeking to block the acquisition, Chief Executive Officer Mark Bertolini said on a conference call on Thursday. Aetna Chief Financial Officer, also speaking on the call, said that based on continued issues during the third quarter in the Affordable Care Act-compliant individual health insurance plans, the company expects a loss of $350 million on that business in 2016.   (Reporting by Caroline Humer)  ",2016-10-27,HUM,"Thu Oct 27, 2016 | 8:54am EDT",Aetna CEO is committed to defending Humana acquisition,http://www.reuters.com//article/aetna-results-ceo-idUSL1N1CX0OU?type=companyNews
199,"  Oct 28 Humana Inc : * Humana Inc - EliteHealth, co to add two primary care practices to Humana's medicare advantage plan networks in South Florida  Source text for Eikon:  Further company coverage:  ",2016-10-28,HUM,"Fri Oct 28, 2016 | 2:13pm EDT",BRIEF-Humana to add EliteHealth's primary care practices to its medicare advantage plan networks in South Florida,http://www.reuters.com//article/idUSFWN1CY1FC?type=companyNews
200,"  Health insurer Humana Inc (HUM.N) reported a higher-than-expected quarterly profit on Friday due to strength in its Medicare Advantage business, which sells plans to the elderly and people with disabilities.Humana's shares were up 2.3 percent at $169.13 on Friday.The company, which said in August it plans to shrink its individual commercial business to 156 counties next year from 1,351 counties, said its individual commercial unit's performance was in line with its expectations.President Barack Obama's Affordable Care Act, popularly known as Obamacare, created online exchanges where consumers can shop for individual health insurance and get subsidies.Insurers including Aetna Inc (AET.N), UnitedHealth Group Inc (UNH.N) and Anthem Inc (ANTM.N) have said they are losing money on the exchanges because of lower-than-anticipated enrollments. Enrollees are also sicker and older than expected.UnitedHealth and Aetna have largely pulled out of the exchanges for 2017.Humana said on Friday it now expected premiums of $1 billion-$1.25 billion in 2017 from its Obamacare plans, up from $750 million-$1 billion it had estimated in August. The company had estimated premiums of about $3.4 billion for 2016. The company said recent market exits from competitors resulted in members being assigned to companies that are continuing to offer Obamacare plans.Credit Suisse analysts said higher revenue exposure could mean a higher level of losses than the brokerage was expecting.Humana, whose acquisition by larger rival Aetna Inc (AET.N) has been challenged by U.S. antitrust authorities, said net income rose to $450 million, or $2.98 per share, in the third quarter ended Sept. 30, from $314 million, or $2.09 per share, a year earlier. Excluding items, the company earned $3.18 per share, beating analysts' average estimate of $3.15, according to Thomson Reuters I/B/E/S.Humana's consolidated benefit ratio, the percentage of premiums spent on claims, improved to 81.5 percent from 83.9 percent a year earlier, primarily due to lower utilization for the company's Medicare Advantage business.The company said its individual commercial business had no material impact on the benefit ratio for the quarter. Membership in the insurer's individual Medicare Advantage business rose 3 percent to 2.83 million at the end of the quarter. Membership in its individual commercial business fell 25 percent to 726,200.Humana's total revenue rose 2.5 percent to $13.69 billion, ahead of estimates of $13.41 billion.Up to Thursday's close, Humana stock had fallen 7.4 percent this year. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta)",2016-11-04,HUM,"Fri Nov 4, 2016 | 11:24am EDT",Humana profit beats on strength in Medicare Advantage unit,http://www.reuters.com//article/us-humana-results-idUSKBN12Z14C?type=companyNews
201,"  Health insurer Humana Inc (HUM.N) reported a higher-than-expected quarterly profit on Friday due to strength in its Medicare Advantage business, which sells plans to the elderly and people with disabilities.Humana's shares were up 2.3 percent at $169.13 on Friday.The company, which said in August it plans to shrink its individual commercial business to 156 counties next year from 1,351 counties, said its individual commercial unit's performance was in line with its expectations.President Barack Obama's Affordable Care Act, popularly known as Obamacare, created online exchanges where consumers can shop for individual health insurance and get subsidies.Insurers including Aetna Inc (AET.N), UnitedHealth Group Inc (UNH.N) and Anthem Inc (ANTM.N) have said they are losing money on the exchanges because of lower-than-anticipated enrollments. Enrollees are also sicker and older than expected.UnitedHealth and Aetna have largely pulled out of the exchanges for 2017.Humana said on Friday it now expected premiums of $1 billion-$1.25 billion in 2017 from its Obamacare plans, up from $750 million-$1 billion it had estimated in August. The company had estimated premiums of about $3.4 billion for 2016. The company said recent market exits from competitors resulted in members being assigned to companies that are continuing to offer Obamacare plans.Credit Suisse analysts said higher revenue exposure could mean a higher level of losses than the brokerage was expecting.Humana, whose acquisition by larger rival Aetna Inc (AET.N) has been challenged by U.S. antitrust authorities, said net income rose to $450 million, or $2.98 per share, in the third quarter ended Sept. 30, from $314 million, or $2.09 per share, a year earlier. Excluding items, the company earned $3.18 per share, beating analysts' average estimate of $3.15, according to Thomson Reuters I/B/E/S.Humana's consolidated benefit ratio, the percentage of premiums spent on claims, improved to 81.5 percent from 83.9 percent a year earlier, primarily due to lower utilization for the company's Medicare Advantage business.The company said its individual commercial business had no material impact on the benefit ratio for the quarter. Membership in the insurer's individual Medicare Advantage business rose 3 percent to 2.83 million at the end of the quarter. Membership in its individual commercial business fell 25 percent to 726,200.Humana's total revenue rose 2.5 percent to $13.69 billion, ahead of estimates of $13.41 billion.Up to Thursday's close, Humana stock had fallen 7.4 percent this year. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta)",2016-11-04,HUM,"Fri Nov 4, 2016 | 11:24am EDT",UPDATE 3-Humana profit beats on strength in Medicare Advantage unit,http://www.reuters.com//article/humana-results-idUSL4N1D53G8?type=companyNews
202,"  Nov 4 Humana Inc* Consolidated revenues (including investment income) for 3q 2016 were $13.69 billion, an increase of $331 million, or 2 percent* 3Q 2016 consolidated benefit ratio of 81.5 percent decreased by 240 basis points from 83.9 percent for 3q 2015* Humana inc says individual medicare advantage membership was 2,831,700 as of september 30, 2016, an increase of 94,600* Humana inc says group medicare advantage membership was 353,900 as of september 30, 2016, a decrease of 127,400, or 26 percent* Fy2016 earnings per share view $9.50 -- Thomson Reuters I/B/E/S * Humana inc says individual commercial and group segment performance in line with management's expectations in the quarter* Humana inc - expects fy17 net growth in individual medicare advantage membership to approximate that for fy16 * Humana-Consolidated benefit decreased in quarter due to lower y-o-y utilization for medicare advantage business, favorable comparisons for prior period development* Qtrly adjusted eps of $3.18* Humana reports third quarter 2016 financial results * Sees fy 2016 adjusted earnings per share about $9.50* Sees fy 2016 gaap earnings per share about $8.68* Q3 earnings per share $2.98* Q3 earnings per share view $3.15 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-11-04,HUM,"Fri Nov 4, 2016 | 6:24am EDT",BRIEF-Humana sees Q3 EPS $2.98,http://www.reuters.com//article/idUSASC09GAF?type=companyNews
203,"  Nov 4 Health insurer Humana Inc's  quarterly pretax profit jumped 39 percent as it added more members to its Medicare Advantage business, which sells plans to the elderly and people with disabilities.The company, whose acquisition by larger rival Aetna Inc  has been challenged by U.S. antitrust authorities, said pretax income rose to $902 million, or $2.98 per share, in the third quarter ended Sept. 30, from $648 million, or $2.09 per share, a year earlier.  Revenue rose to $13.69 billion from $13.36 billion.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta) ",2016-11-04,HUM,"Fri Nov 4, 2016 | 6:11am EDT",Health insurer Humana's quarterly pretax profit rises 39 pct,http://www.reuters.com//article/humana-results-idUSL4N1D53FP?type=companyNews
204,"  Nov 10 (Reuters) -* Third Point LLC takes share stake of 2.1 million Class A shares in Visa Inc - SEC filing * Third Point LLC takes share stake of 1.4 million shares in Humana Inc * Third Point LLC cuts share stake in Allergan Plc by 22.8 percent to 3.8 million shares * Third Point LLC - Change in holdings are as of September 30, 2016 and compared with the previous quarter ended as of June 30, 2016  Source text for quarter ended Sept 30, 2016: bit.ly/2g1HJTg   Source text for quarter ended June 30, 2016:  bit.ly/2aZDRz5",2016-11-10,HUM,"Thu Nov 10, 2016 | 5:45pm EST","BRIEF-Third Point cuts share stake in Allergan, takes share stake in Humana",http://www.reuters.com//article/idUSFWN1DB1L8?type=companyNews
205,  Nov 10 Extendicare Inc : * Extendicare Inc - qtrly AFFO earnings per share $0.223  Source text for Eikon:  Further company coverage:  ,2016-11-10,HUM,"Thu Nov 10, 2016 | 5:32pm EST",BRIEF-Extendicare Inc - qtrly AFFO earnings per share $0.223,http://www.reuters.com//article/idUSFWN1DB1J4?type=companyNews
206,  Nov 10 Extendicare Inc -* Quarterly AFFO earnings per share $0.217 * Quarterly AFFO earnings per share from continuing operations $0.223  * Extendicare announces solid 2016 third quarter results  Source text for Eikon:  Further company coverage:,2016-11-10,HUM,"Thu Nov 10, 2016 | 5:06pm EST",BRIEF-Extendicare announces solid 2016 third quarter results,http://www.reuters.com//article/idUSASC09I50?type=companyNews
207,"   By Diane Bartz | WASHINGTON  WASHINGTON A U.S. Justice Department attorney told a federal judge on Monday that health insurer Aetna Inc's planned acquisition of Humana Inc would break antitrust law by reducing competition in Medicare Advantage and Obamacare exchange businesses, kicking off a trial expected to last weeks.The Justice Department filed a lawsuit in July asking the court to stop Aetna's $34 billion deal for Humana, arguing it would lead to higher prices for seniors and the disabled on Medicare and for people who use the individual insurance program created under the Affordable Care Act, popularly known as Obamacare. Aetna defended the deal on Monday, arguing that Medicare Advantage competes with the government's traditional Medicare program for elderly or disabled patients. It also said that it plans to stay out of the Obamacare exchanges in the near future.Both programs, as well as antitrust enforcement, could face changes under Republican President-elect Donald Trump.Justice Department lawyer Craig Conrath told Judge John Bates of the U.S. District Court for the District of Columbia that traditional government-managed Medicare does not compete with Medicare Advantage, which is run by insurers. A witness called by the government, Aetna executive Nancy Cocozza, president of Aetna's Medicare Business, was shown internal documents that appeared to show that Aetna considered Humana a major competitor but not original Medicare. The documents were not visible in the court.Shown one assessment of top competitors that did not have Medicare, Cocozza protested, ""These are MA (Medicare Advantage) competitors but there are others.""Conrath also said that Aetna's plan to largely exit the Obamacare exchanges in 2017 should be disregarded because the company could re-enter the market as soon as 2018 if it chooses. Conrath said written communications showed that Aetna left Obamacare because of the antitrust lawsuit. Aetna has said it would not return to the exchanges until 2019 at the earliest.Share prices of both companies dropped Monday. Humana closed down 2.2 percent at $208.83 while Aetna was down 3 percent at $129.45.Aetna attorney John Majoras argued that traditional Medicare and Medicare Advantage did compete, citing a U.S. government website. There could soon be more competition, he said, noting ""entry has been common and it has been widespread."" Majoras also argued that the Obamacare exchanges were unprofitable and said that was the real reason the company planned to drop out of 11 of the 15 states where they are on the exchanges. ""The result to Aetna has been mounting losses,"" Majoras said. ""Humana's losses were actually even a bit worse.""The Justice Department filed another lawsuit in July to stop Anthem Inc's planned $45 billion purchase of Cigna Corp. That trial is underway in the same courthouse. The trials will be over before Trump's inauguration on Jan. 20. He has pledged to repeal and replace Obamacare and has said Medicare should be modernized.   Humana is the second largest Medicare Advantage insurer while Aetna is the fourth, and the two compete in more than 600 counties, the government said in its complaint. (Reporting by Diane Bartz and Caroline Humer; Editing by Jonathan Oatis and Leslie Adler)",2016-12-05,HUM,"Mon Dec 5, 2016 | 6:23pm EST",U.S. attorneys argue Aetna-Humana deal violates antitrust law,http://www.reuters.com//article/us-humana-m-a-aetna-idUSKBN13U23N?type=companyNews
